{"completed_at":"2026-11-12T14:55:33.357017","latency_in_ms":1401,"output":{"example_id":"complex_table_headers/complex_header_003","grounded_pages":[],"layout_pages":[],"markdown":"TABLE\n\n## **12**\n\n**Birth registration**\n\n**Refugees by country of origin**\n\n**Internally displaced persons**\n\n**Homeless people due to natural disaster**\n\n**Orphaned children**\n\n**Prison population**\n\n**Homicide rate Suicide rate**\n\n**Justification of wife beating**\n\n**Violence against women ever experienced** **a**\n\n**Depth of food deficit**\n\n(% under age 5) (thousands) (thousands)\n\n(average annual per million people) (thousands)\n\n(per 100,000 people)\n\n(per 100,000 people)\n\n(per 100,000 people) (% ages 15–49)\n\nIntimate partner\n\nNonintimate partner (kilocalories per person per day) Female Male Female Male (%)\n\n**HDI rank** 2010–2015 b 2015 c 2015 2005/2015 2014 2004–2015 b 2010–2014 b 2012 2012 2010–2015 b 2010–2015 b 2005–2015 b 2005–2015 b 2013/2015\n\n179 Eritrea .. 379.8 .. 0 140 .. 9.7 8.7 25.8 51.0 45.0 .. .. .. 179 Sierra Leone 77 4.9 .. 36 310 55 1.9 4.5 11.0 63.0 34.0 45.3 .. 162 181 Mozambique 48 0.1 .. 292 1,800 61 3.6 21.1 34.2 23.0 20.0 33.1 .. 188 181 South Sudan 35 778.6 k 1,697.0 0 570 65 13.9 12.8 27.1 79.0 .. .. .. .. 183 Guinea 58 17.0 .. 33 .. 26 8.7 2.4 7.1 92.0 66.0 .. .. 118 184 Burundi 75 292.8 99.0 519 580 93 4.0 12.5 34.1 73.0 44.0 .. .. .. 185 Burkina Faso 77 2.1 .. 367 830 34 0.7 2.8 7.3 44.0 34.0 11.5 .. 167 186 Chad 12 14.9 107.0 93 970 39 9.2 2.3 7.4 62.0 .. .. .. 276 187 Niger 64 1.4 153.0 449 .. 39 4.5 1.9 5.3 60.0 27.0 .. .. 58 188 Central African Republic 61 471.1 452.0 920 300 16 13.2 5.3 14.1 80.0 75.0 29.8 .. 349 **OTHER COUNTRIES OR TERRITORIES** Korea (Democratic People’s Rep. of) 100 g 1\\.1 .. 1,315 .. .. 4.7 .. .. .. .. .. .. 344 Marshall Islands 96 g 0\\.0 .. 0 .. .. 4.7 .. .. 56.0 g 58\\.0 g 51\\.0 13.0 .. Monaco 100 0.0 .. .. .. 74 d .. .. .. .. .. .. .. .. Nauru 83 g .. .. .. .. 140 1.3 .. .. .. .. 48.1 47.0 .. San Marino 100 0.0 .. .. .. .. 0.0 .. .. .. .. .. .. .. Somalia 3 g 1,123.0 1,223.0 234 630 .. 5.6 6.8 18.1 76.0 f,g .. .. .. .. Tuvalu 50 g 0\\.0 .. 0 .. 110 20.3 .. .. 70.0 g 73\\.0 g 36\\.8 .. .. **Human development groups** Very high human development 100 118.2 l 299\\.0 l 81 .. 289 2.9 5.6 19.9 .. .. .. .. .. High human development .. 1,019.2 l 10,750.6 l 203 .. 174 6.0 6.4 8.9 .. .. .. .. 60 Medium human development 70 1,335.9 l 7,878.9 l 609 .. 66 4.8 11.0 17.3 41.3 .. 37.3 .. 104 Low human development 39 11,584.9 l 20,559.3 l 233 3,982 70 8.2 6.6 15.2 51.8 36.1 .. .. 147 **Developing countries** 65 15,066.6 l 40,683.8 l 399 .. 111 5.8 8.3 13.5 .. .. .. .. 92 **Regions** Arab States 84 7,011.7 l 17,615.0 l 72 .. 116 4.0 2.6 5.5 45.8 .. .. .. 67 East Asia and the Pacific .. 760.1 l 753\\.4 l 241 .. 126 1.5 7.3 7.3 .. .. .. .. 79 Europe and Central Asia 98 456.2 l 3,542.6 l 29 .. 209 3.9 4.8 18.6 21.5 .. 26.2 .. 27 Latin America and the Caribbean 94 197.8 l 7,331.0 l 290 .. 244 21.6 2.8 9.9 .. .. .. .. 41 South Asia 64 3,195.4 l 3,765.0 l 838 .. 48 3.8 14.3 21.6 45.8 .. .. .. 115 Sub-Saharan Africa 41 3,445.3 l 7,404.8 l 189 3,702 88 9.5 6.3 15.5 50.3 35.5 .. .. 131 **Least developed countries** 40 7,859.6 l 13,773.0 l 249 .. 75 6.4 8.5 15.6 51.9 .. .. .. 165 **Small island developing states** 82 50.9 l 6\\.3 l 506 .. 229 12.0 4.3 11.8 13.2 .. .. .. 169\n\n**Organisation for Economic Co‑operation and Development** 99 83.3 l 1,241.0 l 114 .. 274 3.3 5.3 17.4 .. .. .. .. ..\n\n**World 69 15,182.3** **l** **40,710.8** **l** **334 .. 143 5.2 7.9 14.7 .. .. .. .. 91**\n\n**NOTES a** Data collection methods, age ranges, sampled women (ever-partnered, ever-married or all women) and definitions of the forms of violence and of perpetrators vary by survey. Thus data are not necessarily comparable across countries. **b** Data refer to the most recent year available during the period specified. **c** Data refer to people recognized as refugees under the 1951 UN Convention, the 1967 UN Protocol and the 1969 Organization of African Unity Convention. In the absence of government figures, the Office of the UN High Commissioner for Refugees (UNHCR) has estimated the refugee population in many industrial countries based on 10 years of individual asylum-seeker recognition. **d** For more detailed country notes, see www. prisonstudies.org. **e** HDRO calculations based on data from ICPS (2016). **f** Differs from standard definition or refers to only part of the country. **g** Refers to years or periods other than those specified. **h** Refers to Palestinian refugees under the UNHCR mandate only. Another 5,589,488 Palestinian refugees are under the responsibility of United Nations Relief and Works Agency for Palestinian Refugees in the Near East. **i** May include citizens of South Sudan.\n\n**j** Refers to the average for 2009–2011, prior to South Sudan’s independence. **k** An unknown number of refugees and asylum-\n\nseekers from South Sudan may be included under data for Sudan. **l** Unweighted sum of national estimates.\n\n**DEFINITIONS**\n\n**Birth registration:** Percentage of children under age 5 who were registered at the moment of the survey. It includes children whose birth certificate was seen by the interviewer and children whose mother or caretaker says the birth has been registered.\n\n**Refugees by country of origin:** Number of people who have fled their country of origin because of a well founded fear of persecution due to their race, religion, nationality, political opinion or membership in a particular social group and who cannot or do not want to return to their country of origin.\n\n**Internally displaced persons:** Number of people who have been forced to leave their homes or places of habitual residence — in particular, as a result of or to avoid the effects of armed conflict, situations of generalized violence, violations of human rights or natural or human-made disasters — and who have not crossed an internationally recognized state border.\n\n**Homeless people due to natural disaster:** Average annual number of people who lack a shelter for living quarters as a result of natural disasters, who carry their few possessions with them and who sleep in the streets, in doorways or on piers, or in any other space, on a more or less random basis, expressed per million people.\n\n**Orphaned children:** Number of children (ages 0–17) who have lost one or both parents due to any cause.\n\n**Prison population:** Number of adult and juvenile prisoners — including pretrial detainees, unless otherwise noted — expressed per 100,000 people.\n\n**Homicide rate:** Number of unlawful deaths purposefully inflicted on a person by another person, expressed per 100,000 people.\n\n**Suicide rate:** Number of deaths from purposely self-inflicted injuries, expressed per 100,000 people in the reference population.\n\n**Justification of wife beating:** Percentage of women and men ages 15–49 who consider a husband to be justified in hitting or beating his wife for at least one of the following reasons: if his wife burns the food, argues with him, goes out without telling him, neglects the children or refuses sexual relations.\n\n**Violence against women ever experienced, intimate partner:** Percentage of the female\n\npopulation, ages 15 and older, that has ever experienced physical or sexual violence from an intimate partner.\n\n**Violence against women ever experienced, nonintimate partner:** Percentage of the female population, ages 15 and older, that has ever experienced sexual violence from a nonintimate partner.\n\n**Depth of the food deficit:** Number of kilocalories needed to lift the undernourished from their status, holding all other factors constant.\n\n**MAIN DATA SOURCES**\n\n**Columns 1, 5, 10 and 11:** UNICEF (2016).\n\n**Column 2:** UNHCR (2016).\n\n**Column 3:** IDMC (2016).\n\n**Column 4:** CRED EM-DAT (2016) and UNDESA (2015a).\n\n**Column 6:** ICPS (2016).\n\n**Column 7:** UNODC (2016).\n\n**Columns 8 and 9:** WHO (2016).\n\n**Columns 12 and 13:** UN Women (2016).\n\n**Column 14:** FAO (2016a).\n\nHUMAN DEVELOPMENT REPORT **2016** **Human Development for Everyone**\n\nTABLE 12 Human security | 245","pages":[{"line_numbers":[],"markdown":"TABLE\n\n## **12**\n\n**Birth registration**\n\n**Refugees by country of origin**\n\n**Internally displaced persons**\n\n**Homeless people due to natural disaster**\n\n**Orphaned children**\n\n**Prison population**\n\n**Homicide rate Suicide rate**\n\n**Justification of wife beating**\n\n**Violence against women ever experienced** **a**\n\n**Depth of food deficit**\n\n(% under age 5) (thousands) (thousands)\n\n(average annual per million people) (thousands)\n\n(per 100,000 people)\n\n(per 100,000 people)\n\n(per 100,000 people) (% ages 15–49)\n\nIntimate partner\n\nNonintimate partner (kilocalories per person per day) Female Male Female Male (%)\n\n**HDI rank** 2010–2015 b 2015 c 2015 2005/2015 2014 2004–2015 b 2010–2014 b 2012 2012 2010–2015 b 2010–2015 b 2005–2015 b 2005–2015 b 2013/2015\n\n179 Eritrea .. 379.8 .. 0 140 .. 9.7 8.7 25.8 51.0 45.0 .. .. .. 179 Sierra Leone 77 4.9 .. 36 310 55 1.9 4.5 11.0 63.0 34.0 45.3 .. 162 181 Mozambique 48 0.1 .. 292 1,800 61 3.6 21.1 34.2 23.0 20.0 33.1 .. 188 181 South Sudan 35 778.6 k 1,697.0 0 570 65 13.9 12.8 27.1 79.0 .. .. .. .. 183 Guinea 58 17.0 .. 33 .. 26 8.7 2.4 7.1 92.0 66.0 .. .. 118 184 Burundi 75 292.8 99.0 519 580 93 4.0 12.5 34.1 73.0 44.0 .. .. .. 185 Burkina Faso 77 2.1 .. 367 830 34 0.7 2.8 7.3 44.0 34.0 11.5 .. 167 186 Chad 12 14.9 107.0 93 970 39 9.2 2.3 7.4 62.0 .. .. .. 276 187 Niger 64 1.4 153.0 449 .. 39 4.5 1.9 5.3 60.0 27.0 .. .. 58 188 Central African Republic 61 471.1 452.0 920 300 16 13.2 5.3 14.1 80.0 75.0 29.8 .. 349 **OTHER COUNTRIES OR TERRITORIES** Korea (Democratic People’s Rep. of) 100 g 1\\.1 .. 1,315 .. .. 4.7 .. .. .. .. .. .. 344 Marshall Islands 96 g 0\\.0 .. 0 .. .. 4.7 .. .. 56.0 g 58\\.0 g 51\\.0 13.0 .. Monaco 100 0.0 .. .. .. 74 d .. .. .. .. .. .. .. .. Nauru 83 g .. .. .. .. 140 1.3 .. .. .. .. 48.1 47.0 .. San Marino 100 0.0 .. .. .. .. 0.0 .. .. .. .. .. .. .. Somalia 3 g 1,123.0 1,223.0 234 630 .. 5.6 6.8 18.1 76.0 f,g .. .. .. .. Tuvalu 50 g 0\\.0 .. 0 .. 110 20.3 .. .. 70.0 g 73\\.0 g 36\\.8 .. .. **Human development groups** Very high human development 100 118.2 l 299\\.0 l 81 .. 289 2.9 5.6 19.9 .. .. .. .. .. High human development .. 1,019.2 l 10,750.6 l 203 .. 174 6.0 6.4 8.9 .. .. .. .. 60 Medium human development 70 1,335.9 l 7,878.9 l 609 .. 66 4.8 11.0 17.3 41.3 .. 37.3 .. 104 Low human development 39 11,584.9 l 20,559.3 l 233 3,982 70 8.2 6.6 15.2 51.8 36.1 .. .. 147 **Developing countries** 65 15,066.6 l 40,683.8 l 399 .. 111 5.8 8.3 13.5 .. .. .. .. 92 **Regions** Arab States 84 7,011.7 l 17,615.0 l 72 .. 116 4.0 2.6 5.5 45.8 .. .. .. 67 East Asia and the Pacific .. 760.1 l 753\\.4 l 241 .. 126 1.5 7.3 7.3 .. .. .. .. 79 Europe and Central Asia 98 456.2 l 3,542.6 l 29 .. 209 3.9 4.8 18.6 21.5 .. 26.2 .. 27 Latin America and the Caribbean 94 197.8 l 7,331.0 l 290 .. 244 21.6 2.8 9.9 .. .. .. .. 41 South Asia 64 3,195.4 l 3,765.0 l 838 .. 48 3.8 14.3 21.6 45.8 .. .. .. 115 Sub-Saharan Africa 41 3,445.3 l 7,404.8 l 189 3,702 88 9.5 6.3 15.5 50.3 35.5 .. .. 131 **Least developed countries** 40 7,859.6 l 13,773.0 l 249 .. 75 6.4 8.5 15.6 51.9 .. .. .. 165 **Small island developing states** 82 50.9 l 6\\.3 l 506 .. 229 12.0 4.3 11.8 13.2 .. .. .. 169\n\n**Organisation for Economic Co‑operation and Development** 99 83.3 l 1,241.0 l 114 .. 274 3.3 5.3 17.4 .. .. .. .. ..\n\n**World 69 15,182.3** **l** **40,710.8** **l** **334 .. 143 5.2 7.9 14.7 .. .. .. .. 91**\n\n**NOTES a** Data collection methods, age ranges, sampled women (ever-partnered, ever-married or all women) and definitions of the forms of violence and of perpetrators vary by survey. Thus data are not necessarily comparable across countries. **b** Data refer to the most recent year available during the period specified. **c** Data refer to people recognized as refugees under the 1951 UN Convention, the 1967 UN Protocol and the 1969 Organization of African Unity Convention. In the absence of government figures, the Office of the UN High Commissioner for Refugees (UNHCR) has estimated the refugee population in many industrial countries based on 10 years of individual asylum-seeker recognition. **d** For more detailed country notes, see www. prisonstudies.org. **e** HDRO calculations based on data from ICPS (2016). **f** Differs from standard definition or refers to only part of the country. **g** Refers to years or periods other than those specified. **h** Refers to Palestinian refugees under the UNHCR mandate only. Another 5,589,488 Palestinian refugees are under the responsibility of United Nations Relief and Works Agency for Palestinian Refugees in the Near East. **i** May include citizens of South Sudan.\n\n**j** Refers to the average for 2009–2011, prior to South Sudan’s independence. **k** An unknown number of refugees and asylum-\n\nseekers from South Sudan may be included under data for Sudan. **l** Unweighted sum of national estimates.\n\n**DEFINITIONS**\n\n**Birth registration:** Percentage of children under age 5 who were registered at the moment of the survey. It includes children whose birth certificate was seen by the interviewer and children whose mother or caretaker says the birth has been registered.\n\n**Refugees by country of origin:** Number of people who have fled their country of origin because of a well founded fear of persecution due to their race, religion, nationality, political opinion or membership in a particular social group and who cannot or do not want to return to their country of origin.\n\n**Internally displaced persons:** Number of people who have been forced to leave their homes or places of habitual residence — in particular, as a result of or to avoid the effects of armed conflict, situations of generalized violence, violations of human rights or natural or human-made disasters — and who have not crossed an internationally recognized state border.\n\n**Homeless people due to natural disaster:** Average annual number of people who lack a shelter for living quarters as a result of natural disasters, who carry their few possessions with them and who sleep in the streets, in doorways or on piers, or in any other space, on a more or less random basis, expressed per million people.\n\n**Orphaned children:** Number of children (ages 0–17) who have lost one or both parents due to any cause.\n\n**Prison population:** Number of adult and juvenile prisoners — including pretrial detainees, unless otherwise noted — expressed per 100,000 people.\n\n**Homicide rate:** Number of unlawful deaths purposefully inflicted on a person by another person, expressed per 100,000 people.\n\n**Suicide rate:** Number of deaths from purposely self-inflicted injuries, expressed per 100,000 people in the reference population.\n\n**Justification of wife beating:** Percentage of women and men ages 15–49 who consider a husband to be justified in hitting or beating his wife for at least one of the following reasons: if his wife burns the food, argues with him, goes out without telling him, neglects the children or refuses sexual relations.\n\n**Violence against women ever experienced, intimate partner:** Percentage of the female\n\npopulation, ages 15 and older, that has ever experienced physical or sexual violence from an intimate partner.\n\n**Violence against women ever experienced, nonintimate partner:** Percentage of the female population, ages 15 and older, that has ever experienced sexual violence from a nonintimate partner.\n\n**Depth of the food deficit:** Number of kilocalories needed to lift the undernourished from their status, holding all other factors constant.\n\n**MAIN DATA SOURCES**\n\n**Columns 1, 5, 10 and 11:** UNICEF (2016).\n\n**Column 2:** UNHCR (2016).\n\n**Column 3:** IDMC (2016).\n\n**Column 4:** CRED EM-DAT (2016) and UNDESA (2015a).\n\n**Column 6:** ICPS (2016).\n\n**Column 7:** UNODC (2016).\n\n**Columns 8 and 9:** WHO (2016).\n\n**Columns 12 and 13:** UN Women (2016).\n\n**Column 14:** FAO (2016a).\n\nHUMAN DEVELOPMENT REPORT **2016** **Human Development for Everyone**\n\nTABLE 12 Human security | 245","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_003","product_type":"parse","source_file_path":"complex_header_003.pdf"},"started_at":"2026-11-12T14:55:31.955465"} {"completed_at":"2026-11-12T14:55:39.312164","latency_in_ms":2692,"output":{"example_id":"complex_table_headers/complex_header_006","grounded_pages":[],"layout_pages":[],"markdown":"FINAL DRAFT Chapter 13 Supplementary Material IPCC WGII Sixth Assessment Report\n\n**Do Not Cite, Quote or Distribute** SM13-13 Total pages: 120\n\nWCE 0.77 0.08 0.70 0.09 0.58 0.10 0.53 0.10 0.39 0.10\n\nNEU 0.85 0.18 0.81 0.19 0.76 0.20 0.74 0.21 0.67 0.23\n\nSEU 0.75 0.09 0.67 0.11 0.53 0.12 0.47 0.12 0.31 0.12\n\nEEU 0.75 0.12 0.69 0.13 0.58 0.14 0.52 0.15 0.35 0.14\n\n**Insects**\n\nRegions\n\n1\\.5C GWL Std\n\n2C GWL Std\n\n2\\.7C GWL Std\n\n3\\.2C GWL Std\n\n4\\.5C GWL Std\n\nWCE 0.59 0.11 0.49 0.11 0.34 0.11 0.29 0.10 0.17 0.08\n\nNEU 0.90 0.14 0.86 0.18 0.76 0.25 0.72 0.28 0.58 0.34\n\nSEU 0.65 0.13 0.56 0.15 0.43 0.17 0.38 0.17 0.26 0.15\n\nEEU 0.72 0.15 0.64 0.18 0.49 0.20 0.42 0.21 0.25 0.19\n\n**Pollinator**\n\nRegions\n\n1\\.5C GWL Std\n\n2C GWL Std\n\n2\\.7C GWL Std\n\n3\\.2C GWL Std\n\n4\\.5C GWL Std\n\nWCE 0.59 0.14 0.50 0.15 0.39 0.15 0.35 0.14 0.26 0.11\n\nNEU 0.84 0.18 0.78 0.23 0.65 0.29 0.59 0.31 0.43 0.33\n\nSEU 0.75 0.13 0.69 0.14 0.57 0.16 0.52 0.16 0.38 0.15\n\nEEU 0.69 0.21 0.60 0.23 0.43 0.25 0.36 0.24 0.19 0.19\n\n**Amphibians**\n\nRegions\n\n1\\.5C GWL Std\n\n2C GWL Std\n\n2\\.7C GWL Std\n\n3\\.2C GWL Std\n\n4\\.5C GWL Std\n\nWCE 0.88 0.12 0.84 0.14 0.76 0.17 0.72 0.17 0.59 0.18\n\nNEU 0.89 0.24 0.91 0.16 0.87 0.19 0.84 0.21 0.76 0.25\n\nSEU 0.84 0.16 0.79 0.18 0.68 0.21 0.63 0.22 0.50 0.22\n\nEEU 0.83 0.29 0.86 0.20 0.78 0.24 0.75 0.25 0.63 0.30\n\n**Reptiles**\n\nRegions\n\n1\\.5C GWL Std\n\n2C GWL Std\n\n2\\.7C GWL Std\n\n3\\.2C GWL Std\n\n4\\.5C GWL Std\n\nWCE 0.89 0.09 0.86 0.10 0.80 0.11 0.77 0.11 0.67 0.13\n\nNEU 0.90 0.18 0.87 0.19 0.82 0.22 0.79 0.23 0.71 0.25\n\nSEU 0.89 0.10 0.85 0.12 0.76 0.15 0.72 0.15 0.58 0.15\n\nEEU 0.87 0.27 0.84 0.28 0.79 0.30 0.78 0.31 0.68 0.33\n\n**Birds**\n\nRegions\n\n1\\.5C GWL Std\n\n2C GWL Std\n\n2\\.7C GWL Std\n\n3\\.2C GWL Std\n\n4\\.5C GWL Std\n\nWCE 0.88 0.04 0.85 0.05 0.79 0.06 0.76 0.07 0.66 0.11\n\nNEU 0.93 0.13 0.92 0.12 0.90 0.12 0.88 0.13 0.83 0.16\n\nSEU 0.87 0.06 0.82 0.08 0.73 0.10 0.69 0.11 0.54 0.12\n\nEEU 0.86 0.14 0.84 0.15 0.79 0.16 0.77 0.16 0.69 0.18\n\n**Mammals**\n\nRegions\n\n1\\.5C GWL Std\n\n2C GWL Std\n\n2\\.7C GWL Std\n\n3\\.2C GWL Std\n\n4\\.5C GWL Std\n\nWCE 0.79 0.10 0.73 0.11 0.61 0.12 0.55 0.12 0.42 0.12\n\nNEU 0.90 0.11 0.87 0.12 0.81 0.16 0.77 0.17 0.63 0.23\n\nSEU 0.78 0.12 0.70 0.14 0.59 0.16 0.54 0.16 0.38 0.15\n\nEEU 0.80 0.16 0.75 0.19 0.65 0.20 0.60 0.19 0.44 0.16\n\n1 2 **SM13.3 Supplementary Material Supporting Section 13.4** 3 4 5 **Table SM13.4** : Literature sources used for assessment presented in Figure 13.11 6\n\n**Impact/Risk Supporting references of assessment**\n\nLoss of habitat availability\n\n(Coma et al., 2009; Garrabou et al., 2009; Huete-Stauffer et al., 2011; Munari, 2011; Kersting et al., 2013; Brodie et al., 2014; Frolov et al., 2014b; Rivetti et al., 2014; Altieri and Gedan, 2015; García Molinos et al., 2016; Spencer et al., 2016; Bakanev, 2017; Jessen et al., 2017; Orekhova, 2017; Berlinski and Popov, 2018; Buonomo et al., 2018; Jokinen et al., 2018; Reusch et al., 2018; Schuerch et al., 2018; van der Spek, 2018; Wang et al., 2018; Filatov et al., 2019; Garrabou et al., 2019; Saraiva et al., 2019; Spivak et al., 2019; D'Amen and Azzurro, 2020; Jiang et al., 2020; Pavlova, 2020; Sandø et al., 2020; Stepanyan, 2020)\n\n# ACCEPTED VERSION SUBJECT TO FINAL EDITS","pages":[{"line_numbers":[],"markdown":"FINAL DRAFT Chapter 13 Supplementary Material IPCC WGII Sixth Assessment Report\n\n**Do Not Cite, Quote or Distribute** SM13-13 Total pages: 120\n\nWCE 0.77 0.08 0.70 0.09 0.58 0.10 0.53 0.10 0.39 0.10\n\nNEU 0.85 0.18 0.81 0.19 0.76 0.20 0.74 0.21 0.67 0.23\n\nSEU 0.75 0.09 0.67 0.11 0.53 0.12 0.47 0.12 0.31 0.12\n\nEEU 0.75 0.12 0.69 0.13 0.58 0.14 0.52 0.15 0.35 0.14\n\n**Insects**\n\nRegions\n\n1\\.5C GWL Std\n\n2C GWL Std\n\n2\\.7C GWL Std\n\n3\\.2C GWL Std\n\n4\\.5C GWL Std\n\nWCE 0.59 0.11 0.49 0.11 0.34 0.11 0.29 0.10 0.17 0.08\n\nNEU 0.90 0.14 0.86 0.18 0.76 0.25 0.72 0.28 0.58 0.34\n\nSEU 0.65 0.13 0.56 0.15 0.43 0.17 0.38 0.17 0.26 0.15\n\nEEU 0.72 0.15 0.64 0.18 0.49 0.20 0.42 0.21 0.25 0.19\n\n**Pollinator**\n\nRegions\n\n1\\.5C GWL Std\n\n2C GWL Std\n\n2\\.7C GWL Std\n\n3\\.2C GWL Std\n\n4\\.5C GWL Std\n\nWCE 0.59 0.14 0.50 0.15 0.39 0.15 0.35 0.14 0.26 0.11\n\nNEU 0.84 0.18 0.78 0.23 0.65 0.29 0.59 0.31 0.43 0.33\n\nSEU 0.75 0.13 0.69 0.14 0.57 0.16 0.52 0.16 0.38 0.15\n\nEEU 0.69 0.21 0.60 0.23 0.43 0.25 0.36 0.24 0.19 0.19\n\n**Amphibians**\n\nRegions\n\n1\\.5C GWL Std\n\n2C GWL Std\n\n2\\.7C GWL Std\n\n3\\.2C GWL Std\n\n4\\.5C GWL Std\n\nWCE 0.88 0.12 0.84 0.14 0.76 0.17 0.72 0.17 0.59 0.18\n\nNEU 0.89 0.24 0.91 0.16 0.87 0.19 0.84 0.21 0.76 0.25\n\nSEU 0.84 0.16 0.79 0.18 0.68 0.21 0.63 0.22 0.50 0.22\n\nEEU 0.83 0.29 0.86 0.20 0.78 0.24 0.75 0.25 0.63 0.30\n\n**Reptiles**\n\nRegions\n\n1\\.5C GWL Std\n\n2C GWL Std\n\n2\\.7C GWL Std\n\n3\\.2C GWL Std\n\n4\\.5C GWL Std\n\nWCE 0.89 0.09 0.86 0.10 0.80 0.11 0.77 0.11 0.67 0.13\n\nNEU 0.90 0.18 0.87 0.19 0.82 0.22 0.79 0.23 0.71 0.25\n\nSEU 0.89 0.10 0.85 0.12 0.76 0.15 0.72 0.15 0.58 0.15\n\nEEU 0.87 0.27 0.84 0.28 0.79 0.30 0.78 0.31 0.68 0.33\n\n**Birds**\n\nRegions\n\n1\\.5C GWL Std\n\n2C GWL Std\n\n2\\.7C GWL Std\n\n3\\.2C GWL Std\n\n4\\.5C GWL Std\n\nWCE 0.88 0.04 0.85 0.05 0.79 0.06 0.76 0.07 0.66 0.11\n\nNEU 0.93 0.13 0.92 0.12 0.90 0.12 0.88 0.13 0.83 0.16\n\nSEU 0.87 0.06 0.82 0.08 0.73 0.10 0.69 0.11 0.54 0.12\n\nEEU 0.86 0.14 0.84 0.15 0.79 0.16 0.77 0.16 0.69 0.18\n\n**Mammals**\n\nRegions\n\n1\\.5C GWL Std\n\n2C GWL Std\n\n2\\.7C GWL Std\n\n3\\.2C GWL Std\n\n4\\.5C GWL Std\n\nWCE 0.79 0.10 0.73 0.11 0.61 0.12 0.55 0.12 0.42 0.12\n\nNEU 0.90 0.11 0.87 0.12 0.81 0.16 0.77 0.17 0.63 0.23\n\nSEU 0.78 0.12 0.70 0.14 0.59 0.16 0.54 0.16 0.38 0.15\n\nEEU 0.80 0.16 0.75 0.19 0.65 0.20 0.60 0.19 0.44 0.16\n\n1 2 **SM13.3 Supplementary Material Supporting Section 13.4** 3 4 5 **Table SM13.4** : Literature sources used for assessment presented in Figure 13.11 6\n\n**Impact/Risk Supporting references of assessment**\n\nLoss of habitat availability\n\n(Coma et al., 2009; Garrabou et al., 2009; Huete-Stauffer et al., 2011; Munari, 2011; Kersting et al., 2013; Brodie et al., 2014; Frolov et al., 2014b; Rivetti et al., 2014; Altieri and Gedan, 2015; García Molinos et al., 2016; Spencer et al., 2016; Bakanev, 2017; Jessen et al., 2017; Orekhova, 2017; Berlinski and Popov, 2018; Buonomo et al., 2018; Jokinen et al., 2018; Reusch et al., 2018; Schuerch et al., 2018; van der Spek, 2018; Wang et al., 2018; Filatov et al., 2019; Garrabou et al., 2019; Saraiva et al., 2019; Spivak et al., 2019; D'Amen and Azzurro, 2020; Jiang et al., 2020; Pavlova, 2020; Sandø et al., 2020; Stepanyan, 2020)\n\n# ACCEPTED VERSION SUBJECT TO FINAL EDITS","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_006","product_type":"parse","source_file_path":"complex_header_006.pdf"},"started_at":"2026-11-12T14:55:36.620034"} {"completed_at":"2026-11-12T14:55:46.318609","latency_in_ms":1348,"output":{"example_id":"complex_table_headers/complex_header_008","grounded_pages":[],"layout_pages":[],"markdown":"**EXHIBIT 2: SUMMARY OF AVERAGE CLAIM TREND AND ADMINISTRATIVE EXPENSES INCLUDED IN CURRENT AND PRIOR RATE ADJUSTMENT FILINGS**\n\nHNY-IND Healthy NY\n\n1\\.\n\nMarket\n\nSegment\n\n2\\.\n\nDescription of\n\nrating pool within\n\nthe market segment\n\n**Company Name:** Oxford Health Plans (NY), Inc.\n\n**NAIC Code:** 95479\n\n**SERFF Number:** XFRD-128363086\n\nA. Complete a separate ROW for each market segment/rating pool combination included in the current rate adjustment filing:\n\n• Information should be for medical base plans and associated riders combined.\n\n• Use a separate row for each market segment/rating pool combination included in the current rate adjustment filing. • Append additional rows to the end of the existing rows as needed. Only use the first tab for data entry.\n\nB. The average claim trend is the average annualized claim trend for that market segment/rating pool used in the applicable rate adjustment\n\nfiling to project the source data forward to the applicable rating period (eg 10.0%).\n\nC. Enter the required information for the new rate period included in this rate adjustment filing. This refers to the various expense components\n\nincluded in the proposed rates and the average annual claim trend assumed.\n\nD. Enter the corresponding information requested for the immediately prior rate adjustment filing. This refers to the various expense components\n\nincluded in the proposed rates submitted with the immediately prior rate adjustment filing and the average claim trend assumed. If there is no immediately prior rate adjustment filing, enter the data from the initial form and rate filing.\n\nE. This form must be submitted as an Excel file and as a PDF file.\n\n18\\.\n\nPeriod\n\nassumed - beginning\n\ndate\n\n(MM/DD/Y\n\nY)\n\n19\\. Period assumed - ending date (MM/DD/YY)\n\n20\\.\n\nAverage annual claim trend\n\nassumed\n\n21\\.1\n\nRegulator y authority\n\nlicenses and fees, including New York State 332 assessme\n\nnt\n\nexpenses - as a % of\n\ngross\n\npremium\n\n21\\.2\n\nAdministra\n\ntive\n\nexpenses\n\nfor\n\nactivities\n\nthat\n\nimprove health care\n\nquality as defined in the NAIC Annual\n\nStatement Suppleme nt Health\n\nCare\n\nExhibit - as a % of\n\ngross\n\npremium\n\n21\\.3\n\nCommissi ons and broker\n\nfees - as a % of gross premium\n\n21\\.4\n\nPremium Taxes - as\n\na % of gross\n\npremium\n\n21\\.5 Other\n\nstate and\n\nfederal\n\ntaxes and assessme nts (other\n\nthan\n\nincome\n\ntaxes and covered\n\nlives\n\nassessme nt) - as a % of gross premium\n\n21\\.6 Other\n\nadministra\n\ntive\n\nexpenses - as a % of\n\ngross\n\npremium\n\n21\\.7\n\nSubtotal columns\n\n21\\.1\n\nthrough\n\n21\\.6\n\n22\\.\n\nAfter tax underwriti ng margin (profit/cont ribution to surplus) - as a % of\n\ngross\n\npremium\n\n23\\. State\n\nincome tax component -\n\nas a % of\n\ngross\n\npremium\n\n23\\.1\n\nState income tax rate assumed (eg 3%)\n\n24\\.\n\nFederal\n\nincome tax component - as a % of\n\ngross\n\npremium\n\n24\\.1 Federal income tax rate assumed (eg 30%)\n\n25\\.\n\nReduction\n\nfor\n\nassumed\n\nnet\n\ninvestment income - as\n\na % of gross\n\npremium (enter as a\n\nnegative\n\nvalue)\n\n26\\.\n\nSubtotal lines 21.7 + 22 + 23 + 24 + 25\n\n27\\.1\n\nRegulatory\n\nauthority\n\nlicenses and\n\nfees,\n\nincluding New York State 332\n\nassessment expenses - as $pmpm\n\n27\\.2\n\nAdministrati\n\nve\n\nexpenses\n\nfor activities that improve health care quality as defined in the NAIC Annual\n\nStatement Supplement Health Care Exhibit - as\n\n$pmpm\n\n27\\.3\n\nCommissi ons and broker\n\nfees - as $pmpm\n\n27\\.4\n\nPremium Taxes - as\n\n$pmpm\n\n27\\.5 Other\n\nstate and\n\nfederal\n\ntaxes and assessme nts (other\n\nthan\n\nincome\n\ntaxes and covered\n\nlives\n\nassessme\n\nnt) - as $pmpm\n\n27\\.6 Other\n\nadministra\n\ntive\n\nexpenses - as $pmpm\n\n27\\.7\n\nSubtotal lines 27.1 through\n\n27\\.6\n\n28\\.\n\nAfter tax underwriti ng margin\n\n(profit/\n\ncontributio\n\nn to\n\nsurplus) - as $pmpm\n\n29\\. State income\n\ntax\n\ncompone\n\nnt - as $pmpm\n\n30\\.\n\nFederal income\n\ntax\n\ncompone\n\nnt - as $pmpm\n\n31\\.\n\nReduction\n\nfor\n\nassumed\n\nnet\n\ninvestmen t income -\n\nas\n\n$pmpm (enter as a negative\n\nvalue)\n\n32\\.\n\nSubtotal columns\n\n27\\.7\n\nthrough\n\n31\n\nXX 1/1/2012 12/31/2012 15.2% 0.80% 0.00% 1.54% 2.71% 0.00% 6.16% 11.21% -1.21% 0.00% 7.10% 0.00% 34.00% 0.00% 10.00% 2.40 0.00 4.62 8.14 0.00 18.46 33.62 (3.64) 0.00 0.00 0.00 29.98\n\nXX 0.00% 0.00% 0.00 0.00\n\nXX 0.00% 0.00% 0.00 0.00\n\nXX 0.00% 0.00% 0.00 0.00\n\nXX 0.00% 0.00% 0.00 0.00\n\nXX 0.00% 0.00% 0.00 0.00\n\nXX 0.00% 0.00% 0.00 0.00\n\nXX 0.00% 0.00% 0.00 0.00\n\nXX 0.00% 0.00% 0.00 0.00\n\nXX 0.00% 0.00% 0.00 0.00\n\nXX 0.00% 0.00% 0.00 0.00\n\nXX 0.00% 0.00% 0.00 0.00\n\nXX 0.00% 0.00% 0.00 0.00\n\nXX 0.00% 0.00% 0.00 0.00\n\nXX 0.00% 0.00% 0.00 0.00\n\n**For the rate period included in the immediately prior rate adjustment filing (or initial form & rate filing)**\n\n• Enter a description of the rating pool within the indicated market segment. If the rating pools vary by rating region, the rating pool description should include a region identifier (eg., SG HMO Downstate, SG HMO Upstate).\n\n• Indicate the market segment the rating pool belongs to by using the drop down list. Market segment refers to Individual (IND), Small Group (SG), Sole Proprietor (SP), Large Group (LG), Individual Healthy NY (HNY-IND), Small Group Healthy NY (HNY-SG), Individual Medicare Supplement (MS-IND), Small Group Medicare Supplement (MS-SG), and Large Group Medicare Supplement (MS-LG). If the proposed percentage rate change for Sole Proprietor is different from Small Group, then a separate market segment of Sole Proprietor (SP) is to be reported; otherwise, use small group.\n\n**Data Item for Specified Rating Pool**\n\nExhibit 2 2 of 2 Last Revision: 5/18/2012","pages":[{"line_numbers":[],"markdown":"**EXHIBIT 2: SUMMARY OF AVERAGE CLAIM TREND AND ADMINISTRATIVE EXPENSES INCLUDED IN CURRENT AND PRIOR RATE ADJUSTMENT FILINGS**\n\nHNY-IND Healthy NY\n\n1\\.\n\nMarket\n\nSegment\n\n2\\.\n\nDescription of\n\nrating pool within\n\nthe market segment\n\n**Company Name:** Oxford Health Plans (NY), Inc.\n\n**NAIC Code:** 95479\n\n**SERFF Number:** XFRD-128363086\n\nA. Complete a separate ROW for each market segment/rating pool combination included in the current rate adjustment filing:\n\n• Information should be for medical base plans and associated riders combined.\n\n• Use a separate row for each market segment/rating pool combination included in the current rate adjustment filing. • Append additional rows to the end of the existing rows as needed. Only use the first tab for data entry.\n\nB. The average claim trend is the average annualized claim trend for that market segment/rating pool used in the applicable rate adjustment\n\nfiling to project the source data forward to the applicable rating period (eg 10.0%).\n\nC. Enter the required information for the new rate period included in this rate adjustment filing. This refers to the various expense components\n\nincluded in the proposed rates and the average annual claim trend assumed.\n\nD. Enter the corresponding information requested for the immediately prior rate adjustment filing. This refers to the various expense components\n\nincluded in the proposed rates submitted with the immediately prior rate adjustment filing and the average claim trend assumed. If there is no immediately prior rate adjustment filing, enter the data from the initial form and rate filing.\n\nE. This form must be submitted as an Excel file and as a PDF file.\n\n18\\.\n\nPeriod\n\nassumed - beginning\n\ndate\n\n(MM/DD/Y\n\nY)\n\n19\\. Period assumed - ending date (MM/DD/YY)\n\n20\\.\n\nAverage annual claim trend\n\nassumed\n\n21\\.1\n\nRegulator y authority\n\nlicenses and fees, including New York State 332 assessme\n\nnt\n\nexpenses - as a % of\n\ngross\n\npremium\n\n21\\.2\n\nAdministra\n\ntive\n\nexpenses\n\nfor\n\nactivities\n\nthat\n\nimprove health care\n\nquality as defined in the NAIC Annual\n\nStatement Suppleme nt Health\n\nCare\n\nExhibit - as a % of\n\ngross\n\npremium\n\n21\\.3\n\nCommissi ons and broker\n\nfees - as a % of gross premium\n\n21\\.4\n\nPremium Taxes - as\n\na % of gross\n\npremium\n\n21\\.5 Other\n\nstate and\n\nfederal\n\ntaxes and assessme nts (other\n\nthan\n\nincome\n\ntaxes and covered\n\nlives\n\nassessme nt) - as a % of gross premium\n\n21\\.6 Other\n\nadministra\n\ntive\n\nexpenses - as a % of\n\ngross\n\npremium\n\n21\\.7\n\nSubtotal columns\n\n21\\.1\n\nthrough\n\n21\\.6\n\n22\\.\n\nAfter tax underwriti ng margin (profit/cont ribution to surplus) - as a % of\n\ngross\n\npremium\n\n23\\. State\n\nincome tax component -\n\nas a % of\n\ngross\n\npremium\n\n23\\.1\n\nState income tax rate assumed (eg 3%)\n\n24\\.\n\nFederal\n\nincome tax component - as a % of\n\ngross\n\npremium\n\n24\\.1 Federal income tax rate assumed (eg 30%)\n\n25\\.\n\nReduction\n\nfor\n\nassumed\n\nnet\n\ninvestment income - as\n\na % of gross\n\npremium (enter as a\n\nnegative\n\nvalue)\n\n26\\.\n\nSubtotal lines 21.7 + 22 + 23 + 24 + 25\n\n27\\.1\n\nRegulatory\n\nauthority\n\nlicenses and\n\nfees,\n\nincluding New York State 332\n\nassessment expenses - as $pmpm\n\n27\\.2\n\nAdministrati\n\nve\n\nexpenses\n\nfor activities that improve health care quality as defined in the NAIC Annual\n\nStatement Supplement Health Care Exhibit - as\n\n$pmpm\n\n27\\.3\n\nCommissi ons and broker\n\nfees - as $pmpm\n\n27\\.4\n\nPremium Taxes - as\n\n$pmpm\n\n27\\.5 Other\n\nstate and\n\nfederal\n\ntaxes and assessme nts (other\n\nthan\n\nincome\n\ntaxes and covered\n\nlives\n\nassessme\n\nnt) - as $pmpm\n\n27\\.6 Other\n\nadministra\n\ntive\n\nexpenses - as $pmpm\n\n27\\.7\n\nSubtotal lines 27.1 through\n\n27\\.6\n\n28\\.\n\nAfter tax underwriti ng margin\n\n(profit/\n\ncontributio\n\nn to\n\nsurplus) - as $pmpm\n\n29\\. State income\n\ntax\n\ncompone\n\nnt - as $pmpm\n\n30\\.\n\nFederal income\n\ntax\n\ncompone\n\nnt - as $pmpm\n\n31\\.\n\nReduction\n\nfor\n\nassumed\n\nnet\n\ninvestmen t income -\n\nas\n\n$pmpm (enter as a negative\n\nvalue)\n\n32\\.\n\nSubtotal columns\n\n27\\.7\n\nthrough\n\n31\n\nXX 1/1/2012 12/31/2012 15.2% 0.80% 0.00% 1.54% 2.71% 0.00% 6.16% 11.21% -1.21% 0.00% 7.10% 0.00% 34.00% 0.00% 10.00% 2.40 0.00 4.62 8.14 0.00 18.46 33.62 (3.64) 0.00 0.00 0.00 29.98\n\nXX 0.00% 0.00% 0.00 0.00\n\nXX 0.00% 0.00% 0.00 0.00\n\nXX 0.00% 0.00% 0.00 0.00\n\nXX 0.00% 0.00% 0.00 0.00\n\nXX 0.00% 0.00% 0.00 0.00\n\nXX 0.00% 0.00% 0.00 0.00\n\nXX 0.00% 0.00% 0.00 0.00\n\nXX 0.00% 0.00% 0.00 0.00\n\nXX 0.00% 0.00% 0.00 0.00\n\nXX 0.00% 0.00% 0.00 0.00\n\nXX 0.00% 0.00% 0.00 0.00\n\nXX 0.00% 0.00% 0.00 0.00\n\nXX 0.00% 0.00% 0.00 0.00\n\nXX 0.00% 0.00% 0.00 0.00\n\n**For the rate period included in the immediately prior rate adjustment filing (or initial form & rate filing)**\n\n• Enter a description of the rating pool within the indicated market segment. If the rating pools vary by rating region, the rating pool description should include a region identifier (eg., SG HMO Downstate, SG HMO Upstate).\n\n• Indicate the market segment the rating pool belongs to by using the drop down list. Market segment refers to Individual (IND), Small Group (SG), Sole Proprietor (SP), Large Group (LG), Individual Healthy NY (HNY-IND), Small Group Healthy NY (HNY-SG), Individual Medicare Supplement (MS-IND), Small Group Medicare Supplement (MS-SG), and Large Group Medicare Supplement (MS-LG). If the proposed percentage rate change for Sole Proprietor is different from Small Group, then a separate market segment of Sole Proprietor (SP) is to be reported; otherwise, use small group.\n\n**Data Item for Specified Rating Pool**\n\nExhibit 2 2 of 2 Last Revision: 5/18/2012","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_008","product_type":"parse","source_file_path":"complex_header_008.pdf"},"started_at":"2026-11-12T14:55:44.970067"} {"completed_at":"2026-11-12T14:55:58.083268","latency_in_ms":2208,"output":{"example_id":"complex_table_headers/complex_header_013","grounded_pages":[],"layout_pages":[],"markdown":"### 46\n\n2024 ANNUAL REPORT & FINANCIAL STATEMENTS\n\n_Table 3.4: Sectoral Distribution of Banks’ Outstanding Credit_\n\n_Table 3.5: Sectoral Contribution to the Growth of GSE-CI_\n\n_F&B - Food & Beverages; Man - Manufacturing; Distr - Distribution; ETFund - Exchange Traded Fund; Educ - Education; AD. & Prod. - Advertising & Production_\n\n_F&B - Food & Beverages; Man - Manufacturing; Distr - Distribution; ETFund - Exchange Traded Fund; Educ - Education; AD. & Prod. - Advertising & Production_\n\n_Table 3.6: Sectorial Contribution to Market Capitalisation_\n\n**a Public Sector** **6,246.77 6,450.35 6,418.74 203.58 3.26 (31.61) (0.5)**\n\n**b Private Sector** **63,753.45 70,559.32 89,121.60 6,805.87 10.68 18,562.28 26.3**\n\nAgriculture, Forestry & Fisheries 2,664.02 2,884.60 4,495.79 220.58 8.28 1,611.19 55.9\n\nExport Trade 386.70 546.39 653.61 159.69 41.29 107.23 19.6\n\nManufacturing 7,129.87 8,051.85 9,970.79 921.98 12.93 1,918.94 23.8\n\nTransport, Storage & Communication 3,562.29 3,786.24 4,633.18 223.95 6.29 846.94 22.4\n\nMining & Quarrying 1,564.11 2,128.74 2,625.40 564.63 36.10 496.65 23.3\n\nImport Trade 2,092.13 4,815.32 8,396.67 2,723.19 130.16 3,581.35 74.37\n\nConstruction 6,454.74 6,844.49 7,692.85 389.75 6.04 848.36 12.39\n\nCommerce & Finance 11,513.42 11,467.06 15,627.62 -46.36 -0.40 4,160.56 36.28\n\nElectricity, Gas & Water 3,501.71 2,370.27 2,624.66 -1,131.45 -32.31 254.39 10.73\n\nServices 20,855.96 23,084.98 28,143.91 2,229.03 10.69 5,058.93 21.91\n\nMiscellaneous 4,028.50 4,579.38 4,257.12 550.87 13.67 -322.26 -7.04\n\n**c Grand Total 70,000.22 77,009.67 95,540.33 7,009.45 10.01 18,530.67 24.06**\n\n**abs abs per cent per cent Dec-22 Indicator Dec-23 Dec-24**\n\n**As at end-Dec 2023 As at end-Dec 2024**\n\n**Year-on-Year-Variations**\n\n**GH¢ Millions**\n\n**SECTORIAL CONTRIBUTION**\n\n**SECTORIAL CONTRIBUTION GSE-CI**\n\n**GH¢' Millions**\n\n**GH¢' Millions**\n\n**MARKET CAP.**\n\n**MONTH**\n\n**MONTH**\n\nDec-21 1250.50 613.36 2151.85 3000.37 135.22 40.24 1330.00 40.07 4.32 100.00 100.00 2,789.34\n\nDec-22 1204.74 434.73 2052.59 2632.42 159.17 31.90 1530.00 40.26 5028.82 100.01 100.00 2,443.91\n\nDec-23 1722.04 804.95 1901.57 3733.61 165.30 54.66 4400.00 40.58 5044.98 100.01 100.00 3,130.23\n\nDec-24 2535.00 1795.32 2380.79 4824.56 229.44 97.60 5052.00 40.83 9016.32 90.92 100.00 4,888.53\n\nDec-2023 ABS 517.30 370.22 -151.02 1101.19 6.13 22.75 2870.00 0.32 16.16 0.00 0.00 686.32\n\n(%) 42.94 85.16 -7.36 41.83 3.85 71.33 187.58 0.80 0.32 0.00 0.00 28.08\n\nDec-2024 ABS 812.96 990.36 479.22 1090.95 64.14 42.94 652.00 0.25 3971.34 -9.09 0.00 1,758.30\n\n(%) 47.21 123.03 25.20 29.22 38.80 78.57 14.82 0.60 78.72 -9.09 0.00 56.17\n\nDec-21 1074\\.05 440.48 14788.91 1289.20 15940.22 13643.45 231.42 17065.66 0.54 10.57 10.70 64,495.20\n\nDec-22 1034.74 312.20 14382.51 1131.10 18763.84 10816.64 266.22 17147.21 631.62 10.57 10.70 64,507.32\n\nDec-23 1479.04 578.07 13508.94 1604.26 19486.21 18531.66 765.60 17284.49 633.65 10.57 10.70 73,893.17\n\nDec-24 2177.29 1289.30 26257.11 2073.02 27047.13 33091.45 879.05 17388.99 1132.45 9.61 10.70 111,356.09\n\nDec-2023 ABS 444.31 265.87 -873.57 473.16 722.38 7715.02 499.38 137.27 2.03 0.00 0.00 9,385.85\n\n(%) 42.94 85.16 -6.07 41.83 3.85 71.33 187.58 0.80 0.32 0.00 0.00 14.55\n\nDec-2024 ABS 698.25 711.23 12748.17 468.76 7560.92 14559.79 113.45 104.51 498.80 -0.96 0.00 37,462.92\n\n(%) 47.21 123.03 94.37 29.22 38.80 78.57 14.82 0.60 78.72 -9.09 0.00 50.70\n\n**F&B**\n\n**F&B**\n\n**MAN**\n\n**MAN**\n\n**OIL**\n\n**OIL**\n\n**EDUC**\n\n**EDUC**\n\n**VALUE**\n\n**TOTAL**\n\n**ETFund**\n\n**ETFund**\n\n**AD. & PROD.**\n\n**AD. & PROD.**\n\n**IT**\n\n**IT**\n\n**FINANCE**\n\n**FINANCE**\n\n**DISTR**\n\n**DISTR**\n\n**AGRIC**\n\n**AGRIC**\n\n**MINING**\n\n**MINING**\n\n_Source: Bank of Ghana_\n\n_Source: Ghana Stock Exchange_\n\n_Source: Ghana Stock Exchange_\n\n**Year-on-Year-Variations**\n\n**Year-on-Year-Variations**","pages":[{"line_numbers":[],"markdown":"### 46\n\n2024 ANNUAL REPORT & FINANCIAL STATEMENTS\n\n_Table 3.4: Sectoral Distribution of Banks’ Outstanding Credit_\n\n_Table 3.5: Sectoral Contribution to the Growth of GSE-CI_\n\n_F&B - Food & Beverages; Man - Manufacturing; Distr - Distribution; ETFund - Exchange Traded Fund; Educ - Education; AD. & Prod. - Advertising & Production_\n\n_F&B - Food & Beverages; Man - Manufacturing; Distr - Distribution; ETFund - Exchange Traded Fund; Educ - Education; AD. & Prod. - Advertising & Production_\n\n_Table 3.6: Sectorial Contribution to Market Capitalisation_\n\n**a Public Sector** **6,246.77 6,450.35 6,418.74 203.58 3.26 (31.61) (0.5)**\n\n**b Private Sector** **63,753.45 70,559.32 89,121.60 6,805.87 10.68 18,562.28 26.3**\n\nAgriculture, Forestry & Fisheries 2,664.02 2,884.60 4,495.79 220.58 8.28 1,611.19 55.9\n\nExport Trade 386.70 546.39 653.61 159.69 41.29 107.23 19.6\n\nManufacturing 7,129.87 8,051.85 9,970.79 921.98 12.93 1,918.94 23.8\n\nTransport, Storage & Communication 3,562.29 3,786.24 4,633.18 223.95 6.29 846.94 22.4\n\nMining & Quarrying 1,564.11 2,128.74 2,625.40 564.63 36.10 496.65 23.3\n\nImport Trade 2,092.13 4,815.32 8,396.67 2,723.19 130.16 3,581.35 74.37\n\nConstruction 6,454.74 6,844.49 7,692.85 389.75 6.04 848.36 12.39\n\nCommerce & Finance 11,513.42 11,467.06 15,627.62 -46.36 -0.40 4,160.56 36.28\n\nElectricity, Gas & Water 3,501.71 2,370.27 2,624.66 -1,131.45 -32.31 254.39 10.73\n\nServices 20,855.96 23,084.98 28,143.91 2,229.03 10.69 5,058.93 21.91\n\nMiscellaneous 4,028.50 4,579.38 4,257.12 550.87 13.67 -322.26 -7.04\n\n**c Grand Total 70,000.22 77,009.67 95,540.33 7,009.45 10.01 18,530.67 24.06**\n\n**abs abs per cent per cent Dec-22 Indicator Dec-23 Dec-24**\n\n**As at end-Dec 2023 As at end-Dec 2024**\n\n**Year-on-Year-Variations**\n\n**GH¢ Millions**\n\n**SECTORIAL CONTRIBUTION**\n\n**SECTORIAL CONTRIBUTION GSE-CI**\n\n**GH¢' Millions**\n\n**GH¢' Millions**\n\n**MARKET CAP.**\n\n**MONTH**\n\n**MONTH**\n\nDec-21 1250.50 613.36 2151.85 3000.37 135.22 40.24 1330.00 40.07 4.32 100.00 100.00 2,789.34\n\nDec-22 1204.74 434.73 2052.59 2632.42 159.17 31.90 1530.00 40.26 5028.82 100.01 100.00 2,443.91\n\nDec-23 1722.04 804.95 1901.57 3733.61 165.30 54.66 4400.00 40.58 5044.98 100.01 100.00 3,130.23\n\nDec-24 2535.00 1795.32 2380.79 4824.56 229.44 97.60 5052.00 40.83 9016.32 90.92 100.00 4,888.53\n\nDec-2023 ABS 517.30 370.22 -151.02 1101.19 6.13 22.75 2870.00 0.32 16.16 0.00 0.00 686.32\n\n(%) 42.94 85.16 -7.36 41.83 3.85 71.33 187.58 0.80 0.32 0.00 0.00 28.08\n\nDec-2024 ABS 812.96 990.36 479.22 1090.95 64.14 42.94 652.00 0.25 3971.34 -9.09 0.00 1,758.30\n\n(%) 47.21 123.03 25.20 29.22 38.80 78.57 14.82 0.60 78.72 -9.09 0.00 56.17\n\nDec-21 1074\\.05 440.48 14788.91 1289.20 15940.22 13643.45 231.42 17065.66 0.54 10.57 10.70 64,495.20\n\nDec-22 1034.74 312.20 14382.51 1131.10 18763.84 10816.64 266.22 17147.21 631.62 10.57 10.70 64,507.32\n\nDec-23 1479.04 578.07 13508.94 1604.26 19486.21 18531.66 765.60 17284.49 633.65 10.57 10.70 73,893.17\n\nDec-24 2177.29 1289.30 26257.11 2073.02 27047.13 33091.45 879.05 17388.99 1132.45 9.61 10.70 111,356.09\n\nDec-2023 ABS 444.31 265.87 -873.57 473.16 722.38 7715.02 499.38 137.27 2.03 0.00 0.00 9,385.85\n\n(%) 42.94 85.16 -6.07 41.83 3.85 71.33 187.58 0.80 0.32 0.00 0.00 14.55\n\nDec-2024 ABS 698.25 711.23 12748.17 468.76 7560.92 14559.79 113.45 104.51 498.80 -0.96 0.00 37,462.92\n\n(%) 47.21 123.03 94.37 29.22 38.80 78.57 14.82 0.60 78.72 -9.09 0.00 50.70\n\n**F&B**\n\n**F&B**\n\n**MAN**\n\n**MAN**\n\n**OIL**\n\n**OIL**\n\n**EDUC**\n\n**EDUC**\n\n**VALUE**\n\n**TOTAL**\n\n**ETFund**\n\n**ETFund**\n\n**AD. & PROD.**\n\n**AD. & PROD.**\n\n**IT**\n\n**IT**\n\n**FINANCE**\n\n**FINANCE**\n\n**DISTR**\n\n**DISTR**\n\n**AGRIC**\n\n**AGRIC**\n\n**MINING**\n\n**MINING**\n\n_Source: Bank of Ghana_\n\n_Source: Ghana Stock Exchange_\n\n_Source: Ghana Stock Exchange_\n\n**Year-on-Year-Variations**\n\n**Year-on-Year-Variations**","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_013","product_type":"parse","source_file_path":"complex_header_013.pdf"},"started_at":"2026-11-12T14:55:55.875140"} {"completed_at":"2026-11-12T14:56:05.771138","latency_in_ms":2483,"output":{"example_id":"complex_table_headers/complex_header_014","grounded_pages":[],"layout_pages":[],"markdown":"**COLORADO**\n\nEFFECTIVE 1/1/2026\n\n**CLASS FARM: POULTRY OR EGG PRODUCER & DRIVERS**\n\n**0034**\n\nIndustry Group: Goods and Services CONVERTED LOSSES\n\nHazard Group: D INDEMNITY LIKELY INDEMNITY NOT-LIKELY MED LIKELY MED NOT-LIKELY TOTAL TOTAL\n\nPOLICY PERIOD PAYROLL CASES AMOUNT CASES AMOUNT AMOUNT AMOUNT AMOUNT PURE PREM.\n\n3/18 through 2/19 14,448,797 0 0 14 155,528 0 194,420 349,948 2.422\n\n3/19 through 2/20 17,615,203 2 82,335 6 35,868 50,950 85,546 254,699 1.446\n\n3/20 through 2/21 17,172,385 6 287,460 11 248,762 170,700 211,880 918,802 5.351\n\n3/21 through 2/22 18,522,883 0 0 8 97,842 0 176,515 274,357 1.481\n\n3/22 through 2/23 17,213,995 0 0 7 66,407 0 122,457 188,864 1.097\n\n5 YR. TOTAL 84,973,263 8 369,795 46 604,407 221,650 790,818 1,986,670 2.338\n\nINDEMNITY MEDICAL TOTAL\n\nCRED. PURE PREM.\\* CRED. PURE PREM.\\* PURE PREM.\\*\n\nIndicated Pure Premium 14% 1.1465 23% 1.1915 2.338\n\nPure Premium Indicated by National Relativity 43% 0.7688 38% 0.9341 1.703\n\nPure Premium Present on Rate Level 43% 0.8371 39% 1.2195 2.057\n\nPure Premium Derived by Formula 0.8510 1.1046 1.956\n\n**CLASS FARM: FLORIST & DRIVERS**\n\n**0035**\n\nIndustry Group: Goods and Services CONVERTED LOSSES\n\nHazard Group: D INDEMNITY LIKELY INDEMNITY NOT-LIKELY MED LIKELY MED NOT-LIKELY TOTAL TOTAL\n\nPOLICY PERIOD PAYROLL CASES AMOUNT CASES AMOUNT AMOUNT AMOUNT AMOUNT PURE PREM.\n\n3/18 through 2/19 214,102,263 3 268,971 49 629,885 173,661 1,063,949 2,136,466 0.998\n\n3/19 through 2/20 242,659,857 3 198,020 62 479,412 161,684 952,290 1,791,406 0.738\n\n3/20 through 2/21 259,761,420 5 155,524 66 1,066,969 82,868 1,221,121 2,526,482 0.973\n\n3/21 through 2/22 265,113,787 7 618,719 51 742,697 280,278 838,807 2,480,501 0.936\n\n3/22 through 2/23 244,829,051 1 67,362 35 410,754 19,129 710,353 1,207,598 0.493\n\n5 YR. TOTAL 1,226,466,378 19 1,308,596 263 3,329,717 717,620 4,786,520 10,142,453 0.827\n\nINDEMNITY MEDICAL TOTAL\n\nCRED. PURE PREM.\\* CRED. PURE PREM.\\* PURE PREM.\\*\n\nIndicated Pure Premium 37% 0.3782 61% 0.4488 0.827\n\nPure Premium Indicated by National Relativity 31% 0.4510 19% 0.5998 1.051\n\nPure Premium Present on Rate Level 32% 0.4148 20% 0.5759 0.991\n\nPure Premium Derived by Formula 0.4125 0.5029 0.915\n\n**CLASS FARM: DAIRY & DRIVERS**\n\n**0036**\n\nIndustry Group: Goods and Services CONVERTED LOSSES\n\nHazard Group: C INDEMNITY LIKELY INDEMNITY NOT-LIKELY MED LIKELY MED NOT-LIKELY TOTAL TOTAL\n\nPOLICY PERIOD PAYROLL CASES AMOUNT CASES AMOUNT AMOUNT AMOUNT AMOUNT PURE PREM.\n\n3/18 through 2/19 109,652,290 6 129,474 94 1,934,119 455,697 1,633,340 4,152,630 3.787\n\n3/19 through 2/20 117,756,455 5 229,905 84 1,322,034 173,403 1,090,981 2,816,323 2.392\n\n3/20 through 2/21 122,441,692 6 383,699 92 1,519,717 165,669 1,270,153 3,339,238 2.727\n\n3/21 through 2/22 129,200,025 7 739,010 71 900,612 631,056 1,100,805 3,371,483 2.610\n\n3/22 through 2/23 135,945,696 7 525,647 69 792,757 304,410 1,157,147 2,779,961 2.045\n\n5 YR. TOTAL 614,996,158 31 2,007,735 410 6,469,239 1,730,235 6,252,426 16,459,635 2.676\n\nINDEMNITY MEDICAL TOTAL\n\nCRED. PURE PREM.\\* CRED. PURE PREM.\\* PURE PREM.\\*\n\nIndicated Pure Premium 45% 1.3784 65% 1.2980 2.676\n\nPure Premium Indicated by National Relativity 27% 1.1084 17% 1.0676 2.176\n\nPure Premium Present on Rate Level 28% 1.2661 18% 1.3202 2.586\n\nPure Premium Derived by Formula 1.2741 1.2628 2.537\n\nThe pure premiums shown were calculated using unrounded losses, while the converted losses have been rounded for display purposes.\n\nPage 2","pages":[{"line_numbers":[],"markdown":"**COLORADO**\n\nEFFECTIVE 1/1/2026\n\n**CLASS FARM: POULTRY OR EGG PRODUCER & DRIVERS**\n\n**0034**\n\nIndustry Group: Goods and Services CONVERTED LOSSES\n\nHazard Group: D INDEMNITY LIKELY INDEMNITY NOT-LIKELY MED LIKELY MED NOT-LIKELY TOTAL TOTAL\n\nPOLICY PERIOD PAYROLL CASES AMOUNT CASES AMOUNT AMOUNT AMOUNT AMOUNT PURE PREM.\n\n3/18 through 2/19 14,448,797 0 0 14 155,528 0 194,420 349,948 2.422\n\n3/19 through 2/20 17,615,203 2 82,335 6 35,868 50,950 85,546 254,699 1.446\n\n3/20 through 2/21 17,172,385 6 287,460 11 248,762 170,700 211,880 918,802 5.351\n\n3/21 through 2/22 18,522,883 0 0 8 97,842 0 176,515 274,357 1.481\n\n3/22 through 2/23 17,213,995 0 0 7 66,407 0 122,457 188,864 1.097\n\n5 YR. TOTAL 84,973,263 8 369,795 46 604,407 221,650 790,818 1,986,670 2.338\n\nINDEMNITY MEDICAL TOTAL\n\nCRED. PURE PREM.\\* CRED. PURE PREM.\\* PURE PREM.\\*\n\nIndicated Pure Premium 14% 1.1465 23% 1.1915 2.338\n\nPure Premium Indicated by National Relativity 43% 0.7688 38% 0.9341 1.703\n\nPure Premium Present on Rate Level 43% 0.8371 39% 1.2195 2.057\n\nPure Premium Derived by Formula 0.8510 1.1046 1.956\n\n**CLASS FARM: FLORIST & DRIVERS**\n\n**0035**\n\nIndustry Group: Goods and Services CONVERTED LOSSES\n\nHazard Group: D INDEMNITY LIKELY INDEMNITY NOT-LIKELY MED LIKELY MED NOT-LIKELY TOTAL TOTAL\n\nPOLICY PERIOD PAYROLL CASES AMOUNT CASES AMOUNT AMOUNT AMOUNT AMOUNT PURE PREM.\n\n3/18 through 2/19 214,102,263 3 268,971 49 629,885 173,661 1,063,949 2,136,466 0.998\n\n3/19 through 2/20 242,659,857 3 198,020 62 479,412 161,684 952,290 1,791,406 0.738\n\n3/20 through 2/21 259,761,420 5 155,524 66 1,066,969 82,868 1,221,121 2,526,482 0.973\n\n3/21 through 2/22 265,113,787 7 618,719 51 742,697 280,278 838,807 2,480,501 0.936\n\n3/22 through 2/23 244,829,051 1 67,362 35 410,754 19,129 710,353 1,207,598 0.493\n\n5 YR. TOTAL 1,226,466,378 19 1,308,596 263 3,329,717 717,620 4,786,520 10,142,453 0.827\n\nINDEMNITY MEDICAL TOTAL\n\nCRED. PURE PREM.\\* CRED. PURE PREM.\\* PURE PREM.\\*\n\nIndicated Pure Premium 37% 0.3782 61% 0.4488 0.827\n\nPure Premium Indicated by National Relativity 31% 0.4510 19% 0.5998 1.051\n\nPure Premium Present on Rate Level 32% 0.4148 20% 0.5759 0.991\n\nPure Premium Derived by Formula 0.4125 0.5029 0.915\n\n**CLASS FARM: DAIRY & DRIVERS**\n\n**0036**\n\nIndustry Group: Goods and Services CONVERTED LOSSES\n\nHazard Group: C INDEMNITY LIKELY INDEMNITY NOT-LIKELY MED LIKELY MED NOT-LIKELY TOTAL TOTAL\n\nPOLICY PERIOD PAYROLL CASES AMOUNT CASES AMOUNT AMOUNT AMOUNT AMOUNT PURE PREM.\n\n3/18 through 2/19 109,652,290 6 129,474 94 1,934,119 455,697 1,633,340 4,152,630 3.787\n\n3/19 through 2/20 117,756,455 5 229,905 84 1,322,034 173,403 1,090,981 2,816,323 2.392\n\n3/20 through 2/21 122,441,692 6 383,699 92 1,519,717 165,669 1,270,153 3,339,238 2.727\n\n3/21 through 2/22 129,200,025 7 739,010 71 900,612 631,056 1,100,805 3,371,483 2.610\n\n3/22 through 2/23 135,945,696 7 525,647 69 792,757 304,410 1,157,147 2,779,961 2.045\n\n5 YR. TOTAL 614,996,158 31 2,007,735 410 6,469,239 1,730,235 6,252,426 16,459,635 2.676\n\nINDEMNITY MEDICAL TOTAL\n\nCRED. PURE PREM.\\* CRED. PURE PREM.\\* PURE PREM.\\*\n\nIndicated Pure Premium 45% 1.3784 65% 1.2980 2.676\n\nPure Premium Indicated by National Relativity 27% 1.1084 17% 1.0676 2.176\n\nPure Premium Present on Rate Level 28% 1.2661 18% 1.3202 2.586\n\nPure Premium Derived by Formula 1.2741 1.2628 2.537\n\nThe pure premiums shown were calculated using unrounded losses, while the converted losses have been rounded for display purposes.\n\nPage 2","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_014","product_type":"parse","source_file_path":"complex_header_014.pdf"},"started_at":"2026-11-12T14:56:03.287466"} {"completed_at":"2026-11-12T14:56:10.678745","latency_in_ms":2054,"output":{"example_id":"complex_table_headers/complex_header_017","grounded_pages":[],"layout_pages":[],"markdown":"JB10101010 Order No. 3456789\n\nNovember 2023\n\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 Total\n\nContract\n\nRate Total\n\nEmp No.\n\nVantage\n\nNo. Name Discipline\n\nWed\n\nThurs\n\nFri\n\nSat\n\nSun\n\nMon\n\nTues\n\nWed\n\nThurs\n\nFri\n\nSat\n\nSun\n\nMon\n\nTues\n\nWed\n\nThurs\n\nFri\n\nSat\n\nSun\n\nMon\n\nTues\n\nWed\n\nThurs\n\nFri\n\nSat\n\nSun\n\nMon\n\nTues\n\nWed\n\nThurs\n\nOnshore Labour\n\n12345\n\nJohn Doe\n\nPlatform engineering- day 1 1 1 1 1 1 1 1 1 1 1 3 1 1 1 1 1 19 450.50 8559.50\n\n12345\n\nJohn Doe Overtime 1 1 1 1 1 1 1 1 2 2 1 13 450.50 5856.50\n\n12344\n\nJane Doe\n\nPlatform engineering- day 1 1 1 1 1 1 1 1 1 1 1 1 1 1 14 450.50 6307.00\n\n12345\n\nJohn Doe\n\nPlatform engineering- day 1 1 1 1 1 1 1 1 1 1 1 3 1 1 1 1 1 19 450.50 8559.50\n\n12345\n\nJohn Doe Overtime 1 1 1 1 1 1 1 1 2 2 1 13 450.50 5856.50\n\n12344\n\nJane Doe\n\nPlatform engineering- day 1 1 1 1 1 1 1 1 1 1 1 1 1 1 14 450.50 6307.00\n\n12345\n\nJohn Doe\n\nPlatform engineering- day 1 1 1 1 1 1 1 1 1 1 1 3 1 1 1 1 1 19 450.50 8559.50\n\n12345\n\nJohn Doe Overtime 1 1 1 1 1 1 1 1 2 2 1 13 450.50 5856.50\n\n12344\n\nJane Doe\n\nPlatform engineering- day 1 1 1 1 1 1 1 1 1 1 1 1 1 1 14 450.50 6307.00\n\n**£62,169.00**\n\nOffshore Labour\n\n54321\n\nJack Willis\n\nSoftware engineering - night 1 1 1 1 1 1 1 1 2 2 1 13 450.50 5856.50\n\n54321\n\nJack Willis Overtime 1 1 1 1 1 1 1 1 1 1 1 1 1 1 14 450.50 6307.00\n\n54322\n\nJane Willis\n\nSoftware engineering - night 1 1 1 1 1 1 1 1 1 1 1 3 1 1 1 1 1 19 450.50 8559.50\n\n54322\n\nJane WIllis Overtime 1 1 1 1 1 1 1 1 1 1 1 1 1 1 14 450.50 6307.00\n\n**£109,922.00**\n\nElectricals\n\n6345\n\nZaki Pauzi\n\nHardware maintenance 1 1 1 1 1 1 1 3 1 1 1 13 234.34 3046.42\n\n6345\n\nZaki Pauzi Overtime 6 6 34.30 205.80\n\n6344\n\nJane Doe\n\nHardware maintenance 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 1 2 28 256.65 7186.20\n\n6345\n\nZaki Pauzi\n\nHardware maintenance 1 2 1 2 1 2 1 2 1 2 1 2 1 2 3 1 2 1 2 30 43.54 1306.20\n\n6345\n\nZaki Pauzi Overtime 1 1 2 1 1 2 1 1 2 1 1 2 1 1 2 1 1 2 6 1 1 2 1 1 2 1 1 1 2 43 234.34 10076.62","pages":[{"line_numbers":[],"markdown":"JB10101010 Order No. 3456789\n\nNovember 2023\n\n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 Total\n\nContract\n\nRate Total\n\nEmp No.\n\nVantage\n\nNo. Name Discipline\n\nWed\n\nThurs\n\nFri\n\nSat\n\nSun\n\nMon\n\nTues\n\nWed\n\nThurs\n\nFri\n\nSat\n\nSun\n\nMon\n\nTues\n\nWed\n\nThurs\n\nFri\n\nSat\n\nSun\n\nMon\n\nTues\n\nWed\n\nThurs\n\nFri\n\nSat\n\nSun\n\nMon\n\nTues\n\nWed\n\nThurs\n\nOnshore Labour\n\n12345\n\nJohn Doe\n\nPlatform engineering- day 1 1 1 1 1 1 1 1 1 1 1 3 1 1 1 1 1 19 450.50 8559.50\n\n12345\n\nJohn Doe Overtime 1 1 1 1 1 1 1 1 2 2 1 13 450.50 5856.50\n\n12344\n\nJane Doe\n\nPlatform engineering- day 1 1 1 1 1 1 1 1 1 1 1 1 1 1 14 450.50 6307.00\n\n12345\n\nJohn Doe\n\nPlatform engineering- day 1 1 1 1 1 1 1 1 1 1 1 3 1 1 1 1 1 19 450.50 8559.50\n\n12345\n\nJohn Doe Overtime 1 1 1 1 1 1 1 1 2 2 1 13 450.50 5856.50\n\n12344\n\nJane Doe\n\nPlatform engineering- day 1 1 1 1 1 1 1 1 1 1 1 1 1 1 14 450.50 6307.00\n\n12345\n\nJohn Doe\n\nPlatform engineering- day 1 1 1 1 1 1 1 1 1 1 1 3 1 1 1 1 1 19 450.50 8559.50\n\n12345\n\nJohn Doe Overtime 1 1 1 1 1 1 1 1 2 2 1 13 450.50 5856.50\n\n12344\n\nJane Doe\n\nPlatform engineering- day 1 1 1 1 1 1 1 1 1 1 1 1 1 1 14 450.50 6307.00\n\n**£62,169.00**\n\nOffshore Labour\n\n54321\n\nJack Willis\n\nSoftware engineering - night 1 1 1 1 1 1 1 1 2 2 1 13 450.50 5856.50\n\n54321\n\nJack Willis Overtime 1 1 1 1 1 1 1 1 1 1 1 1 1 1 14 450.50 6307.00\n\n54322\n\nJane Willis\n\nSoftware engineering - night 1 1 1 1 1 1 1 1 1 1 1 3 1 1 1 1 1 19 450.50 8559.50\n\n54322\n\nJane WIllis Overtime 1 1 1 1 1 1 1 1 1 1 1 1 1 1 14 450.50 6307.00\n\n**£109,922.00**\n\nElectricals\n\n6345\n\nZaki Pauzi\n\nHardware maintenance 1 1 1 1 1 1 1 3 1 1 1 13 234.34 3046.42\n\n6345\n\nZaki Pauzi Overtime 6 6 34.30 205.80\n\n6344\n\nJane Doe\n\nHardware maintenance 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 1 2 28 256.65 7186.20\n\n6345\n\nZaki Pauzi\n\nHardware maintenance 1 2 1 2 1 2 1 2 1 2 1 2 1 2 3 1 2 1 2 30 43.54 1306.20\n\n6345\n\nZaki Pauzi Overtime 1 1 2 1 1 2 1 1 2 1 1 2 1 1 2 1 1 2 6 1 1 2 1 1 2 1 1 1 2 43 234.34 10076.62","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_017","product_type":"parse","source_file_path":"complex_header_017.pdf"},"started_at":"2026-11-12T14:56:08.624335"} {"completed_at":"2026-11-12T14:56:17.639664","latency_in_ms":1353,"output":{"example_id":"complex_table_headers/complex_header_018","grounded_pages":[],"layout_pages":[],"markdown":"# WA Exhibit 10: Summarized Risk Adjustment (RA)\n\n### Carrier Name: Market: Rate Filing Plan Year: Experience Period Year:\n\n**ACTUAL EXPERIENCE, 2024 PROJECTED (i.e., EXPECTED), 2026 PROJECTED (i.e., EXPECTED), 2026 versus ACTUAL EXPERIENCE, 2024**\n\nCarrier Carrier Carrier Carrier Carrier Carrier\n\nDescription Description\n\nBillable Member Months (MM) 6,183 6,183 - 864 1,645 3,674 - Billable Member Months (MM) 262,536 262,536 - 99,456 54,708 108,372 - 42.462 42.462 115.121 33.256 29.498\n\nActuarial Value (AV) 0.686 0.654552522 0.900 0.800 0.700 0.600 0.570 0.570 Actuarial Value (AV) 0.686 0.697 0.900 0.800 0.700 0.600 0.000 0.000 1.000 1.064 1.000 1.000 1.000 1.000 - -\n\nPlan Liability Risk Score (PLRS) 1.292 2.091 0.000 4.604 3.401 0.914 0.000 0.000 Plan Liability Risk Score (PLRS) 1.344 1.562 0.000 2.134 1.785 0.924 0.000 0.000 1.040 0.747 0.464 0.525 1.011\n\nAllowable Rating Factor (ARF) 1.711 1.776 0.000 1.538 1.754 1.842 0.000 0.000 Allowable Rating Factor (ARF) 1.711 1.732 0.000 1.680 1.667 1.811 0.000 0.000 1.000 0.975 1.093 0.951 0.983\n\nInduced Demand Factor (IDF) 1.030 1.019 0.000 1.080 1.030 1.000 0.000 0.000 Induced Demand Factor (IDF) 1.030 1.037 0.000 1.080 1.030 1.000 0.000 0.000 1.000 1.017 1.000 1.000 1.000\n\nGeographic Cost Factor (GCF) 1.000 1.005 0.000 0.980 1.014 1.007 0.000 0.000 Geographic Cost Factor (GCF) 1.000 1.002 0.000 1.001 1.002 1.004 0.000 0.000 1.000 0.997 1.022 0.989 0.996\n\nStatewide Average Premium (SWAP) PMPM Starting SWAP PMPM $590.07 $0.00\n\nTrend from 2024 to 2025 6.61% 0.00%\n\nTrend from 2025 to 2026 17.06% 0.00%\n\nFinal SWAP PMPM (before 86% adjustment is applied) $590.07 $0.00 Final SWAP PMPM (before 86% adjustment is applied) $736.41 $0.00 1.248\n\nPlan Liability Component approximation = PLRS \\* IDF \\* GCF 1.331 2.143 0.000 4.870 3.551 0.921 0.000 0.000 Plan Liability Component approximation = PLRS \\* IDF \\* GCF 1.384 1.623 0.000 2.307 1.843 0.928 0.000 0.000 1.040 0.757 0.474 0.519 1.007\n\nNormalized PLRS \\* IDF \\* GCF (N1) 1.610 0.000 3.659 2.668 0.692 TBD Normalized PLRS \\* IDF \\* GCF (N1) 1.173 0.000 1.667 1.332 0.670 TBD 0.728 0.455 0.499 0.968\n\nAllowable Rating Component approximation = AV \\* ARF \\* IDF \\* GCF 1.210 1.191 0.000 1.302 1.282 1.114 0.000 0.000 Allowable Rating Component approximation = AV \\* ARF \\* IDF \\* GCF 1.210 1.253 0.000 1.453 1.205 1.091 0.000 0.000 1.000 1.052 1.116 0.940 0.979\n\nNormalized AV \\* PLRS \\* IDF \\* GCF (N2) 0.985 0.000 1.076 1.060 0.920 TBD Normalized AV \\* PLRS \\* IDF \\* GCF (N2) 1.036 0.000 1.201 0.996 0.901 TBD 1.052 1.116 0.940 0.979\n\nApproximate Transfer PMPM (P \\* [N1 - N2] \\* 0.86) **$317.36** $0.00 $1,311.04 $816.27 ($115.84) TBD Approximate Transfer PMPM (P \\* [N1 - N2] \\* 0.86) **$86.65** $0.00 $294.99 $212.62 ($146.37) TBD **0\\.273** 0\\.225 0.260 1.264\n\nApproximate Aggregate Transfer (Transfer PMPM \\* MM) **$1,962,195** $0 $1,132,644 $1,342,801 ($425,565) TBD Approximate Aggregate Transfer (Transfer PMPM \\* MM) **$22,747,580** $0 $29,338,778 $11,632,156 ($15,862,566) TBD **11\\.593** 25\\.903 8.663 37.274\n\nAggregate Experience RA Transfer PMPM 331.542608 $331.54 $0.00 $1,311.04 $816.27 -$115.84 $0.00 Aggregate Projected (Rate Development) RA Transfer PMPM 95.63780935 $95.64 $0.00 $294.99 $212.62 -$146.37 $0.00 0.288 0.288 0.225 0.260 1.264\n\nTransfer PMPM Difference $14.18 $0.00 $0.00 $0.00 $0.00 TBD Transfer PMPM Difference $8.99 $0.00 $0.00 $0.00 $0.00 TBD 0.634 - 0.100 0.158\n\nHCRP assessment PMPM (amounts should be negative) -$2.60 -$2.60 $0.00 -$2.60 -$2.60 -$2.60 $0.00 HCRP assessment PMPM (amounts should be negative) -$5.30 -$5.30 $0.00 -$5.30 -$5.30 -$5.30 $0.00 2.038 2.038 2.038 2.038 2.038\n\nHCRP receipts PMPM (amounts should be positive) $14.04 $14.04 $0.00 $14.04 $14.04 $14.04 $0.00 HCRP receipts PMPM (amounts should be positive) $5.30 $5.30 $0.00 $5.30 $5.30 $5.30 $0.00 0.378 0.378 0.378 0.378 0.378\n\nRADV adjustment PMPM, if applicable $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 RADV adjustment PMPM, if applicable $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00\n\nFinal Risk Adjustment PMPM $342.98 $342.98 $0.00 $1,322.47 $827.70 -$104.40 $0.00 Final Risk Adjustment PMPM $95.64 $95.64 $0.00 $294.99 $212.62 -$146.37 $0.00 0.279 0.279 0.223 0.257 1.402\n\n**PROJECTED (i.e., EXPECTED), 2024 ACTUAL EXPERIENCE, 2024 versus PROJECTED (i.e., EXPECTED), 2024**\n\nCarrier Carrier Carrier Carrier\n\nDescription Billable Member Months (MM) 13,104 13,104 - 888 3,084 9,132 - 0.472 0.472 0.973 0.533 0.402\n\nActuarial Value (AV) 0.670 0.637 0.900 0.800 0.700 0.600 0.000 0.000 1.025 1.027 1.000 1.000 1.000 1.000\n\nPlan Liability Risk Score (PLRS) 1.323 1.425 0.000 2.959 2.346 0.964 0.000 0.000 0.977 1.468 1.556 1.450 0.948\n\nAllowable Rating Factor (ARF) 1.763 1.829 0.000 1.616 1.792 1.863 0.000 0.000 0.971 0.971 0.952 0.979 0.989\n\nInduced Demand Factor (IDF) 1.024 1.012 0.000 1.080 1.030 1.000 0.000 0.000 1.006 1.007 1.000 1.000 1.000\n\nGeographic Cost Factor (GCF) 1.000 1.011 0.000 1.007 1.016 1.010 0.000 0.000 1.000 0.994 0.973 0.998 0.998\n\nStatewide Average Premium (SWAP) PMPM Starting SWAP PMPM $537.44 $0.00\n\nTrend from 2022 to 2023 5.75% 0.00%\n\nTrend from 2023 to 2024 6.28% 0.00%\n\nFinal SWAP PMPM (before 86% adjustment is applied) $604.08 $0.00 0.977\n\nPlan Liability Component approximation = PLRS \\* IDF \\* GCF 1.355 1.458 0.000 3.218 2.455 0.974 0.000 0.000 0.982 1.469 1.513 1.447 0.946\n\nNormalized PLRS \\* IDF \\* GCF (N1) 1.076 0.000 2.376 1.812 0.719 TBD 1.496 1.540 1.472 0.963\n\nAllowable Rating Component approximation = AV \\* ARF \\* IDF \\* GCF 1.209 1.193 0.000 1.406 1.313 1.128 0.000 0.000 1.001 0.999 0.926 0.977 0.987\n\nNormalized AV \\* PLRS \\* IDF \\* GCF (N2) 0.986 0.000 1.163 1.086 0.933 TBD 0.998 0.925 0.976 0.986\n\nApproximate Transfer PMPM (P \\* [N1 - N2] \\* 0.86) **$46.70** $0.00 $630.18 $377.48 ($111.40) TBD **6\\.795** 2\\.080 2.162 1.040\n\nApproximate Aggregate Transfer (Transfer PMPM \\* MM) **$612,009** $0 $559,596 $1,164,143 ($1,017,298) TBD **3\\.206** 2\\.024 1.153 0.418\n\nAggregate Projected (Rate Development) RA Transfer PMPM TBD TBD $0.00 $597.26 $347.20 -$117.72 $0.00 2.195 2.351 0.984\n\nTransfer PMPM Difference TBD $0.00 -$32.92 -$30.28 -$6.32 TBD 0.000 0.000 0.000\n\nHCRP assessment PMPM (amounts should be negative) TBD TBD $0.00 -$4.04 -$4.04 -$4.04 $0.00 0.645 0.645 0.645\n\nHCRP receipts PMPM (amounts should be positive) TBD TBD $0.00 $4.04 $4.04 $4.04 $0.00 3.477 3.477 3.477\n\nRADV adjustment PMPM, if applicable TBD TBD $0.00 $0.00 $0.00 $0.00 $0.00\n\nFinal Risk Adjustment PMPM TBD TBD $0.00 $597.26 $347.20 -$117.72 $0.00 2.214 2.384 0.887\n\n## **Comments**\n\nCata-\n\nstrophic\n\nCata-\n\nstrophic\n\nStatewide Metal Plans\n\nStatewide\n\nCatastrophic\n\nPlans\n\nTotal for Metal + Total for Metal Plans Platinum Gold Silver Bronze\n\nStatewide Metal Plans\n\nStatewide\n\nCatastrophic\n\nPlans\n\nTotal for Metal + Total for Metal Plans Platinum Gold Silver Bronze\n\n### BridgeSpan is using Regence projected risk adjustment for 2026 for credibility see Actuarial Memorandum section 4.4.3.6(b)\n\nCata-\n\nstrophic\n\nStatewide Metal Plans\n\nStatewide\n\nCatastrophic\n\nPlans\n\nTotal for Metal +\n\ncatastrophi Total for Metal Plans Platinum Gold Silver Bronze\n\nTotal for Metal +\n\ncatastrophic.\n\nStatewide\n\nCatastrophic\n\nPlans\n\nCata-\n\nstrophic Bronze\n\n2024\n\n2026\n\nIndividual\n\nBridgeSpan Health Company\n\nStatewide Metal Plans\n\nStatewide\n\nCatastrophic\n\nPlans Total for Metal Plans Platinum Gold Silver Bronze\n\nTotal for Metal +\n\nCatastrophic\n\nCata-\n\nstrophic\n\nStatewide Metal Plans Total for Metal Plans Platinum Gold Silver\n\n2026 IND & SG ACA MEDICAL RATE FILINGS -- COMMON EXHIBITS 04/07/2025","pages":[{"line_numbers":[],"markdown":"# WA Exhibit 10: Summarized Risk Adjustment (RA)\n\n### Carrier Name: Market: Rate Filing Plan Year: Experience Period Year:\n\n**ACTUAL EXPERIENCE, 2024 PROJECTED (i.e., EXPECTED), 2026 PROJECTED (i.e., EXPECTED), 2026 versus ACTUAL EXPERIENCE, 2024**\n\nCarrier Carrier Carrier Carrier Carrier Carrier\n\nDescription Description\n\nBillable Member Months (MM) 6,183 6,183 - 864 1,645 3,674 - Billable Member Months (MM) 262,536 262,536 - 99,456 54,708 108,372 - 42.462 42.462 115.121 33.256 29.498\n\nActuarial Value (AV) 0.686 0.654552522 0.900 0.800 0.700 0.600 0.570 0.570 Actuarial Value (AV) 0.686 0.697 0.900 0.800 0.700 0.600 0.000 0.000 1.000 1.064 1.000 1.000 1.000 1.000 - -\n\nPlan Liability Risk Score (PLRS) 1.292 2.091 0.000 4.604 3.401 0.914 0.000 0.000 Plan Liability Risk Score (PLRS) 1.344 1.562 0.000 2.134 1.785 0.924 0.000 0.000 1.040 0.747 0.464 0.525 1.011\n\nAllowable Rating Factor (ARF) 1.711 1.776 0.000 1.538 1.754 1.842 0.000 0.000 Allowable Rating Factor (ARF) 1.711 1.732 0.000 1.680 1.667 1.811 0.000 0.000 1.000 0.975 1.093 0.951 0.983\n\nInduced Demand Factor (IDF) 1.030 1.019 0.000 1.080 1.030 1.000 0.000 0.000 Induced Demand Factor (IDF) 1.030 1.037 0.000 1.080 1.030 1.000 0.000 0.000 1.000 1.017 1.000 1.000 1.000\n\nGeographic Cost Factor (GCF) 1.000 1.005 0.000 0.980 1.014 1.007 0.000 0.000 Geographic Cost Factor (GCF) 1.000 1.002 0.000 1.001 1.002 1.004 0.000 0.000 1.000 0.997 1.022 0.989 0.996\n\nStatewide Average Premium (SWAP) PMPM Starting SWAP PMPM $590.07 $0.00\n\nTrend from 2024 to 2025 6.61% 0.00%\n\nTrend from 2025 to 2026 17.06% 0.00%\n\nFinal SWAP PMPM (before 86% adjustment is applied) $590.07 $0.00 Final SWAP PMPM (before 86% adjustment is applied) $736.41 $0.00 1.248\n\nPlan Liability Component approximation = PLRS \\* IDF \\* GCF 1.331 2.143 0.000 4.870 3.551 0.921 0.000 0.000 Plan Liability Component approximation = PLRS \\* IDF \\* GCF 1.384 1.623 0.000 2.307 1.843 0.928 0.000 0.000 1.040 0.757 0.474 0.519 1.007\n\nNormalized PLRS \\* IDF \\* GCF (N1) 1.610 0.000 3.659 2.668 0.692 TBD Normalized PLRS \\* IDF \\* GCF (N1) 1.173 0.000 1.667 1.332 0.670 TBD 0.728 0.455 0.499 0.968\n\nAllowable Rating Component approximation = AV \\* ARF \\* IDF \\* GCF 1.210 1.191 0.000 1.302 1.282 1.114 0.000 0.000 Allowable Rating Component approximation = AV \\* ARF \\* IDF \\* GCF 1.210 1.253 0.000 1.453 1.205 1.091 0.000 0.000 1.000 1.052 1.116 0.940 0.979\n\nNormalized AV \\* PLRS \\* IDF \\* GCF (N2) 0.985 0.000 1.076 1.060 0.920 TBD Normalized AV \\* PLRS \\* IDF \\* GCF (N2) 1.036 0.000 1.201 0.996 0.901 TBD 1.052 1.116 0.940 0.979\n\nApproximate Transfer PMPM (P \\* [N1 - N2] \\* 0.86) **$317.36** $0.00 $1,311.04 $816.27 ($115.84) TBD Approximate Transfer PMPM (P \\* [N1 - N2] \\* 0.86) **$86.65** $0.00 $294.99 $212.62 ($146.37) TBD **0\\.273** 0\\.225 0.260 1.264\n\nApproximate Aggregate Transfer (Transfer PMPM \\* MM) **$1,962,195** $0 $1,132,644 $1,342,801 ($425,565) TBD Approximate Aggregate Transfer (Transfer PMPM \\* MM) **$22,747,580** $0 $29,338,778 $11,632,156 ($15,862,566) TBD **11\\.593** 25\\.903 8.663 37.274\n\nAggregate Experience RA Transfer PMPM 331.542608 $331.54 $0.00 $1,311.04 $816.27 -$115.84 $0.00 Aggregate Projected (Rate Development) RA Transfer PMPM 95.63780935 $95.64 $0.00 $294.99 $212.62 -$146.37 $0.00 0.288 0.288 0.225 0.260 1.264\n\nTransfer PMPM Difference $14.18 $0.00 $0.00 $0.00 $0.00 TBD Transfer PMPM Difference $8.99 $0.00 $0.00 $0.00 $0.00 TBD 0.634 - 0.100 0.158\n\nHCRP assessment PMPM (amounts should be negative) -$2.60 -$2.60 $0.00 -$2.60 -$2.60 -$2.60 $0.00 HCRP assessment PMPM (amounts should be negative) -$5.30 -$5.30 $0.00 -$5.30 -$5.30 -$5.30 $0.00 2.038 2.038 2.038 2.038 2.038\n\nHCRP receipts PMPM (amounts should be positive) $14.04 $14.04 $0.00 $14.04 $14.04 $14.04 $0.00 HCRP receipts PMPM (amounts should be positive) $5.30 $5.30 $0.00 $5.30 $5.30 $5.30 $0.00 0.378 0.378 0.378 0.378 0.378\n\nRADV adjustment PMPM, if applicable $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 RADV adjustment PMPM, if applicable $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00\n\nFinal Risk Adjustment PMPM $342.98 $342.98 $0.00 $1,322.47 $827.70 -$104.40 $0.00 Final Risk Adjustment PMPM $95.64 $95.64 $0.00 $294.99 $212.62 -$146.37 $0.00 0.279 0.279 0.223 0.257 1.402\n\n**PROJECTED (i.e., EXPECTED), 2024 ACTUAL EXPERIENCE, 2024 versus PROJECTED (i.e., EXPECTED), 2024**\n\nCarrier Carrier Carrier Carrier\n\nDescription Billable Member Months (MM) 13,104 13,104 - 888 3,084 9,132 - 0.472 0.472 0.973 0.533 0.402\n\nActuarial Value (AV) 0.670 0.637 0.900 0.800 0.700 0.600 0.000 0.000 1.025 1.027 1.000 1.000 1.000 1.000\n\nPlan Liability Risk Score (PLRS) 1.323 1.425 0.000 2.959 2.346 0.964 0.000 0.000 0.977 1.468 1.556 1.450 0.948\n\nAllowable Rating Factor (ARF) 1.763 1.829 0.000 1.616 1.792 1.863 0.000 0.000 0.971 0.971 0.952 0.979 0.989\n\nInduced Demand Factor (IDF) 1.024 1.012 0.000 1.080 1.030 1.000 0.000 0.000 1.006 1.007 1.000 1.000 1.000\n\nGeographic Cost Factor (GCF) 1.000 1.011 0.000 1.007 1.016 1.010 0.000 0.000 1.000 0.994 0.973 0.998 0.998\n\nStatewide Average Premium (SWAP) PMPM Starting SWAP PMPM $537.44 $0.00\n\nTrend from 2022 to 2023 5.75% 0.00%\n\nTrend from 2023 to 2024 6.28% 0.00%\n\nFinal SWAP PMPM (before 86% adjustment is applied) $604.08 $0.00 0.977\n\nPlan Liability Component approximation = PLRS \\* IDF \\* GCF 1.355 1.458 0.000 3.218 2.455 0.974 0.000 0.000 0.982 1.469 1.513 1.447 0.946\n\nNormalized PLRS \\* IDF \\* GCF (N1) 1.076 0.000 2.376 1.812 0.719 TBD 1.496 1.540 1.472 0.963\n\nAllowable Rating Component approximation = AV \\* ARF \\* IDF \\* GCF 1.209 1.193 0.000 1.406 1.313 1.128 0.000 0.000 1.001 0.999 0.926 0.977 0.987\n\nNormalized AV \\* PLRS \\* IDF \\* GCF (N2) 0.986 0.000 1.163 1.086 0.933 TBD 0.998 0.925 0.976 0.986\n\nApproximate Transfer PMPM (P \\* [N1 - N2] \\* 0.86) **$46.70** $0.00 $630.18 $377.48 ($111.40) TBD **6\\.795** 2\\.080 2.162 1.040\n\nApproximate Aggregate Transfer (Transfer PMPM \\* MM) **$612,009** $0 $559,596 $1,164,143 ($1,017,298) TBD **3\\.206** 2\\.024 1.153 0.418\n\nAggregate Projected (Rate Development) RA Transfer PMPM TBD TBD $0.00 $597.26 $347.20 -$117.72 $0.00 2.195 2.351 0.984\n\nTransfer PMPM Difference TBD $0.00 -$32.92 -$30.28 -$6.32 TBD 0.000 0.000 0.000\n\nHCRP assessment PMPM (amounts should be negative) TBD TBD $0.00 -$4.04 -$4.04 -$4.04 $0.00 0.645 0.645 0.645\n\nHCRP receipts PMPM (amounts should be positive) TBD TBD $0.00 $4.04 $4.04 $4.04 $0.00 3.477 3.477 3.477\n\nRADV adjustment PMPM, if applicable TBD TBD $0.00 $0.00 $0.00 $0.00 $0.00\n\nFinal Risk Adjustment PMPM TBD TBD $0.00 $597.26 $347.20 -$117.72 $0.00 2.214 2.384 0.887\n\n## **Comments**\n\nCata-\n\nstrophic\n\nCata-\n\nstrophic\n\nStatewide Metal Plans\n\nStatewide\n\nCatastrophic\n\nPlans\n\nTotal for Metal + Total for Metal Plans Platinum Gold Silver Bronze\n\nStatewide Metal Plans\n\nStatewide\n\nCatastrophic\n\nPlans\n\nTotal for Metal + Total for Metal Plans Platinum Gold Silver Bronze\n\n### BridgeSpan is using Regence projected risk adjustment for 2026 for credibility see Actuarial Memorandum section 4.4.3.6(b)\n\nCata-\n\nstrophic\n\nStatewide Metal Plans\n\nStatewide\n\nCatastrophic\n\nPlans\n\nTotal for Metal +\n\ncatastrophi Total for Metal Plans Platinum Gold Silver Bronze\n\nTotal for Metal +\n\ncatastrophic.\n\nStatewide\n\nCatastrophic\n\nPlans\n\nCata-\n\nstrophic Bronze\n\n2024\n\n2026\n\nIndividual\n\nBridgeSpan Health Company\n\nStatewide Metal Plans\n\nStatewide\n\nCatastrophic\n\nPlans Total for Metal Plans Platinum Gold Silver Bronze\n\nTotal for Metal +\n\nCatastrophic\n\nCata-\n\nstrophic\n\nStatewide Metal Plans Total for Metal Plans Platinum Gold Silver\n\n2026 IND & SG ACA MEDICAL RATE FILINGS -- COMMON EXHIBITS 04/07/2025","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_018","product_type":"parse","source_file_path":"complex_header_018.pdf"},"started_at":"2026-11-12T14:56:16.286488"} {"completed_at":"2026-11-12T14:56:25.712018","latency_in_ms":1224,"output":{"example_id":"complex_table_headers/complex_header_019","grounded_pages":[],"layout_pages":[],"markdown":"Exhibit 6C\n\nGross-to Net Test\n\nUnisex Rating\n\nInsured with Covered Partner Discount\n\nSelect Preferred\n\nStandard Premium Payment Option\n\n$175 DBA\n\nComprehensive Daily Reimbursement\n\n90 Service Day Elimination Period\n\nNo Riders\n\n2 Year Benefit Period\n\nNo Inflation Protection 3% Compound Inflation protection 5% Compound Inflation protection\n\nIssue Gross Valuation Renewal Test Gross Valuation Renewal Test Gross Valuation Renewal Test Issue\n\nAge Premium Premium Expenses Value Pass/Fail Premium Premium Expenses Value Pass/Fail Premium Premium Expenses Value Pass/Fail Age\n\n42 $519.87 $236.69 $130.75 $152.43 Pass $1,200.89 $722.54 $231.38 $246.97 Pass $2,710.07 $1,693.65 $449.41 $567.01 Pass 42\n\n47 $583.82 $300.61 $142.01 $141.20 Pass $1,316.52 $798.87 $249.92 $267.73 Pass $2,731.13 $1,719.19 $456.52 $555.42 Pass 47\n\n52 $678.88 $388.43 $158.48 $131.97 Pass $1,441.27 $886.15 $270.91 $284.21 Pass $2,736.58 $1,721.59 $461.87 $553.12 Pass 52\n\n57 $850.82 $500.94 $186.24 $163.64 Pass $1,620.82 $992.29 $300.95 $327.58 Pass $2,827.28 $1,756.27 $481.02 $589.99 Pass 57\n\n62 $1,143.72 $660.39 $232.99 $250.34 Pass $1,907.72 $1,138.53 $348.70 $420.49 Pass $3,043.44 $1,836.60 $521.04 $685.80 Pass 62\n\n67 $1,689.76 $910.97 $320.57 $458.22 Pass $2,570.13 $1,369.19 $452.97 $747.97 Pass $3,852.66 $2,015.17 $646.61 $1,190.88 Pass 67\n\n72 $2,824.56 $1,377.90 $507.10 $939.56 Pass $3,900.71 $1,798.59 $667.49 $1,434.63 Pass $5,406.20 $2,421.87 $897.78 $2,086.55 Pass 72\n\n77 $4,745.61 $2,288.26 $851.53 $1,605.82 Pass $6,212.01 $2,592.55 $1,065.09 $2,554.37 Pass $8,323.81 $3,263.30 $1,394.43 $3,666.08 Pass 77\n\n3 Year Benefit Period\n\nNo Inflation Protection 3% Compound Inflation protection 5% Compound Inflation protection\n\nIssue Gross Valuation Renewal Test Gross Valuation Renewal Test Gross Valuation Renewal Test Issue\n\nAge Premium Premium Expenses Value Pass/Fail Premium Premium Expenses Value Pass/Fail Premium Premium Expenses Value Pass/Fail Age\n\n42 $636.17 $298.12 $146.89 $191.16 Pass $1,469.55 $883.71 $269.61 $316.23 Pass $3,316.35 $2,038.09 $534.72 $743.54 Pass 42\n\n47 $714.43 $378.02 $160.73 $175.68 Pass $1,611.05 $975.76 $292.21 $343.08 Pass $3,342.12 $2,070.66 $543.46 $728.00 Pass 47\n\n52 $830.76 $487.61 $180.96 $162.19 Pass $1,763.70 $1,079.90 $317.73 $366.07 Pass $3,348.79 $2,070.67 $549.84 $728.28 Pass 52\n\n57 $1,041.16 $626.60 $214.95 $199.61 Pass $1,983.41 $1,205.78 $354.25 $423.38 Pass $3,459.78 $2,109.46 $573.04 $777.28 Pass 57\n\n62 $1,399.59 $822.27 $272.12 $305.20 Pass $2,334.51 $1,379.46 $412.36 $542.69 Pass $3,724.30 $2,202.59 $621.71 $900.00 Pass 62\n\n67 $2,067.78 $1,126.84 $379.09 $561.85 Pass $3,145.10 $1,654.71 $539.53 $950.86 Pass $4,714.55 $2,414.50 $774.96 $1,525.09 Pass 67\n\n72 $3,456.45 $1,689.47 $606.73 $1,160.25 Pass $4,773.35 $2,168.88 $801.34 $1,803.13 Pass $6,615.64 $2,901.90 $1,081.67 $2,632.07 Pass 72\n\n77 $5,807.27 $2,779.40 $1,026.66 $2,001.21 Pass $7,601.72 $3,117.19 $1,286.46 $3,198.07 Pass $10,185.96 $3,913.42 $1,688.26 $4,584.28 Pass 77\n\n4 Year Benefit Period\n\nNo Inflation Protection 3% Compound Inflation protection 5% Compound Inflation protection\n\nIssue Gross Valuation Renewal Test Gross Valuation Renewal Test Gross Valuation Renewal Test Issue\n\nAge Premium Premium Expenses Value Pass/Fail Premium Premium Expenses Value Pass/Fail Premium Premium Expenses Value Pass/Fail Age\n\n42 $712.93 $339.25 $157.58 $216.10 Pass $1,646.86 $981.61 $294.43 $370.82 Pass $3,716.49 $2,243.03 $589.91 $883.55 Pass 42\n\n47 $800.64 $428.99 $173.08 $198.57 Pass $1,805.43 $1,086.29 $319.81 $399.33 Pass $3,745.38 $2,260.05 $598.77 $886.56 Pass 47\n\n52 $931.00 $554.38 $195.86 $180.76 Pass $1,976.51 $1,191.27 $347.84 $437.40 Pass $3,752.85 $2,263.49 $606.06 $883.30 Pass 52\n\n57 $1,166.79 $709.39 $233.88 $223.52 Pass $2,222.73 $1,326.08 $388.45 $508.20 Pass $3,877.23 $2,307.90 $632.09 $937.24 Pass 57\n\n62 $1,568.46 $926.72 $297.82 $343.92 Pass $2,616.19 $1,512.56 $453.16 $650.47 Pass $4,173.66 $2,411.21 $686.54 $1,075.91 Pass 62\n\n67 $2,317.28 $1,262.81 $417.38 $637.09 Pass $3,524.58 $1,813.17 $595.27 $1,116.14 Pass $5,283.40 $2,643.13 $857.98 $1,782.29 Pass 67\n\n72 $3,873.50 $1,880.93 $671.77 $1,320.80 Pass $5,349.30 $2,378.75 $888.09 $2,082.46 Pass $7,413.87 $3,180.51 $1,201.18 $3,032.18 Pass 72\n\n77 $6,507.97 $3,072.31 $1,140.64 $2,295.02 Pass $8,518.93 $3,428.50 $1,430.77 $3,659.66 Pass $11,414.97 $4,295.98 $1,879.86 $5,239.13 Pass 77\n\n5 Year Benefit Period\n\nNo Inflation Protection 3% Compound Inflation protection 5% Compound Inflation protection\n\nIssue Gross Valuation Renewal Test Gross Valuation Renewal Test Gross Valuation Renewal Test Issue\n\nAge Premium Premium Expenses Value Pass/Fail Premium Premium Expenses Value Pass/Fail Premium Premium Expenses Value Pass/Fail Age\n\n42 $782.71 $381.88 $167.60 $233.23 Pass $1,808.06 $1,086.44 $317.84 $403.78 Pass $4,080.26 $2,449.33 $641.20 $989.73 Pass 42\n\n47 $879.00 $482.22 $184.72 $212.06 Pass $1,982.15 $1,201.64 $345.73 $434.78 Pass $4,111.97 $2,469.23 $651.01 $991.73 Pass 47\n\n52 $1,022.12 $622.41 $209.86 $189.85 Pass $2,169.97 $1,316.05 $376.49 $477.43 Pass $4,120.17 $2,472.82 $659.04 $988.31 Pass 52\n\n57 $1,280.99 $794.79 $251.74 $234.46 Pass $2,440.29 $1,463.13 $421.06 $556.10 Pass $4,256.74 $2,521.47 $687.67 $1,047.60 Pass 57\n\n62 $1,721.98 $1,035.95 $322.11 $363.92 Pass $2,872.26 $1,667.06 $492.14 $713.06 Pass $4,582.18 $2,634.80 $747.56 $1,199.82 Pass 62\n\n67 $2,544.09 $1,407.60 $453.67 $682.82 Pass $3,869.57 $1,997.47 $648.37 $1,223.73 Pass $5,800.53 $2,890.50 $936.11 $1,973.92 Pass 67\n\n72 $4,252.63 $2,089.99 $733.63 $1,429.01 Pass $5,872.88 $2,621.13 $970.53 $2,281.22 Pass $8,139.54 $3,483.57 $1,313.75 $3,342.22 Pass 72\n\n77 $7,144.96 $3,400.41 $1,249.68 $2,494.87 Pass $9,352.75 $3,775.95 $1,567.68 $4,009.12 Pass $12,532.26 $4,714.30 $2,060.79 $5,757.17 Pass 77\n\n6 Year Benefit Period\n\nNo Inflation Protection 3% Compound Inflation protection 5% Compound Inflation protection\n\nIssue Gross Valuation Renewal Test Gross Valuation Renewal Test Gross Valuation Renewal Test Issue\n\nAge Premium Premium Expenses Value Pass/Fail Premium Premium Expenses Value Pass/Fail Premium Premium Expenses Value Pass/Fail Age\n\n42 $830.39 $414.17 $174.62 $241.60 Pass $1,918.21 $1,160.65 $333.98 $423.58 Pass $4,328.84 $2,585.86 $676.05 $1,066.93 Pass 42\n\n47 $932.55 $522.32 $192.86 $217.37 Pass $2,102.90 $1,283.05 $363.59 $456.26 Pass $4,362.48 $2,608.21 $686.55 $1,067.72 Pass 47\n\n52 $1,084.39 $673.43 $219.67 $191.29 Pass $2,302.16 $1,403.65 $396.20 $502.31 Pass $4,371.18 $2,612.27 $695.11 $1,063.80 Pass 52\n\n57 $1,359.03 $858.38 $264.22 $236.43 Pass $2,588.95 $1,558.91 $443.48 $586.56 Pass $4,516.06 $2,664.27 $725.55 $1,126.24 Pass 57\n\n62 $1,826.88 $1,116.54 $339.05 $371.29 Pass $3,047.24 $1,774.60 $518.93 $753.71 Pass $4,861.33 $2,784.73 $789.19 $1,287.41 Pass 62\n\n67 $2,699.08 $1,513.84 $478.91 $706.33 Pass $4,105.30 $2,126.15 $684.89 $1,294.26 Pass $6,153.91 $3,057.86 $989.55 $2,106.50 Pass 67\n\n72 $4,511.71 $2,240.72 $776.42 $1,494.57 Pass $6,230.67 $2,789.33 $1,027.13 $2,414.21 Pass $8,635.41 $3,690.04 $1,390.83 $3,554.54 Pass 72\n\n77 $7,580.24 $3,621.58 $1,324.15 $2,634.51 Pass $9,922.54 $4,003.35 $1,660.88 $4,258.31 Pass $13,295.74 $4,985.53 $2,183.85 $6,126.36 Pass 77","pages":[{"line_numbers":[],"markdown":"Exhibit 6C\n\nGross-to Net Test\n\nUnisex Rating\n\nInsured with Covered Partner Discount\n\nSelect Preferred\n\nStandard Premium Payment Option\n\n$175 DBA\n\nComprehensive Daily Reimbursement\n\n90 Service Day Elimination Period\n\nNo Riders\n\n2 Year Benefit Period\n\nNo Inflation Protection 3% Compound Inflation protection 5% Compound Inflation protection\n\nIssue Gross Valuation Renewal Test Gross Valuation Renewal Test Gross Valuation Renewal Test Issue\n\nAge Premium Premium Expenses Value Pass/Fail Premium Premium Expenses Value Pass/Fail Premium Premium Expenses Value Pass/Fail Age\n\n42 $519.87 $236.69 $130.75 $152.43 Pass $1,200.89 $722.54 $231.38 $246.97 Pass $2,710.07 $1,693.65 $449.41 $567.01 Pass 42\n\n47 $583.82 $300.61 $142.01 $141.20 Pass $1,316.52 $798.87 $249.92 $267.73 Pass $2,731.13 $1,719.19 $456.52 $555.42 Pass 47\n\n52 $678.88 $388.43 $158.48 $131.97 Pass $1,441.27 $886.15 $270.91 $284.21 Pass $2,736.58 $1,721.59 $461.87 $553.12 Pass 52\n\n57 $850.82 $500.94 $186.24 $163.64 Pass $1,620.82 $992.29 $300.95 $327.58 Pass $2,827.28 $1,756.27 $481.02 $589.99 Pass 57\n\n62 $1,143.72 $660.39 $232.99 $250.34 Pass $1,907.72 $1,138.53 $348.70 $420.49 Pass $3,043.44 $1,836.60 $521.04 $685.80 Pass 62\n\n67 $1,689.76 $910.97 $320.57 $458.22 Pass $2,570.13 $1,369.19 $452.97 $747.97 Pass $3,852.66 $2,015.17 $646.61 $1,190.88 Pass 67\n\n72 $2,824.56 $1,377.90 $507.10 $939.56 Pass $3,900.71 $1,798.59 $667.49 $1,434.63 Pass $5,406.20 $2,421.87 $897.78 $2,086.55 Pass 72\n\n77 $4,745.61 $2,288.26 $851.53 $1,605.82 Pass $6,212.01 $2,592.55 $1,065.09 $2,554.37 Pass $8,323.81 $3,263.30 $1,394.43 $3,666.08 Pass 77\n\n3 Year Benefit Period\n\nNo Inflation Protection 3% Compound Inflation protection 5% Compound Inflation protection\n\nIssue Gross Valuation Renewal Test Gross Valuation Renewal Test Gross Valuation Renewal Test Issue\n\nAge Premium Premium Expenses Value Pass/Fail Premium Premium Expenses Value Pass/Fail Premium Premium Expenses Value Pass/Fail Age\n\n42 $636.17 $298.12 $146.89 $191.16 Pass $1,469.55 $883.71 $269.61 $316.23 Pass $3,316.35 $2,038.09 $534.72 $743.54 Pass 42\n\n47 $714.43 $378.02 $160.73 $175.68 Pass $1,611.05 $975.76 $292.21 $343.08 Pass $3,342.12 $2,070.66 $543.46 $728.00 Pass 47\n\n52 $830.76 $487.61 $180.96 $162.19 Pass $1,763.70 $1,079.90 $317.73 $366.07 Pass $3,348.79 $2,070.67 $549.84 $728.28 Pass 52\n\n57 $1,041.16 $626.60 $214.95 $199.61 Pass $1,983.41 $1,205.78 $354.25 $423.38 Pass $3,459.78 $2,109.46 $573.04 $777.28 Pass 57\n\n62 $1,399.59 $822.27 $272.12 $305.20 Pass $2,334.51 $1,379.46 $412.36 $542.69 Pass $3,724.30 $2,202.59 $621.71 $900.00 Pass 62\n\n67 $2,067.78 $1,126.84 $379.09 $561.85 Pass $3,145.10 $1,654.71 $539.53 $950.86 Pass $4,714.55 $2,414.50 $774.96 $1,525.09 Pass 67\n\n72 $3,456.45 $1,689.47 $606.73 $1,160.25 Pass $4,773.35 $2,168.88 $801.34 $1,803.13 Pass $6,615.64 $2,901.90 $1,081.67 $2,632.07 Pass 72\n\n77 $5,807.27 $2,779.40 $1,026.66 $2,001.21 Pass $7,601.72 $3,117.19 $1,286.46 $3,198.07 Pass $10,185.96 $3,913.42 $1,688.26 $4,584.28 Pass 77\n\n4 Year Benefit Period\n\nNo Inflation Protection 3% Compound Inflation protection 5% Compound Inflation protection\n\nIssue Gross Valuation Renewal Test Gross Valuation Renewal Test Gross Valuation Renewal Test Issue\n\nAge Premium Premium Expenses Value Pass/Fail Premium Premium Expenses Value Pass/Fail Premium Premium Expenses Value Pass/Fail Age\n\n42 $712.93 $339.25 $157.58 $216.10 Pass $1,646.86 $981.61 $294.43 $370.82 Pass $3,716.49 $2,243.03 $589.91 $883.55 Pass 42\n\n47 $800.64 $428.99 $173.08 $198.57 Pass $1,805.43 $1,086.29 $319.81 $399.33 Pass $3,745.38 $2,260.05 $598.77 $886.56 Pass 47\n\n52 $931.00 $554.38 $195.86 $180.76 Pass $1,976.51 $1,191.27 $347.84 $437.40 Pass $3,752.85 $2,263.49 $606.06 $883.30 Pass 52\n\n57 $1,166.79 $709.39 $233.88 $223.52 Pass $2,222.73 $1,326.08 $388.45 $508.20 Pass $3,877.23 $2,307.90 $632.09 $937.24 Pass 57\n\n62 $1,568.46 $926.72 $297.82 $343.92 Pass $2,616.19 $1,512.56 $453.16 $650.47 Pass $4,173.66 $2,411.21 $686.54 $1,075.91 Pass 62\n\n67 $2,317.28 $1,262.81 $417.38 $637.09 Pass $3,524.58 $1,813.17 $595.27 $1,116.14 Pass $5,283.40 $2,643.13 $857.98 $1,782.29 Pass 67\n\n72 $3,873.50 $1,880.93 $671.77 $1,320.80 Pass $5,349.30 $2,378.75 $888.09 $2,082.46 Pass $7,413.87 $3,180.51 $1,201.18 $3,032.18 Pass 72\n\n77 $6,507.97 $3,072.31 $1,140.64 $2,295.02 Pass $8,518.93 $3,428.50 $1,430.77 $3,659.66 Pass $11,414.97 $4,295.98 $1,879.86 $5,239.13 Pass 77\n\n5 Year Benefit Period\n\nNo Inflation Protection 3% Compound Inflation protection 5% Compound Inflation protection\n\nIssue Gross Valuation Renewal Test Gross Valuation Renewal Test Gross Valuation Renewal Test Issue\n\nAge Premium Premium Expenses Value Pass/Fail Premium Premium Expenses Value Pass/Fail Premium Premium Expenses Value Pass/Fail Age\n\n42 $782.71 $381.88 $167.60 $233.23 Pass $1,808.06 $1,086.44 $317.84 $403.78 Pass $4,080.26 $2,449.33 $641.20 $989.73 Pass 42\n\n47 $879.00 $482.22 $184.72 $212.06 Pass $1,982.15 $1,201.64 $345.73 $434.78 Pass $4,111.97 $2,469.23 $651.01 $991.73 Pass 47\n\n52 $1,022.12 $622.41 $209.86 $189.85 Pass $2,169.97 $1,316.05 $376.49 $477.43 Pass $4,120.17 $2,472.82 $659.04 $988.31 Pass 52\n\n57 $1,280.99 $794.79 $251.74 $234.46 Pass $2,440.29 $1,463.13 $421.06 $556.10 Pass $4,256.74 $2,521.47 $687.67 $1,047.60 Pass 57\n\n62 $1,721.98 $1,035.95 $322.11 $363.92 Pass $2,872.26 $1,667.06 $492.14 $713.06 Pass $4,582.18 $2,634.80 $747.56 $1,199.82 Pass 62\n\n67 $2,544.09 $1,407.60 $453.67 $682.82 Pass $3,869.57 $1,997.47 $648.37 $1,223.73 Pass $5,800.53 $2,890.50 $936.11 $1,973.92 Pass 67\n\n72 $4,252.63 $2,089.99 $733.63 $1,429.01 Pass $5,872.88 $2,621.13 $970.53 $2,281.22 Pass $8,139.54 $3,483.57 $1,313.75 $3,342.22 Pass 72\n\n77 $7,144.96 $3,400.41 $1,249.68 $2,494.87 Pass $9,352.75 $3,775.95 $1,567.68 $4,009.12 Pass $12,532.26 $4,714.30 $2,060.79 $5,757.17 Pass 77\n\n6 Year Benefit Period\n\nNo Inflation Protection 3% Compound Inflation protection 5% Compound Inflation protection\n\nIssue Gross Valuation Renewal Test Gross Valuation Renewal Test Gross Valuation Renewal Test Issue\n\nAge Premium Premium Expenses Value Pass/Fail Premium Premium Expenses Value Pass/Fail Premium Premium Expenses Value Pass/Fail Age\n\n42 $830.39 $414.17 $174.62 $241.60 Pass $1,918.21 $1,160.65 $333.98 $423.58 Pass $4,328.84 $2,585.86 $676.05 $1,066.93 Pass 42\n\n47 $932.55 $522.32 $192.86 $217.37 Pass $2,102.90 $1,283.05 $363.59 $456.26 Pass $4,362.48 $2,608.21 $686.55 $1,067.72 Pass 47\n\n52 $1,084.39 $673.43 $219.67 $191.29 Pass $2,302.16 $1,403.65 $396.20 $502.31 Pass $4,371.18 $2,612.27 $695.11 $1,063.80 Pass 52\n\n57 $1,359.03 $858.38 $264.22 $236.43 Pass $2,588.95 $1,558.91 $443.48 $586.56 Pass $4,516.06 $2,664.27 $725.55 $1,126.24 Pass 57\n\n62 $1,826.88 $1,116.54 $339.05 $371.29 Pass $3,047.24 $1,774.60 $518.93 $753.71 Pass $4,861.33 $2,784.73 $789.19 $1,287.41 Pass 62\n\n67 $2,699.08 $1,513.84 $478.91 $706.33 Pass $4,105.30 $2,126.15 $684.89 $1,294.26 Pass $6,153.91 $3,057.86 $989.55 $2,106.50 Pass 67\n\n72 $4,511.71 $2,240.72 $776.42 $1,494.57 Pass $6,230.67 $2,789.33 $1,027.13 $2,414.21 Pass $8,635.41 $3,690.04 $1,390.83 $3,554.54 Pass 72\n\n77 $7,580.24 $3,621.58 $1,324.15 $2,634.51 Pass $9,922.54 $4,003.35 $1,660.88 $4,258.31 Pass $13,295.74 $4,985.53 $2,183.85 $6,126.36 Pass 77","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_019","product_type":"parse","source_file_path":"complex_header_019.pdf"},"started_at":"2026-11-12T14:56:24.487418"} {"completed_at":"2026-11-12T14:56:36.217329","latency_in_ms":2381,"output":{"example_id":"complex_table_headers/complex_header_020","grounded_pages":[],"layout_pages":[],"markdown":"93 Messages from Management Source of Value Creation —Toyota’s Identity\n\nValue Creation Story\n\n—Future Mobility Society Envisioned by an Automobile Manufacturer\n\nValue Creation Foundations Corporate Data\n\nCorporate Governance\n\nMembers of the Board of Directors and Audit & Supervisory Board Members\n\nBoard of Directors and Related Structures Members of the Board of Directors are selected based on comprehensive consideration of their responsibilities to ensure sustainable growth of Toyota and to enhance its corporate value over the medium to long term. Toyota believes that it is critical to appoint individuals who are capable of practicing product-centered and region-centered management and contributing to decision-making aimed at sustainable growth in accordance with the Toyoda Principles, which describe the Company’s founding philosophy. Moreover, these individuals should be able to play significant roles in transforming Toyota into a mobility company in the areas of electrification, intelligence, diversification, and the formation of partnerships. They must also possess the ability to contribute to the resolution of social issues, such as those pertaining to climate change. In order to make important business decisions and supervise management appropriately, the Board of Directors should consist of diverse members with a balance of abilities. The knowledge, experience, and abilities of members of the Board of Directors are consolidated and disclosed in a skills matrix. The Executive Appointment Meeting, which comprises a majority of outside members of the Board of Directors, makes recommendations to the Board of Directors regarding individual candidates for positions as members of the Board of Directors. Furthermore, four outside members of the Board of Directors have been appointed in order to adequately reflect the opinions of outside stakeholders in the management decision-making process. All of the outside members of the Board of Directors have been registered as independent directors with the relevant financial instrument exchanges. In the appointment of outside members of the Board of Directors designated as independent directors, the Company considers both the requirements for outside directors stipulated in the Companies Act of Japan and the independence standards put forth by the relevant financial instrument exchanges. Outside members of the Board of Directors provide advice in Toyota’s management decision-making process from a standpoint independent of operational execution based on their broad experience and insight. The following measures are implemented to better incorporate the insight of outside members of the Board of Directors and outside Audit & Supervisory Board members. 1. Review of the criteria for the submission of proposals to the Board of Directors as needed to regulate the inflow of proposals submitted in order to secure suffi- cient time to discuss each proposal 2. Provision of explanations of proposals in advance to facilitate better understanding of their background 3. Provision of regular opportunities, outside Board of Directors’ meetings, for two-way communication between members of the executive team with outside mem- bers of the Board of Directors and outside Audit & Supervisory Board members on important management issues and medium- to long-term issues\n\nTo facilitate active discussions at Board of Directors’ meetings, Toyota reduced the number of meeting participants (members of the Board of Directors and Audit & Supervisory Board members) from 34 in 2010 to 15 in 2020. As a result, opportunities for each participant to speak at Board of Directors’ meetings have increased, and outside members of the Board of Directors and outside Audit & Supervisory Board members are able to voice opinions on almost all proposals.\n\nMembers of the Board of Directors (As of June 2024)\n\nName Sex Age Years of Service Outside/Independent\n\nCurrent Position / Responsibility at Toyota Rate of Attendance at Board of Directors’ Meetings (Number of Meetings Attended)\\*\n\nCommittee Membership\n\nResponsibility Executive Appointment Meeting\n\nExecutive Compensation Meeting\n\nAkio Toyoda Male 68 24 Chairman of the Board of Directors 94% (15/16)\n\nShigeru Hayakawa Male 70 9 Chairperson Chairperson Chief Privacy Officer 100% (16/16)\n\nKoji Sato Male 54 1 Chief Executive Officer 100% (13/13)\n\nHiroki Nakajima Male 62 1 Chief Technology Officer 100% (13/13)\n\nYoichi Miyazaki Male 60 1 Member Member Chief Financial Officer Chief Competitive Officer 100% (13/13)\n\nSimon Humphries Male 57 1 Chief Branding Officer 100% (13/13)\n\nIkuro Sugawara Male 67 6 Outside, independent Member Member 100% (16/16)\n\nSir Philip Craven Male 73 6 Outside, independent Member Member 94% (15/16)\n\nMasahiko Oshima Male 63 1 Outside, independent Member Member 100% (13/13)\n\nEmi Osono Female 58 1 Outside, independent Member Member 100% (13/13)\n\n\\* Figures represent attendance at Board of Directors’ meetings in fiscal 2024.\n\nAnalysis and Evaluation of the Effectiveness of the Board of Directors In order to improve the effectiveness of the Board of Directors, Toyota conducts an analysis and evaluation of the Board of Directors every year. Details of the most recent analysis and evaluation are as follows..\n\n1\\. Analysis and Evaluation A survey assessing the membership, meeting proceedings, and supervisory function efficacy of the Board of Directors was carried out. Views and proposals regarding the background and causes of issues identified by the survey, as well as regarding the improvement of such issues, were compiled and reported to the Board of Directors and then discussed at a meeting of the Board of Directors.\n\nMethod of evaluation: Self-evaluation through questionnaires Subject of evaluation: Members of the Board of Directors and Audit & Supervisory Board members Implementation period: March–April 2024 Matters to be evaluated: 1. Membership and meeting proceedings of the Board of Directors 2. Management and business strategies 3. Corporate ethics and risk management 4. Communication with shareholders and other stakeholders\n\n2\\. Summary of Findings In fiscal 2024, a new management team was instituted with the addition of a number of new outside members of the Board of Directors and outside Audit & Supervisory Board members. To invigorate discussions at Board of Directors’ meetings, the Company has been offering more opportunities for communication between members of the executive team and outside members of the Board of Directors and outside Audit & Supervisory Board members, providing outside members of the Board of Directors and outside Audit & Supervisory Board members with on-site tours of facilities and information, and enhancing advance explanations of Board of Directors’ meeting proposals. Against this backdrop, it was determined that improvements had been achieved with regard to advance explanations and provision of information to\n\noutside members of the Board of Directors and outside Audit & Supervisory Board members. Conversely, time allocation, consideration of business strategies, and management with an awareness of sustainability, areas that were identified as issues in fiscal 2023, were once again identified as representing issues in fiscal 2024. In order to further improve the effectiveness of the Board of Directors, Toyota will secure more opportunities for the Board of Directors to discuss impor- tant management strategy topics and promote the appropriate selection of topics to be proposed. At the same time, Toyota will work to make further improve- ments through such measures as enhancing opportunities for dialogue and exchange with the executive team to provide more information to outside members of the Board of Directors and outside Audit & Supervisory Board members, thereby facilitating more effective and vigorous discussions.\n\nAudit & Supervisory Board System Toyota has adopted the board of corporate auditors system. The six Audit & Supervisory Board members, including three outside Audit & Supervisory Board mem- bers, play a key role in Toyota’s corporate governance by undertaking audits in line with the audit policies and plans determined by the Audit & Supervisory Board. In order to appropriately audit Toyota as it transforms into a mobility company with the aim of sustainable global growth, the Audit & Supervisory Board is composed of full-time Audit & Supervisory Board members, all of whom possess deep knowledge of internal Company matters, and outside Audit & Supervisory Board members, all of whom have a high level of expertise and knowledge. Toyota takes steps to ensure that each Audit & Supervisory Board member is able to exert audit authority independently. In appointing Audit & Supervisory Board members, Toyota believes it is necessary to select individuals who have broad experience and insight in their respective fields of expertise and who can advise management from a fair and impartial perspective and are capable of auditing operational execution. Toyota’s Executive Appointment Meeting discusses recommendations to the Audit & Supervisory Board regarding the appointment or dismissal of Audit & Supervisory Board members. Toyota has appointed three outside Audit & Supervisory Board members, all of whom are registered as independent auditors with the relevant financial instrument exchanges. When appointing outside Audit & Supervisory Board members, Toyota considers the requirements set out in the Companies Act of Japan as well as the independence standards established by the relevant financial instrument exchanges.\n\nMessage from the CSO | Roundtable Discussion among Outside Officers | Dialogues with Shareholders and Investors | Corporate Governance | Risk Management and Compliance | Message from the CFO | Capital Strategies Environmental Initiatives (Disclosure Based on TCFD Recommendations) | Human Resource Development | Diversity, Equity, and Inclusion | Health and Safety and Social Contribution Activities | Respect for Human Rights Value Chain Collaboration | Vehicle Safety | Quality and Information Security | Intellectual Property and Privacy","pages":[{"line_numbers":[],"markdown":"93 Messages from Management Source of Value Creation —Toyota’s Identity\n\nValue Creation Story\n\n—Future Mobility Society Envisioned by an Automobile Manufacturer\n\nValue Creation Foundations Corporate Data\n\nCorporate Governance\n\nMembers of the Board of Directors and Audit & Supervisory Board Members\n\nBoard of Directors and Related Structures Members of the Board of Directors are selected based on comprehensive consideration of their responsibilities to ensure sustainable growth of Toyota and to enhance its corporate value over the medium to long term. Toyota believes that it is critical to appoint individuals who are capable of practicing product-centered and region-centered management and contributing to decision-making aimed at sustainable growth in accordance with the Toyoda Principles, which describe the Company’s founding philosophy. Moreover, these individuals should be able to play significant roles in transforming Toyota into a mobility company in the areas of electrification, intelligence, diversification, and the formation of partnerships. They must also possess the ability to contribute to the resolution of social issues, such as those pertaining to climate change. In order to make important business decisions and supervise management appropriately, the Board of Directors should consist of diverse members with a balance of abilities. The knowledge, experience, and abilities of members of the Board of Directors are consolidated and disclosed in a skills matrix. The Executive Appointment Meeting, which comprises a majority of outside members of the Board of Directors, makes recommendations to the Board of Directors regarding individual candidates for positions as members of the Board of Directors. Furthermore, four outside members of the Board of Directors have been appointed in order to adequately reflect the opinions of outside stakeholders in the management decision-making process. All of the outside members of the Board of Directors have been registered as independent directors with the relevant financial instrument exchanges. In the appointment of outside members of the Board of Directors designated as independent directors, the Company considers both the requirements for outside directors stipulated in the Companies Act of Japan and the independence standards put forth by the relevant financial instrument exchanges. Outside members of the Board of Directors provide advice in Toyota’s management decision-making process from a standpoint independent of operational execution based on their broad experience and insight. The following measures are implemented to better incorporate the insight of outside members of the Board of Directors and outside Audit & Supervisory Board members. 1. Review of the criteria for the submission of proposals to the Board of Directors as needed to regulate the inflow of proposals submitted in order to secure suffi- cient time to discuss each proposal 2. Provision of explanations of proposals in advance to facilitate better understanding of their background 3. Provision of regular opportunities, outside Board of Directors’ meetings, for two-way communication between members of the executive team with outside mem- bers of the Board of Directors and outside Audit & Supervisory Board members on important management issues and medium- to long-term issues\n\nTo facilitate active discussions at Board of Directors’ meetings, Toyota reduced the number of meeting participants (members of the Board of Directors and Audit & Supervisory Board members) from 34 in 2010 to 15 in 2020. As a result, opportunities for each participant to speak at Board of Directors’ meetings have increased, and outside members of the Board of Directors and outside Audit & Supervisory Board members are able to voice opinions on almost all proposals.\n\nMembers of the Board of Directors (As of June 2024)\n\nName Sex Age Years of Service Outside/Independent\n\nCurrent Position / Responsibility at Toyota Rate of Attendance at Board of Directors’ Meetings (Number of Meetings Attended)\\*\n\nCommittee Membership\n\nResponsibility Executive Appointment Meeting\n\nExecutive Compensation Meeting\n\nAkio Toyoda Male 68 24 Chairman of the Board of Directors 94% (15/16)\n\nShigeru Hayakawa Male 70 9 Chairperson Chairperson Chief Privacy Officer 100% (16/16)\n\nKoji Sato Male 54 1 Chief Executive Officer 100% (13/13)\n\nHiroki Nakajima Male 62 1 Chief Technology Officer 100% (13/13)\n\nYoichi Miyazaki Male 60 1 Member Member Chief Financial Officer Chief Competitive Officer 100% (13/13)\n\nSimon Humphries Male 57 1 Chief Branding Officer 100% (13/13)\n\nIkuro Sugawara Male 67 6 Outside, independent Member Member 100% (16/16)\n\nSir Philip Craven Male 73 6 Outside, independent Member Member 94% (15/16)\n\nMasahiko Oshima Male 63 1 Outside, independent Member Member 100% (13/13)\n\nEmi Osono Female 58 1 Outside, independent Member Member 100% (13/13)\n\n\\* Figures represent attendance at Board of Directors’ meetings in fiscal 2024.\n\nAnalysis and Evaluation of the Effectiveness of the Board of Directors In order to improve the effectiveness of the Board of Directors, Toyota conducts an analysis and evaluation of the Board of Directors every year. Details of the most recent analysis and evaluation are as follows..\n\n1\\. Analysis and Evaluation A survey assessing the membership, meeting proceedings, and supervisory function efficacy of the Board of Directors was carried out. Views and proposals regarding the background and causes of issues identified by the survey, as well as regarding the improvement of such issues, were compiled and reported to the Board of Directors and then discussed at a meeting of the Board of Directors.\n\nMethod of evaluation: Self-evaluation through questionnaires Subject of evaluation: Members of the Board of Directors and Audit & Supervisory Board members Implementation period: March–April 2024 Matters to be evaluated: 1. Membership and meeting proceedings of the Board of Directors 2. Management and business strategies 3. Corporate ethics and risk management 4. Communication with shareholders and other stakeholders\n\n2\\. Summary of Findings In fiscal 2024, a new management team was instituted with the addition of a number of new outside members of the Board of Directors and outside Audit & Supervisory Board members. To invigorate discussions at Board of Directors’ meetings, the Company has been offering more opportunities for communication between members of the executive team and outside members of the Board of Directors and outside Audit & Supervisory Board members, providing outside members of the Board of Directors and outside Audit & Supervisory Board members with on-site tours of facilities and information, and enhancing advance explanations of Board of Directors’ meeting proposals. Against this backdrop, it was determined that improvements had been achieved with regard to advance explanations and provision of information to\n\noutside members of the Board of Directors and outside Audit & Supervisory Board members. Conversely, time allocation, consideration of business strategies, and management with an awareness of sustainability, areas that were identified as issues in fiscal 2023, were once again identified as representing issues in fiscal 2024. In order to further improve the effectiveness of the Board of Directors, Toyota will secure more opportunities for the Board of Directors to discuss impor- tant management strategy topics and promote the appropriate selection of topics to be proposed. At the same time, Toyota will work to make further improve- ments through such measures as enhancing opportunities for dialogue and exchange with the executive team to provide more information to outside members of the Board of Directors and outside Audit & Supervisory Board members, thereby facilitating more effective and vigorous discussions.\n\nAudit & Supervisory Board System Toyota has adopted the board of corporate auditors system. The six Audit & Supervisory Board members, including three outside Audit & Supervisory Board mem- bers, play a key role in Toyota’s corporate governance by undertaking audits in line with the audit policies and plans determined by the Audit & Supervisory Board. In order to appropriately audit Toyota as it transforms into a mobility company with the aim of sustainable global growth, the Audit & Supervisory Board is composed of full-time Audit & Supervisory Board members, all of whom possess deep knowledge of internal Company matters, and outside Audit & Supervisory Board members, all of whom have a high level of expertise and knowledge. Toyota takes steps to ensure that each Audit & Supervisory Board member is able to exert audit authority independently. In appointing Audit & Supervisory Board members, Toyota believes it is necessary to select individuals who have broad experience and insight in their respective fields of expertise and who can advise management from a fair and impartial perspective and are capable of auditing operational execution. Toyota’s Executive Appointment Meeting discusses recommendations to the Audit & Supervisory Board regarding the appointment or dismissal of Audit & Supervisory Board members. Toyota has appointed three outside Audit & Supervisory Board members, all of whom are registered as independent auditors with the relevant financial instrument exchanges. When appointing outside Audit & Supervisory Board members, Toyota considers the requirements set out in the Companies Act of Japan as well as the independence standards established by the relevant financial instrument exchanges.\n\nMessage from the CSO | Roundtable Discussion among Outside Officers | Dialogues with Shareholders and Investors | Corporate Governance | Risk Management and Compliance | Message from the CFO | Capital Strategies Environmental Initiatives (Disclosure Based on TCFD Recommendations) | Human Resource Development | Diversity, Equity, and Inclusion | Health and Safety and Social Contribution Activities | Respect for Human Rights Value Chain Collaboration | Vehicle Safety | Quality and Information Security | Intellectual Property and Privacy","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_020","product_type":"parse","source_file_path":"complex_header_020.pdf"},"started_at":"2026-11-12T14:56:33.835511"} {"completed_at":"2026-11-12T14:56:31.488346","latency_in_ms":2392,"output":{"example_id":"complex_table_headers/complex_header_021","grounded_pages":[],"layout_pages":[],"markdown":"All workforce is categorized as employees and none as workers.\n\nOther than Permanent includes individuals on direct contract or third party contractors.\n\n9\\. Details of performance and career development reviews of employees and workers:\n\n**Category FY 2024-25 FY 2023-24**\n\n**Total (A) No. (B) % (B/A) Total (C) No. (D) % (D/C)**\n\n**Employees**\n\nMale 10,027 9,669 96.4 10,001 10,001 100.0\n\nFemale 1,894 1,766 93.2 1,779 1,779 100.0\n\n**Total 11,921 11,435 95.9 11,780 11,780 100.0**\n\n**Workers**\n\nMale\n\nNA NA Female **Total**\n\n10\\. Health and Safety Management System:\n\n**a.** **Whether an occupational health and safety management system has been implemented by the entity? (Yes/ No). If yes, the coverage such system?**\n\nYes. Tata Technologies has implemented a health and safety management system in line with ISO 45001:2018 and is assessed for ISO 45001:2018 (HJW Corp & SEZ 4) & TATA BUSINESS EXCELLENCE MANAGEMENT Assessment-Safety Category for global locations. The Company has a Health and Safety management system for global locations.\n\n**b. What are the processes used to identify work-related hazards and assess risks on a routine and non- routine basis by the entity?**\n\nThe Company routinely monitors work-related hazards through regular assessments of work areas, employee reporting of complaints and observations, safety audits for compliance, and ISO certification audits. Additionally, non-routine assessments include incident investigations, reviews of past incidents, new facility planning reviews, and RCA workshops to mitigate incidents and near misses. This information is managed centrally by the OHS team and regularly reviewed by management.\n\n**c. Whether you have processes for workers to report work related hazards and to remove themselves from such risks. (Y/N)**\n\nYes, there is a Safety Management System in place and a multi-channel communication system comprising of Email and Global Safety Management Portal to report the incidents, accidents and near Miss scenarios.\n\n**d. Do the employees/ workers of the entity have access to non-occupational medical and healthcare services? (Yes/ No)**\n\nYes, non-occupational access to medical and healthcare service is provided to all the employees and workers in India and in other locations (global) it is as per local laws.\n\n11\\. Details of safety related incidents, in the following format:\n\n**Safety Incident /Number\\* Category FY 2024-25 FY 2023-24**\n\nLost Time Injury Frequency Rate (LTIFR) (per one million-person hours worked)\n\nEmployees 0 0\n\nWorkers NA NA\n\nTotal recordable work-related injuries Employees 4 0\n\nWorkers NA NA\n\nNo. of fatalities Employees 0 0\n\nWorkers NA NA\n\nHigh consequence work-related injury or ill- health (excluding fatalities)\n\nEmployees 0 0\n\nWorkers NA NA\n\n\\*The safety data presented herein pertains exclusively to incidents occurring within the Company’s owned and leased operational premises. It does not include any incidents that may have occurred at client premises or third-party locations where our employees may be deployed.\n\nBased on the voluntary disclosures received and information available with the company.\n\nAll workforce is categorized as employees and none as workers.\n\nOther than Permanent includes individuals on direct contract or third party contractors\n\n8\\. Details of training given to employees and workers:\n\n**Category**\n\n**FY 2024-25 FY 2023-24**\n\n**Total**\n\n**employees/ workers in respective category**\n\n**(A)**\n\n**No. of**\n\n**employees / workers in respective**\n\n**category, who**\n\n**are part of**\n\n**association(s)**\n\n**or Union (B)**\n\n**%(B/A)**\n\n**Total**\n\n**employees/ workers in respective category**\n\n**(C)**\n\n**No. of**\n\n**employees / workers in respective**\n\n**category, who**\n\n**are part of**\n\n**association(s)**\n\n**or Union (D)**\n\n**%(D/C)**\n\n**Total Permanent Employees**\n\n11,921 0 0.0 11,780 0 0.0\n\n\\- Male 10,027 0 0.0 10,001 NA 0.0\n\n\\- Female 1,894 0 0.0 1,729 NA 0.0\n\n**Total Permanent Workers** NA NA NA NA NA NA\n\n\\- Male NA NA NA NA NA NA\n\n\\- Female NA NA NA NA NA NA\n\n7\\. Membership of employees and workers in association(s) or Unions recognized by the listed entity:\n\n**Category**\n\n**FY 2024-25 FY 2023-24\\***\n\n**Total (A)**\n\n**On health and**\n\n**safety measures**\n\n**On skill**\n\n**upgradation Total (D)**\n\n**On health and safety measures**\n\n**On skill**\n\n**upgradation**\n\n**No. (B) % (B/A) No. (C) % (C/A) No. (E) % (E/D) No. (F) % (F/D)**\n\n**Employees**\n\nMale 10,027 9,768 97.4 9,401 93.8 8,666 8,666 100.0 5,985 69.1\n\nFemale 1,894 1,843 97.3 1,759 92.9 1,520 1,502 98.8 1,153 75.9\n\n**Total 11,921 11,611 97.4 11,160 93.6 10,186 10,168 99.8 7,138 70.1**\n\n**Workers**\n\nMale\n\nNA NA Female **Total**\n\nAll workforce is categorized as employees and none as workers.\n\nOther than Permanent includes individuals on direct contract or third party contractors\n\n\\*Data for India operations only\n\nCORPORATE OVERVIEW **STATUTORY REPORTS** FINANCIAL STATEMENTS\n\nAnnual Report **2024-25** Engineering a software defined future 196 197","pages":[{"line_numbers":[],"markdown":"All workforce is categorized as employees and none as workers.\n\nOther than Permanent includes individuals on direct contract or third party contractors.\n\n9\\. Details of performance and career development reviews of employees and workers:\n\n**Category FY 2024-25 FY 2023-24**\n\n**Total (A) No. (B) % (B/A) Total (C) No. (D) % (D/C)**\n\n**Employees**\n\nMale 10,027 9,669 96.4 10,001 10,001 100.0\n\nFemale 1,894 1,766 93.2 1,779 1,779 100.0\n\n**Total 11,921 11,435 95.9 11,780 11,780 100.0**\n\n**Workers**\n\nMale\n\nNA NA Female **Total**\n\n10\\. Health and Safety Management System:\n\n**a.** **Whether an occupational health and safety management system has been implemented by the entity? (Yes/ No). If yes, the coverage such system?**\n\nYes. Tata Technologies has implemented a health and safety management system in line with ISO 45001:2018 and is assessed for ISO 45001:2018 (HJW Corp & SEZ 4) & TATA BUSINESS EXCELLENCE MANAGEMENT Assessment-Safety Category for global locations. The Company has a Health and Safety management system for global locations.\n\n**b. What are the processes used to identify work-related hazards and assess risks on a routine and non- routine basis by the entity?**\n\nThe Company routinely monitors work-related hazards through regular assessments of work areas, employee reporting of complaints and observations, safety audits for compliance, and ISO certification audits. Additionally, non-routine assessments include incident investigations, reviews of past incidents, new facility planning reviews, and RCA workshops to mitigate incidents and near misses. This information is managed centrally by the OHS team and regularly reviewed by management.\n\n**c. Whether you have processes for workers to report work related hazards and to remove themselves from such risks. (Y/N)**\n\nYes, there is a Safety Management System in place and a multi-channel communication system comprising of Email and Global Safety Management Portal to report the incidents, accidents and near Miss scenarios.\n\n**d. Do the employees/ workers of the entity have access to non-occupational medical and healthcare services? (Yes/ No)**\n\nYes, non-occupational access to medical and healthcare service is provided to all the employees and workers in India and in other locations (global) it is as per local laws.\n\n11\\. Details of safety related incidents, in the following format:\n\n**Safety Incident /Number\\* Category FY 2024-25 FY 2023-24**\n\nLost Time Injury Frequency Rate (LTIFR) (per one million-person hours worked)\n\nEmployees 0 0\n\nWorkers NA NA\n\nTotal recordable work-related injuries Employees 4 0\n\nWorkers NA NA\n\nNo. of fatalities Employees 0 0\n\nWorkers NA NA\n\nHigh consequence work-related injury or ill- health (excluding fatalities)\n\nEmployees 0 0\n\nWorkers NA NA\n\n\\*The safety data presented herein pertains exclusively to incidents occurring within the Company’s owned and leased operational premises. It does not include any incidents that may have occurred at client premises or third-party locations where our employees may be deployed.\n\nBased on the voluntary disclosures received and information available with the company.\n\nAll workforce is categorized as employees and none as workers.\n\nOther than Permanent includes individuals on direct contract or third party contractors\n\n8\\. Details of training given to employees and workers:\n\n**Category**\n\n**FY 2024-25 FY 2023-24**\n\n**Total**\n\n**employees/ workers in respective category**\n\n**(A)**\n\n**No. of**\n\n**employees / workers in respective**\n\n**category, who**\n\n**are part of**\n\n**association(s)**\n\n**or Union (B)**\n\n**%(B/A)**\n\n**Total**\n\n**employees/ workers in respective category**\n\n**(C)**\n\n**No. of**\n\n**employees / workers in respective**\n\n**category, who**\n\n**are part of**\n\n**association(s)**\n\n**or Union (D)**\n\n**%(D/C)**\n\n**Total Permanent Employees**\n\n11,921 0 0.0 11,780 0 0.0\n\n\\- Male 10,027 0 0.0 10,001 NA 0.0\n\n\\- Female 1,894 0 0.0 1,729 NA 0.0\n\n**Total Permanent Workers** NA NA NA NA NA NA\n\n\\- Male NA NA NA NA NA NA\n\n\\- Female NA NA NA NA NA NA\n\n7\\. Membership of employees and workers in association(s) or Unions recognized by the listed entity:\n\n**Category**\n\n**FY 2024-25 FY 2023-24\\***\n\n**Total (A)**\n\n**On health and**\n\n**safety measures**\n\n**On skill**\n\n**upgradation Total (D)**\n\n**On health and safety measures**\n\n**On skill**\n\n**upgradation**\n\n**No. (B) % (B/A) No. (C) % (C/A) No. (E) % (E/D) No. (F) % (F/D)**\n\n**Employees**\n\nMale 10,027 9,768 97.4 9,401 93.8 8,666 8,666 100.0 5,985 69.1\n\nFemale 1,894 1,843 97.3 1,759 92.9 1,520 1,502 98.8 1,153 75.9\n\n**Total 11,921 11,611 97.4 11,160 93.6 10,186 10,168 99.8 7,138 70.1**\n\n**Workers**\n\nMale\n\nNA NA Female **Total**\n\nAll workforce is categorized as employees and none as workers.\n\nOther than Permanent includes individuals on direct contract or third party contractors\n\n\\*Data for India operations only\n\nCORPORATE OVERVIEW **STATUTORY REPORTS** FINANCIAL STATEMENTS\n\nAnnual Report **2024-25** Engineering a software defined future 196 197","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_021","product_type":"parse","source_file_path":"complex_header_021.pdf"},"started_at":"2026-11-12T14:56:29.096073"} {"completed_at":"2026-11-12T14:56:41.890016","latency_in_ms":2220,"output":{"example_id":"complex_table_headers/complex_header_022","grounded_pages":[],"layout_pages":[],"markdown":"## **_Lincoln WealthAccumulate_** **® 2 IUL (2020)**\n\n**The Lincoln National Life Insurance Company, Fort Wayne, IN** LCN-3302468-102620\n\n**This illustration is not complete without all pages.** _Lincoln WealthAccumulate 2 IUL (2020) - 05/10/21_ State: AL TP: 8,616.80 7/18/2022 1:03 PM FLEX-I v57.0 D\n\n, 45 year-old Male, issued in Alabama Preferred Non-Tobacco underwriting class\n\n## **Understanding Your Illustration**\n\n### **Indexed accounts details**\n\nIndexed Account\n\nMaximum Illustrative Rate\n\nGuaranteed Minimum Interest Rate (floor)\n\nCurrent Participation Rate\n\nCurrent Index Growth Cap\n\nCurrent Interest Bonuses\n\nAdditional Cost\n\n**Fidelity AIM** **®** **Dividend Index** Fixed Bonus ¹ 5\\.74%\n\n0% guaranteed minimum\n\n125% †\n\n_25% guaranteed minimum_\n\nN/A\n\n1\\.00% †\n\n0\\.25% guaranteed minimum fixed bonus ⁸\n\nNone\n\nHigh Participation Rate ²\n\n5\\.74%\n\n0% guaranteed minimum\n\n165% †\n\n_25% guaranteed minimum_\n\nN/A N/A None\n\n**S&P 500** **®** **Index** Multiplier ³ 5\\.13%\n\n0% guaranteed minimum\n\n100% †\n\nguaranteed minimum\n\n8\\.50% †\n\n_1\\.00% guaranteed minimum_\n\n50% †\n\nguaranteed minimum multiplier ⁷\n\n2% †\n\nguaranteed maximum asset based charge\n\nTraditional ⁴ 5\\.54%\n\n0\\.25% guaranteed minimum\n\n100% †\n\nguaranteed minimum\n\n8\\.50% †\n\n_1\\.00% guaranteed minimum_\n\nN/A None\n\nFixed Bonus ⁵ 5\\.28%\n\n0\\.25% guaranteed minimum\n\n100% †\n\nguaranteed minimum\n\n8\\.00% †\n\n_1\\.00% guaranteed minimum_\n\n0\\.25% †\n\nguaranteed minimum fixed bonus ⁸\n\nNone\n\nPerformance Trigger ⁶ 4\\.75%\n\n0% guaranteed minimum\n\nN/A\n\n6\\.50% †\\*\n\n_1\\.00% guaranteed minimum_\n\nN/A None\n\n**Cap Reduction Protection** If the current cap on any indexed account is reduced to 4% or lower, the policy owner can fully surrender their policy with no surrender charges.\n\n† Non-Guaranteed Elements (NGE) \\* Current Performance Trigger Rate. Rate is not included in Cap Reduction Protection 1 1 Year Point-to-Point Fidelity AIM ® Dividend Indexed Account - Fixed Bonus 2 1 Year Point-to-Point Fidelity AIM ® Dividend Indexed Account 3 1 Year Point-to-Point S&P 500 ® Multiplier Indexed Account 4 1 Year Point-to-Point S&P 500 ® Traditional Indexed Account\n\n5 1 Year Point-to-Point S&P 500 ® Fixed Bonus Indexed Account 6 1 Year Point-to-Point S&P 500 ® Performance Trigger Indexed Account 7 Index Credit Enhancement (ICE) 8 Account Value Enhancement (AVE)\n\n7 of 56","pages":[{"line_numbers":[],"markdown":"## **_Lincoln WealthAccumulate_** **® 2 IUL (2020)**\n\n**The Lincoln National Life Insurance Company, Fort Wayne, IN** LCN-3302468-102620\n\n**This illustration is not complete without all pages.** _Lincoln WealthAccumulate 2 IUL (2020) - 05/10/21_ State: AL TP: 8,616.80 7/18/2022 1:03 PM FLEX-I v57.0 D\n\n, 45 year-old Male, issued in Alabama Preferred Non-Tobacco underwriting class\n\n## **Understanding Your Illustration**\n\n### **Indexed accounts details**\n\nIndexed Account\n\nMaximum Illustrative Rate\n\nGuaranteed Minimum Interest Rate (floor)\n\nCurrent Participation Rate\n\nCurrent Index Growth Cap\n\nCurrent Interest Bonuses\n\nAdditional Cost\n\n**Fidelity AIM** **®** **Dividend Index** Fixed Bonus ¹ 5\\.74%\n\n0% guaranteed minimum\n\n125% †\n\n_25% guaranteed minimum_\n\nN/A\n\n1\\.00% †\n\n0\\.25% guaranteed minimum fixed bonus ⁸\n\nNone\n\nHigh Participation Rate ²\n\n5\\.74%\n\n0% guaranteed minimum\n\n165% †\n\n_25% guaranteed minimum_\n\nN/A N/A None\n\n**S&P 500** **®** **Index** Multiplier ³ 5\\.13%\n\n0% guaranteed minimum\n\n100% †\n\nguaranteed minimum\n\n8\\.50% †\n\n_1\\.00% guaranteed minimum_\n\n50% †\n\nguaranteed minimum multiplier ⁷\n\n2% †\n\nguaranteed maximum asset based charge\n\nTraditional ⁴ 5\\.54%\n\n0\\.25% guaranteed minimum\n\n100% †\n\nguaranteed minimum\n\n8\\.50% †\n\n_1\\.00% guaranteed minimum_\n\nN/A None\n\nFixed Bonus ⁵ 5\\.28%\n\n0\\.25% guaranteed minimum\n\n100% †\n\nguaranteed minimum\n\n8\\.00% †\n\n_1\\.00% guaranteed minimum_\n\n0\\.25% †\n\nguaranteed minimum fixed bonus ⁸\n\nNone\n\nPerformance Trigger ⁶ 4\\.75%\n\n0% guaranteed minimum\n\nN/A\n\n6\\.50% †\\*\n\n_1\\.00% guaranteed minimum_\n\nN/A None\n\n**Cap Reduction Protection** If the current cap on any indexed account is reduced to 4% or lower, the policy owner can fully surrender their policy with no surrender charges.\n\n† Non-Guaranteed Elements (NGE) \\* Current Performance Trigger Rate. Rate is not included in Cap Reduction Protection 1 1 Year Point-to-Point Fidelity AIM ® Dividend Indexed Account - Fixed Bonus 2 1 Year Point-to-Point Fidelity AIM ® Dividend Indexed Account 3 1 Year Point-to-Point S&P 500 ® Multiplier Indexed Account 4 1 Year Point-to-Point S&P 500 ® Traditional Indexed Account\n\n5 1 Year Point-to-Point S&P 500 ® Fixed Bonus Indexed Account 6 1 Year Point-to-Point S&P 500 ® Performance Trigger Indexed Account 7 Index Credit Enhancement (ICE) 8 Account Value Enhancement (AVE)\n\n7 of 56","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_022","product_type":"parse","source_file_path":"complex_header_022.pdf"},"started_at":"2026-11-12T14:56:39.669140"} {"completed_at":"2026-11-12T14:56:47.503955","latency_in_ms":1424,"output":{"example_id":"complex_table_headers/complex_header_023","grounded_pages":[],"layout_pages":[],"markdown":"SMFG Capital Ratio Information\n\n**SMFG** 2011 183\n\n**(B) Portfolio**\n\n**a. Domestic Corporate, Sovereign and Bank Exposures**\n\nBillions of yen Exposure amount Weighted average CCF\n\nWeighted average PD\n\nWeighted average LGD\n\nWeighted average ELdefault\n\nWeighted average risk weight March 31, 2011 Total On-balance sheet assets Off-balance sheet assets Undrawn amount J1-J3 ...................................¥18,775.3 ¥13,538.6 ¥5,236.6 ¥3,677.9 75.00% 0.06% 34.50% —% 15.62%\n\nJ4-J6 ................................... 14,013.7 10,817.1 3,196.6 920.3 75.00 0.85 29.25 — 42.24\n\nJ7 (excluding J7R) ............... 1,778.7 1,541.3 237.4 20.5 75.00 12.54 27.70 — 112.16\n\nJapanese government and local municipal corporations .... 32,765.0 32,641.9 123.0 30.7 75.00 0.00 35.25 — 0.06\n\nOthers .................................. 5,529.7 5,071.1 458.5 85.4 75.00 1.00 37.06 — 49.16\n\nDefault (J7R, J8-J10) ........... 1,401.0 1,334.5 66.6 0.3 100.00 100.00 53.22 51.84 17.19\n\nTotal .....................................¥74,263.3 ¥64,944.6 ¥9,318.7 ¥4,735.1 — — — — —\n\nBillions of yen Exposure amount Weighted average CCF\n\nWeighted average PD\n\nWeighted average LGD\n\nWeighted average ELdefault\n\nWeighted average risk weight March 31, 2010 Total On-balance sheet assets Off-balance sheet assets Undrawn amount J1-J3 ...................................¥18,017.3 ¥12,663.0 ¥5,354.3 ¥4,012.5 75.00% 0.07% 35.32% —% 16.75% J4-J6 ................................... 15,045.7 11,722.7 3,322.9 1,064.0 75.00 1.63 31.40 — 58.82 J7 (excluding J7R) ............... 2,400.6 2,146.4 254.2 16.4 75.00 16.54 30.14 — 134.64 Japanese government and local municipal corporations .... 22,671.2 22,406.6 264.6 0.8 75.00 0.00 35.09 — 0.09 Others .................................. 5,547.9 5,030.6 517.3 133.0 75.00 1.34 38.01 — 56.63 Default (J7R, J8-J10) ........... 1,429.6 1,379.2 50.3 1.7 100.00 100.00 53.74 52.98 9.54 Total .....................................¥65,112.3 ¥55,348.6 ¥9,763.7 ¥5,228.4 — — — — —\n\nNote: “Others” includes exposures guaranteed by credit guarantee corporations, exposures to public sector entities and voluntary organizations, and exposures to obligors not assigned obligor grades because they have yet to close their books (for example, newly established companies), as well as business loans and standardized SME loans of more than ¥100 million.\n\n**b. Overseas Corporate, Sovereign and Bank Exposures**\n\nBillions of yen Exposure amount Weighted average CCF\n\nWeighted average PD\n\nWeighted average LGD\n\nWeighted average ELdefault\n\nWeighted average risk weight March 31, 2011 Total On-balance sheet assets Off-balance sheet assets Undrawn amount G1-G3 .................................. ¥23,232.7 ¥15,404.6 ¥7,828.1 ¥3,515.5 75.00% 0.15% 29.36% —% 16.66%\n\nG4-G6 .................................. 779.8 610.7 169.1 158.5 75.00 2.34 28.31 — 72.23\n\nG7 (excluding G7R) ............. 288.7 190.1 98.6 99.5 75.00 23.26 27.49 — 146.10\n\nOthers .................................. 118.1 98.6 19.5 16.9 75.00 2.21 38.20 — 111.24\n\nDefault (G7R, G8-G10) ........ 170.1 154.1 15.9 6.7 100.00 100.00 63.54 56.97 82.12\n\nTotal ..................................... ¥24,589.4 ¥16,458.2 ¥8,131.3 ¥3,797.2 — — — — —\n\nBillions of yen Exposure amount Weighted average CCF\n\nWeighted average PD\n\nWeighted average LGD\n\nWeighted average ELdefault\n\nWeighted average risk weight March 31, 2010 Total On-balance sheet assets Off-balance sheet assets Undrawn amount G1-G3 .................................. ¥17,929.1 ¥11,601.0 ¥6,328.1 ¥2,928.6 75.00% 0.18% 29.84% —% 17.54% G4-G6 .................................. 946.2 768.1 178.1 168.0 75.00 2.32 29.39 — 73.64 G7 (excluding G7R) ............. 459.1 280.3 178.8 102.6 75.00 24.59 29.26 — 158.78 Others .................................. 152.5 105.5 47.0 4.4 75.00 1.55 40.66 — 86.53 Default (G7R, G8-G10) ........ 212.0 199.0 13.0 7.2 100.00 100.00 71.52 64.33 89.89 Total ..................................... ¥19,698.8 ¥12,953.9 ¥6,744.9 ¥3,210.9 — — — — —","pages":[{"line_numbers":[],"markdown":"SMFG Capital Ratio Information\n\n**SMFG** 2011 183\n\n**(B) Portfolio**\n\n**a. Domestic Corporate, Sovereign and Bank Exposures**\n\nBillions of yen Exposure amount Weighted average CCF\n\nWeighted average PD\n\nWeighted average LGD\n\nWeighted average ELdefault\n\nWeighted average risk weight March 31, 2011 Total On-balance sheet assets Off-balance sheet assets Undrawn amount J1-J3 ...................................¥18,775.3 ¥13,538.6 ¥5,236.6 ¥3,677.9 75.00% 0.06% 34.50% —% 15.62%\n\nJ4-J6 ................................... 14,013.7 10,817.1 3,196.6 920.3 75.00 0.85 29.25 — 42.24\n\nJ7 (excluding J7R) ............... 1,778.7 1,541.3 237.4 20.5 75.00 12.54 27.70 — 112.16\n\nJapanese government and local municipal corporations .... 32,765.0 32,641.9 123.0 30.7 75.00 0.00 35.25 — 0.06\n\nOthers .................................. 5,529.7 5,071.1 458.5 85.4 75.00 1.00 37.06 — 49.16\n\nDefault (J7R, J8-J10) ........... 1,401.0 1,334.5 66.6 0.3 100.00 100.00 53.22 51.84 17.19\n\nTotal .....................................¥74,263.3 ¥64,944.6 ¥9,318.7 ¥4,735.1 — — — — —\n\nBillions of yen Exposure amount Weighted average CCF\n\nWeighted average PD\n\nWeighted average LGD\n\nWeighted average ELdefault\n\nWeighted average risk weight March 31, 2010 Total On-balance sheet assets Off-balance sheet assets Undrawn amount J1-J3 ...................................¥18,017.3 ¥12,663.0 ¥5,354.3 ¥4,012.5 75.00% 0.07% 35.32% —% 16.75% J4-J6 ................................... 15,045.7 11,722.7 3,322.9 1,064.0 75.00 1.63 31.40 — 58.82 J7 (excluding J7R) ............... 2,400.6 2,146.4 254.2 16.4 75.00 16.54 30.14 — 134.64 Japanese government and local municipal corporations .... 22,671.2 22,406.6 264.6 0.8 75.00 0.00 35.09 — 0.09 Others .................................. 5,547.9 5,030.6 517.3 133.0 75.00 1.34 38.01 — 56.63 Default (J7R, J8-J10) ........... 1,429.6 1,379.2 50.3 1.7 100.00 100.00 53.74 52.98 9.54 Total .....................................¥65,112.3 ¥55,348.6 ¥9,763.7 ¥5,228.4 — — — — —\n\nNote: “Others” includes exposures guaranteed by credit guarantee corporations, exposures to public sector entities and voluntary organizations, and exposures to obligors not assigned obligor grades because they have yet to close their books (for example, newly established companies), as well as business loans and standardized SME loans of more than ¥100 million.\n\n**b. Overseas Corporate, Sovereign and Bank Exposures**\n\nBillions of yen Exposure amount Weighted average CCF\n\nWeighted average PD\n\nWeighted average LGD\n\nWeighted average ELdefault\n\nWeighted average risk weight March 31, 2011 Total On-balance sheet assets Off-balance sheet assets Undrawn amount G1-G3 .................................. ¥23,232.7 ¥15,404.6 ¥7,828.1 ¥3,515.5 75.00% 0.15% 29.36% —% 16.66%\n\nG4-G6 .................................. 779.8 610.7 169.1 158.5 75.00 2.34 28.31 — 72.23\n\nG7 (excluding G7R) ............. 288.7 190.1 98.6 99.5 75.00 23.26 27.49 — 146.10\n\nOthers .................................. 118.1 98.6 19.5 16.9 75.00 2.21 38.20 — 111.24\n\nDefault (G7R, G8-G10) ........ 170.1 154.1 15.9 6.7 100.00 100.00 63.54 56.97 82.12\n\nTotal ..................................... ¥24,589.4 ¥16,458.2 ¥8,131.3 ¥3,797.2 — — — — —\n\nBillions of yen Exposure amount Weighted average CCF\n\nWeighted average PD\n\nWeighted average LGD\n\nWeighted average ELdefault\n\nWeighted average risk weight March 31, 2010 Total On-balance sheet assets Off-balance sheet assets Undrawn amount G1-G3 .................................. ¥17,929.1 ¥11,601.0 ¥6,328.1 ¥2,928.6 75.00% 0.18% 29.84% —% 17.54% G4-G6 .................................. 946.2 768.1 178.1 168.0 75.00 2.32 29.39 — 73.64 G7 (excluding G7R) ............. 459.1 280.3 178.8 102.6 75.00 24.59 29.26 — 158.78 Others .................................. 152.5 105.5 47.0 4.4 75.00 1.55 40.66 — 86.53 Default (G7R, G8-G10) ........ 212.0 199.0 13.0 7.2 100.00 100.00 71.52 64.33 89.89 Total ..................................... ¥19,698.8 ¥12,953.9 ¥6,744.9 ¥3,210.9 — — — — —","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_023","product_type":"parse","source_file_path":"complex_header_023.pdf"},"started_at":"2026-11-12T14:56:46.079072"} {"completed_at":"2026-11-12T14:56:50.836062","latency_in_ms":1505,"output":{"example_id":"complex_table_headers/complex_header_028","grounded_pages":[],"layout_pages":[],"markdown":"### অবভয়র্াগ প্রবিকার ব্যিস্থা সংক্রান্ত কমযপবরকল্পনা, ২০২১-২০২২\n\nকমমসম্পাদ প্রনি প্রেৈ\n\nমান কা মক্রম\n\nকমমসম্পাদন\n\nসূচক একক\n\nকমমসম্পাদ ন সূচদকি\n\nমান\n\nপ্রকৃত অজমন ২০১ ৯-২০\n\nপ্রকৃত অজমন ২০২ ০-২১\n\nলেযমাৈা ২০২১-২০২২\n\nঅসািাি ণ\n\nঅন্ত্রত উিম উিম চলন্ত্রত মান\n\nচলন্ত্রত মাদনি ন্ত্রনদে\n\n১০০% ৯০% ৮০% ৭০% ৬০%\n\n১ ২ ৩ ৪ ৫ ৬ ৭ ৮ ৯ ১০ ১১ ১২ ১৩\n\nপ্রান্ত্রতষ্ঠান্ত্রন\n\nক\n\nব্যিস্থাপনা\n\n৫\n\n[১.১] অবভয়র্াগ বনষ্পবি কমযকিযা (অবনক) ও আবপল কমযকিযার িথ্য ওয়য়িসাইয়ে ত্রৈমাবসকবভবিয়ি হালনাগাদকরণ\n\n[১.১.১] অন্ত্রনক ও আন্ত্রপল কমমকতমাি তথ্য হালনাগাদকৃত এিাং ওদয়িসাইদে আপদলাডকৃত\n\nসংখ্যা\n\n৫ - - ৪ ৩ - - -\n\nপন্ত্রিিীেণ ও সেমতা\n\nউেয়ন\n\n২০\n\n[২.১] বনবদযষ্ট সময়য় অনলাইন/ অফলাইয়ন প্রাপ্ত অবভয়র্াগ বনষ্পবি এিং বনষ্পবি সংক্রান্ত মাবসক\n\nপ্রবিয়িদন উর্ধ্যিন কর্তযপক্ষ িরাির গপ্ররণ\n\n[২.১.১] অবভয়র্াগ বনষ্পবিকৃি % ৮ - - ৯০% ৮০% ৭০% ৬০% -\n\n[২.২] কমযকিযা/কমযচারীয়দর অবভয়র্াগ প্রবিকার ব্যিস্থা এিং বিআরএস সফেওয়যার বিষয়ক প্রবিক্ষণ\n\nআয়য়ািন\n\n[২.২.১] প্রবিক্ষণ আয়য়াবিি সংখ্যা ৫ - - ৪ ৩ ২ ১ -\n\n[২.৩] ত্রৈমান্ত্রসক ন্ত্রভন্ত্রিদত পন্ত্রিিীেণ এিাং ত্রৈমান্ত্রসক পন্ত্রিিীেণ প্রন্ত্রতদিদন উর্ধ্মতন কর্তমপদেি ন্ত্রনকে প্রপ্রিণ\n\n[২.৩.১] ত্রৈমান্ত্রসক প্রন্ত্রতদিদন প্রপ্রন্ত্রিত\n\nসংখ্যা ৩ - - ৪ ৩ ২ ১ -\n\n[২.৪] অবভয়র্াগ প্রবিকার ব্যিস্থাপনা বিষয়য় গেকয়হাল্ডারগয়ণর সমন্বয়য় অিবহিকরণ সভা\n\n[২.৪.১] সভা অনুবষ্ঠি সংখ্যা ৪ - - ২ ১ - -","pages":[{"line_numbers":[],"markdown":"### অবভয়র্াগ প্রবিকার ব্যিস্থা সংক্রান্ত কমযপবরকল্পনা, ২০২১-২০২২\n\nকমমসম্পাদ প্রনি প্রেৈ\n\nমান কা মক্রম\n\nকমমসম্পাদন\n\nসূচক একক\n\nকমমসম্পাদ ন সূচদকি\n\nমান\n\nপ্রকৃত অজমন ২০১ ৯-২০\n\nপ্রকৃত অজমন ২০২ ০-২১\n\nলেযমাৈা ২০২১-২০২২\n\nঅসািাি ণ\n\nঅন্ত্রত উিম উিম চলন্ত্রত মান\n\nচলন্ত্রত মাদনি ন্ত্রনদে\n\n১০০% ৯০% ৮০% ৭০% ৬০%\n\n১ ২ ৩ ৪ ৫ ৬ ৭ ৮ ৯ ১০ ১১ ১২ ১৩\n\nপ্রান্ত্রতষ্ঠান্ত্রন\n\nক\n\nব্যিস্থাপনা\n\n৫\n\n[১.১] অবভয়র্াগ বনষ্পবি কমযকিযা (অবনক) ও আবপল কমযকিযার িথ্য ওয়য়িসাইয়ে ত্রৈমাবসকবভবিয়ি হালনাগাদকরণ\n\n[১.১.১] অন্ত্রনক ও আন্ত্রপল কমমকতমাি তথ্য হালনাগাদকৃত এিাং ওদয়িসাইদে আপদলাডকৃত\n\nসংখ্যা\n\n৫ - - ৪ ৩ - - -\n\nপন্ত্রিিীেণ ও সেমতা\n\nউেয়ন\n\n২০\n\n[২.১] বনবদযষ্ট সময়য় অনলাইন/ অফলাইয়ন প্রাপ্ত অবভয়র্াগ বনষ্পবি এিং বনষ্পবি সংক্রান্ত মাবসক\n\nপ্রবিয়িদন উর্ধ্যিন কর্তযপক্ষ িরাির গপ্ররণ\n\n[২.১.১] অবভয়র্াগ বনষ্পবিকৃি % ৮ - - ৯০% ৮০% ৭০% ৬০% -\n\n[২.২] কমযকিযা/কমযচারীয়দর অবভয়র্াগ প্রবিকার ব্যিস্থা এিং বিআরএস সফেওয়যার বিষয়ক প্রবিক্ষণ\n\nআয়য়ািন\n\n[২.২.১] প্রবিক্ষণ আয়য়াবিি সংখ্যা ৫ - - ৪ ৩ ২ ১ -\n\n[২.৩] ত্রৈমান্ত্রসক ন্ত্রভন্ত্রিদত পন্ত্রিিীেণ এিাং ত্রৈমান্ত্রসক পন্ত্রিিীেণ প্রন্ত্রতদিদন উর্ধ্মতন কর্তমপদেি ন্ত্রনকে প্রপ্রিণ\n\n[২.৩.১] ত্রৈমান্ত্রসক প্রন্ত্রতদিদন প্রপ্রন্ত্রিত\n\nসংখ্যা ৩ - - ৪ ৩ ২ ১ -\n\n[২.৪] অবভয়র্াগ প্রবিকার ব্যিস্থাপনা বিষয়য় গেকয়হাল্ডারগয়ণর সমন্বয়য় অিবহিকরণ সভা\n\n[২.৪.১] সভা অনুবষ্ঠি সংখ্যা ৪ - - ২ ১ - -","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_028","product_type":"parse","source_file_path":"complex_header_028.pdf"},"started_at":"2026-11-12T14:56:49.330314"} {"completed_at":"2026-11-12T14:57:03.585378","latency_in_ms":2238,"output":{"example_id":"complex_table_headers/complex_header_031","grounded_pages":[],"layout_pages":[],"markdown":"NEW YORK MASTER PAC RATES\n\nTERRITORY: 01\n\nFRAME JOISTED MASONRY LT. NON-COMBUSTIBLE FIRE RESISTIVE 500K /\n\n1-6 7-8 9-10 1-6 7-8 9-10 1-6 7-8 9-10 1-6 7-8 9-10 GL LIMIT\n\nStore Pac 13.33 16.57 19.37 9.59 11.86 13.83 7.51 9.29 10.84 4.89 5.82 6.68 N/A\n\nRate Group 1 35.37 37.63 39.27 33.30 35.47 36.98 32.69 34.76 36.28 29.21 31.10 32.42 .94\n\nGroup 2 37.91 40.33 42.09 35.73 38.00 39.65 35.03 37.28 38.90 31.31 33.29 34.74 .97\n\nGroup 3 39.73 42.25 44.08 37.40 39.81 41.52 36.71 39.06 40.73 32.79 34.87 36.40 1.51\n\nGroup 4 41.22 43.84 45.74 38.81 41.28 43.10 38.06 40.50 42.25 34.03 36.18 37.75 1.62\n\nGroup 5 41.86 44.52 46.44 39.41 41.92 43.76 38.65 41.12 42.93 34.51 36.72 38.32 1.51\n\nGroup 6 43.23 45.98 47.99 40.72 43.31 45.19 39.93 42.49 44.32 35.67 37.96 39.61 1.52\n\nGroup 7 42.28 44.97 46.97 39.84 42.37 44.24 39.07 41.57 43.36 34.89 37.14 38.76 1.62\n\nGroup 8 46.85 49.84 52.00 44.12 46.97 48.97 43.28 46.05 48.07 38.68 41.14 42.93 1.51\n\nGroup 9 47.11 50.14 52.30 44.37 47.23 49.25 43.52 46.31 48.32 38.89 41.36 43.18 2.40\n\nGroup 10 49.92 53.11 55.42 47.02 50.02 52.17 46.13 49.07 51.21 41.21 43.82 45.74 2.39\n\nSPRINKLER CREDITS\n\nCONSTRUCTION FRAME JOISTED MASONRY LT. NON-COMBUSTIBLE FIRE RESISTIVE\n\nPROTECTION CLASS 1-6 7-8 9-10 1-6 7-8 9-10 1-6 7-8 9-10 1-6 7-8 9-10\n\nBUILDINGS: Store Pac 5.11 7.20 8.44 3.66 5.13 5.99 2.85 4.01 4.67 1.67 2.33 2.67\n\nBUSINESS PERSONAL PROP.: Rate Groups 1 - 10 8.69 10.23 10.67 8.19 9.62 10.07 8.03 9.45 9.83 7.17 8.44 8.81\n\nNY NB EFF 06-01-2022 RB EFF 06-01-2022 TSR-MP-R-0104 THE TRAVELERS (ACJ)\n\nOCCUPIED BY OWNER\n\nBUS. PERS. PROP.\n\nCLASSIFICATION\n\nBUILDINGS","pages":[{"line_numbers":[],"markdown":"NEW YORK MASTER PAC RATES\n\nTERRITORY: 01\n\nFRAME JOISTED MASONRY LT. NON-COMBUSTIBLE FIRE RESISTIVE 500K /\n\n1-6 7-8 9-10 1-6 7-8 9-10 1-6 7-8 9-10 1-6 7-8 9-10 GL LIMIT\n\nStore Pac 13.33 16.57 19.37 9.59 11.86 13.83 7.51 9.29 10.84 4.89 5.82 6.68 N/A\n\nRate Group 1 35.37 37.63 39.27 33.30 35.47 36.98 32.69 34.76 36.28 29.21 31.10 32.42 .94\n\nGroup 2 37.91 40.33 42.09 35.73 38.00 39.65 35.03 37.28 38.90 31.31 33.29 34.74 .97\n\nGroup 3 39.73 42.25 44.08 37.40 39.81 41.52 36.71 39.06 40.73 32.79 34.87 36.40 1.51\n\nGroup 4 41.22 43.84 45.74 38.81 41.28 43.10 38.06 40.50 42.25 34.03 36.18 37.75 1.62\n\nGroup 5 41.86 44.52 46.44 39.41 41.92 43.76 38.65 41.12 42.93 34.51 36.72 38.32 1.51\n\nGroup 6 43.23 45.98 47.99 40.72 43.31 45.19 39.93 42.49 44.32 35.67 37.96 39.61 1.52\n\nGroup 7 42.28 44.97 46.97 39.84 42.37 44.24 39.07 41.57 43.36 34.89 37.14 38.76 1.62\n\nGroup 8 46.85 49.84 52.00 44.12 46.97 48.97 43.28 46.05 48.07 38.68 41.14 42.93 1.51\n\nGroup 9 47.11 50.14 52.30 44.37 47.23 49.25 43.52 46.31 48.32 38.89 41.36 43.18 2.40\n\nGroup 10 49.92 53.11 55.42 47.02 50.02 52.17 46.13 49.07 51.21 41.21 43.82 45.74 2.39\n\nSPRINKLER CREDITS\n\nCONSTRUCTION FRAME JOISTED MASONRY LT. NON-COMBUSTIBLE FIRE RESISTIVE\n\nPROTECTION CLASS 1-6 7-8 9-10 1-6 7-8 9-10 1-6 7-8 9-10 1-6 7-8 9-10\n\nBUILDINGS: Store Pac 5.11 7.20 8.44 3.66 5.13 5.99 2.85 4.01 4.67 1.67 2.33 2.67\n\nBUSINESS PERSONAL PROP.: Rate Groups 1 - 10 8.69 10.23 10.67 8.19 9.62 10.07 8.03 9.45 9.83 7.17 8.44 8.81\n\nNY NB EFF 06-01-2022 RB EFF 06-01-2022 TSR-MP-R-0104 THE TRAVELERS (ACJ)\n\nOCCUPIED BY OWNER\n\nBUS. PERS. PROP.\n\nCLASSIFICATION\n\nBUILDINGS","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_031","product_type":"parse","source_file_path":"complex_header_031.pdf"},"started_at":"2026-11-12T14:57:01.346504"} {"completed_at":"2026-11-12T14:57:14.373625","latency_in_ms":1523,"output":{"example_id":"complex_table_headers/complex_header_032","grounded_pages":[],"layout_pages":[],"markdown":"p ETcf a b aTeT dTb X RaTPbTS / Tg) O c 1(,-, X X R PaTS c cWT aX a hTPa dPacTa\\* KWT 9K\"K acbETc TgXc TVPcXeT h X PRcTS cWT Va fcW aPcT Qh P a gX PcT h .,, Q b $-,%$&% \\*\n\np XbcaXQdcX aTeT dT STRaTPbTS 3 Tg) O( aX PaX h SaXeT Qh P 5 STRaTPbT X S TbcXR X TPa Ph)KM bdQbRaXQTab P S P\n\nP a gX PcT h .,, Q b X PRc Ua cWT 9K\"K acbETc TgXc( PacXP h UUbTc Qh P 1 X RaTPbT X S TbcXR PUUX XPcT aPcTb\\*\n\np 9SeTacXbX V aTeT dT STRaTPbTS -/ Tg) O( aX PaX h SaXeT Qh S TbcXR Tcf a b PdSXT RT STR X Tb U .- P S cWT b Uc X TPa\n\nPSeTacXbX V Pa Tc X cWT L\\* \\*( PacXP h UUbTc Qh cWT Qa PSRPbc U cWT F h XRb X da T X cWT RdaaT c hTPa\\*\n\np ; cT c aTeT dT X RaTPbTS 2-4 X X ( aX PaX h SaXeT Qh cWT bdQ XRT bX V U F h XR b acb aXVWcb c Qa PSRPbc Tcf a b cWa dVW dc\n\nda T( fWXRW c cP TS 134 X X \\*\n\np ETcf a b TaPcX V Tg T bTb X RaTPbTS -4 Tg) O c .(451 X X R PaTS c cWT aX a hTPa dPacTa\\* KWT 9K\"K acbETc TgXc UPe aPQ h X PRcTS cWT Va fcW aPcT Qh P a gX PcT h 1,, Q b $--%$&% \\*\n\np ; bcb U aTeT dTb X RaTPbTS .. Tg) O( aX PaX h SaXeT Qh cWT Qa PSRPbc U cWT F h XRb X da T X cWT RdaaT c hTPa( fWXRW c cP TS\n\n22/ X X ( PacXP h UUbTc Qh fTa R cT c Tg T bT\\* KWT 9K\"K acbETc TgXc UPe aPQ h X PRcTS cWT Va fcW aPcT Qh P a gX PcT h 3,, Q b\\*\n\np \"9 X RaTPbTS 2 Tg) O( aX PaX h SaXeT Qh WXVWTa eTaWTPS P S F h XRb aT PcTS Pa TcX V Tg T bTb\\*\n\np ETcf a b 9S dbcTS :AK 9 STRaTPbTS -- Tg) O c .(--1 X X R PaTS c cWT aX a hTPa dPacTa\\* KWT Qa PSRPbc U cWT F h XRb X da T TVPcXeT h X PRcTS 9S dbcTS :AK 9 Qh 21 X X \\*\n\n**_4 4 4_**\n\n# **N X T DNP NW**\n\n**EQ NN XW Q 8WMNM DNY N N ,)& RWN XW Q 8WMNM DNY N N ,)&**\n\n**) - ) , 6Q WPN ) - ) , 6Q WPN**\n\n_DH GD DIHL_ **CNYX NM 8a 9H** **%$** **CNYX NM 8a 9H** **%$**\n\n**7R R RXW** .(154 .(4// $4% $3% 4(,3, 4(325 $4% $3%\n\n**4M N R RWP** \\-(05, -(3,5 $-/% $-/% 1(25- 2(/50 $--% $--%\n\n**6XW NW** 4// .-1 ED ED -(/52 300 44 43\n\n**QN** 45 --- $.,% $.-% .1, /,, $-3% $-4%\n\n**EX U N NW N** 1(,-, 0(424 / / -1(0,3 -2(.,3 $1% $0%\n\n**6X XO N NW N NaLU MRWP MNY NLR RXW \" X Rc RXW$** .(-41 -(4,, .- .. 3(,44 3(.0/ $.% $-%\n\n**DNUURWP& PNWN U WM M RWR R N** 3-, 23. 2 2 .(,43 .(-,5 $-% l\n\n**4MS NM 85 E74** .(--1 .(/52 $-.% $--% 2(./. 2(411 $5% $5%\n\n/\n\n**_:D 2 4_**\n\n**_B_**\n\n### **B, ) - RPQURPQ**\n\n**B, ) - 8 WRWP A N CNUN N d X N N 0& ) -**\n\n_, HIH ,, ADH H D G LNK L MC L MDIH LM KMDHB IH B ( MDM ADHDMDIHL INK L AIK DMDIH M D L&_\n\n**_9 0449_**\n\n**_2 C4 D 4:_**\n\n**_D 2E 4 4 0 D_**\n\n**E 6**","pages":[{"line_numbers":[],"markdown":"p ETcf a b aTeT dTb X RaTPbTS / Tg) O c 1(,-, X X R PaTS c cWT aX a hTPa dPacTa\\* KWT 9K\"K acbETc TgXc TVPcXeT h X PRcTS cWT Va fcW aPcT Qh P a gX PcT h .,, Q b $-,%$&% \\*\n\np XbcaXQdcX aTeT dT STRaTPbTS 3 Tg) O( aX PaX h SaXeT Qh P 5 STRaTPbT X S TbcXR X TPa Ph)KM bdQbRaXQTab P S P\n\nP a gX PcT h .,, Q b X PRc Ua cWT 9K\"K acbETc TgXc( PacXP h UUbTc Qh P 1 X RaTPbT X S TbcXR PUUX XPcT aPcTb\\*\n\np 9SeTacXbX V aTeT dT STRaTPbTS -/ Tg) O( aX PaX h SaXeT Qh S TbcXR Tcf a b PdSXT RT STR X Tb U .- P S cWT b Uc X TPa\n\nPSeTacXbX V Pa Tc X cWT L\\* \\*( PacXP h UUbTc Qh cWT Qa PSRPbc U cWT F h XRb X da T X cWT RdaaT c hTPa\\*\n\np ; cT c aTeT dT X RaTPbTS 2-4 X X ( aX PaX h SaXeT Qh cWT bdQ XRT bX V U F h XR b acb aXVWcb c Qa PSRPbc Tcf a b cWa dVW dc\n\nda T( fWXRW c cP TS 134 X X \\*\n\np ETcf a b TaPcX V Tg T bTb X RaTPbTS -4 Tg) O c .(451 X X R PaTS c cWT aX a hTPa dPacTa\\* KWT 9K\"K acbETc TgXc UPe aPQ h X PRcTS cWT Va fcW aPcT Qh P a gX PcT h 1,, Q b $--%$&% \\*\n\np ; bcb U aTeT dTb X RaTPbTS .. Tg) O( aX PaX h SaXeT Qh cWT Qa PSRPbc U cWT F h XRb X da T X cWT RdaaT c hTPa( fWXRW c cP TS\n\n22/ X X ( PacXP h UUbTc Qh fTa R cT c Tg T bT\\* KWT 9K\"K acbETc TgXc UPe aPQ h X PRcTS cWT Va fcW aPcT Qh P a gX PcT h 3,, Q b\\*\n\np \"9 X RaTPbTS 2 Tg) O( aX PaX h SaXeT Qh WXVWTa eTaWTPS P S F h XRb aT PcTS Pa TcX V Tg T bTb\\*\n\np ETcf a b 9S dbcTS :AK 9 STRaTPbTS -- Tg) O c .(--1 X X R PaTS c cWT aX a hTPa dPacTa\\* KWT Qa PSRPbc U cWT F h XRb X da T TVPcXeT h X PRcTS 9S dbcTS :AK 9 Qh 21 X X \\*\n\n**_4 4 4_**\n\n# **N X T DNP NW**\n\n**EQ NN XW Q 8WMNM DNY N N ,)& RWN XW Q 8WMNM DNY N N ,)&**\n\n**) - ) , 6Q WPN ) - ) , 6Q WPN**\n\n_DH GD DIHL_ **CNYX NM 8a 9H** **%$** **CNYX NM 8a 9H** **%$**\n\n**7R R RXW** .(154 .(4// $4% $3% 4(,3, 4(325 $4% $3%\n\n**4M N R RWP** \\-(05, -(3,5 $-/% $-/% 1(25- 2(/50 $--% $--%\n\n**6XW NW** 4// .-1 ED ED -(/52 300 44 43\n\n**QN** 45 --- $.,% $.-% .1, /,, $-3% $-4%\n\n**EX U N NW N** 1(,-, 0(424 / / -1(0,3 -2(.,3 $1% $0%\n\n**6X XO N NW N NaLU MRWP MNY NLR RXW \" X Rc RXW$** .(-41 -(4,, .- .. 3(,44 3(.0/ $.% $-%\n\n**DNUURWP& PNWN U WM M RWR R N** 3-, 23. 2 2 .(,43 .(-,5 $-% l\n\n**4MS NM 85 E74** .(--1 .(/52 $-.% $--% 2(./. 2(411 $5% $5%\n\n/\n\n**_:D 2 4_**\n\n**_B_**\n\n### **B, ) - RPQURPQ**\n\n**B, ) - 8 WRWP A N CNUN N d X N N 0& ) -**\n\n_, HIH ,, ADH H D G LNK L MC L MDIH LM KMDHB IH B ( MDM ADHDMDIHL INK L AIK DMDIH M D L&_\n\n**_9 0449_**\n\n**_2 C4 D 4:_**\n\n**_D 2E 4 4 0 D_**\n\n**E 6**","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_032","product_type":"parse","source_file_path":"complex_header_032.pdf"},"started_at":"2026-11-12T14:57:12.850567"} {"completed_at":"2026-11-12T14:57:19.066844","latency_in_ms":1897,"output":{"example_id":"complex_table_headers/complex_header_037","grounded_pages":[],"layout_pages":[],"markdown":"### **BridgeSpan Health Company - Individual**\n\n### **WAOIC# 500823**\n\n### **Rates Effective 1/1/2026**\n\n**Medical and Rx Paid Claims Triangle**\n\nMedical\n\nIncurred Month\n\nPaid Month 202401 202402 202403 202404 202405 202406 202407 202408 202409 202410 202411 202412\n\n202401 41,539 0 0 0 0 0 0 0 0 0 0 0\n\n202402 191,691 29,902 0 0 0 0 0 0 0 0 0 0\n\n202403 90,233 324,478 55,730 0 0 0 0 0 0 0 0 0\n\n202404 11,157 20,717 326,646 70,804 0 0 0 0 0 0 0 0\n\n202405 5,533 8,224 429,936 308,025 125,102 0 0 0 0 0 0 0\n\n202406 283 -45,171 36,806 13,870 241,742 52,107 0 0 0 0 0 0\n\n202407 152 45 1,070 4,603 110,617 200,990 24,203 0 0 0 0 0\n\n202408 1,771 3,874 463 5,663 9,156 36,228 244,036 125,615 0 0 0 0\n\n202409 -158 427 210 159 824 1,393 2,381 155,273 93,051 0 0 0\n\n202410 3,770 2 0 432 2,763 148 3,020 40,099 142,499 67,181 0 0\n\n202411 -1,766 -46 -634 1,466 336 588 5,236 18,405 35,638 124,934 70,822 0\n\n202412 170 21,487 0 388 0 472 165 1,248 6,054 41,721 134,156 94,095\n\n202501 0 175 0 175 268 0 447 501 224 2,361 30,312 139,640\n\n202502 42 2,990 157 943 1,433 1,316 1,993 1,139 743 120 2,005 4,076\n\n202503 0 0 -8,816 -534 -689 0 268 6,541 4,116 192 640 265,208\n\nRx\n\nIncurred Month\n\nPaid Month 202401 202402 202403 202404 202405 202406 202407 202408 202409 202410 202411 202412\n\n202401 167,241 0 0 0 0 0 0 0 0 0 0 0\n\n202402 5,742 152,079 0 0 0 0 0 0 0 0 0 0\n\n202403 0 -14,031 156,835 0 0 0 0 0 0 0 0 0\n\n202404 0 0 -8,156 184,710 0 0 0 0 0 0 0 0\n\n202405 0 0 0 7,298 218,462 0 0 0 0 0 0 0\n\n202406 0 0 0 0 -2,834 210,157 0 0 0 0 0 0\n\n202407 0 0 0 0 0 -12,886 202,885 0 0 0 0 0\n\n202408 0 0 0 0 0 0 -19,906 530,170 0 0 0 0\n\n202409 0 0 0 0 0 0 11,610 2,807 393,010 0 0 0\n\n202410 0 0 0 0 0 0 0 0 -16,664 462,470 0 0\n\n202411 0 0 0 0 0 0 0 0 0 -10,667 337,725 0\n\n202412 0 0 0 0 0 0 0 0 0 0 484 328,098\n\n202501 0 0 0 0 0 0 0 0 0 0 0 -10,258\n\n202502 0 0 0 0 0 0 0 0 0 0 0 0\n\n202503 0 0 0 0 0 0 0 0 204 0 0 204\n\n\\- Incurred Claims have not been adjusted for unpaid claims estimates or pharmacy rebates","pages":[{"line_numbers":[],"markdown":"### **BridgeSpan Health Company - Individual**\n\n### **WAOIC# 500823**\n\n### **Rates Effective 1/1/2026**\n\n**Medical and Rx Paid Claims Triangle**\n\nMedical\n\nIncurred Month\n\nPaid Month 202401 202402 202403 202404 202405 202406 202407 202408 202409 202410 202411 202412\n\n202401 41,539 0 0 0 0 0 0 0 0 0 0 0\n\n202402 191,691 29,902 0 0 0 0 0 0 0 0 0 0\n\n202403 90,233 324,478 55,730 0 0 0 0 0 0 0 0 0\n\n202404 11,157 20,717 326,646 70,804 0 0 0 0 0 0 0 0\n\n202405 5,533 8,224 429,936 308,025 125,102 0 0 0 0 0 0 0\n\n202406 283 -45,171 36,806 13,870 241,742 52,107 0 0 0 0 0 0\n\n202407 152 45 1,070 4,603 110,617 200,990 24,203 0 0 0 0 0\n\n202408 1,771 3,874 463 5,663 9,156 36,228 244,036 125,615 0 0 0 0\n\n202409 -158 427 210 159 824 1,393 2,381 155,273 93,051 0 0 0\n\n202410 3,770 2 0 432 2,763 148 3,020 40,099 142,499 67,181 0 0\n\n202411 -1,766 -46 -634 1,466 336 588 5,236 18,405 35,638 124,934 70,822 0\n\n202412 170 21,487 0 388 0 472 165 1,248 6,054 41,721 134,156 94,095\n\n202501 0 175 0 175 268 0 447 501 224 2,361 30,312 139,640\n\n202502 42 2,990 157 943 1,433 1,316 1,993 1,139 743 120 2,005 4,076\n\n202503 0 0 -8,816 -534 -689 0 268 6,541 4,116 192 640 265,208\n\nRx\n\nIncurred Month\n\nPaid Month 202401 202402 202403 202404 202405 202406 202407 202408 202409 202410 202411 202412\n\n202401 167,241 0 0 0 0 0 0 0 0 0 0 0\n\n202402 5,742 152,079 0 0 0 0 0 0 0 0 0 0\n\n202403 0 -14,031 156,835 0 0 0 0 0 0 0 0 0\n\n202404 0 0 -8,156 184,710 0 0 0 0 0 0 0 0\n\n202405 0 0 0 7,298 218,462 0 0 0 0 0 0 0\n\n202406 0 0 0 0 -2,834 210,157 0 0 0 0 0 0\n\n202407 0 0 0 0 0 -12,886 202,885 0 0 0 0 0\n\n202408 0 0 0 0 0 0 -19,906 530,170 0 0 0 0\n\n202409 0 0 0 0 0 0 11,610 2,807 393,010 0 0 0\n\n202410 0 0 0 0 0 0 0 0 -16,664 462,470 0 0\n\n202411 0 0 0 0 0 0 0 0 0 -10,667 337,725 0\n\n202412 0 0 0 0 0 0 0 0 0 0 484 328,098\n\n202501 0 0 0 0 0 0 0 0 0 0 0 -10,258\n\n202502 0 0 0 0 0 0 0 0 0 0 0 0\n\n202503 0 0 0 0 0 0 0 0 204 0 0 204\n\n\\- Incurred Claims have not been adjusted for unpaid claims estimates or pharmacy rebates","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_037","product_type":"parse","source_file_path":"complex_header_037.pdf"},"started_at":"2026-11-12T14:57:17.169293"} {"completed_at":"2026-11-12T14:55:19.690954","latency_in_ms":1442,"output":{"example_id":"complex_table_headers/complex_header_039","grounded_pages":[],"layout_pages":[],"markdown":"Page 9 of 9\n\n**RECONCILIATIONS OF THE GROUP’S NON-IFRS FINANCIAL MEASURES TO THE NEAREST MEASURES PREPARED IN ACCORDANCE WITH IFRS**\n\n**As**\n\n**reported**\n\n**Adjustments**\n\n**Non-IFRS**\n\n_RMB in millions, unless specified_\n\n**Share-based**\n\n**compensation (a)**\n\n**Net (gains)/losses**\n\n**from investee companies (b)**\n\n**Amortisation of**\n\n**intangible assets (c)**\n\n**Impairment**\n\n**provisions/ (reversals)**\n\n**(d)**\n\n**SSV & CPP**\n\n**(e)**\n\n**Income**\n\n**tax effects**\n\n**(f)**\n\n**Unaudited three months ended 31 March 2025**\n\n**Operating profit 57,566 10,100 – 1,515 – 139 – 69,320**\n\n**Share of profit/(loss) of associates**\n\n**and joint ventures, net 4,581 968 111 1,713 267 – – 7,640**\n\n**Profit for the period** **49,725 11,068 (31) 3,228 (689) 160 (769) 62,692**\n\n**Profit attributable to equity holders 47,821 10,833 1,081 2,854 (719) 160 (701) 61,329**\n\n**_Operating margin 32% 39%_**\n\nUnaudited three months ended 31 March 2024\n\nOperating profit 52,556 4,694 – 1,249 – 120 – 58,619\n\nShare of profit/(loss) of associates and\n\njoint ventures, net 2,186 1,509 (459) 1,556 699 – – 5,491\n\nProfit for the period 42,651 6,203 (1,476) 2,805 1,562 132 (535) 51,342\n\nProfit attributable to equity holders 41,889 6,035 (1,449) 2,589 1,541 132 (472) 50,265\n\n_Operating margin 33%_ _37%_\n\nUnaudited three months ended 31 December 2024\n\nOperating profit 51,478 6,140 – 1,416 – 441\n\n– 59,475\n\nShare of profit/(loss) of associates and\n\njoint ventures, net 9,253 1,003 (3,799) 1,176 116 –\n\n– 7,749\n\nProfit for the period 51,467 7,143 (6,888) 2,592 1,760 1,109\n\n(706) 56,477\n\nProfit attributable to equity holders 51,324 7,034 (6,931) 2,396 1,037 1,109\n\n(657) 55,312\n\n_Operating margin_ _30% 34%_\n\n_Note:_\n\n_(a) Including put options granted to employees of investee companies on their shares and shares to be issued under investee companies’ share-based incentive plans which can be acquired by the Group, and other incentives (b) Including net (gains)/losses on deemed disposals/disposals of investee companies, fair value changes arising from investee companies, and other expenses in relation to equity transactions of investee companies (c) Amortisation of intangible assets resulting from acquisitions (d) Mainly including impairment provisions/(reversals) for associates, joint ventures, goodwill and other intangible assets arising from acquisitions (e) Mainly including donations and expenses incurred for the Group’s Sustainable Social Value and Common Prosperity Programme (\"SSV & CPP”) initiatives (f) Income tax effects of non-IFRS adjustments_","pages":[{"line_numbers":[],"markdown":"Page 9 of 9\n\n**RECONCILIATIONS OF THE GROUP’S NON-IFRS FINANCIAL MEASURES TO THE NEAREST MEASURES PREPARED IN ACCORDANCE WITH IFRS**\n\n**As**\n\n**reported**\n\n**Adjustments**\n\n**Non-IFRS**\n\n_RMB in millions, unless specified_\n\n**Share-based**\n\n**compensation (a)**\n\n**Net (gains)/losses**\n\n**from investee companies (b)**\n\n**Amortisation of**\n\n**intangible assets (c)**\n\n**Impairment**\n\n**provisions/ (reversals)**\n\n**(d)**\n\n**SSV & CPP**\n\n**(e)**\n\n**Income**\n\n**tax effects**\n\n**(f)**\n\n**Unaudited three months ended 31 March 2025**\n\n**Operating profit 57,566 10,100 – 1,515 – 139 – 69,320**\n\n**Share of profit/(loss) of associates**\n\n**and joint ventures, net 4,581 968 111 1,713 267 – – 7,640**\n\n**Profit for the period** **49,725 11,068 (31) 3,228 (689) 160 (769) 62,692**\n\n**Profit attributable to equity holders 47,821 10,833 1,081 2,854 (719) 160 (701) 61,329**\n\n**_Operating margin 32% 39%_**\n\nUnaudited three months ended 31 March 2024\n\nOperating profit 52,556 4,694 – 1,249 – 120 – 58,619\n\nShare of profit/(loss) of associates and\n\njoint ventures, net 2,186 1,509 (459) 1,556 699 – – 5,491\n\nProfit for the period 42,651 6,203 (1,476) 2,805 1,562 132 (535) 51,342\n\nProfit attributable to equity holders 41,889 6,035 (1,449) 2,589 1,541 132 (472) 50,265\n\n_Operating margin 33%_ _37%_\n\nUnaudited three months ended 31 December 2024\n\nOperating profit 51,478 6,140 – 1,416 – 441\n\n– 59,475\n\nShare of profit/(loss) of associates and\n\njoint ventures, net 9,253 1,003 (3,799) 1,176 116 –\n\n– 7,749\n\nProfit for the period 51,467 7,143 (6,888) 2,592 1,760 1,109\n\n(706) 56,477\n\nProfit attributable to equity holders 51,324 7,034 (6,931) 2,396 1,037 1,109\n\n(657) 55,312\n\n_Operating margin_ _30% 34%_\n\n_Note:_\n\n_(a) Including put options granted to employees of investee companies on their shares and shares to be issued under investee companies’ share-based incentive plans which can be acquired by the Group, and other incentives (b) Including net (gains)/losses on deemed disposals/disposals of investee companies, fair value changes arising from investee companies, and other expenses in relation to equity transactions of investee companies (c) Amortisation of intangible assets resulting from acquisitions (d) Mainly including impairment provisions/(reversals) for associates, joint ventures, goodwill and other intangible assets arising from acquisitions (e) Mainly including donations and expenses incurred for the Group’s Sustainable Social Value and Common Prosperity Programme (\"SSV & CPP”) initiatives (f) Income tax effects of non-IFRS adjustments_","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_039","product_type":"parse","source_file_path":"complex_header_039.pdf"},"started_at":"2026-11-12T14:55:18.248405"} {"completed_at":"2026-11-12T14:55:20.417754","latency_in_ms":2166,"output":{"example_id":"complex_table_headers/complex_header_040","grounded_pages":[],"layout_pages":[],"markdown":"UNITED STATES DISTRICT COURT\n\nNORTHERN DISTRICT OF CALIFORNIA CAND 435 (CAND Rev. 08/2018)\n\nTRANSCRIPT ORDER\n\nPlease use one form per court reporter _._ CJA counsel please use Form CJA24 _Please read instructions on next page._\n\nCOURT USE ONLY\n\nDUE DATE:\n\n1a. CONTACT PERSON FOR THIS ORDER 2a. CONTACT PHONE NUMBER 3. CONTACT EMAIL ADDRESS\n\n1b. ATTORNEY NAME (if different) 2b. ATTORNEY PHONE NUMBER 3. ATTORNEY EMAIL ADDRESS\n\n4\\. MAILING ADDRESS (INCLUDE LAW FIRM NAME, IF APPLICABLE) 5. CASE NAME 6. CASE NUMBER\n\n8\\. THIS TRANSCRIPT ORDER IS FOR:\n\n7\\. COURT REPORTER NAME ( FOR FTR, LEAVE BLANK AND FTR APPEAL\n\nNON-APPEAL\n\nCRIMINAL\n\nCIVIL\n\nIn forma pauperis (NOTE: Court order for transcripts must be attached)\n\nCJA: Do not use this form; use Form CJA24.\n\n9\\. TRANSCRIPT(S) REQUESTED (Specify portion(s) and date(s) of proceeding(s) for which transcript is requested), format(s) & quantity and delivery type:\n\na. HEARING(S) (OR PORTIONS OF HEARINGS) b. SELECT FORMAT(S) ( _NOTE: ECF access is included with purchase of PDF, text, paper or condensed.)_ c. DELIVERY TYPE (Choose one per line)\n\nDATE JUDGE (initials)\n\nTYPE\n\n(e.g. CMC)\n\nPORTION\n\nIf requesting less than full hearing, specify portion (e.g. witness or time)\n\nPDF\n\n(email)\n\nTEXT/ASCII\n\n(email)\n\nPAPER CONDENSED\n\n(email)\n\nECF ACCESS\n\n(web)\n\nORDINARY (30-day)\n\n14-Day EXPEDITED\n\n(7-day)\n\n3-DAY DAILY\n\n(Next day)\n\nHOURLY (2 hrs)\n\nREALTIME\n\n10\\. ADDITIONAL COMMENTS, INSTRUCTIONS, QUESTIONS, ETC:\n\nORDER & CERTIFICATION (11. & 12.) By signing below, I certify that I will pay all charges (deposit plus additional). 12. DATE\n\n11\\. SIGNATURE\n\nClear Form Save as new PDF\n\nPlease send all daily transcripts going forward until the end of the trial.\n\nToni Alford (312) 494- 4133 Toni.Alford@BartlitBeck.com\n\nKarma M. Giulianelli (303) 592-3165 Karma.Giulianelli@BartlitBeck.com\n\nBartlit Beck LLP 1801 Wewetta St. Suite 1200 Denver, Colorado 80202\n\nEpic Games Inc. v. Apple 4:20-cv-5640\n\nDiane Skillman\n\n5/12/21\n\n5/13/21 5/14/21\n\nYGR\n\nYGR\n\nYGR\n\nTrial\n\nTrial\n\nTrial\n\n5/21/2021 /s/ Karma M. Giulianelli\n\n5/17/21 YGR Trial\n\n5/18/21 YGR Trial\n\n5/19/21 YGR Trial\n\n### Case 4:20-cv-05640-YGR Document 752 Filed 05/25/21 Page 1 of 1","pages":[{"line_numbers":[],"markdown":"UNITED STATES DISTRICT COURT\n\nNORTHERN DISTRICT OF CALIFORNIA CAND 435 (CAND Rev. 08/2018)\n\nTRANSCRIPT ORDER\n\nPlease use one form per court reporter _._ CJA counsel please use Form CJA24 _Please read instructions on next page._\n\nCOURT USE ONLY\n\nDUE DATE:\n\n1a. CONTACT PERSON FOR THIS ORDER 2a. CONTACT PHONE NUMBER 3. CONTACT EMAIL ADDRESS\n\n1b. ATTORNEY NAME (if different) 2b. ATTORNEY PHONE NUMBER 3. ATTORNEY EMAIL ADDRESS\n\n4\\. MAILING ADDRESS (INCLUDE LAW FIRM NAME, IF APPLICABLE) 5. CASE NAME 6. CASE NUMBER\n\n8\\. THIS TRANSCRIPT ORDER IS FOR:\n\n7\\. COURT REPORTER NAME ( FOR FTR, LEAVE BLANK AND FTR APPEAL\n\nNON-APPEAL\n\nCRIMINAL\n\nCIVIL\n\nIn forma pauperis (NOTE: Court order for transcripts must be attached)\n\nCJA: Do not use this form; use Form CJA24.\n\n9\\. TRANSCRIPT(S) REQUESTED (Specify portion(s) and date(s) of proceeding(s) for which transcript is requested), format(s) & quantity and delivery type:\n\na. HEARING(S) (OR PORTIONS OF HEARINGS) b. SELECT FORMAT(S) ( _NOTE: ECF access is included with purchase of PDF, text, paper or condensed.)_ c. DELIVERY TYPE (Choose one per line)\n\nDATE JUDGE (initials)\n\nTYPE\n\n(e.g. CMC)\n\nPORTION\n\nIf requesting less than full hearing, specify portion (e.g. witness or time)\n\nPDF\n\n(email)\n\nTEXT/ASCII\n\n(email)\n\nPAPER CONDENSED\n\n(email)\n\nECF ACCESS\n\n(web)\n\nORDINARY (30-day)\n\n14-Day EXPEDITED\n\n(7-day)\n\n3-DAY DAILY\n\n(Next day)\n\nHOURLY (2 hrs)\n\nREALTIME\n\n10\\. ADDITIONAL COMMENTS, INSTRUCTIONS, QUESTIONS, ETC:\n\nORDER & CERTIFICATION (11. & 12.) By signing below, I certify that I will pay all charges (deposit plus additional). 12. DATE\n\n11\\. SIGNATURE\n\nClear Form Save as new PDF\n\nPlease send all daily transcripts going forward until the end of the trial.\n\nToni Alford (312) 494- 4133 Toni.Alford@BartlitBeck.com\n\nKarma M. Giulianelli (303) 592-3165 Karma.Giulianelli@BartlitBeck.com\n\nBartlit Beck LLP 1801 Wewetta St. Suite 1200 Denver, Colorado 80202\n\nEpic Games Inc. v. Apple 4:20-cv-5640\n\nDiane Skillman\n\n5/12/21\n\n5/13/21 5/14/21\n\nYGR\n\nYGR\n\nYGR\n\nTrial\n\nTrial\n\nTrial\n\n5/21/2021 /s/ Karma M. Giulianelli\n\n5/17/21 YGR Trial\n\n5/18/21 YGR Trial\n\n5/19/21 YGR Trial\n\n### Case 4:20-cv-05640-YGR Document 752 Filed 05/25/21 Page 1 of 1","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_040","product_type":"parse","source_file_path":"complex_header_040.pdf"},"started_at":"2026-11-12T14:55:18.251188"} {"completed_at":"2026-11-12T14:55:22.571597","latency_in_ms":1618,"output":{"example_id":"complex_table_headers/complex_header_046","grounded_pages":[],"layout_pages":[],"markdown":"**Rates for Utica/Watertown Region**\n\n**GROUP HEALTH INCORPORATED**\n\n### **GHI-PPO Plan - PLH-SGC-976, HCR-2010**\n\n_Small Group - Employee Groups of Two Or More_\n\n**Monthly Rates For**\n\n**Groups**\n\n**Entering/Renewing**\n\nNon Par Deductible Coinsurance Coinsurance Maximum\n\n**2 TIER RATES**\n\nInd Family\n\n**4 TIER RATES**\n\nInd EC ES ESC\n\nNon Par Annual\n\nMaximum UCR\n\nCopays\n\nMedical/ER/Inpatient/Amb\n\n**7/1/12 - 9/30/12** $30 / $100 / $500 / $250 $1,000 / $3,000 70% / 30% $3,000 / $9,000 **$755.26 $2,190.26 $755.26 $1,397.23 $1,812.64 $2,265.77** $1,000,000 70th%ile\n\n**7/1/12 - 9/30/12** $30 / $100 / $500 / $0 $2,000 / $6,000 70% / 30% $3,000 / $9,000 **$766.04 $2,221.49 $766.04 $1,417.16 $1,838.50 $2,298.12** $500,000 70th%ile\n\n**7/1/12 - 9/30/12** $30 / $100 / $300 x 5 / $250 $2,000 / $6,000 70% / 30% $3,000 / $9,000 **$729.06 $2,114.36 $729.06 $1,348.82 $1,749.82 $2,187.26** $1,000,000 70th%ile\n\n**7/1/12 - 9/30/12** $30 / $100 / $500 / $0 $3,000 / $9,000 70% / 30% $3,000 / $9,000 **$719.34 $2,086.08 $719.34 $1,330.77 $1,726.43 $2,158.00** $500,000 70th%ile\n\n**7/1/12 - 9/30/12** $40 / $100 / $0 / $0 $1,000 / $3,000 70% / 30% $3,000 / $9,000 **$843.87 $2,447.21 $843.87 $1,561.15 $2,025.29 $2,531.59** $500,000 70th%ile\n\n**7/1/12 - 9/30/12** $40 / $100 / $500 / $0 $1,000 / $3,000 70% / 30% $3,000 / $9,000 **$791.14 $2,294.30 $791.14 $1,463.60 $1,898.73 $2,373.42** $500,000 70th%ile\n\n**7/1/12 - 9/30/12** $40 / $100 / $1,000 / $500 $1,000 / $3,000 70% / 30% $3,000 / $9,000 **$707.53 $2,051.78 $707.53 $1,308.86 $1,698.04 $2,122.53** $1,000,000 70th%ile\n\n**7/1/12 - 9/30/12** $40 / $100 / $1,000 / $500 $1,000 / $3,000 50% / 50% $2,500 / $7,500 **$699.83 $2,029.56 $699.83 $1,294.71 $1,679.62 $2,099.52** $1,000,000 70th%ile\n\n**7/1/12 - 9/30/12** $40 / $100 / $500 / $0 $2,000 / $6,000 70% / 30% $3,000 / $9,000 **$713.53 $2,069.21 $713.53 $1,320.02 $1,712.45 $2,140.55** $500,000 70th%ile\n\n**7/1/12 - 9/30/12** $40 / $100 / $1,000 / $500 $2,000 / $6,000 70% / 30% $3,000 / $9,000 **$695.35 $2,016.54 $695.35 $1,286.42 $1,668.87 $2,086.07** $1,000,000 70th%ile\n\n**7/1/12 - 9/30/12** $40 / $100 / $500 x 3 / $500 $2,000 / $6,000 50% / 50% $2,500 / $7,500 **$680.25 $1,972.71 $680.25 $1,258.45 $1,632.59 $2,040.74** $1,000,000 70th%ile\n\n**7/1/12 - 9/30/12** $40 / $100 / $500 / $0 $3,000 / $9,000 70% / 30% $3,000 / $9,000 **$669.64 $1,941.95 $669.64 $1,238.84 $1,607.15 $2,008.93** $500,000 70th%ile\n\n**7/1/12 - 9/30/12** $40 / $100 / $500 x 3 / $500 $3,000 / $9,000 70% / 30% $3,000 / $9,000 **$680.40 $1,973.15 $680.40 $1,258.71 $1,632.94 $2,041.17** $1,000,000 70th%ile\n\n**7/1/12 - 9/30/12** $40 / $100 / $500 x 3 / $500 $3,000 / $9,000 50% / 50% $2,500 / $7,500 **$670.75 $1,945.11 $670.75 $1,240.85 $1,609.74 $2,012.19** $1,000,000 70th%ile\n\n**7/1/12 - 9/30/12** $40 / $100 / $500 x 3 / $500 $3,000 / $9,000 50% / 50% $5,000 / $15,000 **$665.51 $1,929.98 $665.51 $1,231.21 $1,597.23 $1,996.51** $1,000,000 70th%ile\n\n**10/1/12 - 12/31/12** $5 / $50 / $0 / $0 $500 / $1,500 70% / 30% $3,000 / $9,000 **$1,479.91 $4,291.78 $1,479.91 $2,737.85 $3,551.82 $4,439.77** $1,000,000 80th%ile\n\n**10/1/12 - 12/31/12** $5 / $50 / $0 / $0 $500 / $1,500 80% / 20% $2,000 / $6,000 **$1,622.83 $4,706.22 $1,622.83 $3,002.23 $3,894.79 $4,868.49** $1,000,000 80th%ile\n\n**10/1/12 - 12/31/12** $5 / $50 / $0 / $0 $750 / $2,250 70% / 30% $3,000 / $9,000 **$1,456.73 $4,224.59 $1,456.73 $2,695.01 $3,496.22 $4,370.25** $1,000,000 80th%ile\n\n**10/1/12 - 12/31/12** $5 / $50 / $0 / $0 $750 / $2,250 80% / 20% $2,000 / $6,000 **$1,598.36 $4,635.21 $1,598.36 $2,956.95 $3,836.03 $4,795.05** $1,000,000 80th%ile\n\n**10/1/12 - 12/31/12** $5 / $50 / $0 / $0 $1,000 / $3,000 70% / 30% $3,000 / $9,000 **$1,423.92 $4,129.33 $1,423.92 $2,634.22 $3,417.39 $4,271.73** $1,000,000 80th%ile\n\n**10/1/12 - 12/31/12** $5 / $50 / $0 / $0 $1,000 / $3,000 80% / 20% $2,000 / $6,000 **$1,577.08 $4,573.53 $1,577.08 $2,917.59 $3,784.97 $4,731.23** $1,000,000 80th%ile\n\n**10/1/12 - 12/31/12** $10 / $50 / $0 / $0 $500 / $1,500 70% / 30% $3,000 / $9,000 **$1,366.25 $3,962.15 $1,366.25 $2,527.58 $3,279.00 $4,098.76** $1,000,000 80th%ile\n\n**10/1/12 - 12/31/12** $10 / $50 / $0 / $0 $500 / $1,500 80% / 20% $2,000 / $6,000 **$1,499.29 $4,347.92 $1,499.29 $2,773.66 $3,598.28 $4,497.88** $1,000,000 80th%ile\n\n**10/1/12 - 12/31/12** $10 / $50 / $0 / $0 $750 / $2,250 70% / 30% $3,000 / $9,000 **$1,343.86 $3,897.19 $1,343.86 $2,486.15 $3,225.28 $4,031.57** $1,000,000 80th%ile\n\n**10/1/12 - 12/31/12** $10 / $50 / $0 / $0 $750 / $2,250 80% / 20% $2,000 / $6,000 **$1,475.49 $4,278.95 $1,475.49 $2,729.65 $3,541.19 $4,426.48** $1,000,000 80th%ile\n\n**10/1/12 - 12/31/12** $10 / $50 / $0 / $0 $1,000 / $3,000 70% / 30% $3,000 / $9,000 **$1,312.88 $3,807.37 $1,312.88 $2,428.84 $3,150.93 $3,938.66** $1,000,000 80th%ile\n\n**10/1/12 - 12/31/12** $10 / $50 / $0 / $0 $1,000 / $3,000 80% / 20% $2,000 / $6,000 **$1,455.06 $4,219.63 $1,455.06 $2,691.81 $3,492.11 $4,365.13** $1,000,000 80th%ile\n\n**10/1/12 - 12/31/12** $15 / $50 / $0 / $0 $500 / $1,500 70% / 30% $3,000 / $9,000 **$1,272.29 $3,689.65 $1,272.29 $2,353.75 $3,053.49 $3,816.86** $1,000,000 80th%ile\n\n**10/1/12 - 12/31/12** $15 / $50 / $0 / $0 $500 / $1,500 80% / 20% $2,000 / $6,000 **$1,415.53 $4,104.94 $1,415.53 $2,618.67 $3,397.21 $4,246.53** $1,000,000 80th%ile\n\n**10/1/12 - 12/31/12** $15 / $50 / $0 / $0 $750 / $2,250 70% / 30% $3,000 / $9,000 **$1,250.70 $3,627.05 $1,250.70 $2,313.79 $3,001.69 $3,752.11** $1,000,000 80th%ile\n\n6/28/2011 B SECTION ONE - 30","pages":[{"line_numbers":[],"markdown":"**Rates for Utica/Watertown Region**\n\n**GROUP HEALTH INCORPORATED**\n\n### **GHI-PPO Plan - PLH-SGC-976, HCR-2010**\n\n_Small Group - Employee Groups of Two Or More_\n\n**Monthly Rates For**\n\n**Groups**\n\n**Entering/Renewing**\n\nNon Par Deductible Coinsurance Coinsurance Maximum\n\n**2 TIER RATES**\n\nInd Family\n\n**4 TIER RATES**\n\nInd EC ES ESC\n\nNon Par Annual\n\nMaximum UCR\n\nCopays\n\nMedical/ER/Inpatient/Amb\n\n**7/1/12 - 9/30/12** $30 / $100 / $500 / $250 $1,000 / $3,000 70% / 30% $3,000 / $9,000 **$755.26 $2,190.26 $755.26 $1,397.23 $1,812.64 $2,265.77** $1,000,000 70th%ile\n\n**7/1/12 - 9/30/12** $30 / $100 / $500 / $0 $2,000 / $6,000 70% / 30% $3,000 / $9,000 **$766.04 $2,221.49 $766.04 $1,417.16 $1,838.50 $2,298.12** $500,000 70th%ile\n\n**7/1/12 - 9/30/12** $30 / $100 / $300 x 5 / $250 $2,000 / $6,000 70% / 30% $3,000 / $9,000 **$729.06 $2,114.36 $729.06 $1,348.82 $1,749.82 $2,187.26** $1,000,000 70th%ile\n\n**7/1/12 - 9/30/12** $30 / $100 / $500 / $0 $3,000 / $9,000 70% / 30% $3,000 / $9,000 **$719.34 $2,086.08 $719.34 $1,330.77 $1,726.43 $2,158.00** $500,000 70th%ile\n\n**7/1/12 - 9/30/12** $40 / $100 / $0 / $0 $1,000 / $3,000 70% / 30% $3,000 / $9,000 **$843.87 $2,447.21 $843.87 $1,561.15 $2,025.29 $2,531.59** $500,000 70th%ile\n\n**7/1/12 - 9/30/12** $40 / $100 / $500 / $0 $1,000 / $3,000 70% / 30% $3,000 / $9,000 **$791.14 $2,294.30 $791.14 $1,463.60 $1,898.73 $2,373.42** $500,000 70th%ile\n\n**7/1/12 - 9/30/12** $40 / $100 / $1,000 / $500 $1,000 / $3,000 70% / 30% $3,000 / $9,000 **$707.53 $2,051.78 $707.53 $1,308.86 $1,698.04 $2,122.53** $1,000,000 70th%ile\n\n**7/1/12 - 9/30/12** $40 / $100 / $1,000 / $500 $1,000 / $3,000 50% / 50% $2,500 / $7,500 **$699.83 $2,029.56 $699.83 $1,294.71 $1,679.62 $2,099.52** $1,000,000 70th%ile\n\n**7/1/12 - 9/30/12** $40 / $100 / $500 / $0 $2,000 / $6,000 70% / 30% $3,000 / $9,000 **$713.53 $2,069.21 $713.53 $1,320.02 $1,712.45 $2,140.55** $500,000 70th%ile\n\n**7/1/12 - 9/30/12** $40 / $100 / $1,000 / $500 $2,000 / $6,000 70% / 30% $3,000 / $9,000 **$695.35 $2,016.54 $695.35 $1,286.42 $1,668.87 $2,086.07** $1,000,000 70th%ile\n\n**7/1/12 - 9/30/12** $40 / $100 / $500 x 3 / $500 $2,000 / $6,000 50% / 50% $2,500 / $7,500 **$680.25 $1,972.71 $680.25 $1,258.45 $1,632.59 $2,040.74** $1,000,000 70th%ile\n\n**7/1/12 - 9/30/12** $40 / $100 / $500 / $0 $3,000 / $9,000 70% / 30% $3,000 / $9,000 **$669.64 $1,941.95 $669.64 $1,238.84 $1,607.15 $2,008.93** $500,000 70th%ile\n\n**7/1/12 - 9/30/12** $40 / $100 / $500 x 3 / $500 $3,000 / $9,000 70% / 30% $3,000 / $9,000 **$680.40 $1,973.15 $680.40 $1,258.71 $1,632.94 $2,041.17** $1,000,000 70th%ile\n\n**7/1/12 - 9/30/12** $40 / $100 / $500 x 3 / $500 $3,000 / $9,000 50% / 50% $2,500 / $7,500 **$670.75 $1,945.11 $670.75 $1,240.85 $1,609.74 $2,012.19** $1,000,000 70th%ile\n\n**7/1/12 - 9/30/12** $40 / $100 / $500 x 3 / $500 $3,000 / $9,000 50% / 50% $5,000 / $15,000 **$665.51 $1,929.98 $665.51 $1,231.21 $1,597.23 $1,996.51** $1,000,000 70th%ile\n\n**10/1/12 - 12/31/12** $5 / $50 / $0 / $0 $500 / $1,500 70% / 30% $3,000 / $9,000 **$1,479.91 $4,291.78 $1,479.91 $2,737.85 $3,551.82 $4,439.77** $1,000,000 80th%ile\n\n**10/1/12 - 12/31/12** $5 / $50 / $0 / $0 $500 / $1,500 80% / 20% $2,000 / $6,000 **$1,622.83 $4,706.22 $1,622.83 $3,002.23 $3,894.79 $4,868.49** $1,000,000 80th%ile\n\n**10/1/12 - 12/31/12** $5 / $50 / $0 / $0 $750 / $2,250 70% / 30% $3,000 / $9,000 **$1,456.73 $4,224.59 $1,456.73 $2,695.01 $3,496.22 $4,370.25** $1,000,000 80th%ile\n\n**10/1/12 - 12/31/12** $5 / $50 / $0 / $0 $750 / $2,250 80% / 20% $2,000 / $6,000 **$1,598.36 $4,635.21 $1,598.36 $2,956.95 $3,836.03 $4,795.05** $1,000,000 80th%ile\n\n**10/1/12 - 12/31/12** $5 / $50 / $0 / $0 $1,000 / $3,000 70% / 30% $3,000 / $9,000 **$1,423.92 $4,129.33 $1,423.92 $2,634.22 $3,417.39 $4,271.73** $1,000,000 80th%ile\n\n**10/1/12 - 12/31/12** $5 / $50 / $0 / $0 $1,000 / $3,000 80% / 20% $2,000 / $6,000 **$1,577.08 $4,573.53 $1,577.08 $2,917.59 $3,784.97 $4,731.23** $1,000,000 80th%ile\n\n**10/1/12 - 12/31/12** $10 / $50 / $0 / $0 $500 / $1,500 70% / 30% $3,000 / $9,000 **$1,366.25 $3,962.15 $1,366.25 $2,527.58 $3,279.00 $4,098.76** $1,000,000 80th%ile\n\n**10/1/12 - 12/31/12** $10 / $50 / $0 / $0 $500 / $1,500 80% / 20% $2,000 / $6,000 **$1,499.29 $4,347.92 $1,499.29 $2,773.66 $3,598.28 $4,497.88** $1,000,000 80th%ile\n\n**10/1/12 - 12/31/12** $10 / $50 / $0 / $0 $750 / $2,250 70% / 30% $3,000 / $9,000 **$1,343.86 $3,897.19 $1,343.86 $2,486.15 $3,225.28 $4,031.57** $1,000,000 80th%ile\n\n**10/1/12 - 12/31/12** $10 / $50 / $0 / $0 $750 / $2,250 80% / 20% $2,000 / $6,000 **$1,475.49 $4,278.95 $1,475.49 $2,729.65 $3,541.19 $4,426.48** $1,000,000 80th%ile\n\n**10/1/12 - 12/31/12** $10 / $50 / $0 / $0 $1,000 / $3,000 70% / 30% $3,000 / $9,000 **$1,312.88 $3,807.37 $1,312.88 $2,428.84 $3,150.93 $3,938.66** $1,000,000 80th%ile\n\n**10/1/12 - 12/31/12** $10 / $50 / $0 / $0 $1,000 / $3,000 80% / 20% $2,000 / $6,000 **$1,455.06 $4,219.63 $1,455.06 $2,691.81 $3,492.11 $4,365.13** $1,000,000 80th%ile\n\n**10/1/12 - 12/31/12** $15 / $50 / $0 / $0 $500 / $1,500 70% / 30% $3,000 / $9,000 **$1,272.29 $3,689.65 $1,272.29 $2,353.75 $3,053.49 $3,816.86** $1,000,000 80th%ile\n\n**10/1/12 - 12/31/12** $15 / $50 / $0 / $0 $500 / $1,500 80% / 20% $2,000 / $6,000 **$1,415.53 $4,104.94 $1,415.53 $2,618.67 $3,397.21 $4,246.53** $1,000,000 80th%ile\n\n**10/1/12 - 12/31/12** $15 / $50 / $0 / $0 $750 / $2,250 70% / 30% $3,000 / $9,000 **$1,250.70 $3,627.05 $1,250.70 $2,313.79 $3,001.69 $3,752.11** $1,000,000 80th%ile\n\n6/28/2011 B SECTION ONE - 30","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_046","product_type":"parse","source_file_path":"complex_header_046.pdf"},"started_at":"2026-11-12T14:55:20.952766"} {"completed_at":"2026-11-12T14:55:33.430952","latency_in_ms":8791,"output":{"example_id":"complex_table_headers/complex_header_047","grounded_pages":[],"layout_pages":[],"markdown":"CBS siarions™\n\n© CW\n\n1555 Hamilton Street,\n\nAGREEMENT MADE BETWEEN\n\nKYW TV3\n\nPHILADELPHIA PA\n\n19130 KYW TV3\n\nCONTRACT NO. REV.\n1041-79993-1\n\nDATE PRINTED\n08/16/12\n\nPAGE\n\nCancellation Notice\n\nRequired\n\nAnnouncement 28 days\n\nprior notice\n\n24184 AGENCY (OR SERVICE) ACTING AS AGENT FOR 212808 ADVERTISER (OR AGENCY AND ADVERTISER)\nNAME MENTZER MEDIA SERVICES AMERICANS FOR PROSPERITY\nAND 600 Fairmount Ave Ste 306 1726 М St NW Fl 10\nADDRESS Towson MD 21286-1002 Washington DC 20036-4502\nUSA USA\nCONTACT STEPHANIE KOHLBAUER PRODUCTEST\nLOCAL JOHN LINK POL. AGENCY EST. NO. PRODUCT 9820\nSALESPERSON 322 CODE\nNATIONAL\nSALESPERSON\n\nBROADCAST SCHEDULE STARTING 08/08/12 AND ENDING 08/14/12\n\nNO. WEEKS: ik\n\nCBS Television Stations Standard Terms and Conditions for advertising shall apply.\n\nNONDISCRIMINATION POLICY: CBS Television Stations and its Stations do not discriminate in advertising contracts on the basis of race or ethnicity, and will not accept any advertising which is intended to\n\ndiscriminate on the basis of race or ethnicity. Advertiser represents and warrants that it is not purchasing time from CBS Television Stations or its Stations that is intended to discriminate on the basis of race or\n\nSPOTS TIME TOTAL\nITEM DAYS РУК, FROM TO LENGTH | EFFECTIVE DATES PROGRAMS BDCST. | UNIT RATE TOTAL VALUE(1)\n1] 00110.. 2] 05:00Р 06:00P 30S |08/08/12-08/09/12] SPM EARLY NEWS 2 650.00 1300.00\n2 | 00111., 3] 06:00P 06:30P 30S |08/08/12-08/10/12] NEWS 3 AT 6 3 950.00 2850.00\n3 | 0011110 4] 11:00P 11:35Р 305 |08/08/12-08/11/12| LATE МЕМ$ 4 1800.00 7200.00\n& | гиены 1 1] 06;58А 09:00A 30$ |08/12/12-08/12/12] WKND NEWS SUN 7-9A 1 400.00 400.00\n5 eee 1 1] 10:30A 11:00A 30S |08/12/12-08/12/12] FACE THE NATION 10:30-11АМ 1 3500.00 3500.00\n6 | 10000.. 1] 05:00Р 06:00P 30S [08/13/12-08/13/12| 5PM EARLY NEWS 1 650.00 650.00\n7 | 11000.. 2] 06:00Р 06:30P 30S ]08/13/12-08/14/12] NEWS 3 АТ 6 2 950.00 1900.00\n8 | 1100000 2] 11:00P 11:35Р 30S [08/13/12-08/14/12|] LATE МЕМ$ 2 1800.00 3600.00\nTotal Contract: 16 21400.00\nBilling Summary\n\nJul Aug Sep Total\n\nQtr 3112 .00 21400.00 .00 21400.00\n\nGRIAND TOTAL\n\n21400\\.00\n\n(1) Less Agency commission of 15% Except on Non-Commissionable Amounts. Conditions on the reverse of this page and any attachments hereto are an integral\n\npart of this Agreement. If this contract is with an Advertiser, references to Agency apply to Advertiser, except no commission will be allowed an Advertiser.\n\nACCEPTED BY AGENCY\n\nAS AGENT FOR (ADVERTISER)\n\nACCEPTED BY STATION","pages":[{"line_numbers":[],"markdown":"CBS siarions™\n\n© CW\n\n1555 Hamilton Street,\n\nAGREEMENT MADE BETWEEN\n\nKYW TV3\n\nPHILADELPHIA PA\n\n19130 KYW TV3\n\nCONTRACT NO. REV.\n1041-79993-1\n\nDATE PRINTED\n08/16/12\n\nPAGE\n\nCancellation Notice\n\nRequired\n\nAnnouncement 28 days\n\nprior notice\n\n24184 AGENCY (OR SERVICE) ACTING AS AGENT FOR 212808 ADVERTISER (OR AGENCY AND ADVERTISER)\nNAME MENTZER MEDIA SERVICES AMERICANS FOR PROSPERITY\nAND 600 Fairmount Ave Ste 306 1726 М St NW Fl 10\nADDRESS Towson MD 21286-1002 Washington DC 20036-4502\nUSA USA\nCONTACT STEPHANIE KOHLBAUER PRODUCTEST\nLOCAL JOHN LINK POL. AGENCY EST. NO. PRODUCT 9820\nSALESPERSON 322 CODE\nNATIONAL\nSALESPERSON\n\nBROADCAST SCHEDULE STARTING 08/08/12 AND ENDING 08/14/12\n\nNO. WEEKS: ik\n\nCBS Television Stations Standard Terms and Conditions for advertising shall apply.\n\nNONDISCRIMINATION POLICY: CBS Television Stations and its Stations do not discriminate in advertising contracts on the basis of race or ethnicity, and will not accept any advertising which is intended to\n\ndiscriminate on the basis of race or ethnicity. Advertiser represents and warrants that it is not purchasing time from CBS Television Stations or its Stations that is intended to discriminate on the basis of race or\n\nSPOTS TIME TOTAL\nITEM DAYS РУК, FROM TO LENGTH | EFFECTIVE DATES PROGRAMS BDCST. | UNIT RATE TOTAL VALUE(1)\n1] 00110.. 2] 05:00Р 06:00P 30S |08/08/12-08/09/12] SPM EARLY NEWS 2 650.00 1300.00\n2 | 00111., 3] 06:00P 06:30P 30S |08/08/12-08/10/12] NEWS 3 AT 6 3 950.00 2850.00\n3 | 0011110 4] 11:00P 11:35Р 305 |08/08/12-08/11/12| LATE МЕМ$ 4 1800.00 7200.00\n& | гиены 1 1] 06;58А 09:00A 30$ |08/12/12-08/12/12] WKND NEWS SUN 7-9A 1 400.00 400.00\n5 eee 1 1] 10:30A 11:00A 30S |08/12/12-08/12/12] FACE THE NATION 10:30-11АМ 1 3500.00 3500.00\n6 | 10000.. 1] 05:00Р 06:00P 30S [08/13/12-08/13/12| 5PM EARLY NEWS 1 650.00 650.00\n7 | 11000.. 2] 06:00Р 06:30P 30S ]08/13/12-08/14/12] NEWS 3 АТ 6 2 950.00 1900.00\n8 | 1100000 2] 11:00P 11:35Р 30S [08/13/12-08/14/12|] LATE МЕМ$ 2 1800.00 3600.00\nTotal Contract: 16 21400.00\nBilling Summary\n\nJul Aug Sep Total\n\nQtr 3112 .00 21400.00 .00 21400.00\n\nGRIAND TOTAL\n\n21400\\.00\n\n(1) Less Agency commission of 15% Except on Non-Commissionable Amounts. Conditions on the reverse of this page and any attachments hereto are an integral\n\npart of this Agreement. If this contract is with an Advertiser, references to Agency apply to Advertiser, except no commission will be allowed an Advertiser.\n\nACCEPTED BY AGENCY\n\nAS AGENT FOR (ADVERTISER)\n\nACCEPTED BY STATION","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_047","product_type":"parse","source_file_path":"complex_header_047.pdf"},"started_at":"2026-11-12T14:55:24.639484"} {"completed_at":"2026-11-12T14:55:31.954256","latency_in_ms":3501,"output":{"example_id":"complex_table_headers/complex_header_049","grounded_pages":[],"layout_pages":[],"markdown":"# **SOMMER / SUMMER**\n\n## **1\\.5.** **–** **30\\.9.2026**\n\n**AB/FROM ZÜRICH**\n\n**Rapperswil 11.40 12.40 13.40 14.40 15.40 17.40**\n\nSonnenuntergangsfahrt Sunset Cruise\n\n**19\\.45 Rapperswil**\n\n**Insel Ufenau 11.53 12.51 13.51 14.53 15.53 17.51 19.56 Insel Ufenau**\n\nStäfa 13.10 14.10 18.10 20.15 Stäfa\n\nMännedorf 13.21 14.21 18.21 20.26 Männedorf\n\nRichterswil 12.12 15.12 16.12 Richterswil\n\nWädenswil 12.29 13.32 14.32 15.29 16.29 18.32 20.37 Wädenswil\n\n**Halbinsel Au 12.40 13.45 14.45 15.40 16.40 18.45 Halbinsel Au**\n\nMeilen 12.49 15.49 16.49 20.54 Meilen\n\nHorgen 14.00 15.00 19.00 21.07 Horgen\n\nHerrliberg 13.02 16.02 17.02 Herrliberg\n\nOberrieden 14.10 15.10 19.10 Oberrieden\n\nThalwil 14.20 15.20 19.20 21.23 Thalwil\n\nErlenbach ZH 13.13 16.13 17.13 Erlenbach ZH\n\nKüsnacht ZH 13.24 16.24 17.24 21.33 Küsnacht ZH\n\n**Zürich Bürkliplatz** Æ **13\\.50 14.50 15.50 16.50 17.50 19.50 22.00** Æ **Zürich Bürkliplatz**\n\n**Täglich Daily**\n\nKurs / Service 101/102 103/104 105/106 107/108 109/110 113/114 117/118\n\nr r r r r r r\n\n**Zürich Bürkliplatz 09.20 10.20 11.20 12.20 13.20 15.20**\n\nSonnenuntergangsfahrt Sunset Cruise\n\n**17\\.20 Zürich Bürkliplatz**\n\nKüsnacht ZH 09.47 12.47 13.47 Küsnacht ZH\n\nErlenbach ZH 09.58 12.58 13.58 Erlenbach ZH\n\nThalwil 10.51 11.51 15.51 17.51 Thalwil\n\nOberrieden 10.59 11.59 15.59 Oberrieden\n\nHerrliberg 10.09 13.09 14.09 18.04 Herrliberg\n\nHorgen 11.09 12.09 16.09 18.16 Horgen\n\nMeilen 10.22 13.22 14.22 18.29 Meilen\n\n**Halbinsel Au 10.32 11.24 12.24 13.32 14.32 16.24 Halbinsel Au**\n\nWädenswil 10.45 11.37 12.37 13.45 14.45 16.37 18.48 Wädenswil\n\nRichterswil 10.59 13.59 14.59 Richterswil\n\nMännedorf 11.48 12.48 16.48 18.59 Männedorf\n\nStäfa 11.59 12.59 16.59 19.10 Stäfa\n\n**Insel Ufenau 11.19 12.19 13.19 14.19 15.19 17.19 19.29 Insel Ufenau**\n\n**Rapperswil** Æ **11\\.30 12.30 13.30 14.30 15.30 17.30 19.40** Æ **Rapperswil**\n\n**GROSSE SEERUNDFAHRT LONG LAKE CRUISE 4H 30M**\n\n**AB/FROM ZÜRICH**\n\n### m\n\n**Täglich Daily**\n\nKurs / Service 14 17 20 23 26 29 32 35 38 41 44 47 50 53 56 59 62 65 68 71\n\nr r r r r r r r r r r r r r r r r r r r\n\n**Zürich Bürkliplatz 10.00 10.30 11.00 11.30 12.00 12.30 13.00 13.30 14.00 14.30 15.00 15.30 16.00 16.30 17.00 17.30 18.00 18.30 19.00 19.30**\n\nZürich Wollishofen 10.46 11.46 12.46 13.46 14.46 15.46 16.46 17.46 18.46 19.46\n\nKilchberg ZH 10.57 11.57 12.57 13.57 14.57 15.57 16.57 17.57 18.57 19.57\n\nRüschlikon 11.04 12.04 13.04 14.04 15.04 16.04 17.04 18.04 19.04 20.04\n\n**Thalwil 11.13 12.13 13.13 14.13 15.13 16.13 17.13 18.13 19.13 20.13**\n\n**Erlenbach ZH 11.22 12.22 13.22 14.22 15.22 16.22 17.22 18.22 19.22 20.22**\n\nKüsnacht ZH 11.32 12.32 13.32 14.32 15.32 16.32 17.32 18.32 19.32 20.32\n\nZürichhorn 10.13 11.13 12.13 13.13 14.13 15.13 16.13 17.13 18.13 19.13\n\nKüsnacht ZH 10.28 11.28 12.28 13.28 14.28 15.28 16.28 17.28 18.28 19.28\n\nKüsnacht ZH Heslibach 10.35 11.35 12.35 13.35 14.35 15.35 16.35 17.35 18.35 19.35\n\n**Erlenbach ZH 10.39 11.39 12.39 13.39 14.39 15.39 16.39 17.39 18.39 19.39**\n\n**Thalwil 10.47 11.47 12.47 13.47 14.47 15.47 16.47 17.47 18.47 19.47**\n\nRüschlikon 10.54 11.54 12.54 13.54 14.54 15.54 16.54 17.54 18.54 19.54\n\nKilchberg ZH 11.02 12.02 13.02 14.02 15.02 16.02 17.02 18.02 19.02 20.02\n\n**Zürich Bürkliplatz** Æ **11\\.25 11.55 12.25 12.55 13.25 13.55 14.25 14.55 15.25 15.55 16.25 16.55 17.25 17.55 18.25 18.55 19.25 19.55 20.25 20.55**\n\n**KLEINE SEERUNDFAHRT SHORT LAKE CRUISE 1H 30M**\n\n**Änderungen sind ausdrücklich vorbehalten. Konsultieren Sie vor der Fahrt den Online-Fahrplan auf www.zsg.ch Subject to change. Before travelling, consult the online timetable at www.zsg.ch.**","pages":[{"line_numbers":[],"markdown":"# **SOMMER / SUMMER**\n\n## **1\\.5.** **–** **30\\.9.2026**\n\n**AB/FROM ZÜRICH**\n\n**Rapperswil 11.40 12.40 13.40 14.40 15.40 17.40**\n\nSonnenuntergangsfahrt Sunset Cruise\n\n**19\\.45 Rapperswil**\n\n**Insel Ufenau 11.53 12.51 13.51 14.53 15.53 17.51 19.56 Insel Ufenau**\n\nStäfa 13.10 14.10 18.10 20.15 Stäfa\n\nMännedorf 13.21 14.21 18.21 20.26 Männedorf\n\nRichterswil 12.12 15.12 16.12 Richterswil\n\nWädenswil 12.29 13.32 14.32 15.29 16.29 18.32 20.37 Wädenswil\n\n**Halbinsel Au 12.40 13.45 14.45 15.40 16.40 18.45 Halbinsel Au**\n\nMeilen 12.49 15.49 16.49 20.54 Meilen\n\nHorgen 14.00 15.00 19.00 21.07 Horgen\n\nHerrliberg 13.02 16.02 17.02 Herrliberg\n\nOberrieden 14.10 15.10 19.10 Oberrieden\n\nThalwil 14.20 15.20 19.20 21.23 Thalwil\n\nErlenbach ZH 13.13 16.13 17.13 Erlenbach ZH\n\nKüsnacht ZH 13.24 16.24 17.24 21.33 Küsnacht ZH\n\n**Zürich Bürkliplatz** Æ **13\\.50 14.50 15.50 16.50 17.50 19.50 22.00** Æ **Zürich Bürkliplatz**\n\n**Täglich Daily**\n\nKurs / Service 101/102 103/104 105/106 107/108 109/110 113/114 117/118\n\nr r r r r r r\n\n**Zürich Bürkliplatz 09.20 10.20 11.20 12.20 13.20 15.20**\n\nSonnenuntergangsfahrt Sunset Cruise\n\n**17\\.20 Zürich Bürkliplatz**\n\nKüsnacht ZH 09.47 12.47 13.47 Küsnacht ZH\n\nErlenbach ZH 09.58 12.58 13.58 Erlenbach ZH\n\nThalwil 10.51 11.51 15.51 17.51 Thalwil\n\nOberrieden 10.59 11.59 15.59 Oberrieden\n\nHerrliberg 10.09 13.09 14.09 18.04 Herrliberg\n\nHorgen 11.09 12.09 16.09 18.16 Horgen\n\nMeilen 10.22 13.22 14.22 18.29 Meilen\n\n**Halbinsel Au 10.32 11.24 12.24 13.32 14.32 16.24 Halbinsel Au**\n\nWädenswil 10.45 11.37 12.37 13.45 14.45 16.37 18.48 Wädenswil\n\nRichterswil 10.59 13.59 14.59 Richterswil\n\nMännedorf 11.48 12.48 16.48 18.59 Männedorf\n\nStäfa 11.59 12.59 16.59 19.10 Stäfa\n\n**Insel Ufenau 11.19 12.19 13.19 14.19 15.19 17.19 19.29 Insel Ufenau**\n\n**Rapperswil** Æ **11\\.30 12.30 13.30 14.30 15.30 17.30 19.40** Æ **Rapperswil**\n\n**GROSSE SEERUNDFAHRT LONG LAKE CRUISE 4H 30M**\n\n**AB/FROM ZÜRICH**\n\n### m\n\n**Täglich Daily**\n\nKurs / Service 14 17 20 23 26 29 32 35 38 41 44 47 50 53 56 59 62 65 68 71\n\nr r r r r r r r r r r r r r r r r r r r\n\n**Zürich Bürkliplatz 10.00 10.30 11.00 11.30 12.00 12.30 13.00 13.30 14.00 14.30 15.00 15.30 16.00 16.30 17.00 17.30 18.00 18.30 19.00 19.30**\n\nZürich Wollishofen 10.46 11.46 12.46 13.46 14.46 15.46 16.46 17.46 18.46 19.46\n\nKilchberg ZH 10.57 11.57 12.57 13.57 14.57 15.57 16.57 17.57 18.57 19.57\n\nRüschlikon 11.04 12.04 13.04 14.04 15.04 16.04 17.04 18.04 19.04 20.04\n\n**Thalwil 11.13 12.13 13.13 14.13 15.13 16.13 17.13 18.13 19.13 20.13**\n\n**Erlenbach ZH 11.22 12.22 13.22 14.22 15.22 16.22 17.22 18.22 19.22 20.22**\n\nKüsnacht ZH 11.32 12.32 13.32 14.32 15.32 16.32 17.32 18.32 19.32 20.32\n\nZürichhorn 10.13 11.13 12.13 13.13 14.13 15.13 16.13 17.13 18.13 19.13\n\nKüsnacht ZH 10.28 11.28 12.28 13.28 14.28 15.28 16.28 17.28 18.28 19.28\n\nKüsnacht ZH Heslibach 10.35 11.35 12.35 13.35 14.35 15.35 16.35 17.35 18.35 19.35\n\n**Erlenbach ZH 10.39 11.39 12.39 13.39 14.39 15.39 16.39 17.39 18.39 19.39**\n\n**Thalwil 10.47 11.47 12.47 13.47 14.47 15.47 16.47 17.47 18.47 19.47**\n\nRüschlikon 10.54 11.54 12.54 13.54 14.54 15.54 16.54 17.54 18.54 19.54\n\nKilchberg ZH 11.02 12.02 13.02 14.02 15.02 16.02 17.02 18.02 19.02 20.02\n\n**Zürich Bürkliplatz** Æ **11\\.25 11.55 12.25 12.55 13.25 13.55 14.25 14.55 15.25 15.55 16.25 16.55 17.25 17.55 18.25 18.55 19.25 19.55 20.25 20.55**\n\n**KLEINE SEERUNDFAHRT SHORT LAKE CRUISE 1H 30M**\n\n**Änderungen sind ausdrücklich vorbehalten. Konsultieren Sie vor der Fahrt den Online-Fahrplan auf www.zsg.ch Subject to change. Before travelling, consult the online timetable at www.zsg.ch.**","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_049","product_type":"parse","source_file_path":"complex_header_049.pdf"},"started_at":"2026-11-12T14:55:28.452428"} {"completed_at":"2026-11-12T14:55:36.616902","latency_in_ms":2008,"output":{"example_id":"complex_table_headers/complex_header_050","grounded_pages":[],"layout_pages":[],"markdown":"### Garuda Construction and Engineering Limited\n\nCIN: L45400MH2010PLC207963 Registered office: 201, A Wing Fortune 2000, C-3 Block Bandra, Kurla Complex, Bandra (East), Mumbai, Maharashtra, India, 400 051 Phone - 022-26530163 Email 1d - admin@gcel.in, Website: www.garudaconstructionengineering.com\n\nStatement of Unaudited Standalone Results for the Quarter ended 30 June 2026\n\n(% in Lakhs)| sr. Quarter ended Year ended Nt; Particulars 30 June 2026 31 March 2026 30 June 2025 31 March 2026\n\n. (Unaudited) (Unaudited) (Unaudited) (Audited)\n\n1 Income Revenue from operations 17,538.17 14,904.84 12,515.65 53,071.52 Other income 24.73 (40.66) 152.35 324.17 Total Income 17,562.90 14,864.19 12,668.00 53,395.69\n\n2 Expenses Cost of Materials Consumed 1,500.70 3,258.99 2,295.38 14,492.33 Construction Expenses 9,875.03 6,466.86 6,012.50 20,323.34 Employee Benefits Expenses 117.35 133.06 117.64 480.22 Finance Costs 53.35 71.06 45.88 270.48 Depreciation and Amortisation Expenses 8.21 9.85 6:15 28.43 Other Expenses 430.96 248.41 448.24 1,383.96 Total Expenses 11,985.60 10,188.24 8,925.80 36,978.77\n\n3 |Profit before exceptional items and tax (1 - 5,577.29 4,675.95 3,742.20 16,416.92 2) 4 |Exceptional items @ - - - 5 |Profit before Tax (3 - 4) 5,577.29 4,675.95 3,742.20 16,416.92 6 |Tax expense\n\n(a) Current income tax 1,422.00 1,237.74 941.38 4,167.84 (b) Deferred income tax (0.29)] (3.53)] (0.05)| (5.03))\n\n7 |Profit for the period from continuing 4,155.53 3,441.74 2,800.88 12,254.11 operations (5 - 6)\n\n8 |Profit /(Loss) from discontinuing operations - - - - 9 [Tax expense of discontinuing operations - - \" - 10 (Profit /(Loss) from discontinuing operations N R N N (after tax) (8 - 9)\n\n11 |[Profit for the period (7 + 10) 4,155.53 3,441.74 2,800.88 12,254.11\n\n12 |Other Comprehensive Income\n\n| Items not to be reclassified to profit or loss in subsequent periods: (a) Re-measurement gain/(losses) on defined ~ (5.35) benefit plan - (5.35)| - (b) Income Tax effect on above - 1.35 = 135 - (4.00) - (4.00)]\n\n13 |Total Comprehensive Income for the period 4,155.53 3,437.74 2,800.88 12,250.10\n\n14 |Reserves 40,780.05\n\n15 |Details of Equity Share Capital\n\nPaid up Equity Share Capital 4,652.09 Face Value of Equity Share Capital (%) 5.00\n\n16 |Earnings per share\n\n(a) Basic 447 3.70 3.01 13.17 (b) Diluted 447 3.70 3.01 13.17","pages":[{"line_numbers":[],"markdown":"### Garuda Construction and Engineering Limited\n\nCIN: L45400MH2010PLC207963 Registered office: 201, A Wing Fortune 2000, C-3 Block Bandra, Kurla Complex, Bandra (East), Mumbai, Maharashtra, India, 400 051 Phone - 022-26530163 Email 1d - admin@gcel.in, Website: www.garudaconstructionengineering.com\n\nStatement of Unaudited Standalone Results for the Quarter ended 30 June 2026\n\n(% in Lakhs)| sr. Quarter ended Year ended Nt; Particulars 30 June 2026 31 March 2026 30 June 2025 31 March 2026\n\n. (Unaudited) (Unaudited) (Unaudited) (Audited)\n\n1 Income Revenue from operations 17,538.17 14,904.84 12,515.65 53,071.52 Other income 24.73 (40.66) 152.35 324.17 Total Income 17,562.90 14,864.19 12,668.00 53,395.69\n\n2 Expenses Cost of Materials Consumed 1,500.70 3,258.99 2,295.38 14,492.33 Construction Expenses 9,875.03 6,466.86 6,012.50 20,323.34 Employee Benefits Expenses 117.35 133.06 117.64 480.22 Finance Costs 53.35 71.06 45.88 270.48 Depreciation and Amortisation Expenses 8.21 9.85 6:15 28.43 Other Expenses 430.96 248.41 448.24 1,383.96 Total Expenses 11,985.60 10,188.24 8,925.80 36,978.77\n\n3 |Profit before exceptional items and tax (1 - 5,577.29 4,675.95 3,742.20 16,416.92 2) 4 |Exceptional items @ - - - 5 |Profit before Tax (3 - 4) 5,577.29 4,675.95 3,742.20 16,416.92 6 |Tax expense\n\n(a) Current income tax 1,422.00 1,237.74 941.38 4,167.84 (b) Deferred income tax (0.29)] (3.53)] (0.05)| (5.03))\n\n7 |Profit for the period from continuing 4,155.53 3,441.74 2,800.88 12,254.11 operations (5 - 6)\n\n8 |Profit /(Loss) from discontinuing operations - - - - 9 [Tax expense of discontinuing operations - - \" - 10 (Profit /(Loss) from discontinuing operations N R N N (after tax) (8 - 9)\n\n11 |[Profit for the period (7 + 10) 4,155.53 3,441.74 2,800.88 12,254.11\n\n12 |Other Comprehensive Income\n\n| Items not to be reclassified to profit or loss in subsequent periods: (a) Re-measurement gain/(losses) on defined ~ (5.35) benefit plan - (5.35)| - (b) Income Tax effect on above - 1.35 = 135 - (4.00) - (4.00)]\n\n13 |Total Comprehensive Income for the period 4,155.53 3,437.74 2,800.88 12,250.10\n\n14 |Reserves 40,780.05\n\n15 |Details of Equity Share Capital\n\nPaid up Equity Share Capital 4,652.09 Face Value of Equity Share Capital (%) 5.00\n\n16 |Earnings per share\n\n(a) Basic 447 3.70 3.01 13.17 (b) Diluted 447 3.70 3.01 13.17","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_050","product_type":"parse","source_file_path":"complex_header_050.pdf"},"started_at":"2026-11-12T14:55:34.608713"} {"completed_at":"2026-11-12T14:55:55.101026","latency_in_ms":3032,"output":{"example_id":"complex_table_headers/complex_header_051","grounded_pages":[],"layout_pages":[],"markdown":"TABLE\n\n## **3**\n\n**Human Development Index (HDI)**\n\n**Inequality‑adjusted HDI (IHDI)**\n\n**Coefficient of human inequality**\n\n**Inequality in life expectancy**\n\n**Inequality‑ adjusted life expectancy index**\n\n**Inequality in education** **a**\n\n**Inequality‑ adjusted education index**\n\n**Inequality in income** **a**\n\n**Inequality‑ adjusted income index Income inequality**\n\nValue Value\n\nOverall loss (%)\n\nDifference from HDI rank b (%) Value (%) Value (%) Value\n\n**Quintile ratio**\n\n**Palma ratio**\n\n**Gini coefficient**\n\n**HDI rank** 2017 2017 2017 2017 2017 2015–2020 c 2017 2017 d 2017 2017 d 2017 2010–2017 e 2010–2017 e 2010–2017 e\n\n178 Yemen 0.452 0.308 31.9 6 30.9 24.9 0.522 46.1 0.188 21.8 0.297 6.1 1.6 36.7 179 Eritrea 0.440 .. .. .. .. 21.4 0.551 .. .. .. .. .. .. .. 180 Mozambique 0.437 0.294 32.7 2 32.6 35.6 0.385 33.8 0.255 28.4 0.259 14.2 3.9 54.0 181 Liberia 0.435 0.298 31.6 4 31.0 27.5 0.480 42.9 0.248 22.7 0.221 5.4 1.3 33.2 182 Mali 0.427 0.282 34.0 1 32.8 36.8 0.374 46.2 0.158 15.4 0.380 5.2 f 1\\.3 f 33\\.0 f\n\n183 Burkina Faso 0.423 0.288 32.1 3 31.8 32.0 0.427 39.2 0.174 24.2 0.321 5.3 1.5 35.3 184 Sierra Leone 0.419 0.266 36.5 –1 35.4 39.8 0.298 47.3 0.206 19.2 0.307 5.4 1.4 34.0 185 Burundi 0.417 0.278 33.3 3 32.8 38.1 0.361 39.5 0.256 20.9 0.233 6.7 1.7 38.6 186 Chad 0.404 0.249 38.3 –1 37.9 42.4 0.294 43.0 0.170 28.4 0.310 10.0 2.2 43.3 187 South Sudan 0.388 0.247 36.3 –1 36.3 37.0 0.361 39.6 0.180 32.3 0.232 13.0 f 2\\.7 f 46\\.3 f\n\n188 Central African Republic 0.367 0.212 42.1 –1 41.8 41.7 0.295 34.5 0.223 49.2 0.145 18.5 f 4\\.5 f 56\\.2 f\n\n189 Niger 0.354 0.250 29.3 3 28.8 34.9 0.405 35.0 0.139 16.4 0.278 5.4 1.4 34.3 **OTHER COUNTRIES OR TERRITORIES** .. Korea (Democratic People's Rep. of) .. .. .. .. .. 11.6 0.706 .. .. .. .. .. .. .. .. Monaco .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. Nauru .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. San Marino .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. Somalia .. .. .. .. .. 38.9 0.345 .. .. .. .. .. .. .. .. Tuvalu .. .. .. .. .. .. .. 10.5 .. 23.4 0.472 7.0 1.8 39.1 **Human development groups** Very high human development 0.894 0.799 10.7 — 10.4 5.0 0.870 6.3 0.810 20.1 0.723 — — — High human development 0.757 0.636 16.0 — 15.7 9.2 0.782 13.1 0.579 24.8 0.569 — — — Medium human development 0.645 0.483 25.1 — 24.9 20.3 0.602 33.1 0.372 21.2 0.503 — — — Low human development 0.504 0.347 31.1 — 30.9 31.2 0.431 37.0 0.263 24.6 0.368 — — — **Developing countries** 0\\.681 0.531 22.0 — 21.9 17.4 0.644 25.3 0.435 23.1 0.535 — — — **Regions** Arab States 0.699 0.523 25.1 — 24.8 15.7 0.668 32.6 0.381 26.1 0.564 — — — East Asia and the Pacific 0.733 0.619 15.6 — 15.4 10.0 0.757 13.1 0.548 23.1 0.572 — — — Europe and Central Asia 0.771 0.681 11.7 — 11.6 10.9 0.732 7.2 0.680 16.7 0.633 — — — Latin America and the Caribbean 0.758 0.593 21.8 — 21.2 12.1 0.753 18.4 0.558 33.2 0.496 — — — South Asia 0.638 0.471 26.1 — 25.6 21.4 0.596 37.7 0.338 17.6 0.519 — — — Sub-Saharan Africa 0.537 0.372 30.8 — 30.7 30.8 0.434 33.7 0.308 27.7 0.385 — — — **Least developed countries** 0\\.524 0.375 28.5 — 28.2 27.1 0.502 36.2 0.274 21.4 0.382 — — — **Small island developing states** 0\\.722 0.553 23.4 — 23.1 16.1 0.675 19.6 0.501 33.5 0.500 — — — **Organisation for Economic Co‑operation and Development** 0\\.895 0.788 11.9 — 11.6 5.3 0.883 7.7 0.785 21.7 0.708 — — — **World 0.728 0.582 20.0 — 19.9 15.2 0.681 22.0 0.493 22.6 0.588 — — —**\n\n**NOTES a** See http://hdr.undp.org/en/composite/IHDI for the list of surveys used to estimate inequalities. **b** Based on countries for which an Inequality-adjusted Human Development Index value is calculated. **c** Calculated by HDRO from the 2015–2020 period life tables from UNDESA (2017a). **d** Data refer to 2017 or the most recent year available. **e** Data refer to the most recent year available during the period specified. **f** Data refer to a year earlier than 2010.\n\n**DEFINITIONS**\n\n**Human Development Index (HDI):** A composite index measuring average achievement in three basic dimensions of human development — a long and healthy life, knowledge and a decent standard of living. See _Technical note 1_ at http://hdr.undp.org/sites/default/ files/hdr2018\\_technical\\_notes.pdf for details on how the HDI is calculated.\n\n**Inequality‑adjusted HDI (IHDI):** HDI value adjusted for inequalities in the three basic dimensions of human development. See _Technical note 2_ at http://hdr.undp. org/sites/default/files/hdr2018\\_technical\\_notes.pdf for details on how the IHDI is calculated.\n\n**Overall loss:** Percentage difference between the IHDI value and the HDI value.\n\n**Difference from HDI rank:** Difference in ranks on the IHDI and the HDI, calculated only for countries for which an IHDI value is calculated.\n\n**Coefficient of human inequality:** Average inequality in three basic dimensions of human development.\n\n**Inequality in life expectancy:** Inequality in distribution of expected length of life based on data from life tables estimated using the Atkinson inequality index.\n\n**Inequality‑adjusted life expectancy index:** HDI life expectancy index value adjusted for inequality in distribution of expected length of life based on data from life tables listed in _Main data sources_ .\n\n**Inequality in education:** Inequality in distribution of years of schooling based on data from household surveys estimated using the Atkinson inequality index.\n\n**Inequality‑adjusted education index:** HDI education index value adjusted for inequality in distribution of years of schooling based on data from household surveys listed in _Main data sources_ .\n\n**Inequality in income:** Inequality in income distribution based on data from household surveys estimated using the Atkinson inequality index.\n\n**Inequality‑adjusted income index:** HDI income index value adjusted for inequality in income distribution based on data from household surveys listed in _Main data sources_ .\n\n**Quintile ratio:** Ratio of the average income of the richest 20 percent of the population to the average income of the poorest 20 percent of the population.\n\n**Palma ratio:** Ratio of the richest 10 percent of the population’s share of gross national income (GNI) divided by the poorest 40 percent’s share. It is based on the work of Palma (2011).\n\n**Gini coefficient:** Measure of the deviation of the distribution of income among individuals or households within a country from a perfectly equal distribution. A value of 0 represents absolute equality, a value of 100 absolute inequality.\n\n**MAIN DATA SOURCES**\n\n**Column 1:** HDRO calculations based on data from UNDESA (2017a), UNESCO Institute for Statistics (2018), United Nations Statistics Division (2018b), World Bank (2018b), Barro and Lee (2016) and IMF (2018).\n\n**Column 2:** Calculated as the geometric mean of the values in inequality-adjusted life expectancy index, inequality-adjusted education index and inequality- adjusted income index using the methodology in _Technical note 2_ (available at http://hdr.undp.org/sites/ default/files/hdr2018\\_technical\\_notes.pdf) _._\n\n**Column 3:** Calculated based on data in columns 1 and 2.\n\n**Column 4:** Calculated based on IHDI values and recalculated HDI ranks for countries for which an IHDI value is calculated.\n\n**Column 5:** Calculated as the arithmetic mean of the values in inequality in life expectancy, inequality in education and inequality in income using the methodology in _Technical note 2_ (available at http://hdr.undp.org/sites/ default/files/hdr2018\\_technical\\_notes.pdf) _._\n\n**Column 6:** Calculated based on abridged life tables from UNDESA (2017a).\n\n**Column 7:** Calculated based on inequality in life expectancy and the HDI life expectancy index.\n\n**Columns 8 and 10:** Calculated based on data from the Luxembourg Income Study database, Eurostat’s European Union Statistics on Income and Living Conditions, the World Bank’s International Income Distribution Database, the Center for Distributive, Labor and Social Studies and the World Bank’s Socio-Economic Database for Latin America and the Caribbean, ICF Macro Demographic and Health Surveys and United Nations Children’s Fund Multiple Indicator Cluster Surveys using the methodology in _Technical note 2_ (available at http://hdr.undp.org/ sites/default/files/hdr2018\\_technical\\_notes.pdf) _._\n\n**Column 9:** Calculated based on inequality in education and the HDI education index.\n\n**Column 11:** Calculated based on inequality in income and the HDI income index.\n\n**Columns 12 and 13:** HDRO calculations based on data from World Bank (2018a).\n\n**Column 14:** World Bank (2018a).\n\nHUMAN DEVELOPMENT INDICES AND INDICATORS: **2018 STATISTICAL UPDATE**\n\nTABLE 3 Inequality-adjusted Human Development Index | 33","pages":[{"line_numbers":[],"markdown":"TABLE\n\n## **3**\n\n**Human Development Index (HDI)**\n\n**Inequality‑adjusted HDI (IHDI)**\n\n**Coefficient of human inequality**\n\n**Inequality in life expectancy**\n\n**Inequality‑ adjusted life expectancy index**\n\n**Inequality in education** **a**\n\n**Inequality‑ adjusted education index**\n\n**Inequality in income** **a**\n\n**Inequality‑ adjusted income index Income inequality**\n\nValue Value\n\nOverall loss (%)\n\nDifference from HDI rank b (%) Value (%) Value (%) Value\n\n**Quintile ratio**\n\n**Palma ratio**\n\n**Gini coefficient**\n\n**HDI rank** 2017 2017 2017 2017 2017 2015–2020 c 2017 2017 d 2017 2017 d 2017 2010–2017 e 2010–2017 e 2010–2017 e\n\n178 Yemen 0.452 0.308 31.9 6 30.9 24.9 0.522 46.1 0.188 21.8 0.297 6.1 1.6 36.7 179 Eritrea 0.440 .. .. .. .. 21.4 0.551 .. .. .. .. .. .. .. 180 Mozambique 0.437 0.294 32.7 2 32.6 35.6 0.385 33.8 0.255 28.4 0.259 14.2 3.9 54.0 181 Liberia 0.435 0.298 31.6 4 31.0 27.5 0.480 42.9 0.248 22.7 0.221 5.4 1.3 33.2 182 Mali 0.427 0.282 34.0 1 32.8 36.8 0.374 46.2 0.158 15.4 0.380 5.2 f 1\\.3 f 33\\.0 f\n\n183 Burkina Faso 0.423 0.288 32.1 3 31.8 32.0 0.427 39.2 0.174 24.2 0.321 5.3 1.5 35.3 184 Sierra Leone 0.419 0.266 36.5 –1 35.4 39.8 0.298 47.3 0.206 19.2 0.307 5.4 1.4 34.0 185 Burundi 0.417 0.278 33.3 3 32.8 38.1 0.361 39.5 0.256 20.9 0.233 6.7 1.7 38.6 186 Chad 0.404 0.249 38.3 –1 37.9 42.4 0.294 43.0 0.170 28.4 0.310 10.0 2.2 43.3 187 South Sudan 0.388 0.247 36.3 –1 36.3 37.0 0.361 39.6 0.180 32.3 0.232 13.0 f 2\\.7 f 46\\.3 f\n\n188 Central African Republic 0.367 0.212 42.1 –1 41.8 41.7 0.295 34.5 0.223 49.2 0.145 18.5 f 4\\.5 f 56\\.2 f\n\n189 Niger 0.354 0.250 29.3 3 28.8 34.9 0.405 35.0 0.139 16.4 0.278 5.4 1.4 34.3 **OTHER COUNTRIES OR TERRITORIES** .. Korea (Democratic People's Rep. of) .. .. .. .. .. 11.6 0.706 .. .. .. .. .. .. .. .. Monaco .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. Nauru .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. San Marino .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. Somalia .. .. .. .. .. 38.9 0.345 .. .. .. .. .. .. .. .. Tuvalu .. .. .. .. .. .. .. 10.5 .. 23.4 0.472 7.0 1.8 39.1 **Human development groups** Very high human development 0.894 0.799 10.7 — 10.4 5.0 0.870 6.3 0.810 20.1 0.723 — — — High human development 0.757 0.636 16.0 — 15.7 9.2 0.782 13.1 0.579 24.8 0.569 — — — Medium human development 0.645 0.483 25.1 — 24.9 20.3 0.602 33.1 0.372 21.2 0.503 — — — Low human development 0.504 0.347 31.1 — 30.9 31.2 0.431 37.0 0.263 24.6 0.368 — — — **Developing countries** 0\\.681 0.531 22.0 — 21.9 17.4 0.644 25.3 0.435 23.1 0.535 — — — **Regions** Arab States 0.699 0.523 25.1 — 24.8 15.7 0.668 32.6 0.381 26.1 0.564 — — — East Asia and the Pacific 0.733 0.619 15.6 — 15.4 10.0 0.757 13.1 0.548 23.1 0.572 — — — Europe and Central Asia 0.771 0.681 11.7 — 11.6 10.9 0.732 7.2 0.680 16.7 0.633 — — — Latin America and the Caribbean 0.758 0.593 21.8 — 21.2 12.1 0.753 18.4 0.558 33.2 0.496 — — — South Asia 0.638 0.471 26.1 — 25.6 21.4 0.596 37.7 0.338 17.6 0.519 — — — Sub-Saharan Africa 0.537 0.372 30.8 — 30.7 30.8 0.434 33.7 0.308 27.7 0.385 — — — **Least developed countries** 0\\.524 0.375 28.5 — 28.2 27.1 0.502 36.2 0.274 21.4 0.382 — — — **Small island developing states** 0\\.722 0.553 23.4 — 23.1 16.1 0.675 19.6 0.501 33.5 0.500 — — — **Organisation for Economic Co‑operation and Development** 0\\.895 0.788 11.9 — 11.6 5.3 0.883 7.7 0.785 21.7 0.708 — — — **World 0.728 0.582 20.0 — 19.9 15.2 0.681 22.0 0.493 22.6 0.588 — — —**\n\n**NOTES a** See http://hdr.undp.org/en/composite/IHDI for the list of surveys used to estimate inequalities. **b** Based on countries for which an Inequality-adjusted Human Development Index value is calculated. **c** Calculated by HDRO from the 2015–2020 period life tables from UNDESA (2017a). **d** Data refer to 2017 or the most recent year available. **e** Data refer to the most recent year available during the period specified. **f** Data refer to a year earlier than 2010.\n\n**DEFINITIONS**\n\n**Human Development Index (HDI):** A composite index measuring average achievement in three basic dimensions of human development — a long and healthy life, knowledge and a decent standard of living. See _Technical note 1_ at http://hdr.undp.org/sites/default/ files/hdr2018\\_technical\\_notes.pdf for details on how the HDI is calculated.\n\n**Inequality‑adjusted HDI (IHDI):** HDI value adjusted for inequalities in the three basic dimensions of human development. See _Technical note 2_ at http://hdr.undp. org/sites/default/files/hdr2018\\_technical\\_notes.pdf for details on how the IHDI is calculated.\n\n**Overall loss:** Percentage difference between the IHDI value and the HDI value.\n\n**Difference from HDI rank:** Difference in ranks on the IHDI and the HDI, calculated only for countries for which an IHDI value is calculated.\n\n**Coefficient of human inequality:** Average inequality in three basic dimensions of human development.\n\n**Inequality in life expectancy:** Inequality in distribution of expected length of life based on data from life tables estimated using the Atkinson inequality index.\n\n**Inequality‑adjusted life expectancy index:** HDI life expectancy index value adjusted for inequality in distribution of expected length of life based on data from life tables listed in _Main data sources_ .\n\n**Inequality in education:** Inequality in distribution of years of schooling based on data from household surveys estimated using the Atkinson inequality index.\n\n**Inequality‑adjusted education index:** HDI education index value adjusted for inequality in distribution of years of schooling based on data from household surveys listed in _Main data sources_ .\n\n**Inequality in income:** Inequality in income distribution based on data from household surveys estimated using the Atkinson inequality index.\n\n**Inequality‑adjusted income index:** HDI income index value adjusted for inequality in income distribution based on data from household surveys listed in _Main data sources_ .\n\n**Quintile ratio:** Ratio of the average income of the richest 20 percent of the population to the average income of the poorest 20 percent of the population.\n\n**Palma ratio:** Ratio of the richest 10 percent of the population’s share of gross national income (GNI) divided by the poorest 40 percent’s share. It is based on the work of Palma (2011).\n\n**Gini coefficient:** Measure of the deviation of the distribution of income among individuals or households within a country from a perfectly equal distribution. A value of 0 represents absolute equality, a value of 100 absolute inequality.\n\n**MAIN DATA SOURCES**\n\n**Column 1:** HDRO calculations based on data from UNDESA (2017a), UNESCO Institute for Statistics (2018), United Nations Statistics Division (2018b), World Bank (2018b), Barro and Lee (2016) and IMF (2018).\n\n**Column 2:** Calculated as the geometric mean of the values in inequality-adjusted life expectancy index, inequality-adjusted education index and inequality- adjusted income index using the methodology in _Technical note 2_ (available at http://hdr.undp.org/sites/ default/files/hdr2018\\_technical\\_notes.pdf) _._\n\n**Column 3:** Calculated based on data in columns 1 and 2.\n\n**Column 4:** Calculated based on IHDI values and recalculated HDI ranks for countries for which an IHDI value is calculated.\n\n**Column 5:** Calculated as the arithmetic mean of the values in inequality in life expectancy, inequality in education and inequality in income using the methodology in _Technical note 2_ (available at http://hdr.undp.org/sites/ default/files/hdr2018\\_technical\\_notes.pdf) _._\n\n**Column 6:** Calculated based on abridged life tables from UNDESA (2017a).\n\n**Column 7:** Calculated based on inequality in life expectancy and the HDI life expectancy index.\n\n**Columns 8 and 10:** Calculated based on data from the Luxembourg Income Study database, Eurostat’s European Union Statistics on Income and Living Conditions, the World Bank’s International Income Distribution Database, the Center for Distributive, Labor and Social Studies and the World Bank’s Socio-Economic Database for Latin America and the Caribbean, ICF Macro Demographic and Health Surveys and United Nations Children’s Fund Multiple Indicator Cluster Surveys using the methodology in _Technical note 2_ (available at http://hdr.undp.org/ sites/default/files/hdr2018\\_technical\\_notes.pdf) _._\n\n**Column 9:** Calculated based on inequality in education and the HDI education index.\n\n**Column 11:** Calculated based on inequality in income and the HDI income index.\n\n**Columns 12 and 13:** HDRO calculations based on data from World Bank (2018a).\n\n**Column 14:** World Bank (2018a).\n\nHUMAN DEVELOPMENT INDICES AND INDICATORS: **2018 STATISTICAL UPDATE**\n\nTABLE 3 Inequality-adjusted Human Development Index | 33","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_051","product_type":"parse","source_file_path":"complex_header_051.pdf"},"started_at":"2026-11-12T14:55:52.068595"} {"completed_at":"2026-11-12T14:55:44.967732","latency_in_ms":2436,"output":{"example_id":"complex_table_headers/complex_header_053","grounded_pages":[],"layout_pages":[],"markdown":"**State of California Company: AMGUARD INSURANCE COMPANY**\n\n**Department of Insurance (CDI) Line: Multiple Peril**\n\n**CDI File # (Department Use Only):**\n\n## **EXCLUDED EXPENSE RATIO**\n\n## **Countrywide Insurer Group Data**\n\n2nd Prior Calendar\n\nYear\n\n1st Prior Calendar\n\nYear\n\nMost Recent Calendar Year\n\n2016 2017 **2018**\n\n184,846,902 315,302,629 530,386,469\n\n717,118,023 822,691,073 896,640,817\n\nTotal countrywide direct earned premium ($): 901,964,925 1,137,993,702 1,427,027,286\n\n_(Note: Total must reconcile to the countrywide direct earned premium in the Insurance Expense Exhibit, Part 3 for the_ **_insurer group_** _.)_\n\n**Check box if the excluded expenses entered in this page are derived on a countrywide, group basis**\n\n**_CCR §2644.10 (b): Executive Compensation_**\n\n2nd Prior Calendar Year 1st Prior Calendar Year Most Recent Calendar Year\n\n2016 2017 2018\n\nCash & Salary Bonus Cash & Salary Bonus Cash & Salary Bonus\n\n1st Highest Paid 615,000 1,822,540 639,888 2,851,551 641,966 3,986,195\n\n2nd Highest Paid 420,613 619,664 450,737 971,854 445,344 1,358,263\n\n3rd Highest Paid 378,769 546,762 394,753 857,518 410,276 1,198,468\n\n4th Highest Paid 341,944 546,762 372,711 857,518 375,760 1,198,468\n\n5th Highest Paid 372,348 153,198 400,572 471,180 407,031 897,745\n\n2nd Prior Calendar Year 1st Prior Calendar Year Most Recent Calendar Year\n\nMaximum Permissible Excessive Amount Maximum Permissible Excessive Amount Maximum Permissible Excessive Amount\n\n1st Highest Paid 258,548 2,178,992 321,143 3,170,296 396,643 4,231,518\n\n2nd Highest Paid 172,716 867,561 208,100 1,214,491 249,516 1,554,091\n\n3rd Highest Paid 134,629 790,902 165,093 1,087,178 201,377 1,407,367\n\n4th Highest Paid 123,235 765,471 149,197 1,081,032 179,730 1,394,498\n\n5th Highest Paid 113,101 412,445 135,763 735,989 162,191 1,142,585\n\nTotal Excessive 5,015,371 7,288,986 9,730,059\n\n**_CCR §2644.10 (f): Institutional Advertising_**\n\n2nd Prior Calendar Year 1st Prior Calendar Year Most Recent Calendar Year\n\n2016 2017 2018\n\nInstitutional Non-Institutional Institutional Non-Institutional Institutional Non-Institutional\n\nTotal Advertising ¹ 0 320,000 0 801,000 0 943,000\n\n_1 Note: For each calendar year, the sum of Institutional and Non-Institutional advertising expenses must reconcile to the total advertising expenses reported in the Insurance Expense Exhibit, Part 1, Line 4 for the_ **_insurer group_** _._\n\nCountrywide direct earned premium for lines of business subject to Proposition 103 ($): Countrywide direct earned premium for lines of business **_not_** subject to Proposition 103 ($):\n\n2016 2017 2018\n\nPrior Approval Rate Template Page 4.1 04/30/2019 Edition","pages":[{"line_numbers":[],"markdown":"**State of California Company: AMGUARD INSURANCE COMPANY**\n\n**Department of Insurance (CDI) Line: Multiple Peril**\n\n**CDI File # (Department Use Only):**\n\n## **EXCLUDED EXPENSE RATIO**\n\n## **Countrywide Insurer Group Data**\n\n2nd Prior Calendar\n\nYear\n\n1st Prior Calendar\n\nYear\n\nMost Recent Calendar Year\n\n2016 2017 **2018**\n\n184,846,902 315,302,629 530,386,469\n\n717,118,023 822,691,073 896,640,817\n\nTotal countrywide direct earned premium ($): 901,964,925 1,137,993,702 1,427,027,286\n\n_(Note: Total must reconcile to the countrywide direct earned premium in the Insurance Expense Exhibit, Part 3 for the_ **_insurer group_** _.)_\n\n**Check box if the excluded expenses entered in this page are derived on a countrywide, group basis**\n\n**_CCR §2644.10 (b): Executive Compensation_**\n\n2nd Prior Calendar Year 1st Prior Calendar Year Most Recent Calendar Year\n\n2016 2017 2018\n\nCash & Salary Bonus Cash & Salary Bonus Cash & Salary Bonus\n\n1st Highest Paid 615,000 1,822,540 639,888 2,851,551 641,966 3,986,195\n\n2nd Highest Paid 420,613 619,664 450,737 971,854 445,344 1,358,263\n\n3rd Highest Paid 378,769 546,762 394,753 857,518 410,276 1,198,468\n\n4th Highest Paid 341,944 546,762 372,711 857,518 375,760 1,198,468\n\n5th Highest Paid 372,348 153,198 400,572 471,180 407,031 897,745\n\n2nd Prior Calendar Year 1st Prior Calendar Year Most Recent Calendar Year\n\nMaximum Permissible Excessive Amount Maximum Permissible Excessive Amount Maximum Permissible Excessive Amount\n\n1st Highest Paid 258,548 2,178,992 321,143 3,170,296 396,643 4,231,518\n\n2nd Highest Paid 172,716 867,561 208,100 1,214,491 249,516 1,554,091\n\n3rd Highest Paid 134,629 790,902 165,093 1,087,178 201,377 1,407,367\n\n4th Highest Paid 123,235 765,471 149,197 1,081,032 179,730 1,394,498\n\n5th Highest Paid 113,101 412,445 135,763 735,989 162,191 1,142,585\n\nTotal Excessive 5,015,371 7,288,986 9,730,059\n\n**_CCR §2644.10 (f): Institutional Advertising_**\n\n2nd Prior Calendar Year 1st Prior Calendar Year Most Recent Calendar Year\n\n2016 2017 2018\n\nInstitutional Non-Institutional Institutional Non-Institutional Institutional Non-Institutional\n\nTotal Advertising ¹ 0 320,000 0 801,000 0 943,000\n\n_1 Note: For each calendar year, the sum of Institutional and Non-Institutional advertising expenses must reconcile to the total advertising expenses reported in the Insurance Expense Exhibit, Part 1, Line 4 for the_ **_insurer group_** _._\n\nCountrywide direct earned premium for lines of business subject to Proposition 103 ($): Countrywide direct earned premium for lines of business **_not_** subject to Proposition 103 ($):\n\n2016 2017 2018\n\nPrior Approval Rate Template Page 4.1 04/30/2019 Edition","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_053","product_type":"parse","source_file_path":"complex_header_053.pdf"},"started_at":"2026-11-12T14:55:42.531244"} {"completed_at":"2026-11-12T14:56:03.286047","latency_in_ms":1742,"output":{"example_id":"complex_table_headers/complex_header_055","grounded_pages":[],"layout_pages":[],"markdown":"### **0 FONQSR 1 QRS TBQSFQ 1 MBMD BK FRTKSR**\n\n**,5 :B ,OQ Y** K A A fUcd U dc ; Q i $F9K 9I6K A;% d TQi Q e SUT VY Q SYQ bUce dc V b d U VYbcd aeQbdUb .,.2\\* JU QdYfU d d U VYbcd aeQbdUb .,.1( HK Y SbUQcUT Ri ., ( Q T bUfU eU Q T UbQdY W Y S U WbUg Ri -/ Q T .- ( bUc USdYfU i( gYd UbQdY W QbWY Y SbUQcY W d /, \\* G Q QT ecdUT RQcYc( HK Q T UbQdY W Y S U WbUg .- Q T .0 ( bUc USdYfU i( gYd d U QT ecdUT UbQdY W QbWY Y SbUQcY W d /. \\*\n\n**.NMRNK EBSFE UFQU FV** $A d ecQ Tc( UhSU d UQb Y Wc Ub c QbU% b d U L bUU E d c\n\nTUT EQbS m/-( .,.2 .,.1\n\nM\\*K\\* 99H :QcYc JUfU eUc 2..(-4/ 11-(/00 -/\n\nA S U Vb UbQdY c -45(042 -13(,53 .-\n\nG UbQdY W QbWY /, .4 3\n\nFUd Y S U QddbYRedQR U d K A A fUcd U dc -30(043 -1-(1-3 -1\n\nY edUT UQb Y Wc Ub c QbU -\\*0, -\\*-3 .,\n\nF ) 99H :QcYc $-%\n\n9T ecdUT Y S U Vb UbQdY c -54(24/ -2,(102 .0\n\n9T ecdUT TY edUT UQb Y Wc Ub c QbU -\\*00 -\\*-5 .-\n\n9T ecdUT UbQdY W QbWY /. .5 -,\n\n$-% KUU F ) 99H A V b QdY Q T JUS SY YQdY c Wc -,)--\n\noOU RUWQ .,.2 gYd Q TUVY Y W aeQbdUb V b K A( fQ YTQdY W eb cdbQdUWi( UhUSedY ( Q T d U cSQ QRY Ydi V eb UbQdY W TU \\* OU TU YfUbUT cdb W UQb Y Wc Wb gd ( UQ Y WVe QbWY Uh Q cY ( Q T Y SbUTYR U cQ Uc bUce dc( TbYfU Ri Rb QT)RQcUT U de QSb cc eb S bU Wb gd U WY Uc( cQYT ; G JiQ @YS U\\*\n\n; YU d TU Q T V b edc ebSY W( dUS Wi Q T QT Y YcdbQdYfU UhSU U SU( Q T b VUccY Q cUbfYSUc S dY eUc d QSSU UbQdU\\* 9TTYdY Q i( UfYTU SU V b WbUcc Y QccUd Q QWU U d Yc ReY TY W( Q T eb W Y W Y fUcd U d Y 9A Q T Qed QdY Yc cdbU Wd U Y W d U V e TQdY V Q bU Y R U( Y fQdYfU( cSQ QR U( Q T bUcY YU d U dUb bYcU\\* OU RU YUfU K A Yc gU cYdY UT d TU YfUb cecdQY UT fQ eU V b eb S YU dc( U iUUc( Q T c QbU TUbc\\*p\n\n\\-","pages":[{"line_numbers":[],"markdown":"### **0 FONQSR 1 QRS TBQSFQ 1 MBMD BK FRTKSR**\n\n**,5 :B ,OQ Y** K A A fUcd U dc ; Q i $F9K 9I6K A;% d TQi Q e SUT VY Q SYQ bUce dc V b d U VYbcd aeQbdUb .,.2\\* JU QdYfU d d U VYbcd aeQbdUb .,.1( HK Y SbUQcUT Ri ., ( Q T bUfU eU Q T UbQdY W Y S U WbUg Ri -/ Q T .- ( bUc USdYfU i( gYd UbQdY W QbWY Y SbUQcY W d /, \\* G Q QT ecdUT RQcYc( HK Q T UbQdY W Y S U WbUg .- Q T .0 ( bUc USdYfU i( gYd d U QT ecdUT UbQdY W QbWY Y SbUQcY W d /. \\*\n\n**.NMRNK EBSFE UFQU FV** $A d ecQ Tc( UhSU d UQb Y Wc Ub c QbU% b d U L bUU E d c\n\nTUT EQbS m/-( .,.2 .,.1\n\nM\\*K\\* 99H :QcYc JUfU eUc 2..(-4/ 11-(/00 -/\n\nA S U Vb UbQdY c -45(042 -13(,53 .-\n\nG UbQdY W QbWY /, .4 3\n\nFUd Y S U QddbYRedQR U d K A A fUcd U dc -30(043 -1-(1-3 -1\n\nY edUT UQb Y Wc Ub c QbU -\\*0, -\\*-3 .,\n\nF ) 99H :QcYc $-%\n\n9T ecdUT Y S U Vb UbQdY c -54(24/ -2,(102 .0\n\n9T ecdUT TY edUT UQb Y Wc Ub c QbU -\\*00 -\\*-5 .-\n\n9T ecdUT UbQdY W QbWY /. .5 -,\n\n$-% KUU F ) 99H A V b QdY Q T JUS SY YQdY c Wc -,)--\n\noOU RUWQ .,.2 gYd Q TUVY Y W aeQbdUb V b K A( fQ YTQdY W eb cdbQdUWi( UhUSedY ( Q T d U cSQ QRY Ydi V eb UbQdY W TU \\* OU TU YfUbUT cdb W UQb Y Wc Wb gd ( UQ Y WVe QbWY Uh Q cY ( Q T Y SbUTYR U cQ Uc bUce dc( TbYfU Ri Rb QT)RQcUT U de QSb cc eb S bU Wb gd U WY Uc( cQYT ; G JiQ @YS U\\*\n\n; YU d TU Q T V b edc ebSY W( dUS Wi Q T QT Y YcdbQdYfU UhSU U SU( Q T b VUccY Q cUbfYSUc S dY eUc d QSSU UbQdU\\* 9TTYdY Q i( UfYTU SU V b WbUcc Y QccUd Q QWU U d Yc ReY TY W( Q T eb W Y W Y fUcd U d Y 9A Q T Qed QdY Yc cdbU Wd U Y W d U V e TQdY V Q bU Y R U( Y fQdYfU( cSQ QR U( Q T bUcY YU d U dUb bYcU\\* OU RU YUfU K A Yc gU cYdY UT d TU YfUb cecdQY UT fQ eU V b eb S YU dc( U iUUc( Q T c QbU TUbc\\*p\n\n\\-","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_055","product_type":"parse","source_file_path":"complex_header_055.pdf"},"started_at":"2026-11-12T14:56:01.543529"} {"completed_at":"2026-11-12T14:56:08.609055","latency_in_ms":2455,"output":{"example_id":"complex_table_headers/complex_header_057","grounded_pages":[],"layout_pages":[],"markdown":"**Rx** **Trends** **Used** **in** **3Q** **2018** **MVP** **VT** **Large** **Group** **Filing**\n\n2017 Trend 2018 Trend 2019 Trend\n\nUnit Cost Utilization Unit Cost Unit Cost Unit Cost Utilization\n\nGeneric ‐8.3% 0.8% ‐0.4% 2.7% 4.6% 3.1%\n\nBrand 9.9% ‐4.4% 14.9% 2.5% 12.5% 1.4%\n\nSpecialty 10.9% 9.6% 6.9% 7.5% 10.6% 7.4%\n\nPlease see the attached file, “Rolling 12 Medical and Rx Data ‐ LG.xlsx” which contains a rolling 12 month summary of total Rx claim costs as well as Rx data broken out by Generic, Brand, and Specialty. Also included in this filing is a paid trend development exhibit for 4Q 2018. Please see Exhibit 2f which is identical to Exhibit 2b except there is one more quarter of trend reflected in the calculation. **Retention** **Expenses** Retention expenses are outlined in the attached Addendum. The following table represents MVP’s Large Group administrative expenses as filed in the Supplemental Health Care Exhibit over the past four years:\n\n**Administrative** **Expense** **Summary** **‐** **Data** **Taken** **from** **Supplemental** **Health** **Care** **Exhibit**\n\nVT Large Group ‐ AR42 & AR44\n\nMember Months Premium PMPM Admin PMPM\n\nAdmin Expense\n\nRatio\n\n2013 118,563 $363.04 $39.18 10.8%\n\n2014 97,084 $404.11 $38.31 9.5%\n\n2015 68,766 $432.06 $34.13 7.9%\n\n2016 37,858 $450.19 $36.77 8.2%\n\nAdmin PMPM reflects the following lines from Part I of the SHCE: 6.6, 8.3, 10.1, and 10.4\n\nChanges have been made to the following retention items since the 1Q 2017 filing:\n\n‐ Covered Lives Assessment: The 2018 covered lives assessment has been finalized by New York State. MVP has included the updated amounts in the addendum. This assessment is only applied to subscribers residing in NY which is consistent with the way the fee is charged.\n\nThe following taxes/assessments are included in the attached Addendum: _ACA_ _Insurer_ _Tax_ Since 2014, carriers have been taxed based on earned premium. After being reinstated for 2018, this tax has been again delayed for the 2019 plan year. The tax is based on MVP’s share of 2017 nationwide revenue relative to the total tax liability collected by the Federal Government. Using this information, MVP estimates the tax will be 1.0% of premium for 2018 coverage months and 0.0% for 2019 coverage months. _VT_ _Paid_ _Claim_ _Tax_ The State of Vermont charges a 0.999% tax on paid claims. _Comparative_ _Effectiveness_ _Research_ _Fee_ This is a prescribed Federal fee equal to $0.21 PMPM to fund the Federal Research Fund. This fee is unchanged from the previous version of the filing.","pages":[{"line_numbers":[],"markdown":"**Rx** **Trends** **Used** **in** **3Q** **2018** **MVP** **VT** **Large** **Group** **Filing**\n\n2017 Trend 2018 Trend 2019 Trend\n\nUnit Cost Utilization Unit Cost Unit Cost Unit Cost Utilization\n\nGeneric ‐8.3% 0.8% ‐0.4% 2.7% 4.6% 3.1%\n\nBrand 9.9% ‐4.4% 14.9% 2.5% 12.5% 1.4%\n\nSpecialty 10.9% 9.6% 6.9% 7.5% 10.6% 7.4%\n\nPlease see the attached file, “Rolling 12 Medical and Rx Data ‐ LG.xlsx” which contains a rolling 12 month summary of total Rx claim costs as well as Rx data broken out by Generic, Brand, and Specialty. Also included in this filing is a paid trend development exhibit for 4Q 2018. Please see Exhibit 2f which is identical to Exhibit 2b except there is one more quarter of trend reflected in the calculation. **Retention** **Expenses** Retention expenses are outlined in the attached Addendum. The following table represents MVP’s Large Group administrative expenses as filed in the Supplemental Health Care Exhibit over the past four years:\n\n**Administrative** **Expense** **Summary** **‐** **Data** **Taken** **from** **Supplemental** **Health** **Care** **Exhibit**\n\nVT Large Group ‐ AR42 & AR44\n\nMember Months Premium PMPM Admin PMPM\n\nAdmin Expense\n\nRatio\n\n2013 118,563 $363.04 $39.18 10.8%\n\n2014 97,084 $404.11 $38.31 9.5%\n\n2015 68,766 $432.06 $34.13 7.9%\n\n2016 37,858 $450.19 $36.77 8.2%\n\nAdmin PMPM reflects the following lines from Part I of the SHCE: 6.6, 8.3, 10.1, and 10.4\n\nChanges have been made to the following retention items since the 1Q 2017 filing:\n\n‐ Covered Lives Assessment: The 2018 covered lives assessment has been finalized by New York State. MVP has included the updated amounts in the addendum. This assessment is only applied to subscribers residing in NY which is consistent with the way the fee is charged.\n\nThe following taxes/assessments are included in the attached Addendum: _ACA_ _Insurer_ _Tax_ Since 2014, carriers have been taxed based on earned premium. After being reinstated for 2018, this tax has been again delayed for the 2019 plan year. The tax is based on MVP’s share of 2017 nationwide revenue relative to the total tax liability collected by the Federal Government. Using this information, MVP estimates the tax will be 1.0% of premium for 2018 coverage months and 0.0% for 2019 coverage months. _VT_ _Paid_ _Claim_ _Tax_ The State of Vermont charges a 0.999% tax on paid claims. _Comparative_ _Effectiveness_ _Research_ _Fee_ This is a prescribed Federal fee equal to $0.21 PMPM to fund the Federal Research Fund. This fee is unchanged from the previous version of the filing.","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_057","product_type":"parse","source_file_path":"complex_header_057.pdf"},"started_at":"2026-11-12T14:56:06.153797"} {"completed_at":"2026-11-12T14:56:13.566171","latency_in_ms":2883,"output":{"example_id":"complex_table_headers/complex_header_058","grounded_pages":[],"layout_pages":[],"markdown":"MATH +maj1@k GSM8k +maj1@k\n\nPaLM\n\n8B 1.5 - 4.1 -\n\n62B 4.4 - 33.0 -\n\n540B 8.8 - 56.5 -\n\nMinerva\n\n8B 14.1 25.4 16.2 28.4\n\n62B 27.6 43.4 52.4 68.5\n\n540B **33\\.6 50.3 68.5 78.5**\n\nLLaMA\n\n7B 2.9 6.9 11.0 18.1\n\n13B 3.9 8.8 17.8 29.3\n\n33B 7.1 15.2 35.6 53.1\n\n65B 10.6 20.5 50.9 69.7\n\nTable 7: **Model performance on quantitative reason- ing datasets.** For majority voting, we use the same setup as Minerva, with _k_ = 256 samples for MATH and _k_ = 100 for GSM8k (Minerva 540B uses _k_ = 64 for MATH and and _k_ = 40 for GSM8k). LLaMA-65B outperforms Minerva 62B on GSM8k, although it has not been fine-tuned on mathematical data.\n\ndocstring. The model needs to generate a Python program that fits the description and satisfies the test cases. In Table 8, we compare the pass@1 scores of our models with existing language mod- els that have not been finetuned on code, namely PaLM and LaMDA (Thoppilan et al., 2022). PaLM and LLaMA were trained on datasets that contain a similar number of code tokens.\n\nAs show in Table 8, for a similar number\n\nof parameters, LLaMA outperforms other gen- eral models such as LaMDA and PaLM, which are not trained or finetuned specifically for code. LLaMA with 13B parameters and more outper- forms LaMDA 137B on both HumanEval and MBPP. LLaMA 65B also outperforms PaLM 62B, even when it is trained longer. The pass@1 results reported in this table were obtained by sampling with temperature 0.1. The pass@100 and pass@80 metrics were obtained with temperature 0.8. We use the same method as Chen et al. (2021) to obtain unbiased estimates of the pass@k.\n\nIt is possible to greatly improve the performance\n\non code by finetuning models on code-specific to- kens. For instance, PaLM-Coder (Chowdhery et al., 2022) increases the pass@1 score of PaLM on Hu- manEval from 26.2% for PaLM to 36%. Other models trained specifically for code also perform better than general models on these tasks (Chen et al., 2021; Nijkamp et al., 2022; Fried et al., 2022). Finetuning on code tokens is, however, beyond the\n\nscope of this paper.\n\nParams HumanEval MBPP\n\npass@ @1 @100 @1 @80\n\nLaMDA 137B 14.0 47.3 14.8 62.4\n\nPaLM 8B 3.6 _→_ 18\\.7 _→_ 5\\.0 _→_ 35\\.7 _→_\n\nPaLM 62B 15.9 46.3 _→_ 21\\.4 63.2 _→_\n\nPaLM-cont 62B 23.7 - 31.2 -\n\nPaLM 540B **26\\.2** 76\\.2 36.8 75.0\n\nLLaMA\n\n7B 10.5 36.5 17.7 56.2\n\n13B 15.8 52.5 22.0 64.0\n\n33B 21.7 70.7 30.2 73.4\n\n65B 23.7 **79\\.3 37.7 76.8**\n\nTable 8: **Model performance for code generation.** We report the pass@ score on HumanEval and MBPP. Hu- manEval generations are done in zero-shot and MBBP with 3-shot prompts similar to Austin et al. (2021). The values marked with _→_ are read from figures in Chowdh- ery et al. (2022).\n\n**3\\.6 Massive Multitask Language Understanding**\n\nThe massive multitask language understanding benchmark, or MMLU, introduced by Hendrycks et al. (2020) consists of multiple choice questions covering various domains of knowledge, includ- ing humanities, STEM and social sciences. We evaluate our models in the 5-shot setting, using the examples provided by the benchmark, and report results in Table 9. On this benchmark, we observe that the LLaMA-65B is behind both Chinchilla- 70B and PaLM-540B by a few percent in average, and across most domains. A potential explanation is that we have used a limited amount of books and academic papers in our pre-training data, i.e., ArXiv, Gutenberg and Books3, that sums up to only 177GB, while these models were trained on up to 2TB of books. This large quantity of books used by Gopher, Chinchilla and PaLM may also explain why Gopher outperforms GPT-3 on this benchmark, while it is comparable on other benchmarks.\n\n**3\\.7 Evolution of performance during training**\n\nDuring training, we tracked the performance of our models on a few question answering and common sense benchmarks, and report them in Figure 2. On most benchmarks, the performance improves steadily, and correlates with the training perplexity of the model (see Figure 1). The exceptions are SIQA and WinoGrande. Most notably, on SIQA,","pages":[{"line_numbers":[],"markdown":"MATH +maj1@k GSM8k +maj1@k\n\nPaLM\n\n8B 1.5 - 4.1 -\n\n62B 4.4 - 33.0 -\n\n540B 8.8 - 56.5 -\n\nMinerva\n\n8B 14.1 25.4 16.2 28.4\n\n62B 27.6 43.4 52.4 68.5\n\n540B **33\\.6 50.3 68.5 78.5**\n\nLLaMA\n\n7B 2.9 6.9 11.0 18.1\n\n13B 3.9 8.8 17.8 29.3\n\n33B 7.1 15.2 35.6 53.1\n\n65B 10.6 20.5 50.9 69.7\n\nTable 7: **Model performance on quantitative reason- ing datasets.** For majority voting, we use the same setup as Minerva, with _k_ = 256 samples for MATH and _k_ = 100 for GSM8k (Minerva 540B uses _k_ = 64 for MATH and and _k_ = 40 for GSM8k). LLaMA-65B outperforms Minerva 62B on GSM8k, although it has not been fine-tuned on mathematical data.\n\ndocstring. The model needs to generate a Python program that fits the description and satisfies the test cases. In Table 8, we compare the pass@1 scores of our models with existing language mod- els that have not been finetuned on code, namely PaLM and LaMDA (Thoppilan et al., 2022). PaLM and LLaMA were trained on datasets that contain a similar number of code tokens.\n\nAs show in Table 8, for a similar number\n\nof parameters, LLaMA outperforms other gen- eral models such as LaMDA and PaLM, which are not trained or finetuned specifically for code. LLaMA with 13B parameters and more outper- forms LaMDA 137B on both HumanEval and MBPP. LLaMA 65B also outperforms PaLM 62B, even when it is trained longer. The pass@1 results reported in this table were obtained by sampling with temperature 0.1. The pass@100 and pass@80 metrics were obtained with temperature 0.8. We use the same method as Chen et al. (2021) to obtain unbiased estimates of the pass@k.\n\nIt is possible to greatly improve the performance\n\non code by finetuning models on code-specific to- kens. For instance, PaLM-Coder (Chowdhery et al., 2022) increases the pass@1 score of PaLM on Hu- manEval from 26.2% for PaLM to 36%. Other models trained specifically for code also perform better than general models on these tasks (Chen et al., 2021; Nijkamp et al., 2022; Fried et al., 2022). Finetuning on code tokens is, however, beyond the\n\nscope of this paper.\n\nParams HumanEval MBPP\n\npass@ @1 @100 @1 @80\n\nLaMDA 137B 14.0 47.3 14.8 62.4\n\nPaLM 8B 3.6 _→_ 18\\.7 _→_ 5\\.0 _→_ 35\\.7 _→_\n\nPaLM 62B 15.9 46.3 _→_ 21\\.4 63.2 _→_\n\nPaLM-cont 62B 23.7 - 31.2 -\n\nPaLM 540B **26\\.2** 76\\.2 36.8 75.0\n\nLLaMA\n\n7B 10.5 36.5 17.7 56.2\n\n13B 15.8 52.5 22.0 64.0\n\n33B 21.7 70.7 30.2 73.4\n\n65B 23.7 **79\\.3 37.7 76.8**\n\nTable 8: **Model performance for code generation.** We report the pass@ score on HumanEval and MBPP. Hu- manEval generations are done in zero-shot and MBBP with 3-shot prompts similar to Austin et al. (2021). The values marked with _→_ are read from figures in Chowdh- ery et al. (2022).\n\n**3\\.6 Massive Multitask Language Understanding**\n\nThe massive multitask language understanding benchmark, or MMLU, introduced by Hendrycks et al. (2020) consists of multiple choice questions covering various domains of knowledge, includ- ing humanities, STEM and social sciences. We evaluate our models in the 5-shot setting, using the examples provided by the benchmark, and report results in Table 9. On this benchmark, we observe that the LLaMA-65B is behind both Chinchilla- 70B and PaLM-540B by a few percent in average, and across most domains. A potential explanation is that we have used a limited amount of books and academic papers in our pre-training data, i.e., ArXiv, Gutenberg and Books3, that sums up to only 177GB, while these models were trained on up to 2TB of books. This large quantity of books used by Gopher, Chinchilla and PaLM may also explain why Gopher outperforms GPT-3 on this benchmark, while it is comparable on other benchmarks.\n\n**3\\.7 Evolution of performance during training**\n\nDuring training, we tracked the performance of our models on a few question answering and common sense benchmarks, and report them in Figure 2. On most benchmarks, the performance improves steadily, and correlates with the training perplexity of the model (see Figure 1). The exceptions are SIQA and WinoGrande. Most notably, on SIQA,","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_058","product_type":"parse","source_file_path":"complex_header_058.pdf"},"started_at":"2026-11-12T14:56:10.682346"} {"completed_at":"2026-11-12T14:56:22.458368","latency_in_ms":1878,"output":{"example_id":"complex_table_headers/complex_header_061","grounded_pages":[],"layout_pages":[],"markdown":"## **FQ I A IY MYS BM S VN WMYI QVU UI LQ ML**\n\n**6Q KIS ( ( A IY MY 5ULML 6Q KIS ( () A IY MY 5ULML**\n\n**: UM )**\n\n**( (**\n\n**IYKP )**\n\n**( (**\n\n**4MKMTJMY )**\n\n**( ()**\n\n**CMW MTJMY )**\n\n**( ()**\n\n**: UM )**\n\n**( ()**\n\n**QU TQSSQVU**\n\n**M YM MU M .** 1%00. 1%/,- 1%/)2 1% ,\n\n**WMYI QUO 5 WMU M** DQ Q **\\-)** %/), %-02 %-21 %-1\n\nAM WQ U S **)-.** ,,1 2, -), 20\n\nBQ c W M P OQ U S **(** 12 1 20 1\n\nD RQ U M RQQ **(** /) , 0, ,,\n\n9Q QOUM U M P MY UfM U **(,** \\-2 -0 -0 ,.\n\nQ Q M M P MPYU U M UbQ **).(** \\-. ,-) - , -\n\n@U USM U bU U **)** \\-,) 2 2 -.0\n\n**DV IS VWMYI QUO M WMU M ( ,(** ,%- %/1) ,%).2 ,%)22\n\n**WMYI QUO QUKVTM ).** .%,.- .%2.- .%..) .%) -\n\n**VU$VWMYI QUO 9UKVTM 5 WMU M** Q Q Qd Q Q **,** 1 $ 10$ 1,$ 1 $\n\nbQ YQ U O YQ Qd Q Q$ M P TQ **( -** \\- 0. /2 ,)-\n\n**DV IS UVU$VWMYI QUO QUKVTM M WMU M** .2 11 1/\n\n**9UKVTM JMNVYM QUKVTM I M .** .%. , /%)- .%/,/ .% -/\n\nO YQ Md bU U **\\-** 1\\.) % . 2.. 22)\n\n**M QUKVTM .-(** \\-%//, -%12) -%/1 -% ./\n\n2","pages":[{"line_numbers":[],"markdown":"## **FQ I A IY MYS BM S VN WMYI QVU UI LQ ML**\n\n**6Q KIS ( ( A IY MY 5ULML 6Q KIS ( () A IY MY 5ULML**\n\n**: UM )**\n\n**( (**\n\n**IYKP )**\n\n**( (**\n\n**4MKMTJMY )**\n\n**( ()**\n\n**CMW MTJMY )**\n\n**( ()**\n\n**: UM )**\n\n**( ()**\n\n**QU TQSSQVU**\n\n**M YM MU M .** 1%00. 1%/,- 1%/)2 1% ,\n\n**WMYI QUO 5 WMU M** DQ Q **\\-)** %/), %-02 %-21 %-1\n\nAM WQ U S **)-.** ,,1 2, -), 20\n\nBQ c W M P OQ U S **(** 12 1 20 1\n\nD RQ U M RQQ **(** /) , 0, ,,\n\n9Q QOUM U M P MY UfM U **(,** \\-2 -0 -0 ,.\n\nQ Q M M P MPYU U M UbQ **).(** \\-. ,-) - , -\n\n@U USM U bU U **)** \\-,) 2 2 -.0\n\n**DV IS VWMYI QUO M WMU M ( ,(** ,%- %/1) ,%).2 ,%)22\n\n**WMYI QUO QUKVTM ).** .%,.- .%2.- .%..) .%) -\n\n**VU$VWMYI QUO 9UKVTM 5 WMU M** Q Q Qd Q Q **,** 1 $ 10$ 1,$ 1 $\n\nbQ YQ U O YQ Qd Q Q$ M P TQ **( -** \\- 0. /2 ,)-\n\n**DV IS UVU$VWMYI QUO QUKVTM M WMU M** .2 11 1/\n\n**9UKVTM JMNVYM QUKVTM I M .** .%. , /%)- .%/,/ .% -/\n\nO YQ Md bU U **\\-** 1\\.) % . 2.. 22)\n\n**M QUKVTM .-(** \\-%//, -%12) -%/1 -% ./\n\n2","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_061","product_type":"parse","source_file_path":"complex_header_061.pdf"},"started_at":"2026-11-12T14:56:20.580127"} {"completed_at":"2026-11-12T14:56:28.382606","latency_in_ms":2666,"output":{"example_id":"complex_table_headers/complex_header_062","grounded_pages":[],"layout_pages":[],"markdown":"1 8/9/2021\n\n**Relocations to Lower Manhattan**\n\n**Q1 2005 - Q2 2021**\n\n**Firms % Square Footage Leased %**\n\n**TAMI 302 33%** ( 10,444,741) 42%\n\n_TAMI, Technology_ 120 13% ( 2,777,007) 11%\n\n_TAMI, Advertising_ 52 6% ( 2,012,178) 8%\n\n_TAMI, Marketing_ 13 1% ( 433,002) 2%\n\n_TAMI, Media_ 98 11% ( 4,889,356) 20%\n\n_TAMI, Public Relations_ 19 2% ( 208,331) 1%\n\n**Professional Services 229 25%** ( 4,272,320) 17%\n\n_Professional Services, Law_ 80 9% 1,917,636 8%\n\n_Professional Services, Management Consulting_ 31 3% 570,611 2%\n\n_Professional Services, Design_ 51 6% 1,004,812 4%\n\n_Professional Services, Other_ 67 7% 779,261 3%\n\n**FIRE 143 15%** 3,428,580 14%\n\n**Government 11 1%** 494,638 2%\n\n**Healthcare 22 2%** 314,198 1%\n\n**Nonprofit 119 13%** 1,932,129 8%\n\n**Education 26 3%** 993,830 4%\n\n**Other 71 8%** 2,702,047 11%\n\n**TOTAL 923 100% 24,582,483 100%**\n\n**Relocations to Lower Manhattan by Industry**\n\n**TAMI**\n\n**Company SF Leased**\n\n**Year Lease Signed**\n\n**Former Location Industry**\n\nCondé Nast 1,133,000 2011 Midtown TAMI, Media\n\nMeredith Corporation (new owner of Time Inc.) 727,529 2014 Midtown TAMI, Media\n\nGroupM 688,893 2013 Midtown TAMI, Advertising\n\nSpotify 564,000 2017 Midtown South TAMI, Technology\n\nUber 307,970 2019 Midtown TAMI, Technology\n\nJustworks 270,400 2019 Midtown South TAMI, Technology\n\nMacmillan Publishers 264,728 2017 Midtown South TAMI, Media\n\nMDC Partners 199,277 2020 Midtown; Midtown South; Brooklyn TAMI, Advertising\n\nOmnicom 183,768 2007 Midtown TAMI, Advertising\n\nHarperCollins Publishers 180,748 2013 Midtown TAMI, Media\n\nMacmillan Science and Education 176,121 2014 3 Other NYC Locations TAMI, Media\n\nThe Associated Press 172,352 2015 Midtown TAMI, Media\n\nWolters Kluwer E42 130,000 2018 Midtown TAMI, Media\n\nNielsen Media Research 116,258 2012 Midtown South TAMI, Marketing\n\nRefinitiv 108,917 2019 Midtown TAMI, Information\n\nMediaMath 103,131 2014 Midtown TAMI, Technology\n\nAmerican Media, Inc. 99,054 2011 Midtown TAMI, Media\n\nNew York Daily News 99,050 2010 Midtown TAMI, Media\n\nAmerican Lawyer Media 91,818 2007 Midtown TAMI, Media\n\nDroga5 91,442 2013 Midtown South TAMI, Advertising\n\nBusiness Insider 88,050 2017 Midtown South TAMI, Media\n\nHigh Five Games 87,663 2014 Midtown South TAMI, Media\n\nVox Media 85,733 2015 Midtown TAMI, Media\n\nStagwell Group (Including: SKDKnickerbocker, PMX Agency, Code and Theory, and Harris Insights 83,955 2017 Midtown South TAMI, Advertising\n\nSNY (SportsNet NY) 83,546 2015 Midtown TAMI, Media\n\nBounceX 79,118 2018 Midtown TAMI, Technology\n\nGfK Custom Research 75,020 2013 Midtown South TAMI, Marketing\n\nDotDash 68,230 2019 Midtown TAMI, Media\n\nSandbox Studio 67,706 2015 Midtown South & Brooklyn TAMI, Media\n\nEngine USA 64,298 2014 Midtown South TAMI, Marketing\n\nThe Knot 63,822 2011 Midtown TAMI, Media","pages":[{"line_numbers":[],"markdown":"1 8/9/2021\n\n**Relocations to Lower Manhattan**\n\n**Q1 2005 - Q2 2021**\n\n**Firms % Square Footage Leased %**\n\n**TAMI 302 33%** ( 10,444,741) 42%\n\n_TAMI, Technology_ 120 13% ( 2,777,007) 11%\n\n_TAMI, Advertising_ 52 6% ( 2,012,178) 8%\n\n_TAMI, Marketing_ 13 1% ( 433,002) 2%\n\n_TAMI, Media_ 98 11% ( 4,889,356) 20%\n\n_TAMI, Public Relations_ 19 2% ( 208,331) 1%\n\n**Professional Services 229 25%** ( 4,272,320) 17%\n\n_Professional Services, Law_ 80 9% 1,917,636 8%\n\n_Professional Services, Management Consulting_ 31 3% 570,611 2%\n\n_Professional Services, Design_ 51 6% 1,004,812 4%\n\n_Professional Services, Other_ 67 7% 779,261 3%\n\n**FIRE 143 15%** 3,428,580 14%\n\n**Government 11 1%** 494,638 2%\n\n**Healthcare 22 2%** 314,198 1%\n\n**Nonprofit 119 13%** 1,932,129 8%\n\n**Education 26 3%** 993,830 4%\n\n**Other 71 8%** 2,702,047 11%\n\n**TOTAL 923 100% 24,582,483 100%**\n\n**Relocations to Lower Manhattan by Industry**\n\n**TAMI**\n\n**Company SF Leased**\n\n**Year Lease Signed**\n\n**Former Location Industry**\n\nCondé Nast 1,133,000 2011 Midtown TAMI, Media\n\nMeredith Corporation (new owner of Time Inc.) 727,529 2014 Midtown TAMI, Media\n\nGroupM 688,893 2013 Midtown TAMI, Advertising\n\nSpotify 564,000 2017 Midtown South TAMI, Technology\n\nUber 307,970 2019 Midtown TAMI, Technology\n\nJustworks 270,400 2019 Midtown South TAMI, Technology\n\nMacmillan Publishers 264,728 2017 Midtown South TAMI, Media\n\nMDC Partners 199,277 2020 Midtown; Midtown South; Brooklyn TAMI, Advertising\n\nOmnicom 183,768 2007 Midtown TAMI, Advertising\n\nHarperCollins Publishers 180,748 2013 Midtown TAMI, Media\n\nMacmillan Science and Education 176,121 2014 3 Other NYC Locations TAMI, Media\n\nThe Associated Press 172,352 2015 Midtown TAMI, Media\n\nWolters Kluwer E42 130,000 2018 Midtown TAMI, Media\n\nNielsen Media Research 116,258 2012 Midtown South TAMI, Marketing\n\nRefinitiv 108,917 2019 Midtown TAMI, Information\n\nMediaMath 103,131 2014 Midtown TAMI, Technology\n\nAmerican Media, Inc. 99,054 2011 Midtown TAMI, Media\n\nNew York Daily News 99,050 2010 Midtown TAMI, Media\n\nAmerican Lawyer Media 91,818 2007 Midtown TAMI, Media\n\nDroga5 91,442 2013 Midtown South TAMI, Advertising\n\nBusiness Insider 88,050 2017 Midtown South TAMI, Media\n\nHigh Five Games 87,663 2014 Midtown South TAMI, Media\n\nVox Media 85,733 2015 Midtown TAMI, Media\n\nStagwell Group (Including: SKDKnickerbocker, PMX Agency, Code and Theory, and Harris Insights 83,955 2017 Midtown South TAMI, Advertising\n\nSNY (SportsNet NY) 83,546 2015 Midtown TAMI, Media\n\nBounceX 79,118 2018 Midtown TAMI, Technology\n\nGfK Custom Research 75,020 2013 Midtown South TAMI, Marketing\n\nDotDash 68,230 2019 Midtown TAMI, Media\n\nSandbox Studio 67,706 2015 Midtown South & Brooklyn TAMI, Media\n\nEngine USA 64,298 2014 Midtown South TAMI, Marketing\n\nThe Knot 63,822 2011 Midtown TAMI, Media","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_062","product_type":"parse","source_file_path":"complex_header_062.pdf"},"started_at":"2026-11-12T14:56:25.716358"} {"completed_at":"2026-11-12T14:56:34.286901","latency_in_ms":2845,"output":{"example_id":"complex_table_headers/complex_header_063","grounded_pages":[],"layout_pages":[],"markdown":"Bavarian Nordic Announces Interim Results for the First Nine Months of 2021 Page **19** of **20**\n\nCompany Announcement no. 35 / 2021\n\n**17\\. Warrants**\n\n**Outstanding warrants as of September 30, 2021**\n\n**Outstanding**\n\n**as of**\n\n**January 1**\n\n**Addition**\n\n**during the**\n\n**period**\n\n**Warrants exercised Annulled Terminated**\n\n**Trans- ferred**\n\n**Outstanding**\n\n**as of**\n\n**September**\n\n**30**\n\nCorporate Management 439,402 - - - - - 439,402\n\nOther Executive Management 723,326 - (31,709) - - (215,328) 476,289\n\nOther employees 2,062,360 - (307,240) (176,183) - (44,479) 1,534,458\n\nResigned employees 167,901 - (126,056) - - 259,807 301,652\n\n**Total 3,392,989 - (465,005) (176,183) - - 2,751,801**\n\n**Weighted average exercise price 188 217 192 184**\n\n**Weighted average share price at exercise 329**\n\nNumbers of warrants which can be exercised as of September 30, 2021 347,140\n\nat a weighted average exercise price of DKK 238\n\nThe total recognized cost of the warrant programs was DKK 22.8 million in the first nine months of 2021 (DKK 15.9 million).\n\n**Specification of parameters for Black-Scholes model**\n\nDKK\n\n**Dec**\n\n**2016**\n\n**Jul**\n\n**2017**\n\n**Nov**\n\n**2017**\n\n**Nov**\n\n**2018**\n\n**Nov**\n\n**2019**\n\n**Jan**\n\n**2020**\n\n**Nov**\n\n**2020**\n\nAverage share price 222.50 383.50 259.50 159.00 154.05 171.20 179.84\n\nAverage exercise price at grant 260.20 430.40 303.00 179.60 185.40 197.00 206.82\n\nAverage exercise price determined at date of rights issue March 30, 2020 (DKK) 205.80 340.40 239.60 142.00 146.60 155.80 -\n\nApplied volatility rate 44.6% 44.1% 52.4% 53.3% 52.2% 53.0% 39.8%\n\nExpected life (years) 3.0 3.0 3.0 3.0 3.0 3.0 3.0\n\nExpected dividend per share - - - - - - -\n\nRisk-free interest rate p.a. -0.48% -0.46% -0.55% -0.43% -0.69% -0.65% -0.66%\n\nFair value at grant 1) 54 98 80 52 45 53 41\n\nThe applied volatility is based on the historical volatility of the Bavarian Nordic share, except for November 2020 program where the volatility is based on the volatility for a peer group.\n\n1) Fair value of each warrant applying the Black-Scholes model\n\n**18\\. Significant changes in contingent liabilities and other contractual obligations** No significant changes in contingent liabilities and other contractual obligations have occurred since December 31, 2020.\n\n**19\\. Significant events after the balance sheet date**\n\n**20\\. Approval of the unaudited condensed consolidated interim financial statements** The unaudited condensed consolidated interim financial statements were approved by the board of directors and corporate management and authorized for issue on November 12, 2021.","pages":[{"line_numbers":[],"markdown":"Bavarian Nordic Announces Interim Results for the First Nine Months of 2021 Page **19** of **20**\n\nCompany Announcement no. 35 / 2021\n\n**17\\. Warrants**\n\n**Outstanding warrants as of September 30, 2021**\n\n**Outstanding**\n\n**as of**\n\n**January 1**\n\n**Addition**\n\n**during the**\n\n**period**\n\n**Warrants exercised Annulled Terminated**\n\n**Trans- ferred**\n\n**Outstanding**\n\n**as of**\n\n**September**\n\n**30**\n\nCorporate Management 439,402 - - - - - 439,402\n\nOther Executive Management 723,326 - (31,709) - - (215,328) 476,289\n\nOther employees 2,062,360 - (307,240) (176,183) - (44,479) 1,534,458\n\nResigned employees 167,901 - (126,056) - - 259,807 301,652\n\n**Total 3,392,989 - (465,005) (176,183) - - 2,751,801**\n\n**Weighted average exercise price 188 217 192 184**\n\n**Weighted average share price at exercise 329**\n\nNumbers of warrants which can be exercised as of September 30, 2021 347,140\n\nat a weighted average exercise price of DKK 238\n\nThe total recognized cost of the warrant programs was DKK 22.8 million in the first nine months of 2021 (DKK 15.9 million).\n\n**Specification of parameters for Black-Scholes model**\n\nDKK\n\n**Dec**\n\n**2016**\n\n**Jul**\n\n**2017**\n\n**Nov**\n\n**2017**\n\n**Nov**\n\n**2018**\n\n**Nov**\n\n**2019**\n\n**Jan**\n\n**2020**\n\n**Nov**\n\n**2020**\n\nAverage share price 222.50 383.50 259.50 159.00 154.05 171.20 179.84\n\nAverage exercise price at grant 260.20 430.40 303.00 179.60 185.40 197.00 206.82\n\nAverage exercise price determined at date of rights issue March 30, 2020 (DKK) 205.80 340.40 239.60 142.00 146.60 155.80 -\n\nApplied volatility rate 44.6% 44.1% 52.4% 53.3% 52.2% 53.0% 39.8%\n\nExpected life (years) 3.0 3.0 3.0 3.0 3.0 3.0 3.0\n\nExpected dividend per share - - - - - - -\n\nRisk-free interest rate p.a. -0.48% -0.46% -0.55% -0.43% -0.69% -0.65% -0.66%\n\nFair value at grant 1) 54 98 80 52 45 53 41\n\nThe applied volatility is based on the historical volatility of the Bavarian Nordic share, except for November 2020 program where the volatility is based on the volatility for a peer group.\n\n1) Fair value of each warrant applying the Black-Scholes model\n\n**18\\. Significant changes in contingent liabilities and other contractual obligations** No significant changes in contingent liabilities and other contractual obligations have occurred since December 31, 2020.\n\n**19\\. Significant events after the balance sheet date**\n\n**20\\. Approval of the unaudited condensed consolidated interim financial statements** The unaudited condensed consolidated interim financial statements were approved by the board of directors and corporate management and authorized for issue on November 12, 2021.","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_063","product_type":"parse","source_file_path":"complex_header_063.pdf"},"started_at":"2026-11-12T14:56:31.441755"} {"completed_at":"2026-11-12T14:56:37.825765","latency_in_ms":1505,"output":{"example_id":"complex_table_headers/complex_header_065","grounded_pages":[],"layout_pages":[],"markdown":"**97** Robeco | Integrated Annual Report 2024\n\n_Read more about market versus location-based Scope 2 emissions in the following Robeco article: The CO2lumnist: market- versus location- based Scope 2 emissions_ _Read more about our view on the importance and challenges of Scope 3 emissions in our article: Navigating the murky waters of Scope 3 emissions is_ _crucial_\n\nFor sovereign debt issuers we report financed emissions and footprints based on an inflation-adjusted measure of GDP.\n\nThis approach is advocated by PCAF as it is not possible to use EVIC or revenues to attribute ownership of sovereign emissions. Robeco’s sovereign financed emissions fell slightly in 2024 relative to 2023, while total assets in scope increased. We can therefore conclude that we invested higher proportions in less polluting countries.\n\nA conversation with our CEO Table of contents About this report\n\n### About Robeco\n\n### Strategy and value creation\n\n### Governance and managing risks\n\n### Our investing strengths\n\n### Sustainability statements\n\nBasis of preparation Double materiality assessment Sustainability governance Sustainability risk management Environment Climate change Nature Operational environmental footprint Social aspects Our workforce Social issues Governance Business conduct and compliance Avoiding greenwashing Our vendors, procurement and third-party management practices ESG data quality\n\n### Financial statements\n\n### Other\n\nIntegrated carbon report The visual below shows all of Robeco’s Scope 1, 2 and 3 emissions ⁷⁶ . The emissions from our main business operations are Scope 1, Scope 2 and Scope 3 upstream. These add up to 3,993.3 tonnes CO2e. The emissions from our investments are Scope 3 downstream and total 11.3 million tonnes CO2e ⁷⁷ . In other words,\n\nfinanced emissions account for 99.9% of Robeco’s total emissions. Focusing on decarbonizing carbon emissions of our investments is the most material to Robeco in achieving our net-zero roadmap.\n\n_Refer to the Operational environmental_ _footprint section for further details on our operational emissions_\n\n**Table 20 | Financed emissions of Robeco’s government bond client assets**\n\nType In scope client assets\n\n(EUR billion)\n\nFinanced emissions (million tonnes of CO2)\n\nFootprint (tonnes of CO2 per EUR million)\n\nCoverage of in scope total client assets\n\n31 December 2024\n\nFund 4.7 0.7 159 100%\n\nMandate 10.0 1.4 144 100%\n\nTotal 14.7 2.2 149 100%\n\n31 December 2023\n\nFund 4.2 0.7 180 100%\n\nMandate 8.6 1.4 160 100%\n\nTotal 12.8 2.1 167 100%\n\nSource: Robeco, 31 December 2024\n\nSCOPE 1 – emitted directly From sources we own or control (company facilities and vehicles) • 151.1 tonnes CO2e • <0.01%\n\nSCOPE 2 – emitted indirectly From generation of purchased energy (for company facilities and vehicles) • 685.0 tonnes CO2e • <0.01%\n\nSCOPE 3 – upstream Indirect emissions in our value chain (such as business travel and purchased goods and services) • 3,175.2 tonnes CO2e • 0.04%\n\nSCOPE 3 – downstream Carbon footprint of investments • 11.3 million tonnes CO2e\n\nSource: Robeco, 31 December 2024\n\n**Figure 15 | Robeco’s integrated carbon report**\n\n76\\. For definitions, see Greenhouse Gas Protocol. 77. This figure represents the sum of the\n\nfinanced emissions of Robeco’s listed equity and corporate bond client assets for Scope 1 and 2 emissions and the financed emissions of Robeco’s government bond client assets.","pages":[{"line_numbers":[],"markdown":"**97** Robeco | Integrated Annual Report 2024\n\n_Read more about market versus location-based Scope 2 emissions in the following Robeco article: The CO2lumnist: market- versus location- based Scope 2 emissions_ _Read more about our view on the importance and challenges of Scope 3 emissions in our article: Navigating the murky waters of Scope 3 emissions is_ _crucial_\n\nFor sovereign debt issuers we report financed emissions and footprints based on an inflation-adjusted measure of GDP.\n\nThis approach is advocated by PCAF as it is not possible to use EVIC or revenues to attribute ownership of sovereign emissions. Robeco’s sovereign financed emissions fell slightly in 2024 relative to 2023, while total assets in scope increased. We can therefore conclude that we invested higher proportions in less polluting countries.\n\nA conversation with our CEO Table of contents About this report\n\n### About Robeco\n\n### Strategy and value creation\n\n### Governance and managing risks\n\n### Our investing strengths\n\n### Sustainability statements\n\nBasis of preparation Double materiality assessment Sustainability governance Sustainability risk management Environment Climate change Nature Operational environmental footprint Social aspects Our workforce Social issues Governance Business conduct and compliance Avoiding greenwashing Our vendors, procurement and third-party management practices ESG data quality\n\n### Financial statements\n\n### Other\n\nIntegrated carbon report The visual below shows all of Robeco’s Scope 1, 2 and 3 emissions ⁷⁶ . The emissions from our main business operations are Scope 1, Scope 2 and Scope 3 upstream. These add up to 3,993.3 tonnes CO2e. The emissions from our investments are Scope 3 downstream and total 11.3 million tonnes CO2e ⁷⁷ . In other words,\n\nfinanced emissions account for 99.9% of Robeco’s total emissions. Focusing on decarbonizing carbon emissions of our investments is the most material to Robeco in achieving our net-zero roadmap.\n\n_Refer to the Operational environmental_ _footprint section for further details on our operational emissions_\n\n**Table 20 | Financed emissions of Robeco’s government bond client assets**\n\nType In scope client assets\n\n(EUR billion)\n\nFinanced emissions (million tonnes of CO2)\n\nFootprint (tonnes of CO2 per EUR million)\n\nCoverage of in scope total client assets\n\n31 December 2024\n\nFund 4.7 0.7 159 100%\n\nMandate 10.0 1.4 144 100%\n\nTotal 14.7 2.2 149 100%\n\n31 December 2023\n\nFund 4.2 0.7 180 100%\n\nMandate 8.6 1.4 160 100%\n\nTotal 12.8 2.1 167 100%\n\nSource: Robeco, 31 December 2024\n\nSCOPE 1 – emitted directly From sources we own or control (company facilities and vehicles) • 151.1 tonnes CO2e • <0.01%\n\nSCOPE 2 – emitted indirectly From generation of purchased energy (for company facilities and vehicles) • 685.0 tonnes CO2e • <0.01%\n\nSCOPE 3 – upstream Indirect emissions in our value chain (such as business travel and purchased goods and services) • 3,175.2 tonnes CO2e • 0.04%\n\nSCOPE 3 – downstream Carbon footprint of investments • 11.3 million tonnes CO2e\n\nSource: Robeco, 31 December 2024\n\n**Figure 15 | Robeco’s integrated carbon report**\n\n76\\. For definitions, see Greenhouse Gas Protocol. 77. This figure represents the sum of the\n\nfinanced emissions of Robeco’s listed equity and corporate bond client assets for Scope 1 and 2 emissions and the financed emissions of Robeco’s government bond client assets.","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_065","product_type":"parse","source_file_path":"complex_header_065.pdf"},"started_at":"2026-11-12T14:56:36.319920"} {"completed_at":"2026-11-12T14:56:46.039225","latency_in_ms":2428,"output":{"example_id":"complex_table_headers/complex_header_068","grounded_pages":[],"layout_pages":[],"markdown":"**% of Q1 2005 QoQ USD NTD Sales NTD Inc.(Dec.) %** Net Sales 1,910 59,978 100.0 56,858 5.5 Cost of Sales (1,137) (35,724) (59.6) (35,180) 1.5 Gross Profit 773 24,254 40.4 21,678 11.9 Operating Expenses Research and Development Expenses (113) (3,561) (5.9) (3,412) 4.4 General and Administrative Expenses (72) (2,253) (3.8) (2,513) (10.4) Selling and Marketing Expenses (39) (1,227) (2.0) (584) 110.0 Total Operating Expenses (224) (7,041) (11.7) (6,509) 8.2\n\nIncome from Operations 549 17,213 28.7 15,169 13.5\n\nNet Non-operating Income (Expenses) 15 464 0.8 739 (37.2) Investment Gain 7 226 0.4 397 - Income before Income Tax and Minority Interest 571 17,903 29.8 16,305 9.8\n\nIncome Tax Credit 16 491 0.8 513 (4.2)\n\nIncome before Minority Interest 587 18,394 30.7 16,818 9.4\n\nMinority Interest in Loss of Subsidiaries -1 (25) (0.0) 0 (5,435.1)\n\nConsolidated Net Income 586 18,369 30.6 16,818 9.2\n\nDiluted Earnings Per Ordinary Share 0.02 0.74 0.68 9.2\n\nEarnings Per ADR _(2)_ 0\\.12 3.72 3.41\n\nWeighted Average Outstanding Shares ('M) _(3)_ **24,687 24,684**\n\n_Note:(1) New Taiwan dollars have been translated into U.S. dollars at the weighted average rate of NTD31.41 per U.S. dollar for the second quarter of 2005. (2) 1 ADR equals 5 ordinary shares. (3) Total weighted average outstanding shares were 24,687M shares for the second quarter of 2005 and 24,684M shares for the first quarter of 2005 after the retroactive adjustments for stock dividends and stock bonus._\n\n**Q2 2005 Sequential Comparison**\n\n**TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD.**\n\n**CONSOLIDATED INCOME STATEMENT**\n\n**For the Three Months Ended June 30, 2005 (Expressed in Million New Taiwan Dollars (NTD) and U.S. Dollars (USD)** **(1)**\n\n**Except for Per Share Amounts and Shares Outstanding)**","pages":[{"line_numbers":[],"markdown":"**% of Q1 2005 QoQ USD NTD Sales NTD Inc.(Dec.) %** Net Sales 1,910 59,978 100.0 56,858 5.5 Cost of Sales (1,137) (35,724) (59.6) (35,180) 1.5 Gross Profit 773 24,254 40.4 21,678 11.9 Operating Expenses Research and Development Expenses (113) (3,561) (5.9) (3,412) 4.4 General and Administrative Expenses (72) (2,253) (3.8) (2,513) (10.4) Selling and Marketing Expenses (39) (1,227) (2.0) (584) 110.0 Total Operating Expenses (224) (7,041) (11.7) (6,509) 8.2\n\nIncome from Operations 549 17,213 28.7 15,169 13.5\n\nNet Non-operating Income (Expenses) 15 464 0.8 739 (37.2) Investment Gain 7 226 0.4 397 - Income before Income Tax and Minority Interest 571 17,903 29.8 16,305 9.8\n\nIncome Tax Credit 16 491 0.8 513 (4.2)\n\nIncome before Minority Interest 587 18,394 30.7 16,818 9.4\n\nMinority Interest in Loss of Subsidiaries -1 (25) (0.0) 0 (5,435.1)\n\nConsolidated Net Income 586 18,369 30.6 16,818 9.2\n\nDiluted Earnings Per Ordinary Share 0.02 0.74 0.68 9.2\n\nEarnings Per ADR _(2)_ 0\\.12 3.72 3.41\n\nWeighted Average Outstanding Shares ('M) _(3)_ **24,687 24,684**\n\n_Note:(1) New Taiwan dollars have been translated into U.S. dollars at the weighted average rate of NTD31.41 per U.S. dollar for the second quarter of 2005. (2) 1 ADR equals 5 ordinary shares. (3) Total weighted average outstanding shares were 24,687M shares for the second quarter of 2005 and 24,684M shares for the first quarter of 2005 after the retroactive adjustments for stock dividends and stock bonus._\n\n**Q2 2005 Sequential Comparison**\n\n**TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD.**\n\n**CONSOLIDATED INCOME STATEMENT**\n\n**For the Three Months Ended June 30, 2005 (Expressed in Million New Taiwan Dollars (NTD) and U.S. Dollars (USD)** **(1)**\n\n**Except for Per Share Amounts and Shares Outstanding)**","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_068","product_type":"parse","source_file_path":"complex_header_068.pdf"},"started_at":"2026-11-12T14:56:43.610592"} {"completed_at":"2026-11-12T14:56:48.492953","latency_in_ms":1158,"output":{"example_id":"complex_table_headers/complex_header_071","grounded_pages":[],"layout_pages":[],"markdown":"As of December 31, 2003, there remained 72,534 shares for which options may be granted in the future under the 1997 Stock Incentive Plan. The following table summarizes information about stock options outstanding at December 31, 2003:\n\nOPTIONS OUTSTANDING OPTIONS EXERCISABLE WEIGHTED WEIGHTED WEIGHTED AVERAGE AVERAGE AVERAGE NUMBER REMAINING EXERCISE NUMBER EXERCISE\n\nRANGE OF EXERCISE PRICES OUTSTANDING CONTRACTUAL LIFE PRICE EXERCISABLE PRICE\n\n$6.875-$14.063 143,100 5.3 years $ 11.53 112,000 $ 11.04\n\n$14.875-$22.50 85,000 4.2 years $ 18.28 85,000 $ 18.28\n\n$26.13-$31.39 59,500 5.3 years $ 30.15 20,000 $ 27.72\n\n287,600 217,000\n\nPro forma information regarding net income and income per share as required by SFAS No. 123 has been determined as if the Company had accounted for its stock options under the fair value method of that statement. The fair value for these options was estimated at the date of grant using a Black-Scholes option pricing model with the following weighted average assumptions for 2003, 2002 and 2001:\n\n2003 2002 2001\n\nRisk-free interest rate 3.2% 2.7% 5.2%\n\nDividend yield 0.0% 0.0% 0.0%\n\nVolatility factor 39.1% 50.3% 33.0%\n\nExpected life 7 years 2.7 years 7 years\n\nThe resulting estimated weighted average fair values of the options granted in 2003, 2002 and 2001 were $13.51, $7.25 and $7.06, respectively.\n\nThe Black-Scholes option pricing model was developed for use in estimating the fair value of traded options which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including expected stock price volatility. All options grants in 2003, 2002 and 2001 occurred prior to the declaration of dividends by the Company.\n\nR E V E N U E S F R O M M A J O R C U S T O M E R S\n\nThe Company had one major customer which represented approximately $9.1 million (14.4 percent), $7.4 million (12.4 percent) and $11.0 million (19.1 percent) of the Company’s operating revenues during the years 2003, 2002 and 2001, respectively.\n\nI N D U S T R Y S E G M E N T A N D G E O G R A P H I C I N F O R M AT I O N\n\nThe Company operates in one reportable industry segment: designing, developing, manufacturing and marketing products for the medical and health care industry and has no foreign operating subsidiaries. The Company’s product lines include pressure relief valves and inflation systems, which are sold primarily to the aviation and marine industries. Due to the similarities in product technologies and manufacturing processes, these products are managed as part of the medical products segment. The Company recorded incidental revenues from its oxygen pipeline, which totaled approximately $950,000 in each of the years of 2003, 2002 and 2001. Pipeline net assets totaled $2.6 million at December 31, 2003 and 2002. Company revenues from sales to parties outside the United States totaled approximately 26, 25 and 33 percent of the Company’s total revenues in 2003, 2002 and 2001, respectively. No Company assets are located outside the United States. A summary of revenues by geographic territory for the three years 2003, 2002 and 2001 is as follows (in thousands):\n\nYEAR ENDED DECEMBER 31,\n\n2003 2002 2001\n\nUnited States $ 46,721 $ 44,454 $ 38,805\n\nCanada 8,620 6,938 10,635\n\nUnited Kingdom 1,547 1,693 2,182\n\nOther 5,915 6,448 5,983\n\nTotal $ 62,803 $ 59,533 $ 57,605\n\n### 19\n\n9\n\n10","pages":[{"line_numbers":[],"markdown":"As of December 31, 2003, there remained 72,534 shares for which options may be granted in the future under the 1997 Stock Incentive Plan. The following table summarizes information about stock options outstanding at December 31, 2003:\n\nOPTIONS OUTSTANDING OPTIONS EXERCISABLE WEIGHTED WEIGHTED WEIGHTED AVERAGE AVERAGE AVERAGE NUMBER REMAINING EXERCISE NUMBER EXERCISE\n\nRANGE OF EXERCISE PRICES OUTSTANDING CONTRACTUAL LIFE PRICE EXERCISABLE PRICE\n\n$6.875-$14.063 143,100 5.3 years $ 11.53 112,000 $ 11.04\n\n$14.875-$22.50 85,000 4.2 years $ 18.28 85,000 $ 18.28\n\n$26.13-$31.39 59,500 5.3 years $ 30.15 20,000 $ 27.72\n\n287,600 217,000\n\nPro forma information regarding net income and income per share as required by SFAS No. 123 has been determined as if the Company had accounted for its stock options under the fair value method of that statement. The fair value for these options was estimated at the date of grant using a Black-Scholes option pricing model with the following weighted average assumptions for 2003, 2002 and 2001:\n\n2003 2002 2001\n\nRisk-free interest rate 3.2% 2.7% 5.2%\n\nDividend yield 0.0% 0.0% 0.0%\n\nVolatility factor 39.1% 50.3% 33.0%\n\nExpected life 7 years 2.7 years 7 years\n\nThe resulting estimated weighted average fair values of the options granted in 2003, 2002 and 2001 were $13.51, $7.25 and $7.06, respectively.\n\nThe Black-Scholes option pricing model was developed for use in estimating the fair value of traded options which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including expected stock price volatility. All options grants in 2003, 2002 and 2001 occurred prior to the declaration of dividends by the Company.\n\nR E V E N U E S F R O M M A J O R C U S T O M E R S\n\nThe Company had one major customer which represented approximately $9.1 million (14.4 percent), $7.4 million (12.4 percent) and $11.0 million (19.1 percent) of the Company’s operating revenues during the years 2003, 2002 and 2001, respectively.\n\nI N D U S T R Y S E G M E N T A N D G E O G R A P H I C I N F O R M AT I O N\n\nThe Company operates in one reportable industry segment: designing, developing, manufacturing and marketing products for the medical and health care industry and has no foreign operating subsidiaries. The Company’s product lines include pressure relief valves and inflation systems, which are sold primarily to the aviation and marine industries. Due to the similarities in product technologies and manufacturing processes, these products are managed as part of the medical products segment. The Company recorded incidental revenues from its oxygen pipeline, which totaled approximately $950,000 in each of the years of 2003, 2002 and 2001. Pipeline net assets totaled $2.6 million at December 31, 2003 and 2002. Company revenues from sales to parties outside the United States totaled approximately 26, 25 and 33 percent of the Company’s total revenues in 2003, 2002 and 2001, respectively. No Company assets are located outside the United States. A summary of revenues by geographic territory for the three years 2003, 2002 and 2001 is as follows (in thousands):\n\nYEAR ENDED DECEMBER 31,\n\n2003 2002 2001\n\nUnited States $ 46,721 $ 44,454 $ 38,805\n\nCanada 8,620 6,938 10,635\n\nUnited Kingdom 1,547 1,693 2,182\n\nOther 5,915 6,448 5,983\n\nTotal $ 62,803 $ 59,533 $ 57,605\n\n### 19\n\n9\n\n10","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_071","product_type":"parse","source_file_path":"complex_header_071.pdf"},"started_at":"2026-11-12T14:56:47.334801"} {"completed_at":"2026-11-12T14:56:53.812757","latency_in_ms":2172,"output":{"example_id":"complex_table_headers/complex_header_072","grounded_pages":[],"layout_pages":[],"markdown":"THE PHILADELPHIA CONTRIBUTIONSHIP\n\nNEW JERSEY HOMEOWNERS\n\n16 JanuarySeptember 2025\n\n**302\\. BASE RATES, KEY FACTORS, A** **N** **D KEY RATI** **N** **G TABLES**\n\n**302\\.A. Standard Base Rates** **–** **Philadelphia Contributionship Insurance Company**\n\n**HO 00 01 HO 00 02**\n\n**Territory Fire Wind Water Theft Other Liability Fire Wind Water Theft Other Liability**\n\n**07001** 254\\.48 105.55 91.56 14.05 25.99 58.63 220.12 91.3 79.22 12.14 22.46 50.72\n\n**07002** 319\\.25 155.12 106.57 15.15 32.21 79.9 275.52 133.86 91.97 13.06 27.8 68.95\n\n**07003** 190\\.22 85.37 75.01 14.32 25.62 40.97 164.3 73.75 64.79 12.37 22.13 35.39\n\n**07004** 195\\.73 87.86 77.19 14.73 26.36 42.17 169.18 75.93 66.72 12.73 22.79 36.45\n\n**07005** 136\\.14 54.68 53.57 6 15.64 33.1 117.68 47.27 46.31 5.17 13.55 28.62\n\n**07006** 181\\.74 81.58 71.67 13.69 24.49 39.14 157.01 70.48 61.93 11.83 21.16 33.84\n\n**07007** 208\\.91 93.78 82.41 15.74 28.16 44.99 180.5 81.01 71.18 13.59 24.32 38.9\n\n**07008** 244\\.12 101.23 87.82 13.47 24.91 56.24 210.82 87.43 75.85 11.63 21.54 48.54\n\n**07009** 180\\.09 80.84 71.03 13.55 24.27 38.79 155.67 69.89 61.4 11.72 20.96 33.54\n\n**07010** 205\\.36 108.6 84.69 11.05 22.3 49.62 177.29 93.75 73.11 9.53 19.26 42.81\n\n**07011** 245\\.95 114.26 103.88 21.15 32.12 76.98 212.31 98.67 89.68 18.27 27.73 66.46\n\n**07012** 241\\.88 112.37 102.16 20.8 31.59 75.69 208.89 97.07 88.24 17.96 27.27 65.38\n\n**07013** 280\\.98 130.52 118.66 24.16 36.7 87.95 242.55 112.7 102.46 20.87 31.67 75.92\n\n**07014** 243\\.37 113.06 102.79 20.93 31.76 76.17 209.78 97.47 88.6 18.03 27.4 65.66\n\n**07015** 250\\.47 116.35 105.78 21.53 32.72 78.39 216.21 100.46 91.33 18.6 28.22 67.69\n\n**07016** 217\\.97 90.45 77.58 15.69 25.42 53.6 187.94 77.96 66.88 13.52 21.92 46.2\n\n**07017** 391\\.04 86.02 102.67 17.18 36.86 60.28 338.1 74.37 88.76 14.86 31.86 52.14\n\n**07018** 468\\.68 103.11 123.05 20.58 44.19 72.27 405.22 89.14 106.38 17.82 38.19 62.47\n\n**07019** 383\\.49 84.35 100.71 16.86 36.15 59.14 331.4 72.91 87.02 14.56 31.26 51.11\n\n**07020** 244\\.94 129.54 101.02 13.2 26.58 59.18 211.41 111.81 87.19 11.39 22.94 51.09\n\n**07021** 167\\.97 75.4 66.24 12.65 22.63 36.18 145.08 65.14 57.22 10.91 19.54 31.26\n\n**07022** 223\\.58 118.28 92.21 12.04 24.26 54.03 193.13 102.16 79.63 10.4 20.96 46.68\n\n**07023** 206\\.47 85.69 73.46 14.85 24.08 50.78 178.44 74.02 63.49 12.83 20.82 43.88\n\n**07024** 194\\.75 103.01 80.33 10.49 21.1 47.03 167.94 88.83 69.26 9.05 18.21 40.59\n\n**07026** 205\\.16 108.5 84.62 11.04 22.26 49.58 177.12 93.68 73.03 9.53 19.24 42.78\n\n**07027** 233\\.46 96.87 83.08 16.8 27.26 57.41 201.41 83.58 71.68 14.51 23.51 49.53\n\n**07028** 177\\.48 79.66 70 13.37 23.92 38.23 153.08 68.71 60.36 11.52 20.62 32.98\n\n**07029** 354\\.02 106.83 81.55 12.55 31.68 83.51 305.52 92.19 70.38 10.81 27.31 72.07\n\n**07030** 370\\.55 111.82 85.35 13.13 33.14 87.42 320.37 96.67 73.8 11.36 28.65 75.59\n\n**07031** 200\\.94 106.28 82.87 10.81 21.81 48.55 173.43 91.73 71.52 9.35 18.83 41.9\n\n**07032** 290\\.68 87.71 66.97 10.31 25.98 68.58 250.84 75.69 57.79 8.89 22.45 59.19\n\n**07033** 233\\.83 97.02 83.22 16.83 27.28 57.53 201.92 83.79 71.85 14.54 23.56 49.68\n\n**07034** 124\\.66 50.08 49.05 5.49 14.32 30.3 107.73 43.28 42.39 4.75 12.38 26.19\n\n**07035** 136\\.64 54.9 53.76 6.01 15.7 33.22 118.2 47.47 46.51 5.19 13.61 28.72\n\n**07036** 269\\.27 111.72 95.84 19.4 31.41 66.22 232.5 96.47 82.73 16.72 27.12 57.19\n\n**07039** 179\\.36 80.51 70.75 13.52 24.17 38.64 154.97 69.55 61.1 11.68 20.88 33.38\n\n**07040** 244\\.25 109.64 96.31 18.38 32.9 52.62 211.06 94.75 83.25 15.89 28.45 45.47\n\n**07041** 179\\.14 80.41 70.66 13.48 24.14 38.6 154.85 69.53 61.08 11.66 20.86 33.36\n\n**07042** 188\\.51 84.59 74.34 14.18 25.41 40.62 162.92 73.13 64.25 12.27 21.93 35.1\n\n**07043** 230\\.92 103.66 91.08 17.4 31.11 49.76 199.62 89.61 78.73 15.02 26.91 43.02\n\n**07044** 211\\.85 95.09 83.54 15.95 28.53 45.64 183.12 82.21 72.22 13.77 24.68 39.45\n\n**07045** 124\\.66 50.08 49.05 5.49 14.32 30.3 107.73 43.28 42.39 4.75 12.38 26.19\n\n**07046** 174\\.71 70.17 68.73 7.7 20.09 42.45 151.22 60.73 59.51 6.64 17.37 36.75\n\n**07047** 335\\.73 101.3 77.34 11.89 30.01 79.2 290.33 87.59 66.87 10.28 25.95 68.48\n\n**07050** 414\\.75 186.19 163.58 31.23 55.89 89.36 358.11 160.76 141.24 26.97 48.24 77.16\n\n**07051** 255\\.55 114.72 100.8 19.24 34.43 55.07 220.79 99.11 87.06 16.62 29.75 47.57\n\n**07052** 187\\.64 84.23 74 14.12 25.29 40.43 162.06 72.76 63.92 12.21 21.84 34.93\n\n**07054** 125\\.17 50.27 49.26 5.51 14.38 30.44 108.21 43.5 42.59 4.76 12.43 26.32\n\n**07055** 422\\.46 112.78 129.41 17.73 39.62 80.96 365.01 97.45 111.83 15.3 34.23 69.95\n\n**07057** 186\\.44 98.6 76.9 10.03 20.24 45.04 160.95 85.14 66.38 8.69 17.45 38.9\n\n**07058** 161\\.36 64.84 63.49 7.09 18.55 39.21 139.14 55.88 54.75 6.12 16.01 33.81\n\n**07059** 167\\.8 69.6 60.37 9.26 17.14 38.64 144.6 59.97 52.02 7.98 14.75 33.31\n\n**07060** 261\\.49 108.48 93.05 18.84 30.51 64.32 225.79 93.68 80.34 16.25 26.34 55.54\n\n**07061** 268\\.78 111.52 95.67 19.35 31.35 66.09 232.13 96.31 82.61 16.72 27.08 57.07","pages":[{"line_numbers":[],"markdown":"THE PHILADELPHIA CONTRIBUTIONSHIP\n\nNEW JERSEY HOMEOWNERS\n\n16 JanuarySeptember 2025\n\n**302\\. BASE RATES, KEY FACTORS, A** **N** **D KEY RATI** **N** **G TABLES**\n\n**302\\.A. Standard Base Rates** **–** **Philadelphia Contributionship Insurance Company**\n\n**HO 00 01 HO 00 02**\n\n**Territory Fire Wind Water Theft Other Liability Fire Wind Water Theft Other Liability**\n\n**07001** 254\\.48 105.55 91.56 14.05 25.99 58.63 220.12 91.3 79.22 12.14 22.46 50.72\n\n**07002** 319\\.25 155.12 106.57 15.15 32.21 79.9 275.52 133.86 91.97 13.06 27.8 68.95\n\n**07003** 190\\.22 85.37 75.01 14.32 25.62 40.97 164.3 73.75 64.79 12.37 22.13 35.39\n\n**07004** 195\\.73 87.86 77.19 14.73 26.36 42.17 169.18 75.93 66.72 12.73 22.79 36.45\n\n**07005** 136\\.14 54.68 53.57 6 15.64 33.1 117.68 47.27 46.31 5.17 13.55 28.62\n\n**07006** 181\\.74 81.58 71.67 13.69 24.49 39.14 157.01 70.48 61.93 11.83 21.16 33.84\n\n**07007** 208\\.91 93.78 82.41 15.74 28.16 44.99 180.5 81.01 71.18 13.59 24.32 38.9\n\n**07008** 244\\.12 101.23 87.82 13.47 24.91 56.24 210.82 87.43 75.85 11.63 21.54 48.54\n\n**07009** 180\\.09 80.84 71.03 13.55 24.27 38.79 155.67 69.89 61.4 11.72 20.96 33.54\n\n**07010** 205\\.36 108.6 84.69 11.05 22.3 49.62 177.29 93.75 73.11 9.53 19.26 42.81\n\n**07011** 245\\.95 114.26 103.88 21.15 32.12 76.98 212.31 98.67 89.68 18.27 27.73 66.46\n\n**07012** 241\\.88 112.37 102.16 20.8 31.59 75.69 208.89 97.07 88.24 17.96 27.27 65.38\n\n**07013** 280\\.98 130.52 118.66 24.16 36.7 87.95 242.55 112.7 102.46 20.87 31.67 75.92\n\n**07014** 243\\.37 113.06 102.79 20.93 31.76 76.17 209.78 97.47 88.6 18.03 27.4 65.66\n\n**07015** 250\\.47 116.35 105.78 21.53 32.72 78.39 216.21 100.46 91.33 18.6 28.22 67.69\n\n**07016** 217\\.97 90.45 77.58 15.69 25.42 53.6 187.94 77.96 66.88 13.52 21.92 46.2\n\n**07017** 391\\.04 86.02 102.67 17.18 36.86 60.28 338.1 74.37 88.76 14.86 31.86 52.14\n\n**07018** 468\\.68 103.11 123.05 20.58 44.19 72.27 405.22 89.14 106.38 17.82 38.19 62.47\n\n**07019** 383\\.49 84.35 100.71 16.86 36.15 59.14 331.4 72.91 87.02 14.56 31.26 51.11\n\n**07020** 244\\.94 129.54 101.02 13.2 26.58 59.18 211.41 111.81 87.19 11.39 22.94 51.09\n\n**07021** 167\\.97 75.4 66.24 12.65 22.63 36.18 145.08 65.14 57.22 10.91 19.54 31.26\n\n**07022** 223\\.58 118.28 92.21 12.04 24.26 54.03 193.13 102.16 79.63 10.4 20.96 46.68\n\n**07023** 206\\.47 85.69 73.46 14.85 24.08 50.78 178.44 74.02 63.49 12.83 20.82 43.88\n\n**07024** 194\\.75 103.01 80.33 10.49 21.1 47.03 167.94 88.83 69.26 9.05 18.21 40.59\n\n**07026** 205\\.16 108.5 84.62 11.04 22.26 49.58 177.12 93.68 73.03 9.53 19.24 42.78\n\n**07027** 233\\.46 96.87 83.08 16.8 27.26 57.41 201.41 83.58 71.68 14.51 23.51 49.53\n\n**07028** 177\\.48 79.66 70 13.37 23.92 38.23 153.08 68.71 60.36 11.52 20.62 32.98\n\n**07029** 354\\.02 106.83 81.55 12.55 31.68 83.51 305.52 92.19 70.38 10.81 27.31 72.07\n\n**07030** 370\\.55 111.82 85.35 13.13 33.14 87.42 320.37 96.67 73.8 11.36 28.65 75.59\n\n**07031** 200\\.94 106.28 82.87 10.81 21.81 48.55 173.43 91.73 71.52 9.35 18.83 41.9\n\n**07032** 290\\.68 87.71 66.97 10.31 25.98 68.58 250.84 75.69 57.79 8.89 22.45 59.19\n\n**07033** 233\\.83 97.02 83.22 16.83 27.28 57.53 201.92 83.79 71.85 14.54 23.56 49.68\n\n**07034** 124\\.66 50.08 49.05 5.49 14.32 30.3 107.73 43.28 42.39 4.75 12.38 26.19\n\n**07035** 136\\.64 54.9 53.76 6.01 15.7 33.22 118.2 47.47 46.51 5.19 13.61 28.72\n\n**07036** 269\\.27 111.72 95.84 19.4 31.41 66.22 232.5 96.47 82.73 16.72 27.12 57.19\n\n**07039** 179\\.36 80.51 70.75 13.52 24.17 38.64 154.97 69.55 61.1 11.68 20.88 33.38\n\n**07040** 244\\.25 109.64 96.31 18.38 32.9 52.62 211.06 94.75 83.25 15.89 28.45 45.47\n\n**07041** 179\\.14 80.41 70.66 13.48 24.14 38.6 154.85 69.53 61.08 11.66 20.86 33.36\n\n**07042** 188\\.51 84.59 74.34 14.18 25.41 40.62 162.92 73.13 64.25 12.27 21.93 35.1\n\n**07043** 230\\.92 103.66 91.08 17.4 31.11 49.76 199.62 89.61 78.73 15.02 26.91 43.02\n\n**07044** 211\\.85 95.09 83.54 15.95 28.53 45.64 183.12 82.21 72.22 13.77 24.68 39.45\n\n**07045** 124\\.66 50.08 49.05 5.49 14.32 30.3 107.73 43.28 42.39 4.75 12.38 26.19\n\n**07046** 174\\.71 70.17 68.73 7.7 20.09 42.45 151.22 60.73 59.51 6.64 17.37 36.75\n\n**07047** 335\\.73 101.3 77.34 11.89 30.01 79.2 290.33 87.59 66.87 10.28 25.95 68.48\n\n**07050** 414\\.75 186.19 163.58 31.23 55.89 89.36 358.11 160.76 141.24 26.97 48.24 77.16\n\n**07051** 255\\.55 114.72 100.8 19.24 34.43 55.07 220.79 99.11 87.06 16.62 29.75 47.57\n\n**07052** 187\\.64 84.23 74 14.12 25.29 40.43 162.06 72.76 63.92 12.21 21.84 34.93\n\n**07054** 125\\.17 50.27 49.26 5.51 14.38 30.44 108.21 43.5 42.59 4.76 12.43 26.32\n\n**07055** 422\\.46 112.78 129.41 17.73 39.62 80.96 365.01 97.45 111.83 15.3 34.23 69.95\n\n**07057** 186\\.44 98.6 76.9 10.03 20.24 45.04 160.95 85.14 66.38 8.69 17.45 38.9\n\n**07058** 161\\.36 64.84 63.49 7.09 18.55 39.21 139.14 55.88 54.75 6.12 16.01 33.81\n\n**07059** 167\\.8 69.6 60.37 9.26 17.14 38.64 144.6 59.97 52.02 7.98 14.75 33.31\n\n**07060** 261\\.49 108.48 93.05 18.84 30.51 64.32 225.79 93.68 80.34 16.25 26.34 55.54\n\n**07061** 268\\.78 111.52 95.67 19.35 31.35 66.09 232.13 96.31 82.61 16.72 27.08 57.07","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_072","product_type":"parse","source_file_path":"complex_header_072.pdf"},"started_at":"2026-11-12T14:56:51.640377"} {"completed_at":"2026-11-12T14:57:09.264271","latency_in_ms":1369,"output":{"example_id":"complex_table_headers/complex_header_074","grounded_pages":[],"layout_pages":[],"markdown":"M NN R R GL E GJ NN LN\n\nR R\n\nC J N L N GL GM GMN\n\nGM GL M\n\nM N M\n\nY L\n\nAGN GM\n\nY\n\nEGM\n\nY L\n\nGM GL M\n\nGN GM\n\nY L\n\nNN LN\n\nM NN NN LN Y L Á R R Y R Y Y\n\nNN LN M M JG NN L MG L N N Y L Q Q Q Q Q Q\n\nNN LN\n\nM NN J G L GN NN LN Y L Á R R Y Q Q Q\n\nM NN GM GN NN LN Y L Á R R Y R Y Y\n\nNN LN\n\nE GJ M NN L M Y NN LN Y L Á R R R R QC Q Q Q\n\nE GJ M NN L M Y NN LN Y L Á ÁG R R R R Y R R Y Y\n\nÁG M M GN N GL N M N R R Y\n\nÁG M G GJ N R R\n\nÁG M N M G J GL L M M JG G N R R Y\n\nÁG M N M G MGLN M G L GL N M L R R\n\nÁG M OGN L MG L MG LN Y\n\nÁG M N L NN MG J R R Y\n\nÁG M J L QO M L M R R\n\nÁG M N M G J GN GNN N R R Y\n\nÁG M OLN M G MGLN M G L GL N M L R R Y\n\nÁG M M NN L N J M N Q Q Q\n\nÁG M N N J M N\n\nÁG M L J M G L N J M N Y\n\nÁG M OLN M G J GN GNN N R R Y\n\nÁG M MGL N N Q Q Q\n\nÁG M L N L N R R R R QC\n\nE GJ NN LN\n\nE GJ NN LN YJ G L GN Y L Á R R R R QC\n\nE GJ NN LN Y GM GN Y L Á R R R R QC\n\nQ L G J G J QC L GL L J\n\nE M N M L N GN NN LN M R GL G L GJ JG GL M M L G M GL O M L N GN M J Á M MG\n\nL L GL M L GL GM E LGL GJ LN J G L M M N AGL N L GJ G MG LGJ L M J L\n\nR GL G M N L J G GJ L MN M M M GL GM M GL N N G L MN M M\n\nM M M R O GM GN L M M GM N M GM M\n\nM M GM M N M R GL G M N GM GJOG N G N G GL GM M M M L GN N E N N G N N G N G J\n\nG J N N GJ GM G L M JG O G GJ G G GN G G G JG J G M J G LR L J L G O M M G MN GL J M L N\n\nNN LN L J M M L N GN NN LN M N M N OL M L M JJ M R L J L N G LGM N LR J N LR\n\nGL NN LN NN LN GM GJ JG N L É ML L L MN L G MN\n\nE M N L L MG NN LN N M JG NN LN MG L N N M M R L NN LN GM M M L M GL M JG\n\nNN LN EMG L Y E Y\n\nNN LN GM M M N L J G L GN GL GM GN G M G N E J G L GN M J N G MG NN L L LN\n\nJ M M N O M L M LN L MN E GM GN M J N NN LN M J M M M M L MG GJ LN M L N NN L G MN GL M N GJ G G GM N M M É GM L M L M M GL M Y R M JR É NN LN GL L MG L N M L MG G G GN Y R L MLG LGJ L M L Y R GL L M L L ÁGLG G E G MN L J GJJ M L N GN N GL GN N J GJ GM L L GJ MN GL ÁÁ GNN NN L N\n\nG M N R GL GM GJ JG N L G M J R L L M GM N J M N NN LN G G O N L GM N L GN N G N\n\nM M N J M N L GM L GM GM G LN M J GL L M M L GL G G JG J M GM MN N N L GM G G N L G M M L GM\n\nNN LN M OGN L MG L MG LN N GJ JG N L É ML L L MN L G MN M OGN N NGJ E M L L OGN M JG NN LN N\n\nM GM J M L G J O M J OGN N L JGL JJ M L M M L M GM M M M\n\nE MGJJ M GN L N L NN MG J NN LN M J G J G G M GNN LN O L NN L G MN G J G M MG J M JG G\n\nJ L NN LN L M GN M L M M L M R M L M M M G G M NN L GL O M L\n\nN AGL L M L L GJ L M G L\n\nLL GJ M ÁJ G GL","pages":[{"line_numbers":[],"markdown":"M NN R R GL E GJ NN LN\n\nR R\n\nC J N L N GL GM GMN\n\nGM GL M\n\nM N M\n\nY L\n\nAGN GM\n\nY\n\nEGM\n\nY L\n\nGM GL M\n\nGN GM\n\nY L\n\nNN LN\n\nM NN NN LN Y L Á R R Y R Y Y\n\nNN LN M M JG NN L MG L N N Y L Q Q Q Q Q Q\n\nNN LN\n\nM NN J G L GN NN LN Y L Á R R Y Q Q Q\n\nM NN GM GN NN LN Y L Á R R Y R Y Y\n\nNN LN\n\nE GJ M NN L M Y NN LN Y L Á R R R R QC Q Q Q\n\nE GJ M NN L M Y NN LN Y L Á ÁG R R R R Y R R Y Y\n\nÁG M M GN N GL N M N R R Y\n\nÁG M G GJ N R R\n\nÁG M N M G J GL L M M JG G N R R Y\n\nÁG M N M G MGLN M G L GL N M L R R\n\nÁG M OGN L MG L MG LN Y\n\nÁG M N L NN MG J R R Y\n\nÁG M J L QO M L M R R\n\nÁG M N M G J GN GNN N R R Y\n\nÁG M OLN M G MGLN M G L GL N M L R R Y\n\nÁG M M NN L N J M N Q Q Q\n\nÁG M N N J M N\n\nÁG M L J M G L N J M N Y\n\nÁG M OLN M G J GN GNN N R R Y\n\nÁG M MGL N N Q Q Q\n\nÁG M L N L N R R R R QC\n\nE GJ NN LN\n\nE GJ NN LN YJ G L GN Y L Á R R R R QC\n\nE GJ NN LN Y GM GN Y L Á R R R R QC\n\nQ L G J G J QC L GL L J\n\nE M N M L N GN NN LN M R GL G L GJ JG GL M M L G M GL O M L N GN M J Á M MG\n\nL L GL M L GL GM E LGL GJ LN J G L M M N AGL N L GJ G MG LGJ L M J L\n\nR GL G M N L J G GJ L MN M M M GL GM M GL N N G L MN M M\n\nM M M R O GM GN L M M GM N M GM M\n\nM M GM M N M R GL G M N GM GJOG N G N G GL GM M M M L GN N E N N G N N G N G J\n\nG J N N GJ GM G L M JG O G GJ G G GN G G G JG J G M J G LR L J L G O M M G MN GL J M L N\n\nNN LN L J M M L N GN NN LN M N M N OL M L M JJ M R L J L N G LGM N LR J N LR\n\nGL NN LN NN LN GM GJ JG N L É ML L L MN L G MN\n\nE M N L L MG NN LN N M JG NN LN MG L N N M M R L NN LN GM M M L M GL M JG\n\nNN LN EMG L Y E Y\n\nNN LN GM M M N L J G L GN GL GM GN G M G N E J G L GN M J N G MG NN L L LN\n\nJ M M N O M L M LN L MN E GM GN M J N NN LN M J M M M M L MG GJ LN M L N NN L G MN GL M N GJ G G GM N M M É GM L M L M M GL M Y R M JR É NN LN GL L MG L N M L MG G G GN Y R L MLG LGJ L M L Y R GL L M L L ÁGLG G E G MN L J GJJ M L N GN N GL GN N J GJ GM L L GJ MN GL ÁÁ GNN NN L N\n\nG M N R GL GM GJ JG N L G M J R L L M GM N J M N NN LN G G O N L GM N L GN N G N\n\nM M N J M N L GM L GM GM G LN M J GL L M M L GL G G JG J M GM MN N N L GM G G N L G M M L GM\n\nNN LN M OGN L MG L MG LN N GJ JG N L É ML L L MN L G MN M OGN N NGJ E M L L OGN M JG NN LN N\n\nM GM J M L G J O M J OGN N L JGL JJ M L M M L M GM M M M\n\nE MGJJ M GN L N L NN MG J NN LN M J G J G G M GNN LN O L NN L G MN G J G M MG J M JG G\n\nJ L NN LN L M GN M L M M L M R M L M M M G G M NN L GL O M L\n\nN AGL L M L L GJ L M G L\n\nLL GJ M ÁJ G GL","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_074","product_type":"parse","source_file_path":"complex_header_074.pdf"},"started_at":"2026-11-12T14:57:07.894277"} {"completed_at":"2026-11-12T14:57:16.550068","latency_in_ms":2168,"output":{"example_id":"complex_table_headers/complex_header_075","grounded_pages":[],"layout_pages":[],"markdown":"Milliman 6/17/2015\n\n**Exhibit 3D - Voluntary Lapse Study**\n\n**CMFG Life Insurance Company Experience by Policy Duration**\n\n**1993 Product**\n\nPolicy Total Total Terminations Mortality Rate Voluntary Lapse Rate\n\nDuration Lives Count Rate Actual Expected Actual Implied \"Current\"\n\n1 547 22 4.0% 0.5% 0.2% 3.5% 3.8% 6.0%\n\n2 525 15 2.9% 0.4% 0.3% 2.5% 2.6% 4.0%\n\n3 510 11 2.2% 1.0% 0.4% 1.2% 1.7% 3.0%\n\n4 499 14 2.8% 2.0% 0.6% 0.8% 2.2% 2.0%\n\n5 485 5 1.0% 0.4% 0.8% 0.6% 0.2% 2.0%\n\n6 480 4 0.8% 0.8% 1.0% 0.0% -0.2% 1.5%\n\n7 476 11 2.3% 1.5% 1.3% 0.8% 1.0% 1.5%\n\n8 465 4 0.9% 0.9% 1.6% 0.0% -0.7% 1.5%\n\n9 461 16 3.5% 2.6% 1.9% 0.9% 1.6% 1.0%\n\n10 445 9 2.0% 1.3% 2.1% 0.7% -0.1% 1.0%\n\n11 436 16 3.7% 2.5% 2.3% 1.1% 1.4% 1.0%\n\n12 420 13 3.1% 1.2% 2.5% 1.9% 0.6% 1.0%\n\n13 407 17 4.2% 2.5% 2.7% 1.7% 1.4% 1.0%\n\n14 390 13 3.3% 2.8% 3.0% 0.5% 0.4% 1.0%\n\n15 377 18 4.8% 2.9% 3.2% 1.9% 1.6% 1.0%\n\n16 357 11 3.1% 2.0% 3.5% 1.1% -0.4% 1.0%\n\n17 323 13 4.0% 3.1% 3.9% 0.9% 0.2% 1.0%\n\n18 257 28 10.9% 7.0% 4.1% 3.9% 6.8% 1.0%\n\n19 156 6 3.8% 1.9% 4.5% 1.9% -0.6% 1.0%\n\n20 62 4 6.5% 6.5% 4.7% 0.0% 1.7% 1.0%\n\n21 20 1 5.0% 5.0% 6.0% 0.0% -1.0% 1.0%\n\nTotal 8,098 251 3.1% 1.8% 1.9% 1.3% 1.2%\n\nWeighted Average Lapse Rate Durations 6+ => 1.1% 0.8%\n\nWeighted Average Lapse Rate Durations 8+ => 1.2% 0.9%\n\nWeighted Average Lapse Rate Durations 10+ => 1.4% 1.0%\n\nNotes: 1) Experience from inception through December 31, 2014 2) Actual Mortality Rate based on either match to Death Master File or termination reason coded as \"death\" 3) Expected Mortality Rate based on Annuity 2000 table projected to 2007 along with selection factors 4) Actual Voluntary Lapse Rate is the Total Termination Rate minus the Actual Mortality Rate 5) Implied Voluntary Lapse Rate is the Total Termination Rate minus the Expected Mortality Rate 6) Current Voluntary Lapse Rate is the set provided by CMFG Life Insurance Company 7) Includes only lifetime pay policies (excludes single pay, 10 pay and paid-up at 65)","pages":[{"line_numbers":[],"markdown":"Milliman 6/17/2015\n\n**Exhibit 3D - Voluntary Lapse Study**\n\n**CMFG Life Insurance Company Experience by Policy Duration**\n\n**1993 Product**\n\nPolicy Total Total Terminations Mortality Rate Voluntary Lapse Rate\n\nDuration Lives Count Rate Actual Expected Actual Implied \"Current\"\n\n1 547 22 4.0% 0.5% 0.2% 3.5% 3.8% 6.0%\n\n2 525 15 2.9% 0.4% 0.3% 2.5% 2.6% 4.0%\n\n3 510 11 2.2% 1.0% 0.4% 1.2% 1.7% 3.0%\n\n4 499 14 2.8% 2.0% 0.6% 0.8% 2.2% 2.0%\n\n5 485 5 1.0% 0.4% 0.8% 0.6% 0.2% 2.0%\n\n6 480 4 0.8% 0.8% 1.0% 0.0% -0.2% 1.5%\n\n7 476 11 2.3% 1.5% 1.3% 0.8% 1.0% 1.5%\n\n8 465 4 0.9% 0.9% 1.6% 0.0% -0.7% 1.5%\n\n9 461 16 3.5% 2.6% 1.9% 0.9% 1.6% 1.0%\n\n10 445 9 2.0% 1.3% 2.1% 0.7% -0.1% 1.0%\n\n11 436 16 3.7% 2.5% 2.3% 1.1% 1.4% 1.0%\n\n12 420 13 3.1% 1.2% 2.5% 1.9% 0.6% 1.0%\n\n13 407 17 4.2% 2.5% 2.7% 1.7% 1.4% 1.0%\n\n14 390 13 3.3% 2.8% 3.0% 0.5% 0.4% 1.0%\n\n15 377 18 4.8% 2.9% 3.2% 1.9% 1.6% 1.0%\n\n16 357 11 3.1% 2.0% 3.5% 1.1% -0.4% 1.0%\n\n17 323 13 4.0% 3.1% 3.9% 0.9% 0.2% 1.0%\n\n18 257 28 10.9% 7.0% 4.1% 3.9% 6.8% 1.0%\n\n19 156 6 3.8% 1.9% 4.5% 1.9% -0.6% 1.0%\n\n20 62 4 6.5% 6.5% 4.7% 0.0% 1.7% 1.0%\n\n21 20 1 5.0% 5.0% 6.0% 0.0% -1.0% 1.0%\n\nTotal 8,098 251 3.1% 1.8% 1.9% 1.3% 1.2%\n\nWeighted Average Lapse Rate Durations 6+ => 1.1% 0.8%\n\nWeighted Average Lapse Rate Durations 8+ => 1.2% 0.9%\n\nWeighted Average Lapse Rate Durations 10+ => 1.4% 1.0%\n\nNotes: 1) Experience from inception through December 31, 2014 2) Actual Mortality Rate based on either match to Death Master File or termination reason coded as \"death\" 3) Expected Mortality Rate based on Annuity 2000 table projected to 2007 along with selection factors 4) Actual Voluntary Lapse Rate is the Total Termination Rate minus the Actual Mortality Rate 5) Implied Voluntary Lapse Rate is the Total Termination Rate minus the Expected Mortality Rate 6) Current Voluntary Lapse Rate is the set provided by CMFG Life Insurance Company 7) Includes only lifetime pay policies (excludes single pay, 10 pay and paid-up at 65)","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_075","product_type":"parse","source_file_path":"complex_header_075.pdf"},"started_at":"2026-11-12T14:57:14.381223"} {"completed_at":"2026-11-12T14:57:21.109769","latency_in_ms":2061,"output":{"example_id":"complex_table_headers/complex_header_077","grounded_pages":[],"layout_pages":[],"markdown":"### NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 30 JUNE 2000\n\n42\n\n**Note Consolidated Company 2000 1999 2000 1999 $ $ $ $ 2. OPERATING (LOSS) PROFIT**\n\n**The operating (loss) profit before income tax includes the following items of revenue and expense:**\n\n**Operating Revenue**\n\nRendering of services 14,522,968 26,051,736 – – Dividend received from controlled entity – – – 1,100,000 Rent 390,966 287,737 – – Interest - other persons 210,840 44,551 185,959 21,319\n\nInterest - related parties – 23,861 – –\n\n15,124,774 26,407,885 185,959 1,121,319\n\n**Non Operating Revenue**\n\nProceeds from sale of assets:\n\nProperty, plant and equipment 225,000 – – –\n\n**Expenses**\n\nDepreciation: Leasehold buildings and improvements 202,300 145,549 – – Vessels 382,217 416,918 – – Vessels - hire purchase 233,908 179,414 – – Plant and equipment 207,824 362,026 – – Plant and equipment - hire purchase 52,065 75,249 – –\n\nWrite off of goodwill – 95,105 – –\n\nWrite off of shares - other corporations – 2,647 – –\n\nBad debts 13,136 29,064 – –\n\nBorrowing costs expensed: Interest expense - other persons 574,479 743,437 – – Finance charges - hire purchase 514,889 261,409 – –\n\nRental - operating leases 88,447 72,384 – – Employee Entitlements 1,630,357 3,515,875 – –\n\n**3\\. ABNORMAL ITEMS**\n\nIncluded in the operating (loss) profit are the following abnormal items:\n\nFinance costs incurred upon restructure of the group financing facilities – 273,430 – –\n\nApplicable income tax – (98,435) – –\n\n– 174,995 – –","pages":[{"line_numbers":[],"markdown":"### NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 30 JUNE 2000\n\n42\n\n**Note Consolidated Company 2000 1999 2000 1999 $ $ $ $ 2. OPERATING (LOSS) PROFIT**\n\n**The operating (loss) profit before income tax includes the following items of revenue and expense:**\n\n**Operating Revenue**\n\nRendering of services 14,522,968 26,051,736 – – Dividend received from controlled entity – – – 1,100,000 Rent 390,966 287,737 – – Interest - other persons 210,840 44,551 185,959 21,319\n\nInterest - related parties – 23,861 – –\n\n15,124,774 26,407,885 185,959 1,121,319\n\n**Non Operating Revenue**\n\nProceeds from sale of assets:\n\nProperty, plant and equipment 225,000 – – –\n\n**Expenses**\n\nDepreciation: Leasehold buildings and improvements 202,300 145,549 – – Vessels 382,217 416,918 – – Vessels - hire purchase 233,908 179,414 – – Plant and equipment 207,824 362,026 – – Plant and equipment - hire purchase 52,065 75,249 – –\n\nWrite off of goodwill – 95,105 – –\n\nWrite off of shares - other corporations – 2,647 – –\n\nBad debts 13,136 29,064 – –\n\nBorrowing costs expensed: Interest expense - other persons 574,479 743,437 – – Finance charges - hire purchase 514,889 261,409 – –\n\nRental - operating leases 88,447 72,384 – – Employee Entitlements 1,630,357 3,515,875 – –\n\n**3\\. ABNORMAL ITEMS**\n\nIncluded in the operating (loss) profit are the following abnormal items:\n\nFinance costs incurred upon restructure of the group financing facilities – 273,430 – –\n\nApplicable income tax – (98,435) – –\n\n– 174,995 – –","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_077","product_type":"parse","source_file_path":"complex_header_077.pdf"},"started_at":"2026-11-12T14:57:19.047956"} {"completed_at":"2026-11-12T14:57:23.125157","latency_in_ms":2010,"output":{"example_id":"complex_table_headers/complex_header_081","grounded_pages":[],"layout_pages":[],"markdown":"THE PHILADELPHIA CONTRIBUTIONSHIP\n\nNEW JERSEY HOMEOWNERS\n\n22 September 2025\n\n**302\\.A. Standard Base Rates** **–** **Philadelphia Contributionship Insurance Company** **–** **(** **_CONT’D_** **)**\n\n**HO 00 01 HO 00 02**\n\n**Territory Fire Wind Water Theft Other Liability Fire Wind Water Theft Other Liability**\n\n**07922** 203\\.40 84.40 72.39 14.65 23.71 50.03 175.76 72.93 62.55 12.64 20.51 43.22\n\n**07924** 163\\.85 67.96 58.97 9.06 16.74 37.73 141.69 58.77 50.99 7.81 14.47 32.65\n\n**07926** 173\\.44 69.66 68.24 7.64 19.92 42.17 149.94 60.22 58.99 6.58 17.24 36.45\n\n**07927** 172\\.16 69.17 67.75 7.59 19.80 41.85 148.68 59.71 58.50 6.53 17.09 36.14\n\n**07928** 124\\.38 49.96 48.92 5.47 14.28 30.25 107.49 43.18 42.29 4.74 12.35 26.11\n\n**07930** 121\\.09 48.64 47.64 5.34 13.93 29.42 104.20 41.86 40.99 4.59 11.97 25.33\n\n**07931** 145\\.68 60.43 52.43 8.05 14.88 33.57 125.92 52.21 45.29 6.96 12.86 29.01\n\n**07932** 130\\.48 52.40 51.34 5.73 15.00 31.72 112.64 45.24 44.31 4.95 12.94 27.38\n\n**07933** 118\\.29 47.51 46.53 5.20 13.61 28.73 102.34 41.09 40.27 4.50 11.75 24.88\n\n**07934** 135\\.72 56.30 48.84 7.48 13.86 31.25 117.46 48.70 42.26 6.50 12.02 27.04\n\n**07935** 160\\.71 64.58 63.24 7.07 18.48 39.08 138.49 55.63 54.48 6.09 15.91 33.67\n\n**07936** 160\\.12 64.30 62.98 7.04 18.39 38.92 138.49 55.63 54.48 6.09 15.91 33.67\n\n**07938** 181\\.09 75.11 65.18 9.98 18.49 41.73 156.22 64.80 56.22 8.62 15.95 36.00\n\n**07939** 218\\.43 90.61 78.60 12.07 22.31 50.30 188.57 78.21 67.85 10.41 19.28 43.43\n\n**07940** 117\\.32 47.15 46.18 5.16 13.47 28.53 101.39 40.74 39.89 4.45 11.66 24.65\n\n**07945** 128\\.68 51.69 50.62 5.66 14.80 31.27 111.22 44.66 43.76 4.90 12.78 27.03\n\n**07946** 158\\.81 63.83 62.49 6.98 18.26 38.61 137.21 55.14 53.98 6.03 15.79 33.38\n\n**07950** 128\\.68 51.69 50.62 5.66 14.80 31.27 111.22 44.66 43.76 4.90 12.78 27.03\n\n**07960** 144\\.17 57.91 56.70 6.36 16.56 35.04 124.62 50.07 49.04 5.47 14.32 30.28\n\n**07961** 158\\.81 63.83 62.49 6.98 18.26 38.61 137.21 55.14 53.98 6.03 15.79 33.38\n\n**07962** 173\\.44 69.66 68.24 7.64 19.92 42.17 149.94 60.22 58.99 6.58 17.24 36.45\n\n**07963** 173\\.44 69.66 68.24 7.64 19.92 42.17 149.94 60.22 58.99 6.58 17.24 36.45\n\n**07970** 163\\.91 65.86 64.50 7.21 18.84 39.82 141.70 56.90 55.75 6.22 16.31 34.43\n\n**07974** 191\\.16 79.33 68.02 13.76 22.29 47.01 165.20 68.54 58.78 11.89 19.25 40.62\n\n**07976** 118\\.29 47.51 46.53 5.20 13.61 28.73 102.34 41.09 40.27 4.50 11.75 24.88\n\n**07977** 145\\.71 60.45 52.44 8.05 14.88 33.58 125.95 52.24 45.31 6.97 12.87 29.03\n\n**07978** 181\\.09 75.11 65.18 9.98 18.49 41.73 156.22 64.80 56.22 8.62 15.95 36.00\n\n**07979** 142\\.91 43.59 48.51 3.91 18.89 39.43 123.05 37.54 41.79 3.38 16.28 33.95\n\n**07980** 125\\.69 50.49 49.45 5.53 14.44 30.53 108.71 43.67 42.78 4.78 12.50 26.42\n\n**07981** 136\\.64 54.90 53.76 6.01 15.70 33.22 117.68 47.27 46.31 5.17 13.55 28.62\n\n**07999** 174\\.09 69.92 68.46 7.66 19.99 42.32 149.94 60.22 58.99 6.58 17.24 36.45\n\n**08001** 581\\.37 144.14 137.86 24.81 71.62 87.00 502.06 124.48 119.06 21.44 61.85 75.12\n\n**08002** 374\\.24 118.07 154.91 19.44 40.17 89.23 323.32 102.02 133.83 16.82 34.70 77.08\n\n**08003** 324\\.92 102.53 134.51 16.90 34.88 77.47 280.53 88.52 116.13 14.59 30.12 66.89\n\n**08004** 301\\.70 95.19 124.88 15.68 32.40 71.95 260.49 82.22 107.81 13.54 27.95 62.11\n\n**08005** 259\\.41 344.93 111.70 9.38 33.42 73.30 223.83 297.63 96.39 8.11 28.84 63.23\n\n**08006** 377\\.64 502.16 162.63 13.65 48.66 106.69 326.34 433.97 140.53 11.81 42.06 92.21\n\n**08007** 290\\.20 91.57 120.13 15.09 31.14 69.21 250.27 78.97 103.60 13.02 26.85 59.68\n\n**08008** 378\\.39 503.17 162.96 13.68 48.76 106.90 327.00 434.83 140.82 11.84 42.15 92.39\n\n**08009** 331\\.85 104.72 137.38 17.26 35.62 79.12 286.40 90.38 118.57 14.89 30.74 68.29\n\n**08010** 383\\.67 146.39 142.17 17.83 46.31 96.20 331.05 126.32 122.66 15.38 39.95 83.00\n\n**08011** 425\\.86 162.50 157.78 19.80 51.39 106.80 368.43 140.59 136.53 17.12 44.45 92.38\n\n**08012** 295\\.67 93.30 122.41 15.38 31.73 70.51 255.58 80.65 105.80 13.29 27.43 60.94\n\n**08014** 363\\.67 138.77 134.75 16.91 43.90 91.21 314.23 119.90 116.44 14.59 37.90 78.79\n\n**08015** 328\\.10 125.20 121.56 15.23 39.58 82.27 283.23 108.07 104.95 13.16 34.18 71.02\n\n**08016** 406\\.18 154.98 150.52 18.88 49.02 101.85 351.40 134.10 130.21 16.34 42.41 88.11\n\n**08018** 329\\.10 103.85 136.25 17.11 35.32 78.46 284.03 89.64 117.59 14.76 30.49 67.73\n\n**08019** 370\\.66 141.44 137.36 17.24 44.73 92.93 319.77 122.01 118.49 14.88 38.57 80.18\n\n**08020** 369\\.92 141.15 137.06 17.19 44.63 92.76 319.34 121.85 118.32 14.84 38.53 80.07\n\n**08021** 531\\.71 167.79 220.11 27.66 57.06 126.77 459.54 145.02 190.22 23.90 49.31 109.58\n\n**08022** 328\\.17 125.24 121.60 15.27 39.59 82.29 283.48 108.18 105.05 13.18 34.21 71.08\n\n**08023** 570\\.24 141.38 135.21 24.34 70.24 85.32 492.23 122.06 116.72 21.02 60.62 73.65\n\n**08025** 487\\.37 186.00 180.59 22.64 58.82 122.24 421.01 160.65 156.01 19.57 50.82 105.56\n\n**08026** 262\\.36 82.78 108.60 13.64 28.14 62.56 226.39 71.42 93.71 11.78 24.30 53.98","pages":[{"line_numbers":[],"markdown":"THE PHILADELPHIA CONTRIBUTIONSHIP\n\nNEW JERSEY HOMEOWNERS\n\n22 September 2025\n\n**302\\.A. Standard Base Rates** **–** **Philadelphia Contributionship Insurance Company** **–** **(** **_CONT’D_** **)**\n\n**HO 00 01 HO 00 02**\n\n**Territory Fire Wind Water Theft Other Liability Fire Wind Water Theft Other Liability**\n\n**07922** 203\\.40 84.40 72.39 14.65 23.71 50.03 175.76 72.93 62.55 12.64 20.51 43.22\n\n**07924** 163\\.85 67.96 58.97 9.06 16.74 37.73 141.69 58.77 50.99 7.81 14.47 32.65\n\n**07926** 173\\.44 69.66 68.24 7.64 19.92 42.17 149.94 60.22 58.99 6.58 17.24 36.45\n\n**07927** 172\\.16 69.17 67.75 7.59 19.80 41.85 148.68 59.71 58.50 6.53 17.09 36.14\n\n**07928** 124\\.38 49.96 48.92 5.47 14.28 30.25 107.49 43.18 42.29 4.74 12.35 26.11\n\n**07930** 121\\.09 48.64 47.64 5.34 13.93 29.42 104.20 41.86 40.99 4.59 11.97 25.33\n\n**07931** 145\\.68 60.43 52.43 8.05 14.88 33.57 125.92 52.21 45.29 6.96 12.86 29.01\n\n**07932** 130\\.48 52.40 51.34 5.73 15.00 31.72 112.64 45.24 44.31 4.95 12.94 27.38\n\n**07933** 118\\.29 47.51 46.53 5.20 13.61 28.73 102.34 41.09 40.27 4.50 11.75 24.88\n\n**07934** 135\\.72 56.30 48.84 7.48 13.86 31.25 117.46 48.70 42.26 6.50 12.02 27.04\n\n**07935** 160\\.71 64.58 63.24 7.07 18.48 39.08 138.49 55.63 54.48 6.09 15.91 33.67\n\n**07936** 160\\.12 64.30 62.98 7.04 18.39 38.92 138.49 55.63 54.48 6.09 15.91 33.67\n\n**07938** 181\\.09 75.11 65.18 9.98 18.49 41.73 156.22 64.80 56.22 8.62 15.95 36.00\n\n**07939** 218\\.43 90.61 78.60 12.07 22.31 50.30 188.57 78.21 67.85 10.41 19.28 43.43\n\n**07940** 117\\.32 47.15 46.18 5.16 13.47 28.53 101.39 40.74 39.89 4.45 11.66 24.65\n\n**07945** 128\\.68 51.69 50.62 5.66 14.80 31.27 111.22 44.66 43.76 4.90 12.78 27.03\n\n**07946** 158\\.81 63.83 62.49 6.98 18.26 38.61 137.21 55.14 53.98 6.03 15.79 33.38\n\n**07950** 128\\.68 51.69 50.62 5.66 14.80 31.27 111.22 44.66 43.76 4.90 12.78 27.03\n\n**07960** 144\\.17 57.91 56.70 6.36 16.56 35.04 124.62 50.07 49.04 5.47 14.32 30.28\n\n**07961** 158\\.81 63.83 62.49 6.98 18.26 38.61 137.21 55.14 53.98 6.03 15.79 33.38\n\n**07962** 173\\.44 69.66 68.24 7.64 19.92 42.17 149.94 60.22 58.99 6.58 17.24 36.45\n\n**07963** 173\\.44 69.66 68.24 7.64 19.92 42.17 149.94 60.22 58.99 6.58 17.24 36.45\n\n**07970** 163\\.91 65.86 64.50 7.21 18.84 39.82 141.70 56.90 55.75 6.22 16.31 34.43\n\n**07974** 191\\.16 79.33 68.02 13.76 22.29 47.01 165.20 68.54 58.78 11.89 19.25 40.62\n\n**07976** 118\\.29 47.51 46.53 5.20 13.61 28.73 102.34 41.09 40.27 4.50 11.75 24.88\n\n**07977** 145\\.71 60.45 52.44 8.05 14.88 33.58 125.95 52.24 45.31 6.97 12.87 29.03\n\n**07978** 181\\.09 75.11 65.18 9.98 18.49 41.73 156.22 64.80 56.22 8.62 15.95 36.00\n\n**07979** 142\\.91 43.59 48.51 3.91 18.89 39.43 123.05 37.54 41.79 3.38 16.28 33.95\n\n**07980** 125\\.69 50.49 49.45 5.53 14.44 30.53 108.71 43.67 42.78 4.78 12.50 26.42\n\n**07981** 136\\.64 54.90 53.76 6.01 15.70 33.22 117.68 47.27 46.31 5.17 13.55 28.62\n\n**07999** 174\\.09 69.92 68.46 7.66 19.99 42.32 149.94 60.22 58.99 6.58 17.24 36.45\n\n**08001** 581\\.37 144.14 137.86 24.81 71.62 87.00 502.06 124.48 119.06 21.44 61.85 75.12\n\n**08002** 374\\.24 118.07 154.91 19.44 40.17 89.23 323.32 102.02 133.83 16.82 34.70 77.08\n\n**08003** 324\\.92 102.53 134.51 16.90 34.88 77.47 280.53 88.52 116.13 14.59 30.12 66.89\n\n**08004** 301\\.70 95.19 124.88 15.68 32.40 71.95 260.49 82.22 107.81 13.54 27.95 62.11\n\n**08005** 259\\.41 344.93 111.70 9.38 33.42 73.30 223.83 297.63 96.39 8.11 28.84 63.23\n\n**08006** 377\\.64 502.16 162.63 13.65 48.66 106.69 326.34 433.97 140.53 11.81 42.06 92.21\n\n**08007** 290\\.20 91.57 120.13 15.09 31.14 69.21 250.27 78.97 103.60 13.02 26.85 59.68\n\n**08008** 378\\.39 503.17 162.96 13.68 48.76 106.90 327.00 434.83 140.82 11.84 42.15 92.39\n\n**08009** 331\\.85 104.72 137.38 17.26 35.62 79.12 286.40 90.38 118.57 14.89 30.74 68.29\n\n**08010** 383\\.67 146.39 142.17 17.83 46.31 96.20 331.05 126.32 122.66 15.38 39.95 83.00\n\n**08011** 425\\.86 162.50 157.78 19.80 51.39 106.80 368.43 140.59 136.53 17.12 44.45 92.38\n\n**08012** 295\\.67 93.30 122.41 15.38 31.73 70.51 255.58 80.65 105.80 13.29 27.43 60.94\n\n**08014** 363\\.67 138.77 134.75 16.91 43.90 91.21 314.23 119.90 116.44 14.59 37.90 78.79\n\n**08015** 328\\.10 125.20 121.56 15.23 39.58 82.27 283.23 108.07 104.95 13.16 34.18 71.02\n\n**08016** 406\\.18 154.98 150.52 18.88 49.02 101.85 351.40 134.10 130.21 16.34 42.41 88.11\n\n**08018** 329\\.10 103.85 136.25 17.11 35.32 78.46 284.03 89.64 117.59 14.76 30.49 67.73\n\n**08019** 370\\.66 141.44 137.36 17.24 44.73 92.93 319.77 122.01 118.49 14.88 38.57 80.18\n\n**08020** 369\\.92 141.15 137.06 17.19 44.63 92.76 319.34 121.85 118.32 14.84 38.53 80.07\n\n**08021** 531\\.71 167.79 220.11 27.66 57.06 126.77 459.54 145.02 190.22 23.90 49.31 109.58\n\n**08022** 328\\.17 125.24 121.60 15.27 39.59 82.29 283.48 108.18 105.05 13.18 34.21 71.08\n\n**08023** 570\\.24 141.38 135.21 24.34 70.24 85.32 492.23 122.06 116.72 21.02 60.62 73.65\n\n**08025** 487\\.37 186.00 180.59 22.64 58.82 122.24 421.01 160.65 156.01 19.57 50.82 105.56\n\n**08026** 262\\.36 82.78 108.60 13.64 28.14 62.56 226.39 71.42 93.71 11.78 24.30 53.98","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_081","product_type":"parse","source_file_path":"complex_header_081.pdf"},"started_at":"2026-11-12T14:57:21.114813"} {"completed_at":"2026-11-12T14:55:19.750164","latency_in_ms":1500,"output":{"example_id":"complex_table_headers/complex_header_082","grounded_pages":[],"layout_pages":[],"markdown":"**MARITIME SAFETY STANDARDS GLOBAL SHIPPING DEPT.**\n\n**500GT &OVER**\n\n**INTN'L**\n\n**UNDER 500GT**\n\n**INTN'L**\n\n**DOMESTIC TRADE**\n\n**ALL VESSELS**\n\n**500GT &OVER**\n\n**INTN'L**\n\n**UNDER 500GT**\n\n**INTN'L**\n\n**DOMESTIC TRADE**\n\n**ALL VESSELS**\n\n**1** Administrative due diligence verification carried out according to CEMEX guideline for chartered & hired vessels **X X**\n\n**2** Equasis/Mou deficiency verification carried out according to CEMEX guidelines for chartered & hired vessels **X X**\n\n**3** Additional verification undertaken to confirm satisfactory correction of Deficiencies according to CEMEX guidelines **X X**\n\n**4** Physical vessel inspection undertaken - results of inspection appended to charter/hire documentation **X X X X X**\n\n**5**\n\nVessel is warranted by Owner/Manager/Agent to be; registered in the territory of an IMO contracting government; not registered in a territory appearing on a Paris or Tokyo MOU 'Black List' or in a USCG list of target States; not subject to a banning or detention order of either the Paris or Tokyo MOU or appearing in a USCG list of banned vessels\n\n**X X**\n\n**6**\n\nVessel is warranted by Owner/Manager/Agent to be; not classed with a Recognised Organisation (RO) appearing in the 'Low' or 'Very Low' category of a published list of RO performance tables of the Paris or Tokyo MOU or with a RO appearing in a published USCG list of target RO's\n\n**X X**\n\n**7**\n\nVessel is warranted by the Owner/Manager/Agent to be; not subject to any overdue annotation, memoranda, or condition attached to the vessel's certificate of entry into class or like document; free of any diminuation or wastage of material, defect of structure, machinery or equipment not yet advised to a relevant Recognised Organisation or insurer.\n\n**X X X X X X**\n\n**8** The vessel is warranted by the Owner/Manager/Agent; where not required to be entered with a Recognised Organisation/Classification Society, to comply with the relevant National Schedule or Code requirements applicable to the vessel(s) **X X X X**\n\n**9**\n\nThe vessel is warranted by the Owner/Manager/Agent to be; furnished with all necessary current & valid International Maritime Safety Convention certification relevant to the vessel’s operation or, where this is not the case, then the situation shall be rectified at the Owner/Operator’s cost before the period of employment with CEMEX commences.\n\n**X X**\n\n**10**\n\nThe vessel is warranted by the Owner/Manger/Agent; where not required to be furnished with International Maritime Safety Convention certification, then furnished with all necessary current & valid certification applicable under the National Schedule or Code under which the vessel is regulated.\n\n**X X X X**\n\n**11**\n\nThe vessel is warranted by the Owner/Manager/Agent to be; provided with adequate Protection and Indemnity (P& I) or other suitable insurance cover in respect of damage or risk to Crew, 3 rd party persons or property & damage to or pollution of the marine environment; in respect of general risks and any special operations applicable to the vessel; sufficient to indemnify CEMEX against the consequences of the actions, errors or omissions of the Owner/Operator, Manager, Master & Crew of the vessel.\n\n**X X X X X X**\n\n**12**\n\nThe vessel is warranted by the Owner/Manager/Agent to be; not belonging, commercially controlled, chartered, sublet or hired, by or from owners, head owners or disponent owners listed in the Office of Foreign Assets Control (OFAC) Sanctioned List. This list includes but shall not be limited to the following countries: Belarus, Burma (Myanmar), Cote d’Ivoire (Ivory Coast), Cuba, Democratic Republic of the Congo, Iran, Iraq, Liberia (former Liberian Regime of Charles Taylor), North Korea, Sudan, Syria, and Zimbabwe.\n\n**X X X X X X**\n\n**13**\n\nVessels spot hired for one or more single voyages under separate charter party or hire agreements or hired for shipment under a Contract of affreightment shall be classed with Recognised Organisation or Classification Society which is a member of the **International Association of Classification Societies (IACS)** and/or appears in the **‘high’ performing category of the latest published Paris MOU/EMSA Recognised Organisation Performance table.** (Vessels hired for more than one voyage under a single charter party or hire agreement shall be deemed to be time chartered and shall undergo physical inspection together with periodic verification of condition and certification).\n\n**X X**\n\n**14** Verify that all certification with which the vessel is required to be furnished under the CEMEX guidelines for chartered & hired vessel is current, valid & carried in the vessel **X X X X X X**\n\n**15**\n\nVerify that periodic verification; of compliance with regulations and checks on the condition of the vessel, according to the intervals laid down by the Flag State Administration or RO, where specified; or otherwise as required by CEMEX; has been undertaken, sufficient to maintain acceptable standards of condition and performance.\n\n**X X X**\n\n**16** Verify that a vessel engaged in commercial activity other than a ship engaged in fishing; of traditional build; or navigating exclusively in or closely adjacent to sheltered waters or where port regulations apply has been issued with a Maritime labour Convention (MLC2006) Certificate. There is no lower tonnage limit below which the provisions of MLC 2006 do not apply.\n\n**X X X X X X**\n\n**17**\n\nVerify in accordance with the requirement that every vessel chartered, hired or otherwise engaged for maritime operations or the provision of maritime services for or on behalf of CEMEX shall, without exception be marked at the fore and aft end of the vessel with ‘Draught Marks’ and on the sides of the vessel ‘amidships’, with a ‘Loadline’ indicating the deepest draught to which the vessel may be immersed; in accordance with either the International Loadline Convention or the requirements of the territory in which the vessel is registered; that the vessel is marked as required by the CEMEX guidelines for chartered & hired vessels.\n\n**X X X X X X**\n\n**18**\n\nVerify so far as practicable that the vessel is not under any circumstances loaded and proceeding to sea with the Loadline immersed or at a ‘mean’ draught exceeding that specified in the vessel’s certification. Establish so far as practicable whether a practice of overloading the vessel occurs or has occurred in the past.\n\n**X X X X X X**\n\n**19** Verify that the vessel's actual or intended area of operation is consistent with that stated in the vessel's certificate of entry into class; code of operation; 'permis de navaire' or like document. **X X X X X X**\n\n**20**\n\nVerify that vessel, without minimum tonnage limit, engaged on International voyages, from the relevant qualifying date for each vessel, an IMO homologated Ballast water treatment system is fitted and in service onboard, for the management of the Ballast Water, at all times during the trip to comply with the requirements of the Ballast Water Management Convention, entered into force on September 8th 2017. Any time after the final date of entry into force of the Convention for the specific ship, a copy of the Certification of the homologated system, issued by the manufacturer, shall be made available for Cemex if it is so required\n\n**X X X X**\n\n**Master's Responsibilities**\n\n**21**\n\nVerify that the vessel is manned with sufficient appropriate qualified personnel in accordance the vessel's safe manning document, where issued; or with any other applicable minimum manning requirement. Crew certificates must be currently valid and original documents carried on board by all crew members.\n\n**X X X X X X**\n\n**MARITIME SAFETY STANDARDS**\n\n**Compliance with the requirements identified below by an X for the respective category of vessel shall be verified by the CEMEX's Manager responsible for chartering, hiring or operating any particular vessel. Verification for spot chartered & COA vessels shall be undertaken prior to engagement for conducting martime operations or the provision of maritime sevices to CEMEX; verification for time chartered vessels shall be undertaken prior to**\n\n**engagement and annually thereafter for the duration of the period of hire .**\n\n**Where an 'X' is not shown, this does not imply the requirement listed should not be verified where present; only that the item is not a mandatory requirement for CEMEX. There is no obligation under this guidance for CEMEX**\n\n**personnel to verify physical compliance where compliance has already been demonstrated by the issue of IMO Convention certification or for domestically trading vessels, certification verifying compliance with a relevant**\n\n**Flag State Code or Standard.**\n\n**SPOT CHARTER OR COA TIME OR BAREBOAT CHARTER**\n\n**Inspections & verifications undertaken in accordance with this Maritime Standards Checklist shall also be undertaken also in accordance with CEMEX guidelines for Chartered & Hired vessels**","pages":[{"line_numbers":[],"markdown":"**MARITIME SAFETY STANDARDS GLOBAL SHIPPING DEPT.**\n\n**500GT &OVER**\n\n**INTN'L**\n\n**UNDER 500GT**\n\n**INTN'L**\n\n**DOMESTIC TRADE**\n\n**ALL VESSELS**\n\n**500GT &OVER**\n\n**INTN'L**\n\n**UNDER 500GT**\n\n**INTN'L**\n\n**DOMESTIC TRADE**\n\n**ALL VESSELS**\n\n**1** Administrative due diligence verification carried out according to CEMEX guideline for chartered & hired vessels **X X**\n\n**2** Equasis/Mou deficiency verification carried out according to CEMEX guidelines for chartered & hired vessels **X X**\n\n**3** Additional verification undertaken to confirm satisfactory correction of Deficiencies according to CEMEX guidelines **X X**\n\n**4** Physical vessel inspection undertaken - results of inspection appended to charter/hire documentation **X X X X X**\n\n**5**\n\nVessel is warranted by Owner/Manager/Agent to be; registered in the territory of an IMO contracting government; not registered in a territory appearing on a Paris or Tokyo MOU 'Black List' or in a USCG list of target States; not subject to a banning or detention order of either the Paris or Tokyo MOU or appearing in a USCG list of banned vessels\n\n**X X**\n\n**6**\n\nVessel is warranted by Owner/Manager/Agent to be; not classed with a Recognised Organisation (RO) appearing in the 'Low' or 'Very Low' category of a published list of RO performance tables of the Paris or Tokyo MOU or with a RO appearing in a published USCG list of target RO's\n\n**X X**\n\n**7**\n\nVessel is warranted by the Owner/Manager/Agent to be; not subject to any overdue annotation, memoranda, or condition attached to the vessel's certificate of entry into class or like document; free of any diminuation or wastage of material, defect of structure, machinery or equipment not yet advised to a relevant Recognised Organisation or insurer.\n\n**X X X X X X**\n\n**8** The vessel is warranted by the Owner/Manager/Agent; where not required to be entered with a Recognised Organisation/Classification Society, to comply with the relevant National Schedule or Code requirements applicable to the vessel(s) **X X X X**\n\n**9**\n\nThe vessel is warranted by the Owner/Manager/Agent to be; furnished with all necessary current & valid International Maritime Safety Convention certification relevant to the vessel’s operation or, where this is not the case, then the situation shall be rectified at the Owner/Operator’s cost before the period of employment with CEMEX commences.\n\n**X X**\n\n**10**\n\nThe vessel is warranted by the Owner/Manger/Agent; where not required to be furnished with International Maritime Safety Convention certification, then furnished with all necessary current & valid certification applicable under the National Schedule or Code under which the vessel is regulated.\n\n**X X X X**\n\n**11**\n\nThe vessel is warranted by the Owner/Manager/Agent to be; provided with adequate Protection and Indemnity (P& I) or other suitable insurance cover in respect of damage or risk to Crew, 3 rd party persons or property & damage to or pollution of the marine environment; in respect of general risks and any special operations applicable to the vessel; sufficient to indemnify CEMEX against the consequences of the actions, errors or omissions of the Owner/Operator, Manager, Master & Crew of the vessel.\n\n**X X X X X X**\n\n**12**\n\nThe vessel is warranted by the Owner/Manager/Agent to be; not belonging, commercially controlled, chartered, sublet or hired, by or from owners, head owners or disponent owners listed in the Office of Foreign Assets Control (OFAC) Sanctioned List. This list includes but shall not be limited to the following countries: Belarus, Burma (Myanmar), Cote d’Ivoire (Ivory Coast), Cuba, Democratic Republic of the Congo, Iran, Iraq, Liberia (former Liberian Regime of Charles Taylor), North Korea, Sudan, Syria, and Zimbabwe.\n\n**X X X X X X**\n\n**13**\n\nVessels spot hired for one or more single voyages under separate charter party or hire agreements or hired for shipment under a Contract of affreightment shall be classed with Recognised Organisation or Classification Society which is a member of the **International Association of Classification Societies (IACS)** and/or appears in the **‘high’ performing category of the latest published Paris MOU/EMSA Recognised Organisation Performance table.** (Vessels hired for more than one voyage under a single charter party or hire agreement shall be deemed to be time chartered and shall undergo physical inspection together with periodic verification of condition and certification).\n\n**X X**\n\n**14** Verify that all certification with which the vessel is required to be furnished under the CEMEX guidelines for chartered & hired vessel is current, valid & carried in the vessel **X X X X X X**\n\n**15**\n\nVerify that periodic verification; of compliance with regulations and checks on the condition of the vessel, according to the intervals laid down by the Flag State Administration or RO, where specified; or otherwise as required by CEMEX; has been undertaken, sufficient to maintain acceptable standards of condition and performance.\n\n**X X X**\n\n**16** Verify that a vessel engaged in commercial activity other than a ship engaged in fishing; of traditional build; or navigating exclusively in or closely adjacent to sheltered waters or where port regulations apply has been issued with a Maritime labour Convention (MLC2006) Certificate. There is no lower tonnage limit below which the provisions of MLC 2006 do not apply.\n\n**X X X X X X**\n\n**17**\n\nVerify in accordance with the requirement that every vessel chartered, hired or otherwise engaged for maritime operations or the provision of maritime services for or on behalf of CEMEX shall, without exception be marked at the fore and aft end of the vessel with ‘Draught Marks’ and on the sides of the vessel ‘amidships’, with a ‘Loadline’ indicating the deepest draught to which the vessel may be immersed; in accordance with either the International Loadline Convention or the requirements of the territory in which the vessel is registered; that the vessel is marked as required by the CEMEX guidelines for chartered & hired vessels.\n\n**X X X X X X**\n\n**18**\n\nVerify so far as practicable that the vessel is not under any circumstances loaded and proceeding to sea with the Loadline immersed or at a ‘mean’ draught exceeding that specified in the vessel’s certification. Establish so far as practicable whether a practice of overloading the vessel occurs or has occurred in the past.\n\n**X X X X X X**\n\n**19** Verify that the vessel's actual or intended area of operation is consistent with that stated in the vessel's certificate of entry into class; code of operation; 'permis de navaire' or like document. **X X X X X X**\n\n**20**\n\nVerify that vessel, without minimum tonnage limit, engaged on International voyages, from the relevant qualifying date for each vessel, an IMO homologated Ballast water treatment system is fitted and in service onboard, for the management of the Ballast Water, at all times during the trip to comply with the requirements of the Ballast Water Management Convention, entered into force on September 8th 2017. Any time after the final date of entry into force of the Convention for the specific ship, a copy of the Certification of the homologated system, issued by the manufacturer, shall be made available for Cemex if it is so required\n\n**X X X X**\n\n**Master's Responsibilities**\n\n**21**\n\nVerify that the vessel is manned with sufficient appropriate qualified personnel in accordance the vessel's safe manning document, where issued; or with any other applicable minimum manning requirement. Crew certificates must be currently valid and original documents carried on board by all crew members.\n\n**X X X X X X**\n\n**MARITIME SAFETY STANDARDS**\n\n**Compliance with the requirements identified below by an X for the respective category of vessel shall be verified by the CEMEX's Manager responsible for chartering, hiring or operating any particular vessel. Verification for spot chartered & COA vessels shall be undertaken prior to engagement for conducting martime operations or the provision of maritime sevices to CEMEX; verification for time chartered vessels shall be undertaken prior to**\n\n**engagement and annually thereafter for the duration of the period of hire .**\n\n**Where an 'X' is not shown, this does not imply the requirement listed should not be verified where present; only that the item is not a mandatory requirement for CEMEX. There is no obligation under this guidance for CEMEX**\n\n**personnel to verify physical compliance where compliance has already been demonstrated by the issue of IMO Convention certification or for domestically trading vessels, certification verifying compliance with a relevant**\n\n**Flag State Code or Standard.**\n\n**SPOT CHARTER OR COA TIME OR BAREBOAT CHARTER**\n\n**Inspections & verifications undertaken in accordance with this Maritime Standards Checklist shall also be undertaken also in accordance with CEMEX guidelines for Chartered & Hired vessels**","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_082","product_type":"parse","source_file_path":"complex_header_082.pdf"},"started_at":"2026-11-12T14:55:18.249636"} {"completed_at":"2026-11-12T14:55:21.257027","latency_in_ms":1564,"output":{"example_id":"complex_table_headers/complex_header_084","grounded_pages":[],"layout_pages":[],"markdown":"Washington State OIC 2026 Individual Medical Rate Filing Checklist\n\n2026 RATE IND MED CHECKLIST Page 3 of 58 04/07/2025\n\n**Standard Plans Offered (excluding the subsidized benefit plan variations)**\n\n**HIOS Plan ID Standard Plan Name Public Option Plan** (Yes, Cascade Select/ No, Cascade)\n\n**Metal Level AV Metal Value**\n\n53732WA0790024 BridgeSpan Cascade Complete Gold No Gold 81.81%\n\n53732WA0790025 BridgeSpan Cascade Silver No Silver 71.84%\n\n53732WA0790026 BridgeSpan Cascade Bronze No Bronze 64.97%\n\n53732WA0790030 BridgeSpan Cascade Vital Gold No Gold 78.06%\n\n**All Plans Offered (excluding the subsidized benefit plan variations)**\n\n**HIOS Plan ID Plan Name Unique Benefit Design (UBD) Pediatric Dental Embedded (Yes/No)**\n\n**Description of Non-Essential Health Benefits (Non-EHBs) (Yes/No) If yes, briefly explain why. If no, “N/A.”**\n\n53732WA0790024 BridgeSpan Cascade Complete\n\nGold\n\nNo See Footnote No N/A\n\n53732WA0790025 BridgeSpan Cascade Silver Yes See Footnote No N/A\n\n53732WA0790026 BridgeSpan Cascade Bronze Yes See Footnote No N/A\n\n53732WA0790030 BridgeSpan Cascade Vital Gold No See Footnote No N/A\n\n**_For Cascade Plans, please see the “Standard Plan Unique Design and AV Screenshots” document for description of unique benefit designs._**\n\nD. **Do you have any expanded bronze plans as described under 45 CFR §156.140(c) in which the variation in AV Metal Value is between +2% and +5%**\n\n**(i.e., the AV is between 62% and 65%)?**\n\n☐ No\n\n☒ Yes, and they are listed in the table below. We confirm each of the following:\n\n(a) That the plans’ member cost-shares are equivalent to less than 50% coinsurance and\n\n(b) That each plan is either\n\n(1) A High Deductible Health Plan ¹ or\n\n(2) Has at least one major service ² , other than preventive services, covered prior to the deductible.\n\nNote: Only one major service needs to be listed in the table even if multiple major services are covered prior to the deductible.","pages":[{"line_numbers":[],"markdown":"Washington State OIC 2026 Individual Medical Rate Filing Checklist\n\n2026 RATE IND MED CHECKLIST Page 3 of 58 04/07/2025\n\n**Standard Plans Offered (excluding the subsidized benefit plan variations)**\n\n**HIOS Plan ID Standard Plan Name Public Option Plan** (Yes, Cascade Select/ No, Cascade)\n\n**Metal Level AV Metal Value**\n\n53732WA0790024 BridgeSpan Cascade Complete Gold No Gold 81.81%\n\n53732WA0790025 BridgeSpan Cascade Silver No Silver 71.84%\n\n53732WA0790026 BridgeSpan Cascade Bronze No Bronze 64.97%\n\n53732WA0790030 BridgeSpan Cascade Vital Gold No Gold 78.06%\n\n**All Plans Offered (excluding the subsidized benefit plan variations)**\n\n**HIOS Plan ID Plan Name Unique Benefit Design (UBD) Pediatric Dental Embedded (Yes/No)**\n\n**Description of Non-Essential Health Benefits (Non-EHBs) (Yes/No) If yes, briefly explain why. If no, “N/A.”**\n\n53732WA0790024 BridgeSpan Cascade Complete\n\nGold\n\nNo See Footnote No N/A\n\n53732WA0790025 BridgeSpan Cascade Silver Yes See Footnote No N/A\n\n53732WA0790026 BridgeSpan Cascade Bronze Yes See Footnote No N/A\n\n53732WA0790030 BridgeSpan Cascade Vital Gold No See Footnote No N/A\n\n**_For Cascade Plans, please see the “Standard Plan Unique Design and AV Screenshots” document for description of unique benefit designs._**\n\nD. **Do you have any expanded bronze plans as described under 45 CFR §156.140(c) in which the variation in AV Metal Value is between +2% and +5%**\n\n**(i.e., the AV is between 62% and 65%)?**\n\n☐ No\n\n☒ Yes, and they are listed in the table below. We confirm each of the following:\n\n(a) That the plans’ member cost-shares are equivalent to less than 50% coinsurance and\n\n(b) That each plan is either\n\n(1) A High Deductible Health Plan ¹ or\n\n(2) Has at least one major service ² , other than preventive services, covered prior to the deductible.\n\nNote: Only one major service needs to be listed in the table even if multiple major services are covered prior to the deductible.","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_084","product_type":"parse","source_file_path":"complex_header_084.pdf"},"started_at":"2026-11-12T14:55:19.692544"} {"completed_at":"2026-11-12T14:55:23.925685","latency_in_ms":1352,"output":{"example_id":"complex_table_headers/complex_header_087","grounded_pages":[],"layout_pages":[],"markdown":"**US 2009/0197849 Al**\n\n1 ). The highest pH formulation evaluated, Pax-3, provided up to 6-fold more flux than in the absence ofNaOH.\n\nExample 23\n\n**[0410]** An in vitro skin permeation study was conducted using three galanthamine hydrobromide transdermal sys- tems, designated Gala-I, Gala-2 and Gala-3, the composi- tions of which are set forth in Table 78. **[0411]** Round disc samples were prepared in a manner similar to that described in the Methods section, except that the formulation was dried at a temperature of 65° C. and the discs were cut into discs having a diameter _of9/26_ inch. **[0412]** The theoretical percent weight for each ingredient after drying ( calculated assuming all volatile ingredients were completely removed during drying) is set forth in Table 79. TABLE 78\n\nComponent Weight and Weight Percent Based on Total Solution Wei t\n\nGala-! Gala-2 Gala-3 g(wt%) g(wt%) g(wt%)\n\nGalanthamine 0.40 (4.7) 0.40 (4.6) 0.40 (4.6) HBr DI Water 0.30 (3.5) 0.34 (3.9) 0.38 (4.3) NaOH 0 0.04 (0.5) 0.08 (0.9) Glycerin 1.00 (11.6) 1.00 (11.5) 1.00 (11.4) Benzyl Alcohol 0.40 (4.7) 0.40 (4.6) 0.40 (4.6) PIB adhesive 6.00 (69.8) 6.00 (69.1) 6.00 (68.5) (30% solid) n-Heptane 0.50 (5.8) 0.50 (5.8) 0.50 (5.7)\n\nTABLE 79\n\nWeight and Theoretical Weight Percent Based on Dried Film Weight\n\nGala-! Gala-2 Gala-3 g(wt%) g(wt%) g(wt%)\n\nGalanthamine HBr 0.40 (11.1) 0.40 (11.0) 0.40 (10.9) NaOH 0 0.04 (1.1) 0.08 (2.2) Glycerin 1.00 (27.8) 1.00 (27.5) 1.00 (27.2) Benzyl Alcohol 0.40 (11.1) 0.40 (11.0) 0.40 (10.9) PIB adhesive 1.80 (50.0) 1.80 (49.5) 1.80 (48.9)\n\n**[0413]** Since galanthamine HBr is an acid addition salt of a free base, it reacts with NaOH. The concentration ofNaOH in the system after the reaction is completed depends on the amount of galanthamine HBr added. The remaining NaOH concentration after the reaction is completed is defined as the excess NaOH concentration, and was calculated as described in Example 2. The pH was measured as described in the Methods section but using a 2.4 cm ² circular patch. The pH of the galanthamine HBr patch increased from 8.73 to 10.56 when the calculated excess NaOH concentration in the dried patch was increased from 0% to 1.0%. The pH of the formu- lation without NaOH was 6.53. TABLE 80\n\nExcess NaOH Concentration (wt%) and pH\n\nExcessNaOH **Concentration** pH\n\nGala-!\n\n6\\.53\n\nGala-2\n\n**0%**\n\n8\\.73\n\nGala-3\n\n1\\.0%\n\n10\\.56\n\n### 38\n\n**Aug. 6, 2009**\n\n**[0414]** The in vitro permeation of galanthamine HBr through human cadaver skin from these discs was measured as described in the Methods. Three diffusion cells were used for each formulation. The receiver solution, 5% ethanol/95% PBS buffer (0.05 M KH2PO4 with0.15 MNaCl, pH adjusted to 6.5), was completely withdrawn and replaced with fresh receiver solution at each time point. The samples taken were analyzed by an HPLC for the concentration galanthamine HBr in the receiver solution. The cumulative amount of gal- anthamine HBr that permeated across the human cadaver skin was calculated using the measured galanthamine HBr con- centrations in the receiver solutions.\n\nTABLE 81\n\nCumulative Amount of Galanthamine HBr (mg/cm ² )\n\n**Time**\n\n6 hours 18 hours 24 hours\n\nGala-!\n\n0\\.140 0.429 0.624\n\nGala-2\n\n0\\.480 1.058 1.254\n\nGala-3\n\n0\\.475 1.412 1.750\n\n**[0415]** The cumulative amount of galanthamine HBr across human cadaver skin at 24 hours increased from 1.254 mg/cm ²\n\nto 1.750 mg/cm ² when the calculated excess NaOH concen- tration in the dried patch was increased from 0% to 1.0% as compared to 0.624 mg/cm ² for the formulation without NaOH. **[0416]** The formulation of Gala-2 provided up to 2-fold more galanthamine HBr flux than in the absence of NaOH (Gala-I). The highest pH formulation evaluated, Gala-3, pro- vided up to 3-fold more flux than in the absence ofNaOH.\n\nExample 24\n\n**[0417]** An in vitro skin permeation study was conducted using three hydromorphone hydrochloride transdermal sys- tems, designated Hymo-1, Hymo-2 and Hymo-3, the compo- sitions of which are set forth in Table 82. **[0418]** Round disc samples were prepared as described in the Methods section, except that the formulation was dried at a temperature of 65° C. and the discs were cut into discs having a diameter of ⁹ /16 inch. **[0419]** The theoretical percent weight for each ingredient after drying ( calculated assuming all volatile ingredients were completely removed during drying) is set forth in Table 83.\n\nTABLE 82\n\nComponent Weight and Weight Percent Based on Total Solution Weight\n\nHymo-1 Hymo-2 g(wt%) g(wt%)\n\nHydromorphone HCl 0.20 (2.8) 0.20 (2.7) DI Water 0.30 (4.1) 0.38 (5.1) NaOH 0 0.08 (1.0) Glycerin 1.25 (17.2) 1.25 (16.9) PIB adhesive 5.00 (69.0) 5.00 (67.6) (30% solid) n-Heptane 0.50 (6.9) 0.50 (6.8)\n\nHymo-3 g(wt%)\n\n0\\.20 (2.7) 0.43 (5.7) 0.13 (1.7) 1.25 (16. 7) 4.00 (66.7)\n\n0\\.50 (6.7)","pages":[{"line_numbers":[],"markdown":"**US 2009/0197849 Al**\n\n1 ). The highest pH formulation evaluated, Pax-3, provided up to 6-fold more flux than in the absence ofNaOH.\n\nExample 23\n\n**[0410]** An in vitro skin permeation study was conducted using three galanthamine hydrobromide transdermal sys- tems, designated Gala-I, Gala-2 and Gala-3, the composi- tions of which are set forth in Table 78. **[0411]** Round disc samples were prepared in a manner similar to that described in the Methods section, except that the formulation was dried at a temperature of 65° C. and the discs were cut into discs having a diameter _of9/26_ inch. **[0412]** The theoretical percent weight for each ingredient after drying ( calculated assuming all volatile ingredients were completely removed during drying) is set forth in Table 79. TABLE 78\n\nComponent Weight and Weight Percent Based on Total Solution Wei t\n\nGala-! Gala-2 Gala-3 g(wt%) g(wt%) g(wt%)\n\nGalanthamine 0.40 (4.7) 0.40 (4.6) 0.40 (4.6) HBr DI Water 0.30 (3.5) 0.34 (3.9) 0.38 (4.3) NaOH 0 0.04 (0.5) 0.08 (0.9) Glycerin 1.00 (11.6) 1.00 (11.5) 1.00 (11.4) Benzyl Alcohol 0.40 (4.7) 0.40 (4.6) 0.40 (4.6) PIB adhesive 6.00 (69.8) 6.00 (69.1) 6.00 (68.5) (30% solid) n-Heptane 0.50 (5.8) 0.50 (5.8) 0.50 (5.7)\n\nTABLE 79\n\nWeight and Theoretical Weight Percent Based on Dried Film Weight\n\nGala-! Gala-2 Gala-3 g(wt%) g(wt%) g(wt%)\n\nGalanthamine HBr 0.40 (11.1) 0.40 (11.0) 0.40 (10.9) NaOH 0 0.04 (1.1) 0.08 (2.2) Glycerin 1.00 (27.8) 1.00 (27.5) 1.00 (27.2) Benzyl Alcohol 0.40 (11.1) 0.40 (11.0) 0.40 (10.9) PIB adhesive 1.80 (50.0) 1.80 (49.5) 1.80 (48.9)\n\n**[0413]** Since galanthamine HBr is an acid addition salt of a free base, it reacts with NaOH. The concentration ofNaOH in the system after the reaction is completed depends on the amount of galanthamine HBr added. The remaining NaOH concentration after the reaction is completed is defined as the excess NaOH concentration, and was calculated as described in Example 2. The pH was measured as described in the Methods section but using a 2.4 cm ² circular patch. The pH of the galanthamine HBr patch increased from 8.73 to 10.56 when the calculated excess NaOH concentration in the dried patch was increased from 0% to 1.0%. The pH of the formu- lation without NaOH was 6.53. TABLE 80\n\nExcess NaOH Concentration (wt%) and pH\n\nExcessNaOH **Concentration** pH\n\nGala-!\n\n6\\.53\n\nGala-2\n\n**0%**\n\n8\\.73\n\nGala-3\n\n1\\.0%\n\n10\\.56\n\n### 38\n\n**Aug. 6, 2009**\n\n**[0414]** The in vitro permeation of galanthamine HBr through human cadaver skin from these discs was measured as described in the Methods. Three diffusion cells were used for each formulation. The receiver solution, 5% ethanol/95% PBS buffer (0.05 M KH2PO4 with0.15 MNaCl, pH adjusted to 6.5), was completely withdrawn and replaced with fresh receiver solution at each time point. The samples taken were analyzed by an HPLC for the concentration galanthamine HBr in the receiver solution. The cumulative amount of gal- anthamine HBr that permeated across the human cadaver skin was calculated using the measured galanthamine HBr con- centrations in the receiver solutions.\n\nTABLE 81\n\nCumulative Amount of Galanthamine HBr (mg/cm ² )\n\n**Time**\n\n6 hours 18 hours 24 hours\n\nGala-!\n\n0\\.140 0.429 0.624\n\nGala-2\n\n0\\.480 1.058 1.254\n\nGala-3\n\n0\\.475 1.412 1.750\n\n**[0415]** The cumulative amount of galanthamine HBr across human cadaver skin at 24 hours increased from 1.254 mg/cm ²\n\nto 1.750 mg/cm ² when the calculated excess NaOH concen- tration in the dried patch was increased from 0% to 1.0% as compared to 0.624 mg/cm ² for the formulation without NaOH. **[0416]** The formulation of Gala-2 provided up to 2-fold more galanthamine HBr flux than in the absence of NaOH (Gala-I). The highest pH formulation evaluated, Gala-3, pro- vided up to 3-fold more flux than in the absence ofNaOH.\n\nExample 24\n\n**[0417]** An in vitro skin permeation study was conducted using three hydromorphone hydrochloride transdermal sys- tems, designated Hymo-1, Hymo-2 and Hymo-3, the compo- sitions of which are set forth in Table 82. **[0418]** Round disc samples were prepared as described in the Methods section, except that the formulation was dried at a temperature of 65° C. and the discs were cut into discs having a diameter of ⁹ /16 inch. **[0419]** The theoretical percent weight for each ingredient after drying ( calculated assuming all volatile ingredients were completely removed during drying) is set forth in Table 83.\n\nTABLE 82\n\nComponent Weight and Weight Percent Based on Total Solution Weight\n\nHymo-1 Hymo-2 g(wt%) g(wt%)\n\nHydromorphone HCl 0.20 (2.8) 0.20 (2.7) DI Water 0.30 (4.1) 0.38 (5.1) NaOH 0 0.08 (1.0) Glycerin 1.25 (17.2) 1.25 (16.9) PIB adhesive 5.00 (69.0) 5.00 (67.6) (30% solid) n-Heptane 0.50 (6.9) 0.50 (6.8)\n\nHymo-3 g(wt%)\n\n0\\.20 (2.7) 0.43 (5.7) 0.13 (1.7) 1.25 (16. 7) 4.00 (66.7)\n\n0\\.50 (6.7)","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_087","product_type":"parse","source_file_path":"complex_header_087.pdf"},"started_at":"2026-11-12T14:55:22.572882"} {"completed_at":"2026-11-12T14:55:29.327109","latency_in_ms":3463,"output":{"example_id":"complex_table_headers/complex_header_089","grounded_pages":[],"layout_pages":[],"markdown":"Exhibit 11: Traditional and total (traditional + virtual) MVPD subscriber forecasts\n\nSource: Company reports, SNL Kagan, RBC Capital Markets estimates\n\nWe note that Disney networks are broadly well represented across vMVPDs with scale (e.g., Hulu, which DIS has operational control over), YouTube TV, Sling’s Orange package, and AT&T TV Now. While its networks are for the most part not included in Philo or Fubo, these services have fewer subscribers and are less significant to Disney’s affiliate revenue growth trajectory. A+E Networks properties on the other hand are not included on YouTube TV and lower-priced AT&T TV Now packages but are widely represented across each Sling package, Philo and Fubo.\n\nExhibit 12: Portion of U.S. cable and broadcast networks revenue represented by various tiers across vMVPDs\n\nNote: Excludes RSNs and premium networks. DIS (equity) reflects Disney including A+E networks. Analysis based on data gathered between December 2019-March 2020. CW is a JV between VIAC and T. Revenue based off SNL Kagan’s total 2019 U.S. revenue forecasts for the sum of each network across each company. LGF’s Starz property is typically available as an add-on option. Source: Company websites, SNL Kagan, RBC Capital Markets estimates\n\nAs Pay TV subscribers continue to migrate toward virtual MPVD services, the carriage of Disney’s networks on these platforms will only increase in importance.\n\n\\-4.9%\n\n\\-5.6%\n\n\\-6.4%-7.1%\n\n\\-7.7%-8.1%-8.1%-8.1%\n\n\\-4.2%\n\n\\-7.1%\n\n\\-8.1% \\-7.8%\n\n\\-1.9%\n\n\\-2.5%\n\n\\-3.1%\n\n\\-3.8%-4.2%-4.6%-4.7%-4.2%\n\n\\-1.0%\n\n\\-3.8%\n\n\\-4.2%\n\n\\-3.7%\n\n\\-10.0%\n\n\\-8.0%\n\n\\-6.0%\n\n\\-4.0%\n\n\\-2.0%\n\n0\\.0%\n\nLinear MVPDs\n\nTotal MVPDs\n\n**Y/Y % change in Pay TV subscribers**\n\n**AT&T TV Now DISH Network Hulu + Live TV YouTube TV Philo Fubo**\n\n**Network Name PLUS MAX Entertainment Sling Orange Sling Blue Sling Orange &**\n\n**Blue Hulu + Live TV YouTube TV Philo TV Standard Family Ultra**\n\nMonthly price $65 $80 $93 $30 $30 $45 $54.99 $49.99 $20 $54.99 $59.99 $79.99\n\n\\# of channels marketed +45 +60 +65 32 47 53 65+ 70+ 59 116 116 184\n\nRSNs included ☓ ✔ ☓ ☓ ✔ ✔ ✔ ✔ ☓ ✔ ✔ ✔\n\nAMCX 0% 0% 77% 74% 74% 74% 0% 100% 100% 100% 100% 100%\n\nCMCSA 95% 99% 91% 0% 81% 81% 99% 99% 0% 96% 96% 96%\n\nDIS 89% 95% 92% 63% 12% 71% 99% 95% 4% 15% 15% 15%\n\nDIS (equity) 0% 0% 79% 79% 79% 79% 79% 0% 94% 94% 94% 94%\n\nDISCA 0% 0% 75% 49% 72% 75% 80% 80% 99% 86% 86% 99%\n\nFOXA 92% 99% 89% 0% 86% 86% 96% 99% 0% 87% 87% 87%\n\nT 98% 98% 97% 87% 94% 94% 99% 97% 0% 97% 97% 99%\n\nVIAC 81% 92% 92% 4% 15% 15% 47% 47% 51% 94% 94% 99%\n\nVIAB 68% 88% 89% 8% 28% 28% 0% 0% 98% 88% 88% 99%\n\nCBS 95% 97% 95% 0% 0% 0% 100% 100% 0% 100% 100% 100%\n\n**The Walt Disney Company**\n\n**Media**\n\nApril 27, 2020 **Kutgun Maral, CFA** (212) 437-9151; kutgun.maral@rbccm.com 13","pages":[{"line_numbers":[],"markdown":"Exhibit 11: Traditional and total (traditional + virtual) MVPD subscriber forecasts\n\nSource: Company reports, SNL Kagan, RBC Capital Markets estimates\n\nWe note that Disney networks are broadly well represented across vMVPDs with scale (e.g., Hulu, which DIS has operational control over), YouTube TV, Sling’s Orange package, and AT&T TV Now. While its networks are for the most part not included in Philo or Fubo, these services have fewer subscribers and are less significant to Disney’s affiliate revenue growth trajectory. A+E Networks properties on the other hand are not included on YouTube TV and lower-priced AT&T TV Now packages but are widely represented across each Sling package, Philo and Fubo.\n\nExhibit 12: Portion of U.S. cable and broadcast networks revenue represented by various tiers across vMVPDs\n\nNote: Excludes RSNs and premium networks. DIS (equity) reflects Disney including A+E networks. Analysis based on data gathered between December 2019-March 2020. CW is a JV between VIAC and T. Revenue based off SNL Kagan’s total 2019 U.S. revenue forecasts for the sum of each network across each company. LGF’s Starz property is typically available as an add-on option. Source: Company websites, SNL Kagan, RBC Capital Markets estimates\n\nAs Pay TV subscribers continue to migrate toward virtual MPVD services, the carriage of Disney’s networks on these platforms will only increase in importance.\n\n\\-4.9%\n\n\\-5.6%\n\n\\-6.4%-7.1%\n\n\\-7.7%-8.1%-8.1%-8.1%\n\n\\-4.2%\n\n\\-7.1%\n\n\\-8.1% \\-7.8%\n\n\\-1.9%\n\n\\-2.5%\n\n\\-3.1%\n\n\\-3.8%-4.2%-4.6%-4.7%-4.2%\n\n\\-1.0%\n\n\\-3.8%\n\n\\-4.2%\n\n\\-3.7%\n\n\\-10.0%\n\n\\-8.0%\n\n\\-6.0%\n\n\\-4.0%\n\n\\-2.0%\n\n0\\.0%\n\nLinear MVPDs\n\nTotal MVPDs\n\n**Y/Y % change in Pay TV subscribers**\n\n**AT&T TV Now DISH Network Hulu + Live TV YouTube TV Philo Fubo**\n\n**Network Name PLUS MAX Entertainment Sling Orange Sling Blue Sling Orange &**\n\n**Blue Hulu + Live TV YouTube TV Philo TV Standard Family Ultra**\n\nMonthly price $65 $80 $93 $30 $30 $45 $54.99 $49.99 $20 $54.99 $59.99 $79.99\n\n\\# of channels marketed +45 +60 +65 32 47 53 65+ 70+ 59 116 116 184\n\nRSNs included ☓ ✔ ☓ ☓ ✔ ✔ ✔ ✔ ☓ ✔ ✔ ✔\n\nAMCX 0% 0% 77% 74% 74% 74% 0% 100% 100% 100% 100% 100%\n\nCMCSA 95% 99% 91% 0% 81% 81% 99% 99% 0% 96% 96% 96%\n\nDIS 89% 95% 92% 63% 12% 71% 99% 95% 4% 15% 15% 15%\n\nDIS (equity) 0% 0% 79% 79% 79% 79% 79% 0% 94% 94% 94% 94%\n\nDISCA 0% 0% 75% 49% 72% 75% 80% 80% 99% 86% 86% 99%\n\nFOXA 92% 99% 89% 0% 86% 86% 96% 99% 0% 87% 87% 87%\n\nT 98% 98% 97% 87% 94% 94% 99% 97% 0% 97% 97% 99%\n\nVIAC 81% 92% 92% 4% 15% 15% 47% 47% 51% 94% 94% 99%\n\nVIAB 68% 88% 89% 8% 28% 28% 0% 0% 98% 88% 88% 99%\n\nCBS 95% 97% 95% 0% 0% 0% 100% 100% 0% 100% 100% 100%\n\n**The Walt Disney Company**\n\n**Media**\n\nApril 27, 2020 **Kutgun Maral, CFA** (212) 437-9151; kutgun.maral@rbccm.com 13","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_089","product_type":"parse","source_file_path":"complex_header_089.pdf"},"started_at":"2026-11-12T14:55:25.863249"} {"completed_at":"2026-11-12T14:55:34.327008","latency_in_ms":1255,"output":{"example_id":"complex_table_headers/complex_header_090","grounded_pages":[],"layout_pages":[],"markdown":"**VERISK ANALYTICS, INC.**\n\n**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)**\n\nThe following table provides the Company’s revenue and operating income performance by reportable segment for the years ended December 31, as well as a reconciliation to income before income taxes for all periods presented in the accompanying consolidated statements of operations:\n\n**2012 2011 2010**\n\n**Decision Analytics**\n\n**Risk Assessment Total**\n\n**Decision Analytics**\n\n**Risk Assessment Total**\n\n**Decision Analytics**\n\n**Risk Assessment Total**\n\nRevenues . . . . . . . . . . . . . . . . $954,814 $579,506 $1,534,320 $768,479 $563,361 $1,331,840 $596,205 $542,138 $1,138,343 Expenses: Cost of revenues (exclusive of items shown separately below) . . . . . . 424,746 182,428 607,174 340,068 193,667 533,735 268,742 194,731 463,473 Selling, general and administrative . . . . . . . . . 150,413 80,946 231,359 125,938 83,531 209,469 87,384 78,990 166,374 Acquisition related liabilities adjustment . . . . — — — (3,364) — (3,364) (544) — (544) Investment income and realized (loss) gain on securities, net . . . . . . . . . — (128) (128) — (887) (887) — (400) (400)\n\nEBITDA . . . . . . . . . . . . . . . 379,655 316,260 695,915 305,837 287,050 592,887 240,623 268,817 509,440 Depreciation and amortization of fixed assets . . . . . . . . . . . . . . . . 37,093 13,531 50,624 29,608 14,219 43,827 23,956 16,772 40,728 Amortization of intangible assets . . . . . . . . . . . . . . . . 53,575 — 53,575 34,671 121 34,792 27,253 145 27,398 Investment income and realized (loss) gain on securities, net . . . . . . . . . — 128 128 — 887 887 — 400 400\n\nOperating income . . . . . . . . . . $288,987 $302,601 591,588 $241,558 $271,823 513,381 $189,414 $251,500 440,914\n\nInvestment income and realized (loss) gain on securities, net . . . . . . . . . . . 128 887 400 Interest expense . . . . . . . . . . . (72,508) (53,847) (34,664)\n\nIncome before income taxes . . . . . . . . . . . . . . . . . . $ 519,208 $ 460,421 $ 406,650\n\nCapital expenditures, including non-cash purchases of fixed assets and capital lease obligations . . . . . . . . . . . . . $ 64,747 $ 15,004 $ 79,751 $ 56,486 $ 11,890 $ 68,376 $ 32,622 $ 8,323 $ 40,945\n\n105","pages":[{"line_numbers":[],"markdown":"**VERISK ANALYTICS, INC.**\n\n**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)**\n\nThe following table provides the Company’s revenue and operating income performance by reportable segment for the years ended December 31, as well as a reconciliation to income before income taxes for all periods presented in the accompanying consolidated statements of operations:\n\n**2012 2011 2010**\n\n**Decision Analytics**\n\n**Risk Assessment Total**\n\n**Decision Analytics**\n\n**Risk Assessment Total**\n\n**Decision Analytics**\n\n**Risk Assessment Total**\n\nRevenues . . . . . . . . . . . . . . . . $954,814 $579,506 $1,534,320 $768,479 $563,361 $1,331,840 $596,205 $542,138 $1,138,343 Expenses: Cost of revenues (exclusive of items shown separately below) . . . . . . 424,746 182,428 607,174 340,068 193,667 533,735 268,742 194,731 463,473 Selling, general and administrative . . . . . . . . . 150,413 80,946 231,359 125,938 83,531 209,469 87,384 78,990 166,374 Acquisition related liabilities adjustment . . . . — — — (3,364) — (3,364) (544) — (544) Investment income and realized (loss) gain on securities, net . . . . . . . . . — (128) (128) — (887) (887) — (400) (400)\n\nEBITDA . . . . . . . . . . . . . . . 379,655 316,260 695,915 305,837 287,050 592,887 240,623 268,817 509,440 Depreciation and amortization of fixed assets . . . . . . . . . . . . . . . . 37,093 13,531 50,624 29,608 14,219 43,827 23,956 16,772 40,728 Amortization of intangible assets . . . . . . . . . . . . . . . . 53,575 — 53,575 34,671 121 34,792 27,253 145 27,398 Investment income and realized (loss) gain on securities, net . . . . . . . . . — 128 128 — 887 887 — 400 400\n\nOperating income . . . . . . . . . . $288,987 $302,601 591,588 $241,558 $271,823 513,381 $189,414 $251,500 440,914\n\nInvestment income and realized (loss) gain on securities, net . . . . . . . . . . . 128 887 400 Interest expense . . . . . . . . . . . (72,508) (53,847) (34,664)\n\nIncome before income taxes . . . . . . . . . . . . . . . . . . $ 519,208 $ 460,421 $ 406,650\n\nCapital expenditures, including non-cash purchases of fixed assets and capital lease obligations . . . . . . . . . . . . . $ 64,747 $ 15,004 $ 79,751 $ 56,486 $ 11,890 $ 68,376 $ 32,622 $ 8,323 $ 40,945\n\n105","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_090","product_type":"parse","source_file_path":"complex_header_090.pdf"},"started_at":"2026-11-12T14:55:33.071566"} {"completed_at":"2026-11-12T14:55:40.426920","latency_in_ms":1411,"output":{"example_id":"complex_table_headers/complex_header_094","grounded_pages":[],"layout_pages":[],"markdown":"AS OF JUNE 30, 2019\n\npage |\n\n## REAL ASSETS IMPACT INVESTING\n\nSINCE INCEPTION IRR & MULTIPLES BY FUND VINTAGE YEAR & ASSET CLASS\n\nNet to Limited Partners\n\n### REAL ASSETS IMPACT INVESTING\n\n18\n\n**TIMBER IMPACT INVESTING FUNDS**\n\n**VINTAGE**\n\n**YEAR**\n\n**POOLED RETURN**\n\n**(%)**\n\n**ARITHMETIC**\n\n**MEAN**\n\n**(%)**\n\n**MEDIAN**\n\n**(%)**\n\n**EQUAL-WEIGHTED POOLED RETURN**\n\n**(%)**\n\n**UPPER**\n\n**QUARTILE**\n\n**(%)**\n\n**LOWER**\n\n**QUARTILE**\n\n**(%)**\n\n**STANDARD DEVIATION**\n\n**(%) DPI RVPI TVPI**\n\n**NUMBER**\n\n**OF FUNDS**\n\n1997-2001 — — — — — — — — — — 2\n\n2002-2004 3.11 3.58 — 3.55 — — — 0.94 0.45 1.39 4\n\n2005-2007 4.05 5.44 5.56 5.36 — — — 0.86 0.60 1.46 6\n\n2008-2010 4.38 4.51 4.66 4.03 — — — 0.30 0.98 1.28 5\n\n2011-2013 — — — — — — — — — — 1\n\n2014-2017 6.06 7.55 — 5.83 — — — 0.14 1.00 1.14 3\n\n**1997-2017 4.06 5.50 4.94 5.09 7.04 4.46 3.75 0.76 0.64 1.40 21**\n\n**REAL ESTATE IMPACT INVESTING FUNDS**\n\n**VINTAGE**\n\n**YEAR**\n\n**POOLED RETURN**\n\n**(%)**\n\n**ARITHMETIC**\n\n**MEAN**\n\n**(%)**\n\n**MEDIAN**\n\n**(%)**\n\n**EQUAL-WEIGHTED POOLED RETURN**\n\n**(%)**\n\n**UPPER**\n\n**QUARTILE**\n\n**(%)**\n\n**LOWER**\n\n**QUARTILE**\n\n**(%)**\n\n**STANDARD DEVIATION**\n\n**(%) DPI RVPI TVPI**\n\n**NUMBER**\n\n**OF FUNDS**\n\n1997-2001 — — — — — — — — — — 0\n\n2002-2004 — — — — — — — — — — 1\n\n2005-2007 3.47 2.46 — 2.13 — — — 1.12 0.02 1.14 3\n\n2008-2010 -2.33 0.08 2.09 -0.06 — — — 0.30 0.58 0.88 6\n\n2011-2013 10.05 15.86 18.34 15.91 20.74 10.98 7.24 0.65 0.78 1.43 8\n\n2014-2017 5.44 9.53 — 7.85 — — — 0.21 0.91 1.12 3\n\n**1997-2017 0.86 7.28 7.59 5.13 16.66 0.83 11.59 0.60 0.43 1.04 21**\n\n**INFRASTRUCTURE IMPACT INVESTING FUNDS**\n\n**VINTAGE**\n\n**YEAR**\n\n**POOLED RETURN**\n\n**(%)**\n\n**ARITHMETIC**\n\n**MEAN**\n\n**(%)**\n\n**MEDIAN**\n\n**(%)**\n\n**EQUAL-WEIGHTED POOLED RETURN**\n\n**(%)**\n\n**UPPER**\n\n**QUARTILE**\n\n**(%)**\n\n**LOWER**\n\n**QUARTILE**\n\n**(%)**\n\n**STANDARD DEVIATION**\n\n**(%) DPI RVPI TVPI**\n\n**NUMBER**\n\n**OF FUNDS**\n\n1997-2001 — — — — — — — — — — 0\n\n2002-2004 — — — — — — — — — — 0\n\n2005-2007 -16.18 -17.97 — -15.04 — — — 0.41 0.04 0.45 4\n\n2008-2010 5.20 5.83 5.24 5.53 — — — 0.84 0.49 1.34 5\n\n2011-2013 6.82 7.47 6.60 6.49 — — — 0.67 0.60 1.28 5\n\n2014-2017 5.74 4.66 7.51 5.08 — — — 0.15 0.95 1.09 7\n\n**1997-2017 1.41 1.30 5.24 1.24 7.69 -0.66 11.98 0.60 0.47 1.07 21**\n\nNotes: Based on data compiled from 63 timber, real estate, and infrastructure funds, including fully liquidated partnerships, formed between 1997 and 2017. Internal rates of returns are net of fees, expenses and carried interest. CA research shows that most funds take at least six years to settle into their final quartile ranking, and previous to this settling they typically rank in 2-3 other quartiles; therefore fund or benchmark performance metrics from more recent vintage years may be less meaningful. Benchmarks with “—” have an insufficient number of funds in the vintage year sample to produce a meaningful return.","pages":[{"line_numbers":[],"markdown":"AS OF JUNE 30, 2019\n\npage |\n\n## REAL ASSETS IMPACT INVESTING\n\nSINCE INCEPTION IRR & MULTIPLES BY FUND VINTAGE YEAR & ASSET CLASS\n\nNet to Limited Partners\n\n### REAL ASSETS IMPACT INVESTING\n\n18\n\n**TIMBER IMPACT INVESTING FUNDS**\n\n**VINTAGE**\n\n**YEAR**\n\n**POOLED RETURN**\n\n**(%)**\n\n**ARITHMETIC**\n\n**MEAN**\n\n**(%)**\n\n**MEDIAN**\n\n**(%)**\n\n**EQUAL-WEIGHTED POOLED RETURN**\n\n**(%)**\n\n**UPPER**\n\n**QUARTILE**\n\n**(%)**\n\n**LOWER**\n\n**QUARTILE**\n\n**(%)**\n\n**STANDARD DEVIATION**\n\n**(%) DPI RVPI TVPI**\n\n**NUMBER**\n\n**OF FUNDS**\n\n1997-2001 — — — — — — — — — — 2\n\n2002-2004 3.11 3.58 — 3.55 — — — 0.94 0.45 1.39 4\n\n2005-2007 4.05 5.44 5.56 5.36 — — — 0.86 0.60 1.46 6\n\n2008-2010 4.38 4.51 4.66 4.03 — — — 0.30 0.98 1.28 5\n\n2011-2013 — — — — — — — — — — 1\n\n2014-2017 6.06 7.55 — 5.83 — — — 0.14 1.00 1.14 3\n\n**1997-2017 4.06 5.50 4.94 5.09 7.04 4.46 3.75 0.76 0.64 1.40 21**\n\n**REAL ESTATE IMPACT INVESTING FUNDS**\n\n**VINTAGE**\n\n**YEAR**\n\n**POOLED RETURN**\n\n**(%)**\n\n**ARITHMETIC**\n\n**MEAN**\n\n**(%)**\n\n**MEDIAN**\n\n**(%)**\n\n**EQUAL-WEIGHTED POOLED RETURN**\n\n**(%)**\n\n**UPPER**\n\n**QUARTILE**\n\n**(%)**\n\n**LOWER**\n\n**QUARTILE**\n\n**(%)**\n\n**STANDARD DEVIATION**\n\n**(%) DPI RVPI TVPI**\n\n**NUMBER**\n\n**OF FUNDS**\n\n1997-2001 — — — — — — — — — — 0\n\n2002-2004 — — — — — — — — — — 1\n\n2005-2007 3.47 2.46 — 2.13 — — — 1.12 0.02 1.14 3\n\n2008-2010 -2.33 0.08 2.09 -0.06 — — — 0.30 0.58 0.88 6\n\n2011-2013 10.05 15.86 18.34 15.91 20.74 10.98 7.24 0.65 0.78 1.43 8\n\n2014-2017 5.44 9.53 — 7.85 — — — 0.21 0.91 1.12 3\n\n**1997-2017 0.86 7.28 7.59 5.13 16.66 0.83 11.59 0.60 0.43 1.04 21**\n\n**INFRASTRUCTURE IMPACT INVESTING FUNDS**\n\n**VINTAGE**\n\n**YEAR**\n\n**POOLED RETURN**\n\n**(%)**\n\n**ARITHMETIC**\n\n**MEAN**\n\n**(%)**\n\n**MEDIAN**\n\n**(%)**\n\n**EQUAL-WEIGHTED POOLED RETURN**\n\n**(%)**\n\n**UPPER**\n\n**QUARTILE**\n\n**(%)**\n\n**LOWER**\n\n**QUARTILE**\n\n**(%)**\n\n**STANDARD DEVIATION**\n\n**(%) DPI RVPI TVPI**\n\n**NUMBER**\n\n**OF FUNDS**\n\n1997-2001 — — — — — — — — — — 0\n\n2002-2004 — — — — — — — — — — 0\n\n2005-2007 -16.18 -17.97 — -15.04 — — — 0.41 0.04 0.45 4\n\n2008-2010 5.20 5.83 5.24 5.53 — — — 0.84 0.49 1.34 5\n\n2011-2013 6.82 7.47 6.60 6.49 — — — 0.67 0.60 1.28 5\n\n2014-2017 5.74 4.66 7.51 5.08 — — — 0.15 0.95 1.09 7\n\n**1997-2017 1.41 1.30 5.24 1.24 7.69 -0.66 11.98 0.60 0.47 1.07 21**\n\nNotes: Based on data compiled from 63 timber, real estate, and infrastructure funds, including fully liquidated partnerships, formed between 1997 and 2017. Internal rates of returns are net of fees, expenses and carried interest. CA research shows that most funds take at least six years to settle into their final quartile ranking, and previous to this settling they typically rank in 2-3 other quartiles; therefore fund or benchmark performance metrics from more recent vintage years may be less meaningful. Benchmarks with “—” have an insufficient number of funds in the vintage year sample to produce a meaningful return.","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_094","product_type":"parse","source_file_path":"complex_header_094.pdf"},"started_at":"2026-11-12T14:55:39.014964"} {"completed_at":"2026-11-12T14:56:14.517352","latency_in_ms":1501,"output":{"example_id":"complex_table_headers/complex_header_096","grounded_pages":[],"layout_pages":[],"markdown":"**Exhibit 5**\n\n**The Wawanesa General Insurance Company**\n\n**Homeowners Multiple Peril**\n\n**Premium Trend**\n\n**_California Company-Specific Premium Trend Data_**\n\n**_HO3_**\n\n**Quarterly Data Rolling 4-Quarter Data**\n\n**Calendar YYYYQ Earned Exposures Earned Premium On-Level Earned**\n\n**Premium**\n\n**On-Level Earned**\n\n**Premium per**\n\n**Exposure**\n\n**Earned Exposures Earned Premium On-Level Earned**\n\n**Premium**\n\n**On-Level Earned**\n\n**Premium per**\n\n**Exposure**\n\n**20181** 7,922 7,176,347 12,371,356 1,562\n\n**20182** 8,182 7,482,355 12,699,979 1,552\n\n**20183** 8,457 7,873,442 13,047,208 1,543\n\n**20184** 8,533 5,931,377 9,267,627 1,086 33,095 28,463,522 47,386,171 1,432\n\n**20191** 8,455 7,542,332 11,782,122 1,393 33,627 28,829,507 46,796,936 1,392\n\n**20192** 8,731 8,310,237 12,647,017 1,448 34,176 29,657,389 46,743,974 1,368\n\n**20193** 9,134 9,086,066 13,586,039 1,487 34,854 30,870,013 47,282,805 1,357\n\n**20194** 9,478 9,576,564 14,240,140 1,502 35,798 34,515,199 52,255,318 1,460\n\n**20201** 9,298 9,493,395 14,057,891 1,512 36,640 36,466,262 54,531,087 1,488\n\n**20202** 9,179 9,512,054 13,951,769 1,520 37,088 37,668,079 55,835,839 1,505\n\n**20203** 9,004 9,692,635 13,684,554 1,520 36,959 38,274,648 55,934,354 1,513\n\n**20204** 8,811 9,874,073 13,407,956 1,522 36,292 38,572,157 55,102,170 1,518\n\n**20211** 8,488 9,681,382 12,773,122 1,505 35,482 38,760,143 53,817,401 1,517\n\n**20212** 8,421 9,764,390 12,574,595 1,493 34,724 39,012,480 52,440,227 1,510\n\n**20213** 8,318 9,875,789 12,403,359 1,491 34,037 39,195,634 51,159,032 1,503\n\n**20214** 8,136 9,930,376 12,061,865 1,483 33,362 39,251,937 49,812,942 1,493\n\n**20221** 7,840 9,832,504 11,655,895 1,487 32,715 39,403,059 48,695,715 1,488\n\n**20222** 7,810 10,124,433 11,689,190 1,497 32,104 39,763,102 47,810,309 1,489\n\n**20223** 7,785 10,359,749 11,846,491 1,522 31,571 40,247,062 47,253,441 1,497\n\n**20224** 7,697 10,464,953 11,966,904 1,555 31,132 40,781,639 47,158,479 1,515\n\n**20231** 7,477 10,350,636 11,836,394 1,583 30,768 41,299,771 47,338,978 1,539\n\n**20232** 7,447 10,482,844 11,986,155 1,610 30,405 41,658,181 47,635,943 1,567\n\n**20233** 7,293 10,376,937 11,862,714 1,627 29,913 41,675,370 47,652,165 1,593\n\n**20234** 6,956 10,117,708 11,429,345 1,643 29,172 41,328,125 47,114,607 1,615\n\n**20241** 6,651 9,875,202 10,996,695 1,653 28,346 40,852,691 46,274,908 1,633\n\n**20242** 6,553 9,901,198 10,839,292 1,654 27,452 40,271,045 45,128,046 1,644\n\n**20243** 6,762 10,399,111 11,171,105 1,652 26,922 40,293,219 44,436,437 1,651\n\n(Justify Selection and Trend Period in Filing Memorandum)\n\n**Trend** Rolling 4-Qtr Annual Trend\n\nSelected: **24 pt 2.7%** 8 pt 5.2%\n\n12 pt 4.6%\n\nTrend Period (Years) for Most Recent Year in Experience Period: 2.251 16 pt 2.8%\n\n20 pt 2.2%\n\n24 pt 2.7%\n\n**Trend Factors:**\n\n6 th Prior Year **1\\.209**\n\n5 th Prior Year **1\\.178**\n\n4 th Prior Year **1\\.148**\n\n3 rd Prior Year **1\\.118**\n\n2 nd Prior Year **1\\.089**\n\nMost Recent Year **1\\.061**\n\nStandard Exhibits Template Page 2.1 10/19/2023 Edition","pages":[{"line_numbers":[],"markdown":"**Exhibit 5**\n\n**The Wawanesa General Insurance Company**\n\n**Homeowners Multiple Peril**\n\n**Premium Trend**\n\n**_California Company-Specific Premium Trend Data_**\n\n**_HO3_**\n\n**Quarterly Data Rolling 4-Quarter Data**\n\n**Calendar YYYYQ Earned Exposures Earned Premium On-Level Earned**\n\n**Premium**\n\n**On-Level Earned**\n\n**Premium per**\n\n**Exposure**\n\n**Earned Exposures Earned Premium On-Level Earned**\n\n**Premium**\n\n**On-Level Earned**\n\n**Premium per**\n\n**Exposure**\n\n**20181** 7,922 7,176,347 12,371,356 1,562\n\n**20182** 8,182 7,482,355 12,699,979 1,552\n\n**20183** 8,457 7,873,442 13,047,208 1,543\n\n**20184** 8,533 5,931,377 9,267,627 1,086 33,095 28,463,522 47,386,171 1,432\n\n**20191** 8,455 7,542,332 11,782,122 1,393 33,627 28,829,507 46,796,936 1,392\n\n**20192** 8,731 8,310,237 12,647,017 1,448 34,176 29,657,389 46,743,974 1,368\n\n**20193** 9,134 9,086,066 13,586,039 1,487 34,854 30,870,013 47,282,805 1,357\n\n**20194** 9,478 9,576,564 14,240,140 1,502 35,798 34,515,199 52,255,318 1,460\n\n**20201** 9,298 9,493,395 14,057,891 1,512 36,640 36,466,262 54,531,087 1,488\n\n**20202** 9,179 9,512,054 13,951,769 1,520 37,088 37,668,079 55,835,839 1,505\n\n**20203** 9,004 9,692,635 13,684,554 1,520 36,959 38,274,648 55,934,354 1,513\n\n**20204** 8,811 9,874,073 13,407,956 1,522 36,292 38,572,157 55,102,170 1,518\n\n**20211** 8,488 9,681,382 12,773,122 1,505 35,482 38,760,143 53,817,401 1,517\n\n**20212** 8,421 9,764,390 12,574,595 1,493 34,724 39,012,480 52,440,227 1,510\n\n**20213** 8,318 9,875,789 12,403,359 1,491 34,037 39,195,634 51,159,032 1,503\n\n**20214** 8,136 9,930,376 12,061,865 1,483 33,362 39,251,937 49,812,942 1,493\n\n**20221** 7,840 9,832,504 11,655,895 1,487 32,715 39,403,059 48,695,715 1,488\n\n**20222** 7,810 10,124,433 11,689,190 1,497 32,104 39,763,102 47,810,309 1,489\n\n**20223** 7,785 10,359,749 11,846,491 1,522 31,571 40,247,062 47,253,441 1,497\n\n**20224** 7,697 10,464,953 11,966,904 1,555 31,132 40,781,639 47,158,479 1,515\n\n**20231** 7,477 10,350,636 11,836,394 1,583 30,768 41,299,771 47,338,978 1,539\n\n**20232** 7,447 10,482,844 11,986,155 1,610 30,405 41,658,181 47,635,943 1,567\n\n**20233** 7,293 10,376,937 11,862,714 1,627 29,913 41,675,370 47,652,165 1,593\n\n**20234** 6,956 10,117,708 11,429,345 1,643 29,172 41,328,125 47,114,607 1,615\n\n**20241** 6,651 9,875,202 10,996,695 1,653 28,346 40,852,691 46,274,908 1,633\n\n**20242** 6,553 9,901,198 10,839,292 1,654 27,452 40,271,045 45,128,046 1,644\n\n**20243** 6,762 10,399,111 11,171,105 1,652 26,922 40,293,219 44,436,437 1,651\n\n(Justify Selection and Trend Period in Filing Memorandum)\n\n**Trend** Rolling 4-Qtr Annual Trend\n\nSelected: **24 pt 2.7%** 8 pt 5.2%\n\n12 pt 4.6%\n\nTrend Period (Years) for Most Recent Year in Experience Period: 2.251 16 pt 2.8%\n\n20 pt 2.2%\n\n24 pt 2.7%\n\n**Trend Factors:**\n\n6 th Prior Year **1\\.209**\n\n5 th Prior Year **1\\.178**\n\n4 th Prior Year **1\\.148**\n\n3 rd Prior Year **1\\.118**\n\n2 nd Prior Year **1\\.089**\n\nMost Recent Year **1\\.061**\n\nStandard Exhibits Template Page 2.1 10/19/2023 Edition","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_096","product_type":"parse","source_file_path":"complex_header_096.pdf"},"started_at":"2026-11-12T14:56:13.016260"} {"completed_at":"2026-11-12T14:56:24.481279","latency_in_ms":2542,"output":{"example_id":"complex_table_headers/complex_header_097","grounded_pages":[],"layout_pages":[],"markdown":"**_ODQ SHMF \\*NRS SHN_**\n\nKZW abWdSf Y Uaef dSf a VWUdWSeWV bd \\_Sd k VgW fa abWdSf Y Uaef \\_S SYW\\_W f S V YS e dW SfWV fa Tge Wee badfXa a dWX W\\_W f' U gV Y efdSfWY U fdS eSUf a e' bSdf S k aXXeWf Tk fZW \\_bSUf aX agd V dWUf dWeba eW WXXadfe fa fZW :ZS YW WS fZUSdW UkTWdSffSU S V hWef\\_W fe fa egbbadf XgfgdW YdaifZ)\n\n**_2NRR NM KD NE TARHCH QX MC TARHCH QHDR DKC ENQ KD_**\n\nF =WTdgSdk 1' -+-/' fZW :a\\_bS k Ua\\_b WfWV fZW eS W aX fe 9dSl abWdSf a e) ;gd Y fZW kWSd W VWV ;WUW\\_TWd .,' -+-/' iW dWUadVWV S aee aX 2), T a ' aX iZ UZ /), T a dW SfWV fa fZW \\_bSUf aX Ug\\_g Sf hW XadW Y UgddW Uk fdS e Sf a aeeWe bdWh age k U gVWV SUUg\\_g SfWV afZWd Ua\\_bdWZW e hW aee)\n\nfZW eWUa V cgSdfWd aX -+-/' fZW :a\\_bS k f SfWV S b S fa eW fe dW\\_S Y JagfZ 8\\_Wd US abWdSf a e' iZ UZ iWdW U See X WV Se ZW V Xad eS W Se aX ;WUW\\_TWd .,' -+-/) ;gd Y fZW kWSd W VWV ;WUW\\_TWd .,' -+-/' iW dWUadVWV S aee aX ,)- T a ' aX iZ UZ 300 \\_ a dW SfWV fa fZW \\_bSUf aX Ug\\_g Sf hW XadW Y UgddW Uk fdS e Sf a aeeWe)\n\n**DR \\_aNOYR ERTZR a**\n\nJWW EafW ,/ aX EafWe fa fZW :a ea VSfWV = S U S JfSfW\\_W fe U gVWV GSdf ' fW\\_ 3' q= S U S JfSfW\\_W fe S V Jgbb W\\_W fSdk ;SfSr Xad \\_adW Xad\\_Sf a a agd eWY\\_W fe) NW gf lW hSd age \\_Wfd Ue fa WhS gSfW S V \\_S SYW agd dWbadfST W eWY\\_W fe' U gV Y V h VgS e eWdhWV Tk L fWV WS fZUSdW Tk \\_S ad \\_Sd Wf eWY\\_W f S V Xg V Y SddS YW\\_W f' bWab W eWdhWV Tk Fbfg\\_ WS fZ S V SV gefWV eUd bfe Xad Fbfg\\_ Ij) KZWeW \\_Wfd Ue SdW fZW \\_S Vd hWde aX dWhW gW' WSd Ye S V USeZ X aie Sf WSUZ Tge Wee) KZW \\_Wfd Ue S ea S ai \\_S SYW\\_W f S V hWefade fa WhS gSfW S V g VWdefS V Tge Wee \\_ j' U gV Y fZW WhW S V eUabW aX eWdh UWe bdah VWV fa bWab W S V bd U Y fdW Ve iZW Ua\\_bSd Y fZW \\_Wfd Ue fa dWhW gW Tk eWY\\_W f)\n\nKZW Xa ai Y fST W bdWeW fe S eg\\_\\_Sdk aX fZW dWbadfST W eWY\\_W f X S U S Xad\\_Sf a 5\n\n**8 \\_ aUR KRN\\_ 7 QRQ 6RPRZOR\\_ )$ 5UN TR**\n\n**V ZVYYV $ RePR a R\\_PR aNTR ( , ( ( ( , c & (**\n\n**DRcR bR**\n\nL fWV WS fZUSdW )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) -43'-+3 -3,'.1+ -/4'2/, ,1'3/3 1\n\nFbfg\\_ WS fZ )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) ,+0'.03 40'.,4 2,',2/ ,+'+.4 ,,\n\nFbfg\\_ e YZf )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) ,3'202 ,3'4.- ,/'03, ,20$ ,$\n\nFbfg\\_ Ij )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) ,..'-., ,,1'+32 44'22. ,2',// ,0\n\nFbfg\\_ W \\_ Sf a e ))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) /'.34$ .'2+.$ -'21+$ 131$ ,4\n\nFbfg\\_ ))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) -0-'402 --1'1.0 ,3-'213 -1'.-- ,-\n\n\\_ Sf a e )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) ,0+'332$ ,.1'.2.$ ,+3'./2$ ,/'0,/$ ,,\n\n:a ea VSfWV dWhW gWe )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) /++'-23 .2,'1-- .-/',1- -3'101 3\n\n**7N\\_ V T S\\_ Z R\\_NaV**\n\nL fWV WS fZUSdW )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) ,0'03/ ,1'/,0 ,/'.24 3.,$ 0$\n\nFbfg\\_ WS fZ )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) 2'22+ 1'01+ 1'+.- ,'-,+ ,3\n\nFbfg\\_ e YZf )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) .'+42 /'-13 .'033 ,',2,$ -2$\n\nFbfg\\_ Ij )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) 0'3.1 0',,0 /'/.1 2-, ,/\n\nFbfg\\_ ))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) ,1'2+. ,0'4/. ,/'+01 21+ 0\n\n:a ea VSfWV WSd Ye Xda\\_ abWdSf a e )))))))))))))))))))))))))))))))))))))))))))))))))) .-'-32 .-'.03 -3'/.0 2,$ p\n\n**A R\\_NaV T ZN\\_TV**\n\nL fWV WS fZUSdW )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) 0)- 0)3 0)3 +)1$\n\nFbfg\\_ WS fZ )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) 2)/ 1)4 3)0 +)0\n\nFbfg\\_ e YZf )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) ,1)0 --)0 -/)1 1)+$\n\nFbfg\\_ Ij )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) /)/ /)/ /)/ p\n\nFbfg\\_ ))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) 1)1 2)+ 2)2 +)/$\n\n:a ea VSfWV abWdSf Y \\_SdY )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) 3), 3)2 3)3 +)1$\n\n\\-3","pages":[{"line_numbers":[],"markdown":"**_ODQ SHMF \\*NRS SHN_**\n\nKZW abWdSf Y Uaef dSf a VWUdWSeWV bd \\_Sd k VgW fa abWdSf Y Uaef \\_S SYW\\_W f S V YS e dW SfWV fa Tge Wee badfXa a dWX W\\_W f' U gV Y efdSfWY U fdS eSUf a e' bSdf S k aXXeWf Tk fZW \\_bSUf aX agd V dWUf dWeba eW WXXadfe fa fZW :ZS YW WS fZUSdW UkTWdSffSU S V hWef\\_W fe fa egbbadf XgfgdW YdaifZ)\n\n**_2NRR NM KD NE TARHCH QX MC TARHCH QHDR DKC ENQ KD_**\n\nF =WTdgSdk 1' -+-/' fZW :a\\_bS k Ua\\_b WfWV fZW eS W aX fe 9dSl abWdSf a e) ;gd Y fZW kWSd W VWV ;WUW\\_TWd .,' -+-/' iW dWUadVWV S aee aX 2), T a ' aX iZ UZ /), T a dW SfWV fa fZW \\_bSUf aX Ug\\_g Sf hW XadW Y UgddW Uk fdS e Sf a aeeWe bdWh age k U gVWV SUUg\\_g SfWV afZWd Ua\\_bdWZW e hW aee)\n\nfZW eWUa V cgSdfWd aX -+-/' fZW :a\\_bS k f SfWV S b S fa eW fe dW\\_S Y JagfZ 8\\_Wd US abWdSf a e' iZ UZ iWdW U See X WV Se ZW V Xad eS W Se aX ;WUW\\_TWd .,' -+-/) ;gd Y fZW kWSd W VWV ;WUW\\_TWd .,' -+-/' iW dWUadVWV S aee aX ,)- T a ' aX iZ UZ 300 \\_ a dW SfWV fa fZW \\_bSUf aX Ug\\_g Sf hW XadW Y UgddW Uk fdS e Sf a aeeWe)\n\n**DR \\_aNOYR ERTZR a**\n\nJWW EafW ,/ aX EafWe fa fZW :a ea VSfWV = S U S JfSfW\\_W fe U gVWV GSdf ' fW\\_ 3' q= S U S JfSfW\\_W fe S V Jgbb W\\_W fSdk ;SfSr Xad \\_adW Xad\\_Sf a a agd eWY\\_W fe) NW gf lW hSd age \\_Wfd Ue fa WhS gSfW S V \\_S SYW agd dWbadfST W eWY\\_W fe' U gV Y V h VgS e eWdhWV Tk L fWV WS fZUSdW Tk \\_S ad \\_Sd Wf eWY\\_W f S V Xg V Y SddS YW\\_W f' bWab W eWdhWV Tk Fbfg\\_ WS fZ S V SV gefWV eUd bfe Xad Fbfg\\_ Ij) KZWeW \\_Wfd Ue SdW fZW \\_S Vd hWde aX dWhW gW' WSd Ye S V USeZ X aie Sf WSUZ Tge Wee) KZW \\_Wfd Ue S ea S ai \\_S SYW\\_W f S V hWefade fa WhS gSfW S V g VWdefS V Tge Wee \\_ j' U gV Y fZW WhW S V eUabW aX eWdh UWe bdah VWV fa bWab W S V bd U Y fdW Ve iZW Ua\\_bSd Y fZW \\_Wfd Ue fa dWhW gW Tk eWY\\_W f)\n\nKZW Xa ai Y fST W bdWeW fe S eg\\_\\_Sdk aX fZW dWbadfST W eWY\\_W f X S U S Xad\\_Sf a 5\n\n**8 \\_ aUR KRN\\_ 7 QRQ 6RPRZOR\\_ )$ 5UN TR**\n\n**V ZVYYV $ RePR a R\\_PR aNTR ( , ( ( ( , c & (**\n\n**DRcR bR**\n\nL fWV WS fZUSdW )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) -43'-+3 -3,'.1+ -/4'2/, ,1'3/3 1\n\nFbfg\\_ WS fZ )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) ,+0'.03 40'.,4 2,',2/ ,+'+.4 ,,\n\nFbfg\\_ e YZf )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) ,3'202 ,3'4.- ,/'03, ,20$ ,$\n\nFbfg\\_ Ij )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) ,..'-., ,,1'+32 44'22. ,2',// ,0\n\nFbfg\\_ W \\_ Sf a e ))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) /'.34$ .'2+.$ -'21+$ 131$ ,4\n\nFbfg\\_ ))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) -0-'402 --1'1.0 ,3-'213 -1'.-- ,-\n\n\\_ Sf a e )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) ,0+'332$ ,.1'.2.$ ,+3'./2$ ,/'0,/$ ,,\n\n:a ea VSfWV dWhW gWe )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) /++'-23 .2,'1-- .-/',1- -3'101 3\n\n**7N\\_ V T S\\_ Z R\\_NaV**\n\nL fWV WS fZUSdW )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) ,0'03/ ,1'/,0 ,/'.24 3.,$ 0$\n\nFbfg\\_ WS fZ )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) 2'22+ 1'01+ 1'+.- ,'-,+ ,3\n\nFbfg\\_ e YZf )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) .'+42 /'-13 .'033 ,',2,$ -2$\n\nFbfg\\_ Ij )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) 0'3.1 0',,0 /'/.1 2-, ,/\n\nFbfg\\_ ))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) ,1'2+. ,0'4/. ,/'+01 21+ 0\n\n:a ea VSfWV WSd Ye Xda\\_ abWdSf a e )))))))))))))))))))))))))))))))))))))))))))))))))) .-'-32 .-'.03 -3'/.0 2,$ p\n\n**A R\\_NaV T ZN\\_TV**\n\nL fWV WS fZUSdW )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) 0)- 0)3 0)3 +)1$\n\nFbfg\\_ WS fZ )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) 2)/ 1)4 3)0 +)0\n\nFbfg\\_ e YZf )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) ,1)0 --)0 -/)1 1)+$\n\nFbfg\\_ Ij )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) /)/ /)/ /)/ p\n\nFbfg\\_ ))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) 1)1 2)+ 2)2 +)/$\n\n:a ea VSfWV abWdSf Y \\_SdY )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))) 3), 3)2 3)3 +)1$\n\n\\-3","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_097","product_type":"parse","source_file_path":"complex_header_097.pdf"},"started_at":"2026-11-12T14:56:21.939148"} {"completed_at":"2026-11-12T14:56:29.093330","latency_in_ms":2717,"output":{"example_id":"complex_table_headers/complex_header_098","grounded_pages":[],"layout_pages":[],"markdown":"de mantenimiento\n\nInfraestructuras para el transporte con bajas emisiones: ferrocarriles y metros •\n\n### •\n\nODS 9 ODS 8 ODS 13\n\nSOLUCIÓN ÁMBITO ACTIVIDAD\n\nTAXONOMÍA EUROPEA DE ACTIVIDADES SOSTENIBLES MPACTO SOBRE LOS ODS\n\nMITIGACIÓN ADAPTACIÓN CONTAMI- NACIÓN\n\nECONOMÍA CIRCULAR AGUA BIODIVERSIDAD #1 #2 #3\n\n### TRANSPORTE\n\nActividades de construcción,\n\ninmobiliarias y de mantenimiento\n\nEstructuras de ingeniería civil a partir del\n\nuso de hormigón\n\n### •\n\nODS 8 ODS 1 ODS 9 Mantenimiento de calles, carreteras y\n\nautopistas, y peatonales\n\n### •\n\nCanales navegables, puertos, obras fluviales, puertos deportivos, esclusas, presas y diques\n\n### • •\n\nMedidas destinadas a la prevención y protección\n\ncontra inundaciones\n\n### •\n\nODS 6 ODS 11\n\nODS 7\n\nConstrucción y renovación de edificios\n\n### •\n\nODS 9\n\n### AGUA\n\nAgua,\n\nalcantarillado y saneamiento\n\nTratamiento de aguas residuales\n\nODS 13 ODS 14 ODS 12\n\nSuministro de agua de uso doméstico e industrial\n\n### • •\n\nSistemas de recogida, tratamiento y suministro de\n\nagua para el consumo humano\n\n### •\n\nDesalinización para suministro de agua potable\n\n### •\n\nTecnologías de control de fugas en los sistemas de\n\nsuministro de agua\n\n### •\n\n### CIUDADES\n\nGestión de residuos\n\nRecogida selectiva y transporte de residuos no\n\npeligrosos\n\n### • •\n\nODS 12\n\nODS 8\n\nODS 11 Recogida y transporte por separado de residuos\n\npeligrosos\n\n### •\n\nODS 9\n\nTransporte cero\n\nemisiones\n\nVehículos, material rodante y embarcaciones de\n\ntransporte hipo carbónico\n\n### • •\n\nODS 16 ODS 7 ODS 12\n\nTurismos, vehículos comerciales ligeros y vehículos\n\ncon cero emisioneS\n\n### •\n\nActividades de servicios relacionados con el servicio\n\nen aeropuertos\n\n### •\n\nEstaciones de recarga para vehículos eléctricos\n\nActividades de restauración y gestión forestal\n\nRehabilitación y restauración de los bosques\n\n### •\n\nODS 11 ODS 15 ODS 3\n\nGestión forestal\n\n### • •","pages":[{"line_numbers":[],"markdown":"de mantenimiento\n\nInfraestructuras para el transporte con bajas emisiones: ferrocarriles y metros •\n\n### •\n\nODS 9 ODS 8 ODS 13\n\nSOLUCIÓN ÁMBITO ACTIVIDAD\n\nTAXONOMÍA EUROPEA DE ACTIVIDADES SOSTENIBLES MPACTO SOBRE LOS ODS\n\nMITIGACIÓN ADAPTACIÓN CONTAMI- NACIÓN\n\nECONOMÍA CIRCULAR AGUA BIODIVERSIDAD #1 #2 #3\n\n### TRANSPORTE\n\nActividades de construcción,\n\ninmobiliarias y de mantenimiento\n\nEstructuras de ingeniería civil a partir del\n\nuso de hormigón\n\n### •\n\nODS 8 ODS 1 ODS 9 Mantenimiento de calles, carreteras y\n\nautopistas, y peatonales\n\n### •\n\nCanales navegables, puertos, obras fluviales, puertos deportivos, esclusas, presas y diques\n\n### • •\n\nMedidas destinadas a la prevención y protección\n\ncontra inundaciones\n\n### •\n\nODS 6 ODS 11\n\nODS 7\n\nConstrucción y renovación de edificios\n\n### •\n\nODS 9\n\n### AGUA\n\nAgua,\n\nalcantarillado y saneamiento\n\nTratamiento de aguas residuales\n\nODS 13 ODS 14 ODS 12\n\nSuministro de agua de uso doméstico e industrial\n\n### • •\n\nSistemas de recogida, tratamiento y suministro de\n\nagua para el consumo humano\n\n### •\n\nDesalinización para suministro de agua potable\n\n### •\n\nTecnologías de control de fugas en los sistemas de\n\nsuministro de agua\n\n### •\n\n### CIUDADES\n\nGestión de residuos\n\nRecogida selectiva y transporte de residuos no\n\npeligrosos\n\n### • •\n\nODS 12\n\nODS 8\n\nODS 11 Recogida y transporte por separado de residuos\n\npeligrosos\n\n### •\n\nODS 9\n\nTransporte cero\n\nemisiones\n\nVehículos, material rodante y embarcaciones de\n\ntransporte hipo carbónico\n\n### • •\n\nODS 16 ODS 7 ODS 12\n\nTurismos, vehículos comerciales ligeros y vehículos\n\ncon cero emisioneS\n\n### •\n\nActividades de servicios relacionados con el servicio\n\nen aeropuertos\n\n### •\n\nEstaciones de recarga para vehículos eléctricos\n\nActividades de restauración y gestión forestal\n\nRehabilitación y restauración de los bosques\n\n### •\n\nODS 11 ODS 15 ODS 3\n\nGestión forestal\n\n### • •","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_098","product_type":"parse","source_file_path":"complex_header_098.pdf"},"started_at":"2026-11-12T14:56:26.375671"} {"completed_at":"2026-11-12T14:56:32.875715","latency_in_ms":1379,"output":{"example_id":"complex_table_headers/complex_header_099","grounded_pages":[],"layout_pages":[],"markdown":"### 表 **1 : 2005** 年 **Q2** 業務收益指數 **\\#**\n\n### **Table 1 : Business Receipts Indices for Q2 2005** **\\#**\n\n2005年Q2與 2005年Q2與 2005年Q1至Q2與\n\n2005年Q1比較 2004年Q2比較 2004年Q1至Q2比較\n\nQ2 2005 Q2 2005 Q1-Q2 2005\n\ncompared with compared with compared with\n\nQ1 2005 Q2 2004 Q1-Q2 2004 (點) (百分率) (點) (百分率) (點) (百分率)\n\n服務行業 **Service Industry** (Points) (%) (Points) (%) (Points) (%)\n\n批發/零售 **Wholesale/Retail 102.3 -1.1 -1.1 +7.2 +7.6 +7.2 +7.5**\n\n細分 _breakdown_ : 批發 Wholesale 81.7 +1.3 +1.6 +6.6 +8.8 +4.8 +6.3\n\n零售 Retail 109.7 \\* -2.0 -1.8 +7.4 +7.3 +8.1 +7.9\n\n進口與出口貿易 **Import and export trades 108.5 +11.0 +11.3 +10.1 +10.3 +10.9 +11.8**\n\n飲食 **Restaurants 92.5 -3.0 -3.1 +4.0 +4.5 +4.7 +5.3**\n\n酒店 **Hotels 113.6 -0.9 -0.8 +20.8 +22.4 +21.0 +22.6**\n\n運輸 **Transport 135.1 +9.9 +7.9 +17.7 +15.1 +18.9 +17.0**\n\n其中 _within which_ : 航空運輸 Air transport 139.6 +13.1 +10.4 +26.7 +23.6 +25.7 +23.9\n\n陸上運輸 Land transport 107.3 +5.6 +5.5 +7.3 +7.3 +5.4 +5.5\n\n海運 Maritime transport 159.4 +10.5 +7.1 +13.2 +9.0 +18.9 +13.9\n\n倉庫 **Storage 83.9 +6.1 +7.8 +8.1 +10.8 +6.0 +8.0**\n\n通訊 **Communications 85.7 +2.1 +2.5 +3.5 +4.3 +3.3 +4.0**\n\n其中 _within which_ : 電訊 Telecommunications 76.2 +0.3 +0.4 +1.2 +1.6 +1.0 +1.4\n\n銀行 **Banking 114.4 +2.4 +2.1 +11.9 +11.6 +9.1 +8.7**\n\n金融(銀行除外) **Financing (except banking) 119.4 -1.2 -1.0 +11.9 +11.1 +4.7 +4.1**\n\n其中 _within which_ : 金融市場及 Financial markets 107.3 -12.4 -10.4 +2.5 +2.4 -3.4 -2.9 基金管理 服務 and fund management services\n\n保險 **Insurance 211.5 +23.3 +12.4 +26.8 +14.5 +21.5 +12.0**\n\n地產 **Real estate 116.0 +2.9 +2.6 +33.9 +41.2 +25.5 +28.6**\n\n商用服務 **Business services 97.0 +5.9 +6.5 +4.8 +5.2 +3.2 +3.5**\n\n其中 _within which_ : 專業服務 Professional services 112.3 +9.7 +9.4 +9.7 +9.5 +6.5 +6.4\n\n電影 **Film entertainment 116.4 -2.7 -2.2 +6.1 +5.6 +8.0 +7.3**\n\n服務界別 **Service Domain**\n\n旅遊、會議及 **Tourism, convention and 132.1 -4.0 -3.0 +14.1 +11.9 +16.4 +13.9**\n\n展覽服務 **exhibition services**\n\n電腦及有關服務 **Computer and information services 145.4 +22.5 +18.3 +31.1 +27.2 +23.3 +21.0**\n\n註釋: # 臨時數字(除另有註明外)。 Notes : # Provisional figures (unless otherwise specified).\n\n\\* 修訂數字。 \\* Revised figure.\n\n(2000年按季平均指數 = 100) (Quarterly average of 2000 = 100)\n\n(點) (Points)\n\n2005年\n\nIndex for\n\nQ2 2005\n\nQ2指數","pages":[{"line_numbers":[],"markdown":"### 表 **1 : 2005** 年 **Q2** 業務收益指數 **\\#**\n\n### **Table 1 : Business Receipts Indices for Q2 2005** **\\#**\n\n2005年Q2與 2005年Q2與 2005年Q1至Q2與\n\n2005年Q1比較 2004年Q2比較 2004年Q1至Q2比較\n\nQ2 2005 Q2 2005 Q1-Q2 2005\n\ncompared with compared with compared with\n\nQ1 2005 Q2 2004 Q1-Q2 2004 (點) (百分率) (點) (百分率) (點) (百分率)\n\n服務行業 **Service Industry** (Points) (%) (Points) (%) (Points) (%)\n\n批發/零售 **Wholesale/Retail 102.3 -1.1 -1.1 +7.2 +7.6 +7.2 +7.5**\n\n細分 _breakdown_ : 批發 Wholesale 81.7 +1.3 +1.6 +6.6 +8.8 +4.8 +6.3\n\n零售 Retail 109.7 \\* -2.0 -1.8 +7.4 +7.3 +8.1 +7.9\n\n進口與出口貿易 **Import and export trades 108.5 +11.0 +11.3 +10.1 +10.3 +10.9 +11.8**\n\n飲食 **Restaurants 92.5 -3.0 -3.1 +4.0 +4.5 +4.7 +5.3**\n\n酒店 **Hotels 113.6 -0.9 -0.8 +20.8 +22.4 +21.0 +22.6**\n\n運輸 **Transport 135.1 +9.9 +7.9 +17.7 +15.1 +18.9 +17.0**\n\n其中 _within which_ : 航空運輸 Air transport 139.6 +13.1 +10.4 +26.7 +23.6 +25.7 +23.9\n\n陸上運輸 Land transport 107.3 +5.6 +5.5 +7.3 +7.3 +5.4 +5.5\n\n海運 Maritime transport 159.4 +10.5 +7.1 +13.2 +9.0 +18.9 +13.9\n\n倉庫 **Storage 83.9 +6.1 +7.8 +8.1 +10.8 +6.0 +8.0**\n\n通訊 **Communications 85.7 +2.1 +2.5 +3.5 +4.3 +3.3 +4.0**\n\n其中 _within which_ : 電訊 Telecommunications 76.2 +0.3 +0.4 +1.2 +1.6 +1.0 +1.4\n\n銀行 **Banking 114.4 +2.4 +2.1 +11.9 +11.6 +9.1 +8.7**\n\n金融(銀行除外) **Financing (except banking) 119.4 -1.2 -1.0 +11.9 +11.1 +4.7 +4.1**\n\n其中 _within which_ : 金融市場及 Financial markets 107.3 -12.4 -10.4 +2.5 +2.4 -3.4 -2.9 基金管理 服務 and fund management services\n\n保險 **Insurance 211.5 +23.3 +12.4 +26.8 +14.5 +21.5 +12.0**\n\n地產 **Real estate 116.0 +2.9 +2.6 +33.9 +41.2 +25.5 +28.6**\n\n商用服務 **Business services 97.0 +5.9 +6.5 +4.8 +5.2 +3.2 +3.5**\n\n其中 _within which_ : 專業服務 Professional services 112.3 +9.7 +9.4 +9.7 +9.5 +6.5 +6.4\n\n電影 **Film entertainment 116.4 -2.7 -2.2 +6.1 +5.6 +8.0 +7.3**\n\n服務界別 **Service Domain**\n\n旅遊、會議及 **Tourism, convention and 132.1 -4.0 -3.0 +14.1 +11.9 +16.4 +13.9**\n\n展覽服務 **exhibition services**\n\n電腦及有關服務 **Computer and information services 145.4 +22.5 +18.3 +31.1 +27.2 +23.3 +21.0**\n\n註釋: # 臨時數字(除另有註明外)。 Notes : # Provisional figures (unless otherwise specified).\n\n\\* 修訂數字。 \\* Revised figure.\n\n(2000年按季平均指數 = 100) (Quarterly average of 2000 = 100)\n\n(點) (Points)\n\n2005年\n\nIndex for\n\nQ2 2005\n\nQ2指數","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_099","product_type":"parse","source_file_path":"complex_header_099.pdf"},"started_at":"2026-11-12T14:56:31.495996"} {"completed_at":"2026-11-12T14:56:43.607051","latency_in_ms":6922,"output":{"example_id":"complex_table_headers/complex_header_100","grounded_pages":[],"layout_pages":[],"markdown":"Our year 2024 This is Stora Enso Our strategy Our people Governance Shareholders Report of the Board of Directors Financial Statements Appendices\n\nParent company Stora Enso Oyj financial statements\n\nParent company income statement As at 31 December\nYear ended 31 December EUR million Note 2024 2023\nEUR million Note 2024 2023\nCurrent assets\nSales oh 2,809 Inventories 543 473\nShort-term receivables 1,296 2,257\nChanges in inventories of finished goods and work in progress + /- 25 -43 Financial securities 1007 1550\nProduction for own use 2 8 Cash in hand and at bank 764 661\nOther operating income We 858 Total current assets 3,610 4,941\nMaterials and services -1992 -1985 Total assets 13,746 14,508\nPersonnel expenses -298 -341\nDepreciation and impairment -183 -274 Equity and liabilities\nOther operating expenses -895 1,283\n2,877 3,265 Equity\nOperating profit / loss -246 -455 Share capital 1342 1342\nFinancial income and expenses 238 278 share premium 3,639 3,639\nProfit before appropriations and taxes -8 -77 Fair value reserve -9 14\nAppropriations 68 222 Invested non-restricted equity fund 633 633\nIncome tax expense 3 0 Retained earnings 751 864\nProfit for the period 57 45 Profit for the period 57 45\nTotal equity 6,421 6,537\nParent company statement of financial position\nAs at 31 December\nAccumulated appropriations 192 201\nEUR million Note 2024 2023\nObligatory provisions 25 36\nAssets ganeryP\nLiabilities\nNon-current assets\n: Non-current liabilities 3,386 4123\nIntangible assets 54 53\n. Current liabilities 3,722 3,611\nTangible assets 834 917\nTotal liabilities 7,109 7,734\nInvestments 9,250 8,596\nTotal equity and liabilities 13,746 14,508\nNon-current assets total 10,137 9,567\n\nAudited 196","pages":[{"line_numbers":[],"markdown":"Our year 2024 This is Stora Enso Our strategy Our people Governance Shareholders Report of the Board of Directors Financial Statements Appendices\n\nParent company Stora Enso Oyj financial statements\n\nParent company income statement As at 31 December\nYear ended 31 December EUR million Note 2024 2023\nEUR million Note 2024 2023\nCurrent assets\nSales oh 2,809 Inventories 543 473\nShort-term receivables 1,296 2,257\nChanges in inventories of finished goods and work in progress + /- 25 -43 Financial securities 1007 1550\nProduction for own use 2 8 Cash in hand and at bank 764 661\nOther operating income We 858 Total current assets 3,610 4,941\nMaterials and services -1992 -1985 Total assets 13,746 14,508\nPersonnel expenses -298 -341\nDepreciation and impairment -183 -274 Equity and liabilities\nOther operating expenses -895 1,283\n2,877 3,265 Equity\nOperating profit / loss -246 -455 Share capital 1342 1342\nFinancial income and expenses 238 278 share premium 3,639 3,639\nProfit before appropriations and taxes -8 -77 Fair value reserve -9 14\nAppropriations 68 222 Invested non-restricted equity fund 633 633\nIncome tax expense 3 0 Retained earnings 751 864\nProfit for the period 57 45 Profit for the period 57 45\nTotal equity 6,421 6,537\nParent company statement of financial position\nAs at 31 December\nAccumulated appropriations 192 201\nEUR million Note 2024 2023\nObligatory provisions 25 36\nAssets ganeryP\nLiabilities\nNon-current assets\n: Non-current liabilities 3,386 4123\nIntangible assets 54 53\n. Current liabilities 3,722 3,611\nTangible assets 834 917\nTotal liabilities 7,109 7,734\nInvestments 9,250 8,596\nTotal equity and liabilities 13,746 14,508\nNon-current assets total 10,137 9,567\n\nAudited 196","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_100","product_type":"parse","source_file_path":"complex_header_100.pdf"},"started_at":"2026-11-12T14:56:36.684459"} {"completed_at":"2026-11-12T14:56:47.332096","latency_in_ms":3488,"output":{"example_id":"complex_table_headers/complex_header_101","grounded_pages":[],"layout_pages":[],"markdown":"Recowery a J Ss 11\n\nNumber Neis Ne13 Nett Neo\n\nTransformation in(x+3) None None None\n\nCochrana Test C=031NS C=0.40 P<0.01 C=0.40, P<0.05 Cad. WS\n\nSource 838 OF F P ss oF F Pp 88 of F P 8s OF F P\nTreatranna Te) 40s +t 304.18 0.01 15021 1 40029 0.01 271.76 1 54 002 13.902 1 O38 O5¢\nTissue (Ti) 9s2 2 wz 0.01 0639 2 63.53 0.01 39709 2 384 «6001 1920.9 2 23 01\nTraTi 216 2 609 0.01 2831.23 2 3.59 1.01 33.947 2 o33 «6072 72017 2 1 O38\nResidual 12 & 2863.68 72 3063.1 a 17557 48\n\nTotal 63a 8 25660.8 7 7Ta7 ] S7634 53","pages":[{"line_numbers":[],"markdown":"Recowery a J Ss 11\n\nNumber Neis Ne13 Nett Neo\n\nTransformation in(x+3) None None None\n\nCochrana Test C=031NS C=0.40 P<0.01 C=0.40, P<0.05 Cad. WS\n\nSource 838 OF F P ss oF F Pp 88 of F P 8s OF F P\nTreatranna Te) 40s +t 304.18 0.01 15021 1 40029 0.01 271.76 1 54 002 13.902 1 O38 O5¢\nTissue (Ti) 9s2 2 wz 0.01 0639 2 63.53 0.01 39709 2 384 «6001 1920.9 2 23 01\nTraTi 216 2 609 0.01 2831.23 2 3.59 1.01 33.947 2 o33 «6072 72017 2 1 O38\nResidual 12 & 2863.68 72 3063.1 a 17557 48\n\nTotal 63a 8 25660.8 7 7Ta7 ] S7634 53","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_101","product_type":"parse","source_file_path":"complex_header_101.pdf"},"started_at":"2026-11-12T14:56:43.843966"} {"completed_at":"2026-11-12T14:56:51.635833","latency_in_ms":4128,"output":{"example_id":"complex_table_headers/complex_header_102","grounded_pages":[],"layout_pages":[],"markdown":"Types of hospital Before pay performance act After pay performance act\n\npayment [Period 1} (Period 2)\nn= 6,043 n= 6,350\nN hospitals Hospital ad: for a hip N. hospitals Hospi di for a hap\nfracture fracture\nN Median interquartile N Median interquartile\nrange (IQR) range (IQR)\nLocal health unet 2 268 1680 1649 23 aS71 1786 1786\nPublic and teaching 1402 2 01 } 1484 43 «\nClassified t $06 253 252 4 313 12\n\nPrivate e418 420 419 ; an","pages":[{"line_numbers":[],"markdown":"Types of hospital Before pay performance act After pay performance act\n\npayment [Period 1} (Period 2)\nn= 6,043 n= 6,350\nN hospitals Hospital ad: for a hip N. hospitals Hospi di for a hap\nfracture fracture\nN Median interquartile N Median interquartile\nrange (IQR) range (IQR)\nLocal health unet 2 268 1680 1649 23 aS71 1786 1786\nPublic and teaching 1402 2 01 } 1484 43 «\nClassified t $06 253 252 4 313 12\n\nPrivate e418 420 419 ; an","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_102","product_type":"parse","source_file_path":"complex_header_102.pdf"},"started_at":"2026-11-12T14:56:47.506867"} {"completed_at":"2026-11-12T14:57:12.837172","latency_in_ms":19012,"output":{"example_id":"complex_table_headers/complex_header_103","grounded_pages":[],"layout_pages":[],"markdown":"Bartonella Anaplasma Hemot. Mycoplasma Bvb I Sub Byb 7 Sh Bh SA2 Bk\nits ‏عن‎ GroEl 165 rONA and RNaseP IFA reciprocal titers\n\nNeg Neg Neg\n12 enum Neg A. platys Neg Neg\nBlood Neg Neg Neg A. platys Neg Neg\n012 ‏كيك‎ Neg A. platys\nBlood Neg Neg Neg Neg\n1/01 enum Neg A. platys\nBlood Neg Neg Neg A. platys Neg Neg\n202012 enum Neg A platys A. platys AL platys 16 4 7 < 16 128 2\nBlood Neg Neg Neg Neg A. platys A platys\n\n5000 enum Neg Ne weg\nBlood Neg Neg Neg Neg Neq\n\n‎serum Neg Neg Neg Neq‏ 2مظ11\n‎Blood Neg Neg Neg Neg Neg Neg‏\n\n‏وعد ‎Serum A. platys Ne‏ 2 اب5\n\n‎Neg Bh SA2 Neg Neg Neq\n\n‎210201 2\" Serum Neg ‏وعد‎ 6 2% 12 128 128 /\nBlood Neg Neg Neg Neg Neg\n2122012\" Neg Neg Neg veg\nBh SA2 Neg Neg Neg Neg\n2142012\" Neg Neg Neg\nNeg Neg Neg Neg eq","pages":[{"line_numbers":[],"markdown":"Bartonella Anaplasma Hemot. Mycoplasma Bvb I Sub Byb 7 Sh Bh SA2 Bk\nits ‏عن‎ GroEl 165 rONA and RNaseP IFA reciprocal titers\n\nNeg Neg Neg\n12 enum Neg A. platys Neg Neg\nBlood Neg Neg Neg A. platys Neg Neg\n012 ‏كيك‎ Neg A. platys\nBlood Neg Neg Neg Neg\n1/01 enum Neg A. platys\nBlood Neg Neg Neg A. platys Neg Neg\n202012 enum Neg A platys A. platys AL platys 16 4 7 < 16 128 2\nBlood Neg Neg Neg Neg A. platys A platys\n\n5000 enum Neg Ne weg\nBlood Neg Neg Neg Neg Neq\n\n‎serum Neg Neg Neg Neq‏ 2مظ11\n‎Blood Neg Neg Neg Neg Neg Neg‏\n\n‏وعد ‎Serum A. platys Ne‏ 2 اب5\n\n‎Neg Bh SA2 Neg Neg Neq\n\n‎210201 2\" Serum Neg ‏وعد‎ 6 2% 12 128 128 /\nBlood Neg Neg Neg Neg Neg\n2122012\" Neg Neg Neg veg\nBh SA2 Neg Neg Neg Neg\n2142012\" Neg Neg Neg\nNeg Neg Neg Neg eq","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_103","product_type":"parse","source_file_path":"complex_header_103.pdf"},"started_at":"2026-11-12T14:56:53.824393"} {"completed_at":"2026-11-12T14:57:13.345110","latency_in_ms":4076,"output":{"example_id":"complex_table_headers/complex_header_104","grounded_pages":[],"layout_pages":[],"markdown":"Bernese Mountain Dogs Control dogs\n& burgdorferi serology total B. burgdorfen! serology total\npositive negative positive negative\nhair color hate color\nfair dark fair = dark\n\nDoes your dog often have attached ticks?! Yes #0 1a ss t 2 7 3 3\nNo a) 33 73 t 4 24 i 40\n\nDo you perform tick prevention! Yes 82 38 w~ 2 6 2 5 36\nNo % 4 a] 0 0 7 7 14\n\nDid your dog suffer from ifectious diseases? No 62 4? 109 2 3 3 12 42\nYes is 4 \"9 0 3 s 2 10\n\nGeneral health Normal a $2 in 2 6 » 14 $2\nAbnormal ts) 0 ts) 0 i) 0 0 0\nEndurance Normal % 50 126 2 6 28 4 SO\nDecreased 4 2 6 0 0 2 0 2\n\nWeight loss No 7s 82 127 2 6 w» 14 $2\nYes 3 ! 4 0 ts) 0 0 0\nSkin marmal Yes o 48 7 ' 6 2 '4 49\nNo ] 4 iE} ' 0 2 t] 3\n\nAppetive Normal 72 50 in ' 6 w 14 SI\nDecreased s 2 7 ty) 0 0 0 0\n\nIncreased i 0 i t 0 0 t ] |\n\nThirst Normal 72 $2 124 2 6 » 14 SI\nDecreased s 0 s 0 0 i 0 !\n\nIncreased i 0 i Dy] 0 0 ci) 0\n\nVomiting No 7 52 129 2 6 » 14 SI\nYes i 0 ' 0 0 ' t) |\nCoughing No 7 52 129 2 6 ” 14 §2\nYes ts) 0 ts) 0 0 0 0 0\nUrine volume Normal 4 52 126 2 6 BI) '4 52\nDecreased i 0 i 0 0 0 0 0\n\nIncreased i 0 i ty) 0 0 0 0\nDefecation Normal 7% Ss! 7% 2 6 »” 14 82\nDiarrhea 2 ' 2 ty] 0 0 0 0\nLameness No % 3% % t 6 24 14 45\nYes s 3 s t 0 6 0 7\nFever No a 53 a 2 6 » 14 82\nYes ts) 0 ts) 0 0 0 o 0\nEdema No Si ” Si 2 6 » 14 82\nYes ts) 0 0 0 0 0 6 0","pages":[{"line_numbers":[],"markdown":"Bernese Mountain Dogs Control dogs\n& burgdorferi serology total B. burgdorfen! serology total\npositive negative positive negative\nhair color hate color\nfair dark fair = dark\n\nDoes your dog often have attached ticks?! Yes #0 1a ss t 2 7 3 3\nNo a) 33 73 t 4 24 i 40\n\nDo you perform tick prevention! Yes 82 38 w~ 2 6 2 5 36\nNo % 4 a] 0 0 7 7 14\n\nDid your dog suffer from ifectious diseases? No 62 4? 109 2 3 3 12 42\nYes is 4 \"9 0 3 s 2 10\n\nGeneral health Normal a $2 in 2 6 » 14 $2\nAbnormal ts) 0 ts) 0 i) 0 0 0\nEndurance Normal % 50 126 2 6 28 4 SO\nDecreased 4 2 6 0 0 2 0 2\n\nWeight loss No 7s 82 127 2 6 w» 14 $2\nYes 3 ! 4 0 ts) 0 0 0\nSkin marmal Yes o 48 7 ' 6 2 '4 49\nNo ] 4 iE} ' 0 2 t] 3\n\nAppetive Normal 72 50 in ' 6 w 14 SI\nDecreased s 2 7 ty) 0 0 0 0\n\nIncreased i 0 i t 0 0 t ] |\n\nThirst Normal 72 $2 124 2 6 » 14 SI\nDecreased s 0 s 0 0 i 0 !\n\nIncreased i 0 i Dy] 0 0 ci) 0\n\nVomiting No 7 52 129 2 6 » 14 SI\nYes i 0 ' 0 0 ' t) |\nCoughing No 7 52 129 2 6 ” 14 §2\nYes ts) 0 ts) 0 0 0 0 0\nUrine volume Normal 4 52 126 2 6 BI) '4 52\nDecreased i 0 i 0 0 0 0 0\n\nIncreased i 0 i ty) 0 0 0 0\nDefecation Normal 7% Ss! 7% 2 6 »” 14 82\nDiarrhea 2 ' 2 ty] 0 0 0 0\nLameness No % 3% % t 6 24 14 45\nYes s 3 s t 0 6 0 7\nFever No a 53 a 2 6 » 14 82\nYes ts) 0 ts) 0 0 0 o 0\nEdema No Si ” Si 2 6 » 14 82\nYes ts) 0 0 0 0 0 6 0","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_104","product_type":"parse","source_file_path":"complex_header_104.pdf"},"started_at":"2026-11-12T14:57:09.268877"} {"completed_at":"2026-11-12T14:57:33.966369","latency_in_ms":17991,"output":{"example_id":"complex_table_headers/complex_header_105","grounded_pages":[],"layout_pages":[],"markdown":"Days post inoculation Serum neutralizing (SN) trter\\*\nimmune groups Control groups\n\nRoute and dose of inoculation\nPcDNA3.1(+) OPV attenuated vaccine 100 wl 0.85% saline 100 pl\n\nGene gun IM\nbombardment 100 pg\n6ug 3p9 lpg 200ug 100yg 50 pg\n\n3 s 1234 244\n5 8 13\n; 4 g 0\n14 4.73 8 t\n28 r 4 3 o4\n42 549 6 1282 I S5 3 4\n\n70 14","pages":[{"line_numbers":[],"markdown":"Days post inoculation Serum neutralizing (SN) trter\\*\nimmune groups Control groups\n\nRoute and dose of inoculation\nPcDNA3.1(+) OPV attenuated vaccine 100 wl 0.85% saline 100 pl\n\nGene gun IM\nbombardment 100 pg\n6ug 3p9 lpg 200ug 100yg 50 pg\n\n3 s 1234 244\n5 8 13\n; 4 g 0\n14 4.73 8 t\n28 r 4 3 o4\n42 549 6 1282 I S5 3 4\n\n70 14","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_105","product_type":"parse","source_file_path":"complex_header_105.pdf"},"started_at":"2026-11-12T14:57:15.974673"} {"completed_at":"2026-11-12T14:57:21.431780","latency_in_ms":2361,"output":{"example_id":"complex_table_headers/complex_header_106","grounded_pages":[],"layout_pages":[],"markdown":"Aortic dilation \\* Aortic diameter and growth\n\nTumer syndrome Controls Turner syndrome\n\nBaseline Change Change rate °\n\nn= 80 n=67 n= 80 n= 80 n= 80 n= 80\n\n% % mn mm mm/year mm/yearim\\*\n\nAortic stnus ao § 792439 o+.9\"\\* o38+a? Om + as\nSimotubullar junction “3° 29 3243 04413\" 11405 aur +a3\nMid-ascending aorta “7 5 275250 16 + 14°\\* 024406 a162a\n\nDestal ascending aorta 333° 29 M3444 o1+10 Ob! +04 oo1+a\nProximal transverse aortic arch 241° 26 23433 a12ag Ob! +04 ool +02\nDistal transverse aortic arch 103 30 mS +2 g1+as iol +a4 aoa\n\nAortic isthmus 41° 20 4 3 d12+0 Dy ‘ d\nProximal descending aorta 342° 5 9$228 o1+08 OD! + 03 ub1 +02\nDistal descending aorta “re s B24 01+06 O03 + 03","pages":[{"line_numbers":[],"markdown":"Aortic dilation \\* Aortic diameter and growth\n\nTumer syndrome Controls Turner syndrome\n\nBaseline Change Change rate °\n\nn= 80 n=67 n= 80 n= 80 n= 80 n= 80\n\n% % mn mm mm/year mm/yearim\\*\n\nAortic stnus ao § 792439 o+.9\"\\* o38+a? Om + as\nSimotubullar junction “3° 29 3243 04413\" 11405 aur +a3\nMid-ascending aorta “7 5 275250 16 + 14°\\* 024406 a162a\n\nDestal ascending aorta 333° 29 M3444 o1+10 Ob! +04 oo1+a\nProximal transverse aortic arch 241° 26 23433 a12ag Ob! +04 ool +02\nDistal transverse aortic arch 103 30 mS +2 g1+as iol +a4 aoa\n\nAortic isthmus 41° 20 4 3 d12+0 Dy ‘ d\nProximal descending aorta 342° 5 9$228 o1+08 OD! + 03 ub1 +02\nDistal descending aorta “re s B24 01+06 O03 + 03","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_106","product_type":"parse","source_file_path":"complex_header_106.pdf"},"started_at":"2026-11-12T14:57:19.070182"} {"completed_at":"2026-11-12T14:55:44.131799","latency_in_ms":22802,"output":{"example_id":"complex_table_headers/complex_header_107","grounded_pages":[],"layout_pages":[],"markdown":"Nulltparous 7+\nCases Controls Cases Controls Cases Controls Cases Controls\n(n= 38] (n= 12] {п = 130) (п=76) (n=227) (n= 197} (n= 98) (n= 208)\nп (%) п (%) п (%) п (9) п [55] п (56) п (%) п 9$}\nAge at menarche (years)\n<12 #19 on 15 (12) 6 (8) We Ум 343) 14(%)\n12 - 15 № 9) 11 82) 66 В” 188 [83] 169 185) 83 485) 179 (Bo)\n15 $ 113) я 4 (5) 22 (10) 23 (12) 12 (12) 15 (4)\nEducation\nNome 1$ (39) om 24 (1% 23 39 21 (31) 99 (50) a9 (70) 164 (75\nElementary 6 (14) 21 (16) 120g 102 (45) 9 (35) 26 (27) 40 (1%)\nHigh school $113) 2? GG 44 (20) 27 (14) 3 (3) 42)\nUniversity 12 (32) om 40g 10 (4) 20) om om\nOccupation\nHousewete 20 ($3) 10 483) #2 5401 202 183] 192 (97) 39% 206 (99\nEmployed 18 47) ги” 58 (45) 22 2% 2511] $3] {1) 201)\n11129) 84) 40 (31) 16 21) % (25) 49 [25] 36 (37) $9 (28)\n152 - 156 14 (37) 217) 36 (28) 18 (24) 85 (37) 49 [25] 25 (20) $3 20)\n157 - 160 #18) я 25 1% 25 (34) 43 [19] 67 134] 1$ 115) 70 (24)\n4411) 0 24 (18) 17 22) 317) 32 (14) 18 (18) 26 (12)\nMissing 2 om $ (4) 0 0 4 [2] om 4 4) om\nBMI\n185 on on om 23} 1) $ [3] 318) 7 (3)\n185 - 249 11 129) $42) 37 2% 209 ел 693 [35] 27 128)\n25 - 299 19 1450) 7159) $2 (40) 30 (35 97 (43) 77 [393] 4041)\nen 6 па) om 36 25) 209 25 [33] 45 [23] 24 (24)\nMissing 245) ом 5 (4) 00} 412] om 4 №)","pages":[{"line_numbers":[],"markdown":"Nulltparous 7+\nCases Controls Cases Controls Cases Controls Cases Controls\n(n= 38] (n= 12] {п = 130) (п=76) (n=227) (n= 197} (n= 98) (n= 208)\nп (%) п (%) п (%) п (9) п [55] п (56) п (%) п 9$}\nAge at menarche (years)\n<12 #19 on 15 (12) 6 (8) We Ум 343) 14(%)\n12 - 15 № 9) 11 82) 66 В” 188 [83] 169 185) 83 485) 179 (Bo)\n15 $ 113) я 4 (5) 22 (10) 23 (12) 12 (12) 15 (4)\nEducation\nNome 1$ (39) om 24 (1% 23 39 21 (31) 99 (50) a9 (70) 164 (75\nElementary 6 (14) 21 (16) 120g 102 (45) 9 (35) 26 (27) 40 (1%)\nHigh school $113) 2? GG 44 (20) 27 (14) 3 (3) 42)\nUniversity 12 (32) om 40g 10 (4) 20) om om\nOccupation\nHousewete 20 ($3) 10 483) #2 5401 202 183] 192 (97) 39% 206 (99\nEmployed 18 47) ги” 58 (45) 22 2% 2511] $3] {1) 201)\n11129) 84) 40 (31) 16 21) % (25) 49 [25] 36 (37) $9 (28)\n152 - 156 14 (37) 217) 36 (28) 18 (24) 85 (37) 49 [25] 25 (20) $3 20)\n157 - 160 #18) я 25 1% 25 (34) 43 [19] 67 134] 1$ 115) 70 (24)\n4411) 0 24 (18) 17 22) 317) 32 (14) 18 (18) 26 (12)\nMissing 2 om $ (4) 0 0 4 [2] om 4 4) om\nBMI\n185 on on om 23} 1) $ [3] 318) 7 (3)\n185 - 249 11 129) $42) 37 2% 209 ел 693 [35] 27 128)\n25 - 299 19 1450) 7159) $2 (40) 30 (35 97 (43) 77 [393] 4041)\nen 6 па) om 36 25) 209 25 [33] 45 [23] 24 (24)\nMissing 245) ом 5 (4) 00} 412] om 4 №)","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_107","product_type":"parse","source_file_path":"complex_header_107.pdf"},"started_at":"2026-11-12T14:55:21.328858"} {"completed_at":"2026-11-12T14:55:20.560547","latency_in_ms":2310,"output":{"example_id":"complex_table_headers/complex_header_108","grounded_pages":[],"layout_pages":[],"markdown":"Cases Controls\n\nN=96 N=76\nCIN2 HPV+ GINS HPV+ N= 55 НРУ + НРУ.\nМ= 31 (% Methylation) N=42 М= 34\n(% Methylation) (% Methylation) {55 Methylation)\nCpG {5 рт\" mean methylation 83 83 82.7 #24\nRange } x 65 -93\nCpG fenh }\\*\\* mean Ну 33.8 №3 338 32.5\n\nRange 21-53 13-68 21-50 20-96","pages":[{"line_numbers":[],"markdown":"Cases Controls\n\nN=96 N=76\nCIN2 HPV+ GINS HPV+ N= 55 НРУ + НРУ.\nМ= 31 (% Methylation) N=42 М= 34\n(% Methylation) (% Methylation) {55 Methylation)\nCpG {5 рт\" mean methylation 83 83 82.7 #24\nRange } x 65 -93\nCpG fenh }\\*\\* mean Ну 33.8 №3 338 32.5\n\nRange 21-53 13-68 21-50 20-96","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_108","product_type":"parse","source_file_path":"complex_header_108.pdf"},"started_at":"2026-11-12T14:55:18.250166"} {"completed_at":"2026-11-12T14:55:24.839734","latency_in_ms":5088,"output":{"example_id":"complex_table_headers/complex_header_109","grounded_pages":[],"layout_pages":[],"markdown":"Body regions Reliability\nPosture indices Kappa (%A)\nGroup 1 Group 2 Group 3\n(s 2 years} (2.5 to 9.5 years} (> 10 years)\n(n=21) (n= 16) (n= 15)\nHead : Protraction OS1 (63) DAD (60) OS6 (67)\nLateral bending 0.18 (37) 0.08 (31) OD4 (25)\nActation O25 (44) ~i01 (1) 002 (23)\nCervical : > Lordasts O32 (43) —112 25) 006 (254\n< Lordosis OS1 (63) 0.43 (00) DBD (85)\nShoulders = Elevated 0.30 (48) 0.10 (33) 023 (43)\nProtracted ow 0.11 (4a) O14 (5)\nRounded O41 (71) 049 (62) O83 (28)\nScapulas © Adducted 0.28 (44) 0.26 (45) O26 (24\nAbducted 031 (49) OS9 (7\nThoracte : > Kyphoys 0.91 (93) 1.00 (100)\n Lardasts O79 (84) 063 (74)\n< lordosis = 0.15 (34) 0.05 (19) 069 (70\nPebds : Anterice tilt 0.39 (SS) 0.24 (60) O68 (74)\nPosterior tit 0.90 (63) O54 (6) 079 (35)\nKnees : Valqus Os (x) O45 (71) 04? (6)\nVarus O35 (4) O59 (6% 079 (85)\nReorvatum 0.21 (41) 023 36) O18 (34)\nFlexurn O26 (27) D0 (41) oD! 24\nFeet : < Plantar arch 0.30 (48) 0.26 (45) OAI ($5)\n> Aantararch 0.29 (47) 029 (46) DGG (74)\nValgus 043 ($7) 0.26 (45) 034 ($0)\nVarus 0.39 (SS) 0.73 (2D) 076 (2)","pages":[{"line_numbers":[],"markdown":"Body regions Reliability\nPosture indices Kappa (%A)\nGroup 1 Group 2 Group 3\n(s 2 years} (2.5 to 9.5 years} (> 10 years)\n(n=21) (n= 16) (n= 15)\nHead : Protraction OS1 (63) DAD (60) OS6 (67)\nLateral bending 0.18 (37) 0.08 (31) OD4 (25)\nActation O25 (44) ~i01 (1) 002 (23)\nCervical : > Lordasts O32 (43) —112 25) 006 (254\n< Lordosis OS1 (63) 0.43 (00) DBD (85)\nShoulders = Elevated 0.30 (48) 0.10 (33) 023 (43)\nProtracted ow 0.11 (4a) O14 (5)\nRounded O41 (71) 049 (62) O83 (28)\nScapulas © Adducted 0.28 (44) 0.26 (45) O26 (24\nAbducted 031 (49) OS9 (7\nThoracte : > Kyphoys 0.91 (93) 1.00 (100)\n Lardasts O79 (84) 063 (74)\n< lordosis = 0.15 (34) 0.05 (19) 069 (70\nPebds : Anterice tilt 0.39 (SS) 0.24 (60) O68 (74)\nPosterior tit 0.90 (63) O54 (6) 079 (35)\nKnees : Valqus Os (x) O45 (71) 04? (6)\nVarus O35 (4) O59 (6% 079 (85)\nReorvatum 0.21 (41) 023 36) O18 (34)\nFlexurn O26 (27) D0 (41) oD! 24\nFeet : < Plantar arch 0.30 (48) 0.26 (45) OAI ($5)\n> Aantararch 0.29 (47) 029 (46) DGG (74)\nValgus 043 ($7) 0.26 (45) 034 ($0)\nVarus 0.39 (SS) 0.73 (2D) 076 (2)","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_109","product_type":"parse","source_file_path":"complex_header_109.pdf"},"started_at":"2026-11-12T14:55:19.751647"} {"completed_at":"2026-11-12T14:55:27.615628","latency_in_ms":4180,"output":{"example_id":"complex_table_headers/complex_header_110","grounded_pages":[],"layout_pages":[],"markdown":"8 mid-way 8 ths mid-way\nTotal sample Girls Boys\nControl Intervention Control intervention Control intervention\nMean’ а Mean’ Ci р Mean’ Ci Mean’ а р Mean’ а Мы’ а р\nп' = 840 п' = 469 п' = 416 п! = 241 п' = 424 п' = 228\n\n558, di/d 11 012) 10 911) 9019 OS Юва 098 0609 023 14 1215] 13 (14,15) 052\n> week\n\nGroup х WS 080 ax or\nGroup х PE 081 а 92 076\n> weekend 24 (2325) 23 12124 020 21) 412423 19 02721) 008 26 12524 26 0429 100\nGroup х WS 77 a3 097\nGroup x PE 035 aa? or\nTV/DVD, hours/d 16 (1617 18 {1415} 0002 16 1519 13 02159 0001 17 пая 16 IS 00\n> week\n\nGroup х WS 0.05 935 0.03\nGroup х PE 026 983 026\n> weekend 23 (2324) 22 412123] 004 23 12224] 21 0920 0.03 24 412329 23 (224) 044\nGroup х WS 068 985 03\nGroup х PE 023 ars 0.18\nComputer/games, 12 (14 1 1012 006 10 ПИ 09 0809 0004 13 ПА 13 (214) Ол\nhours/d\n\n> week\n\nGroup х WS 0.01 908 0.02\nGroup х PE 031 934 0.73\n> weekend 16 (1617) 15 1419 0003 14 1П319Я 11) (1013) <001 19 Пя 18 0749 058\nGroup x WS 019 ars bos\nGroup х PE 014 aia 090","pages":[{"line_numbers":[],"markdown":"8 mid-way 8 ths mid-way\nTotal sample Girls Boys\nControl Intervention Control intervention Control intervention\nMean’ а Mean’ Ci р Mean’ Ci Mean’ а р Mean’ а Мы’ а р\nп' = 840 п' = 469 п' = 416 п! = 241 п' = 424 п' = 228\n\n558, di/d 11 012) 10 911) 9019 OS Юва 098 0609 023 14 1215] 13 (14,15) 052\n> week\n\nGroup х WS 080 ax or\nGroup х PE 081 а 92 076\n> weekend 24 (2325) 23 12124 020 21) 412423 19 02721) 008 26 12524 26 0429 100\nGroup х WS 77 a3 097\nGroup x PE 035 aa? or\nTV/DVD, hours/d 16 (1617 18 {1415} 0002 16 1519 13 02159 0001 17 пая 16 IS 00\n> week\n\nGroup х WS 0.05 935 0.03\nGroup х PE 026 983 026\n> weekend 23 (2324) 22 412123] 004 23 12224] 21 0920 0.03 24 412329 23 (224) 044\nGroup х WS 068 985 03\nGroup х PE 023 ars 0.18\nComputer/games, 12 (14 1 1012 006 10 ПИ 09 0809 0004 13 ПА 13 (214) Ол\nhours/d\n\n> week\n\nGroup х WS 0.01 908 0.02\nGroup х PE 031 934 0.73\n> weekend 16 (1617) 15 1419 0003 14 1П319Я 11) (1013) <001 19 Пя 18 0749 058\nGroup x WS 019 ars bos\nGroup х PE 014 aia 090","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_110","product_type":"parse","source_file_path":"complex_header_110.pdf"},"started_at":"2026-11-12T14:55:23.435479"} {"completed_at":"2026-11-12T14:55:55.873005","latency_in_ms":29662,"output":{"example_id":"complex_table_headers/complex_header_111","grounded_pages":[],"layout_pages":[],"markdown":"Absole duction (ii } of g cases (n) versus base case GNV Rel di a e) of ining cases (%)\n\nvaccination strategy versus base case GNV vaccination strategy\nDuration of protection Lifetime 32 years\nCoverage rate 50% 90% 70% 50% 90%\nVaccination strategy & c dD — F 8 c o — F\nFernale Genital warts 24568 a3! I8.674 1606 $80 4308 $43\nCervical cancer 1692 5685 aasd 3,092 14a¢ ‘8 M2 405. M22\nVulvar cancer 437 —158 38 925 28 1303 —hl2 2195 3574\nVaginal cancer 138 ~03 2% 338 116 1403 37 2382 392.2\nAnd cancer is? 192 38 978 pita) 108.6 ~43 7s) 286.4\nHead/neck cancer 305 —163 Sa4 8312 230 108.6 —SS9 1730 285.4 aS\nTotal cancers 438) -2.209 19M | 408d 1379 -9 MOL a6 1282\nMale Genital warts 2846 43,104 140 978 92 248.6 1223\nPenile cancers 145 ~124 237 358 ww 447 ~3$2 672 101.6\nAnd cancers ~119 $/6 3 v0 ~S0 132. sao\nHead/neck cancer 1669 331 2636 433) 1,206 1086 fh tis 28a\nTotal cancers -1184 i224 5,264 1609 mM? -$59 i$22 2485 $9\nFemale + Mele Genital warts a9805 -S9013 145592 230855 1485 -979 2414 382.4 1356\nTotal cancers 6,400 ~34S3 Q81S 4683 114 655 205.) 326.9","pages":[{"line_numbers":[],"markdown":"Absole duction (ii } of g cases (n) versus base case GNV Rel di a e) of ining cases (%)\n\nvaccination strategy versus base case GNV vaccination strategy\nDuration of protection Lifetime 32 years\nCoverage rate 50% 90% 70% 50% 90%\nVaccination strategy & c dD — F 8 c o — F\nFernale Genital warts 24568 a3! I8.674 1606 $80 4308 $43\nCervical cancer 1692 5685 aasd 3,092 14a¢ ‘8 M2 405. M22\nVulvar cancer 437 —158 38 925 28 1303 —hl2 2195 3574\nVaginal cancer 138 ~03 2% 338 116 1403 37 2382 392.2\nAnd cancer is? 192 38 978 pita) 108.6 ~43 7s) 286.4\nHead/neck cancer 305 —163 Sa4 8312 230 108.6 —SS9 1730 285.4 aS\nTotal cancers 438) -2.209 19M | 408d 1379 -9 MOL a6 1282\nMale Genital warts 2846 43,104 140 978 92 248.6 1223\nPenile cancers 145 ~124 237 358 ww 447 ~3$2 672 101.6\nAnd cancers ~119 $/6 3 v0 ~S0 132. sao\nHead/neck cancer 1669 331 2636 433) 1,206 1086 fh tis 28a\nTotal cancers -1184 i224 5,264 1609 mM? -$59 i$22 2485 $9\nFemale + Mele Genital warts a9805 -S9013 145592 230855 1485 -979 2414 382.4 1356\nTotal cancers 6,400 ~34S3 Q81S 4683 114 655 205.) 326.9","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_111","product_type":"parse","source_file_path":"complex_header_111.pdf"},"started_at":"2026-11-12T14:55:26.210988"} {"completed_at":"2026-11-12T14:55:36.543906","latency_in_ms":3185,"output":{"example_id":"complex_table_headers/complex_header_112","grounded_pages":[],"layout_pages":[],"markdown":"Non-RCT participants\n\nSG ts\n\nNumber of stud leting N= 68 N= 36\nQuestionnaire A\n\nstrongly disagree neutral agree gly gly disagree neutral agree strongly\n\ndisagree agree disagree agree\n\n% %\n\nin general | prefer working in smal groups” oO 0 2S sa? 328 0 147 x6 x0 14?\n| retain information much better when | work 0 0 11.9 S82 299 0 lar 412 324 118\nin a smal group\\*\\*\n| want to participate actively during lectures 0 5D xg 478 224 Oo 176 265 412 4?\nand seminars\n(like to have the material demonstrated to 15 ad 224 $3? 194 0 29 17.6 29 235\nre.\n| appreciate direct feedback from a tutor/ 0 ao 134 6s? 179 29 29 17.6 so 265\nlecturer\n| delke compukory couse components.\\*\\*\\* 18 373 433 a0 9D 88 88 m5 412 147\n| prefer to determine for myself when | study. 0 18 224 $22 239 0 29 11.8 $29 324\n| prefer to work oun the matena for mys 1s 194 as8 388 4S s9 118 382 382 s9\nTa me, small group teaching ts an extra and 164 S82 4s 134 4s 118 412 x6 mS 0\nnet essential preparation for the exam\n| prefer to start studying just before the 284 403 149 134 3D 147 412 6 176 S95\n\neam\n\n| erjoy preparing for small group tutonak. 30 1344 mg x? 60 $9 14? 234 382 118","pages":[{"line_numbers":[],"markdown":"Non-RCT participants\n\nSG ts\n\nNumber of stud leting N= 68 N= 36\nQuestionnaire A\n\nstrongly disagree neutral agree gly gly disagree neutral agree strongly\n\ndisagree agree disagree agree\n\n% %\n\nin general | prefer working in smal groups” oO 0 2S sa? 328 0 147 x6 x0 14?\n| retain information much better when | work 0 0 11.9 S82 299 0 lar 412 324 118\nin a smal group\\*\\*\n| want to participate actively during lectures 0 5D xg 478 224 Oo 176 265 412 4?\nand seminars\n(like to have the material demonstrated to 15 ad 224 $3? 194 0 29 17.6 29 235\nre.\n| appreciate direct feedback from a tutor/ 0 ao 134 6s? 179 29 29 17.6 so 265\nlecturer\n| delke compukory couse components.\\*\\*\\* 18 373 433 a0 9D 88 88 m5 412 147\n| prefer to determine for myself when | study. 0 18 224 $22 239 0 29 11.8 $29 324\n| prefer to work oun the matena for mys 1s 194 as8 388 4S s9 118 382 382 s9\nTa me, small group teaching ts an extra and 164 S82 4s 134 4s 118 412 x6 mS 0\nnet essential preparation for the exam\n| prefer to start studying just before the 284 403 149 134 3D 147 412 6 176 S95\n\neam\n\n| erjoy preparing for small group tutonak. 30 1344 mg x? 60 $9 14? 234 382 118","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_112","product_type":"parse","source_file_path":"complex_header_112.pdf"},"started_at":"2026-11-12T14:55:33.358451"} {"completed_at":"2026-11-12T14:55:42.527676","latency_in_ms":3214,"output":{"example_id":"complex_table_headers/complex_header_113","grounded_pages":[],"layout_pages":[],"markdown":"Dependent variable:\n\nGSR log10 (Prevalence2008)\nOLs Linear\nMixed effects\nModel 1 Model 2 Model 3\nSex male oss7\" 0570\"\n(0.043) (0.057)\nSeale (GEM) 0.142\" 0.189\" 0.220\"\n(0.037) (0.047) (0.042)\nSeale (TFR2010) —0.235\"\n(0.079)\nSeale (GINI) 0.022 0.027 0.003\n(0.026) (0.029) (0.017)\nlog10 (GNI2008) o211\\* o.4s9\"\"\" 0.064\n(0.083) (0.092) (0.068)\nSex male:seale (GEM) —0.354\"\"\" —0.297\"\"\"\n(0.043) (0.041)\nSex male:scale (TFR2010) 0.110\n(0.080)\nConstant —0.427 —0.878\" 0.704\"\n(0.329) (0.372) (0.279)\nObservations 4 M49 149\nRv 0.538\nAdjusted &\\* 0.519\nLog Likelihood —40.330 —2.351\nAkaike Inf. Crit. 96.660 28.703\nBayesian Inf. Crit. 120.363 64.088\nResidual Std. Error 0.210 (df= 70)\n\nwee\n\nF Statistic 27.213\" (df=3; 70)","pages":[{"line_numbers":[],"markdown":"Dependent variable:\n\nGSR log10 (Prevalence2008)\nOLs Linear\nMixed effects\nModel 1 Model 2 Model 3\nSex male oss7\" 0570\"\n(0.043) (0.057)\nSeale (GEM) 0.142\" 0.189\" 0.220\"\n(0.037) (0.047) (0.042)\nSeale (TFR2010) —0.235\"\n(0.079)\nSeale (GINI) 0.022 0.027 0.003\n(0.026) (0.029) (0.017)\nlog10 (GNI2008) o211\\* o.4s9\"\"\" 0.064\n(0.083) (0.092) (0.068)\nSex male:seale (GEM) —0.354\"\"\" —0.297\"\"\"\n(0.043) (0.041)\nSex male:scale (TFR2010) 0.110\n(0.080)\nConstant —0.427 —0.878\" 0.704\"\n(0.329) (0.372) (0.279)\nObservations 4 M49 149\nRv 0.538\nAdjusted &\\* 0.519\nLog Likelihood —40.330 —2.351\nAkaike Inf. Crit. 96.660 28.703\nBayesian Inf. Crit. 120.363 64.088\nResidual Std. Error 0.210 (df= 70)\n\nwee\n\nF Statistic 27.213\" (df=3; 70)","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_113","product_type":"parse","source_file_path":"complex_header_113.pdf"},"started_at":"2026-11-12T14:55:39.313570"} {"completed_at":"2026-11-12T14:55:48.214306","latency_in_ms":1893,"output":{"example_id":"complex_table_headers/complex_header_114","grounded_pages":[],"layout_pages":[],"markdown":"ادعتماكء\n\nNon-6.0 Age<6.0 Age>6.0\nTime Mean SD MeanSD MeanSD Mean SD\nAt diagnosis 93 76 93 98 94 12 BF 12\nt-yearfolowup 92 67 92 BF 83 11 7B 72\nyear followup 89 98 \\* 7 987 75 95\nS-year followup 69 87 88 58 79 11 76 96","pages":[{"line_numbers":[],"markdown":"— ‘i Tand2\n\nFemoral head cover\nCatterall groups 3 and 4\n\n6\\.0 Age>6.0 Age<6.0 Age>6.0\nTime Mean SD MeanSD MeanSD Mean SD\nAt diagnosis 93 76 93 98 94 12 BF 12\nt-yearfolowup 92 67 92 BF 83 11 7B 72\nyear followup 89 98 \\* 7 987 75 95\nS-year followup 69 87 88 58 79 11 76 96","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_138","product_type":"parse","source_file_path":"complex_header_138.pdf"},"started_at":"2026-11-12T14:56:13.571164"} {"completed_at":"2026-11-12T14:56:24.935432","latency_in_ms":2474,"output":{"example_id":"complex_table_headers/complex_header_139","grounded_pages":[],"layout_pages":[],"markdown":"Parameters Groups\nControl (mn = 20) Heart failure due to coronary heart disease (mn = 14)\nAfter Before After\nMean +8D Mean 280 Mean 28D Mean +80\nEF % 627 5.6 62.9 5.3 46.5 3.9 475 43\nTei index 0.41 3.8 0.41 39 0.49 5.4 0.47 38\nEIA 1.3 a3 12 0.4 09 0.3 0.85 07","pages":[{"line_numbers":[],"markdown":"Parameters Groups\nControl (mn = 20) Heart failure due to coronary heart disease (mn = 14)\nAfter Before After\nMean +8D Mean 280 Mean 28D Mean +80\nEF % 627 5.6 62.9 5.3 46.5 3.9 475 43\nTei index 0.41 3.8 0.41 39 0.49 5.4 0.47 38\nEIA 1.3 a3 12 0.4 09 0.3 0.85 07","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_139","product_type":"parse","source_file_path":"complex_header_139.pdf"},"started_at":"2026-11-12T14:56:22.461388"} {"completed_at":"2026-11-12T15:16:52.293655","latency_in_ms":3801,"output":{"example_id":"complex_table_headers/complex_header_140","grounded_pages":[],"layout_pages":[],"markdown":"Cumulative number of deaths\n\nOver 20 years (2006-2025) Over 50 years (2006-2055)\nWithout cohort effect With cohort effece Without cohort effect With cohort effect\nAge Class Va No Vi No vi No vi No\n\n0-4 74 123 68 9s 18s 308 162 29\n5-9 50 15.7 44 12.1 105 392 92 29.3\n10-19 99 19.9 as 149 179 494 ISS 36.0\n20-29 13.5 213 13 153 23.7 532 19.7 36.6\n30-39 17.0 27.1 139 1906 ng 677 275 455\n40-59 48.9 79.2 334 468 109.7 198.0 81.7 1227\n60+ 159.6 265.6 593 8546 367.7 64640 205.5 3114\nAll Ages 261.6 4410 137.9 203.2 5818 tors 375.3 6045","pages":[{"line_numbers":[],"markdown":"Cumulative number of deaths\n\nOver 20 years (2006-2025) Over 50 years (2006-2055)\nWithout cohort effect With cohort effece Without cohort effect With cohort effect\nAge Class Va No Vi No vi No vi No\n\n0-4 74 123 68 9s 18s 308 162 29\n5-9 50 15.7 44 12.1 105 392 92 29.3\n10-19 99 19.9 as 149 179 494 ISS 36.0\n20-29 13.5 213 13 153 23.7 532 19.7 36.6\n30-39 17.0 27.1 139 1906 ng 677 275 455\n40-59 48.9 79.2 334 468 109.7 198.0 81.7 1227\n60+ 159.6 265.6 593 8546 367.7 64640 205.5 3114\nAll Ages 261.6 4410 137.9 203.2 5818 tors 375.3 6045","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_140","product_type":"parse","source_file_path":"complex_header_140.pdf"},"started_at":"2026-11-12T15:16:48.492451"} {"completed_at":"2026-11-12T14:56:36.682284","latency_in_ms":3989,"output":{"example_id":"complex_table_headers/complex_header_141","grounded_pages":[],"layout_pages":[],"markdown":"Birth cohorts\\*\n\n=1925 1925-1945 19481972.\n№= 465 М= 1,587 №= 1,008\nCases Controls Cases Controls Cases Controls\nм [93 } м [93 } N (9%) м (3%) мы № [95]\nAge at reference < 0 (0.0) 000) 609 ond 39 (84) 41 25]\n35-44 0 (00) 000) 009 ond 181 (38.1) 245 [45]\n4554 0 (00) 0 (00) 154 (19.7) 164 (20.3) 243 (52.5) 259 47$]\n5544 0 (00) 600) 372 (47.7) 403 (49.3) oy 0 [20\n65-74 111 (41.9 70 (35.0) 254 (326) 240 (297) oy 0 [20\n75-84 134 (506) 112 (66.0 609 ond oy 0 (OD\n85+ 20 075) 18 (9.0) 009 ond 0 (oy 0 (bo)\nHousehold Income 95 (26.0) 63 (1.2) 74 (9.5) rr (gay 19 441) 28 (5.1)\n20,000-34,999 112 (42.4) 82 (41. 195 (25.1) 193 (23.9) 3678] 62 (11.4)\n35000-49905 28 (106) 23 (11.6) 159 (205) 157 (19.5) 56 121] 83 [152\n53000-8.999 16 (6.1) 14 (7.0) 121 (15.6) 154 (19.1) 115 (248) 130 220)\n70,000-89,000 7 (27) 7 (35) 91 (11.7) 105 (13.0) 92 (19.9) 96 [176\n>90,000 6 (23) 10 (5.0) 137 (17.6) 120 (14.9) 146 131.3) 155 286]\nBody Mass Index at referent <185 30 59 (228) 201 (25.3) 209 (27.2) 201 (25.3) 70 11$.1) 99 (18.4)\nLactation Newer 173 (65.3) 114 (57.0 $71 (73.2 569 (70.5) 284 161.3) 316 580]\nEver 92 (34.7) 86 (43.0) 209 (268) 238 (29.5) 179 (38.7) 229 (42.0)\nMenopa.nal Status Pre 0 (00) 75 94 46 (7.2 397 (88.0) 443 [875]\nPast- 265 (100.4 687 (902) 727 (924) 54 (120) 63 (125)","pages":[{"line_numbers":[],"markdown":"Birth cohorts\\*\n\n=1925 1925-1945 19481972.\n№= 465 М= 1,587 №= 1,008\nCases Controls Cases Controls Cases Controls\nм [93 } м [93 } N (9%) м (3%) мы № [95]\nAge at reference < 0 (0.0) 000) 609 ond 39 (84) 41 25]\n35-44 0 (00) 000) 009 ond 181 (38.1) 245 [45]\n4554 0 (00) 0 (00) 154 (19.7) 164 (20.3) 243 (52.5) 259 47$]\n5544 0 (00) 600) 372 (47.7) 403 (49.3) oy 0 [20\n65-74 111 (41.9 70 (35.0) 254 (326) 240 (297) oy 0 [20\n75-84 134 (506) 112 (66.0 609 ond oy 0 (OD\n85+ 20 075) 18 (9.0) 009 ond 0 (oy 0 (bo)\nHousehold Income 95 (26.0) 63 (1.2) 74 (9.5) rr (gay 19 441) 28 (5.1)\n20,000-34,999 112 (42.4) 82 (41. 195 (25.1) 193 (23.9) 3678] 62 (11.4)\n35000-49905 28 (106) 23 (11.6) 159 (205) 157 (19.5) 56 121] 83 [152\n53000-8.999 16 (6.1) 14 (7.0) 121 (15.6) 154 (19.1) 115 (248) 130 220)\n70,000-89,000 7 (27) 7 (35) 91 (11.7) 105 (13.0) 92 (19.9) 96 [176\n>90,000 6 (23) 10 (5.0) 137 (17.6) 120 (14.9) 146 131.3) 155 286]\nBody Mass Index at referent <185 30 59 (228) 201 (25.3) 209 (27.2) 201 (25.3) 70 11$.1) 99 (18.4)\nLactation Newer 173 (65.3) 114 (57.0 $71 (73.2 569 (70.5) 284 161.3) 316 580]\nEver 92 (34.7) 86 (43.0) 209 (268) 238 (29.5) 179 (38.7) 229 (42.0)\nMenopa.nal Status Pre 0 (00) 75 94 46 (7.2 397 (88.0) 443 [875]\nPast- 265 (100.4 687 (902) 727 (924) 54 (120) 63 (125)","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_141","product_type":"parse","source_file_path":"complex_header_141.pdf"},"started_at":"2026-11-12T14:56:32.692904"} {"completed_at":"2026-11-12T14:56:39.655322","latency_in_ms":2841,"output":{"example_id":"complex_table_headers/complex_header_142","grounded_pages":[],"layout_pages":[],"markdown":"20% 25% 30%\nPower Power Power\nр 4 30% 90% 80% 90% 80% 90%\n04 S49% 550 730 860 1140 1238 1642\nOS 458% 292 1060 1238 1642 1782 2364\n06 367% 1238 1642 1952 2564 2782 3692","pages":[{"line_numbers":[],"markdown":"20% 25% 30%\nPower Power Power\nр 4 30% 90% 80% 90% 80% 90%\n04 S49% 550 730 860 1140 1238 1642\nOS 458% 292 1060 1238 1642 1782 2364\n06 367% 1238 1642 1952 2564 2782 3692","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_142","product_type":"parse","source_file_path":"complex_header_142.pdf"},"started_at":"2026-11-12T14:56:36.813500"} {"completed_at":"2026-11-12T14:56:46.791542","latency_in_ms":2443,"output":{"example_id":"complex_table_headers/complex_header_143","grounded_pages":[],"layout_pages":[],"markdown":"lodine containing supplement user\n\nAll No Yes\n\nn(%) 61,904 42,329 (68.4) 19,575 (31.6)\n\nlodine intake, ng/day n % Cum% n เล \" Cum™%\n<50 674 1.1 1.1 667 1.6 7 00\n50-70 2272 3.7 4.8 2208 6.8 64 0.4\n70-100 7006 11.3 16.1 6658 22.5 348 2.1\n100-150 16.061 25.0 42.0 14,267 56.2 1794 113\n150-175 7572 12.2 $4.3 6044 70.5 1528 19.1\n175-250 14,886 24.0 78.3 8970 91.7 5916 49.3\n250-500 12,663 20.5 98.8 3463 99.9 9200 96.3\n\n=500 770 1.2 100 52 100 718 100","pages":[{"line_numbers":[],"markdown":"lodine containing supplement user\n\nAll No Yes\n\nn(%) 61,904 42,329 (68.4) 19,575 (31.6)\n\nlodine intake, ng/day n % Cum% n เล \" Cum™%\n<50 674 1.1 1.1 667 1.6 7 00\n50-70 2272 3.7 4.8 2208 6.8 64 0.4\n70-100 7006 11.3 16.1 6658 22.5 348 2.1\n100-150 16.061 25.0 42.0 14,267 56.2 1794 113\n150-175 7572 12.2 $4.3 6044 70.5 1528 19.1\n175-250 14,886 24.0 78.3 8970 91.7 5916 49.3\n250-500 12,663 20.5 98.8 3463 99.9 9200 96.3\n\n=500 770 1.2 100 52 100 718 100","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_143","product_type":"parse","source_file_path":"complex_header_143.pdf"},"started_at":"2026-11-12T14:56:44.348059"} {"completed_at":"2026-11-12T14:56:53.829416","latency_in_ms":5918,"output":{"example_id":"complex_table_headers/complex_header_144","grounded_pages":[],"layout_pages":[],"markdown":"Prmesscsicn®\n\n07\n\naay\n\naa\n\nars\n\n2 55 nmol/L\n\nReferern\n\nReferert\n\nReferer\n\nReferer\n\nReferere\n\nReferere\n\nReferer\nReferer\n\nSerum 25(0H)D\n\nCategorical\n35-55 nmol/L\n‏بر‎ 959:6\n000 55 206\n060 019% 1.92\n0463 030 5512\nOS? 022 6 1.48\n061 031 59\n1١.17 046 6١ 298\n672 039% 1.38\nO81 021 59\n\n> 35 nmol/L\n\nto\n\nto?\n\n026\nO28\n\nO62\n\nO25\n\n05\n\n08\n\n189\n\n089\n\n10\n148\n\nContinuous\n\nper 10 nmol/L decrement\n‏ليوو‎ Ped MR 9S%CI\n\n05\n003\n\n00s\n073\n\n017\nast\n\nO66 to 144\nOM to 136\n\n101 to 125\n086 to 121\n\nO97 to 1.19\n084 to 145\n\nHR\n\n113\n103\n\n108\n1s\n\nVariable\nBML, km\n< 26\n= 26\n\nLeisure time physical activity, MET-twk\n\nHAT use\nNever, past\nCurrent\nER status\nER”\nER","pages":[{"line_numbers":[],"markdown":"Prmesscsicn®\n\n07\n\naay\n\naa\n\nars\n\n2 55 nmol/L\n\nReferern\n\nReferert\n\nReferer\n\nReferer\n\nReferere\n\nReferere\n\nReferer\nReferer\n\nSerum 25(0H)D\n\nCategorical\n35-55 nmol/L\n‏بر‎ 959:6\n000 55 206\n060 019% 1.92\n0463 030 5512\nOS? 022 6 1.48\n061 031 59\n1١.17 046 6١ 298\n672 039% 1.38\nO81 021 59\n\n> 35 nmol/L\n\nto\n\nto?\n\n026\nO28\n\nO62\n\nO25\n\n05\n\n08\n\n189\n\n089\n\n10\n148\n\nContinuous\n\nper 10 nmol/L decrement\n‏ليوو‎ Ped MR 9S%CI\n\n05\n003\n\n00s\n073\n\n017\nast\n\nO66 to 144\nOM to 136\n\n101 to 125\n086 to 121\n\nO97 to 1.19\n084 to 145\n\nHR\n\n113\n103\n\n108\n1s\n\nVariable\nBML, km\n< 26\n= 26\n\nLeisure time physical activity, MET-twk\n\nHAT use\nNever, past\nCurrent\nER status\nER”\nER","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_144","product_type":"parse","source_file_path":"complex_header_144.pdf"},"started_at":"2026-11-12T14:56:47.910931"} {"completed_at":"2026-11-12T14:57:01.342078","latency_in_ms":7509,"output":{"example_id":"complex_table_headers/complex_header_145","grounded_pages":[],"layout_pages":[],"markdown":"Group А Group 8 P intergroup\nPeriod 1 temperature 38°C Period 1 temperature 36°C\nn=16 n=14\n41 M6 H6-H1 Р мита HT H6 H6-H1 Pintra H&H1\ngroup\nSAP mmHg 18 [26] 12 [189 113 [26 1 xy 12344 an 006\nDAP mmHg 58 [13] 60 1.4 [9 Sp 6.3 (104) 0055 128\nMAP mmHg ’ [15] в 1 114 os 89 [1 001 008\nHA beat/min 95 [1d #2 (18 $ 59 006 103 [23 55 [283 049 086\nLactates (гп Пи 4.1 [34 49 14 [22 28 [23 26 [20 а 3] 031 12\nМер ‹ age yoko min 047 [ о 1.3 0013 (12) 193 [081 062 [0.5 155 [0.3 004 015\nIncrease of СА se (ma. patierts} 6 4\nDecrease of CA dose го patients} 6\nFluid infusion (no. patients 5 2\nTatal volume infused [mi 3500 2500\nTherapeutic action (no. patients) 8 5","pages":[{"line_numbers":[],"markdown":"Group А Group 8 P intergroup\nPeriod 1 temperature 38°C Period 1 temperature 36°C\nn=16 n=14\n41 M6 H6-H1 Р мита HT H6 H6-H1 Pintra H&H1\ngroup\nSAP mmHg 18 [26] 12 [189 113 [26 1 xy 12344 an 006\nDAP mmHg 58 [13] 60 1.4 [9 Sp 6.3 (104) 0055 128\nMAP mmHg ’ [15] в 1 114 os 89 [1 001 008\nHA beat/min 95 [1d #2 (18 $ 59 006 103 [23 55 [283 049 086\nLactates (гп Пи 4.1 [34 49 14 [22 28 [23 26 [20 а 3] 031 12\nМер ‹ age yoko min 047 [ о 1.3 0013 (12) 193 [081 062 [0.5 155 [0.3 004 015\nIncrease of СА se (ma. patierts} 6 4\nDecrease of CA dose го patients} 6\nFluid infusion (no. patients 5 2\nTatal volume infused [mi 3500 2500\nTherapeutic action (no. patients) 8 5","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_145","product_type":"parse","source_file_path":"complex_header_145.pdf"},"started_at":"2026-11-12T14:56:53.832508"} {"completed_at":"2026-11-12T14:57:12.564355","latency_in_ms":3011,"output":{"example_id":"complex_table_headers/complex_header_146","grounded_pages":[],"layout_pages":[],"markdown":"Control Cold-shock\n\nLocus (LG)' Female Male\nWild-type, Orange, Abnormal\nNormal\nCiploid Haploid\nla’ ‏عه‎ aa} te/d or ‏اعت‎ a/c ad 03 bid 3 a\n3 GA 124/124 1 0 1 0 2 0\n‏لاتوت‎ 1 4 0 {","pages":[{"line_numbers":[],"markdown":"Control Cold-shock\n\nLocus (LG)' Female Male\nWild-type, Orange, Abnormal\nNormal\nCiploid Haploid\nla’ ‏عه‎ aa} te/d or ‏اعت‎ a/c ad 03 bid 3 a\n3 GA 124/124 1 0 1 0 2 0\n‏لاتوت‎ 1 4 0 {","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_146","product_type":"parse","source_file_path":"complex_header_146.pdf"},"started_at":"2026-11-12T14:57:09.552650"} {"completed_at":"2026-11-12T14:57:19.045879","latency_in_ms":2489,"output":{"example_id":"complex_table_headers/complex_header_147","grounded_pages":[],"layout_pages":[],"markdown":"Placebo Hormone therapy\n\nAdherence greater than 90% 72.0% (n=13,417) 66.5% (n=13,709)\nCharacteristic Has characteristic (nm) tvalue” P-value Has characteristic (nm) tvalue’ P value\nYes’ No\\* Yes’\n\nEducation after high schoo 15% (S30 1S 3 Wi. 1% (SSBB OM 134\nLuirrermt smoker t 91 Ol 7 120 if\nMammogram ever rE} rm Be ry od 42) 620% (97 2.06 1b\n\noloncscapy ewer /32% (S300 & x 66.1% (2413) b.24 181\nLaw fat diet 130% (4923 Bo “ o (8662) Ose 058\nMultivitamins 1S 2% l 92 4M 4422 65.2% (5484) 4.4 iu)\nRegular recreational physical activity 132% yf 397 a % ote 644% (4743) 241 102","pages":[{"line_numbers":[],"markdown":"Placebo Hormone therapy\n\nAdherence greater than 90% 72.0% (n=13,417) 66.5% (n=13,709)\nCharacteristic Has characteristic (nm) tvalue” P-value Has characteristic (nm) tvalue’ P value\nYes’ No\\* Yes’\n\nEducation after high schoo 15% (S30 1S 3 Wi. 1% (SSBB OM 134\nLuirrermt smoker t 91 Ol 7 120 if\nMammogram ever rE} rm Be ry od 42) 620% (97 2.06 1b\n\noloncscapy ewer /32% (S300 & x 66.1% (2413) b.24 181\nLaw fat diet 130% (4923 Bo “ o (8662) Ose 058\nMultivitamins 1S 2% l 92 4M 4422 65.2% (5484) 4.4 iu)\nRegular recreational physical activity 132% yf 397 a % ote 644% (4743) 241 102","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_147","product_type":"parse","source_file_path":"complex_header_147.pdf"},"started_at":"2026-11-12T14:57:16.556132"} {"completed_at":"2026-11-12T14:57:29.931127","latency_in_ms":9698,"output":{"example_id":"complex_table_headers/complex_header_148","grounded_pages":[],"layout_pages":[],"markdown":"У YLD\nLong-term Short-term\nMale Female Male Female Male Female Male\n\n9-4 11 450 {SO} 952 49) 2 760 1.3] 1 828 (09) 91 [204] 49 (0.02) 14 301 (7\n5-14 31 696 (6.0) 18 254 (40) 3 463 © 7) 2 704 (06) 367 (DDS) 145 (a3) 35 526 [7 4)\n252 265 (327) 33 566 (45) 27311 {3 5] 4 646 106] 1 269 019 301 (004) 280 845 (36 5]\n\n11 088 138] 18 178 (22) 3 414 04] 616 [208] 208 (dz) 125 090 (155) 21 800 (26)\n\n(124) 3 273 (0.6) 357 (DD?) 151 093) 72 032 (13 8] 22 344% 133]\n\n770 (67) 263 01] 59 (003) 14 832 [85] 6 248 131]\n\n6 309 166] 258 02| 38 (993) 6 683 24 2 031 116]\n\n382 131] - 00] - 909 1 147 34) 421 (09)\n\n490 185 159] 16 385 (05) 2 950 (0.03) 550 456 (17.8) 123 876 {35}","pages":[{"line_numbers":[],"markdown":"У YLD\nLong-term Short-term\nMale Female Male Female Male Female Male\n\n9-4 11 450 {SO} 952 49) 2 760 1.3] 1 828 (09) 91 [204] 49 (0.02) 14 301 (7\n5-14 31 696 (6.0) 18 254 (40) 3 463 © 7) 2 704 (06) 367 (DDS) 145 (a3) 35 526 [7 4)\n252 265 (327) 33 566 (45) 27311 {3 5] 4 646 106] 1 269 019 301 (004) 280 845 (36 5]\n\n11 088 138] 18 178 (22) 3 414 04] 616 [208] 208 (dz) 125 090 (155) 21 800 (26)\n\n(124) 3 273 (0.6) 357 (DD?) 151 093) 72 032 (13 8] 22 344% 133]\n\n770 (67) 263 01] 59 (003) 14 832 [85] 6 248 131]\n\n6 309 166] 258 02| 38 (993) 6 683 24 2 031 116]\n\n382 131] - 00] - 909 1 147 34) 421 (09)\n\n490 185 159] 16 385 (05) 2 950 (0.03) 550 456 (17.8) 123 876 {35}","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_148","product_type":"parse","source_file_path":"complex_header_148.pdf"},"started_at":"2026-11-12T14:57:20.232502"} {"completed_at":"2026-11-12T14:57:16.870885","latency_in_ms":4302,"output":{"example_id":"complex_table_headers/complex_header_149","grounded_pages":[],"layout_pages":[],"markdown":"Docetere™ Docetere™ Taxotere®\nName of the Product 80 mg 20 mg 80 mg\nBatch No. A7469 A8252 A7486 A8331 D6D400\nMonths before Expiry 9 14 10 16 9\nКВТ K' Мате % Impurity\n0\\.119 4.5 10-Deacetylbaccatin Ш ND ND ND ND ND\n0\\.200 83 /EPEIONeacelyk ко ND ND № ND\naccatin |!\n7-Epi-10-oxo-10-\n0\\.233 9.8 deacetylbaccatin iil ND ND ND ND ND\n0\\.425 18.6 Placebo NA NA NA NA NA\n0\\.447 19.8 Placebo NA NA NA NA NA\n0\\.827 37.4 Placebo МА МА МА МА МА\n0\\.872 39.5 Unknown 0.01 0.09 0.04 0.06 0.04\n0\\.893 40.5 2',3'-Eepidocetaxel ND ND ND ND ND\n0\\.902 40.9 Unknown 0.09 0.11 0.02 0.04 0.00\n0\\.945 42.9 2'-Epidocetaxel ND ND ND ND ND\n0\\.967 43.9 Unknown 0.03 0.05 0.03 0.01 0.12\nOxetane ring opened\n0\\.972 44.2 припуо ка ND ND № № ND\n0\\.98 44.5 Unknown 0.01 0.01 0.01 0.05 0.01\n1\\.00 45.5 Docetaxel NA NA NA NA NA\n1\\.05 47.8 10-Oxodocetaxel 0.19 0.20 0.22 0.12 0.20\n1\\.11 50.6 7'-Epidocetaxel 0.11 0.09 0.11 0.13 0.04\n1\\.14 52.0 10-Oxo-7\"-epidocetaxel 0.02 0.03 0.01 0.04 0.00\nTotel 045 045 032 045 041\n\nImpurities","pages":[{"line_numbers":[],"markdown":"Docetere™ Docetere™ Taxotere®\nName of the Product 80 mg 20 mg 80 mg\nBatch No. A7469 A8252 A7486 A8331 D6D400\nMonths before Expiry 9 14 10 16 9\nКВТ K' Мате % Impurity\n0\\.119 4.5 10-Deacetylbaccatin Ш ND ND ND ND ND\n0\\.200 83 /EPEIONeacelyk ко ND ND № ND\naccatin |!\n7-Epi-10-oxo-10-\n0\\.233 9.8 deacetylbaccatin iil ND ND ND ND ND\n0\\.425 18.6 Placebo NA NA NA NA NA\n0\\.447 19.8 Placebo NA NA NA NA NA\n0\\.827 37.4 Placebo МА МА МА МА МА\n0\\.872 39.5 Unknown 0.01 0.09 0.04 0.06 0.04\n0\\.893 40.5 2',3'-Eepidocetaxel ND ND ND ND ND\n0\\.902 40.9 Unknown 0.09 0.11 0.02 0.04 0.00\n0\\.945 42.9 2'-Epidocetaxel ND ND ND ND ND\n0\\.967 43.9 Unknown 0.03 0.05 0.03 0.01 0.12\nOxetane ring opened\n0\\.972 44.2 припуо ка ND ND № № ND\n0\\.98 44.5 Unknown 0.01 0.01 0.01 0.05 0.01\n1\\.00 45.5 Docetaxel NA NA NA NA NA\n1\\.05 47.8 10-Oxodocetaxel 0.19 0.20 0.22 0.12 0.20\n1\\.11 50.6 7'-Epidocetaxel 0.11 0.09 0.11 0.13 0.04\n1\\.14 52.0 10-Oxo-7\"-epidocetaxel 0.02 0.03 0.01 0.04 0.00\nTotel 045 045 032 045 041\n\nImpurities","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_149","product_type":"parse","source_file_path":"complex_header_149.pdf"},"started_at":"2026-11-12T14:57:12.568559"} {"completed_at":"2026-11-12T14:55:21.327649","latency_in_ms":3077,"output":{"example_id":"complex_table_headers/complex_header_150","grounded_pages":[],"layout_pages":[],"markdown":"Prevalence of vegetable and fruit breaks\\* Odds Ratio (OR) pevalue\nIntervention Comparison | Compari:\nne) i) ea\nBaseline Follow-up Basebne Follow-up\nAll Schools 19 ($0.3) 318 (22.0) 116 (454) 15? (604\nSchool Type\n\n\\* Government\n\n{140-349} 1 <001\"\n\n89 (45.0) 125 (62.8) 252 (140-397) 1 vs pvor b 323 129 a4 863 40\ncontacts at the terminus of the ring:\nech ws kau 6 18 wi 10.1 as 4? ao\n\nerch ws kau ‏بيع ت‎ 57 105 06 1000 240","pages":[{"line_numbers":[],"markdown":"Population N Response Variable Predictor Variables\n\ncomparison\nDegree of Genetic Genet Divergence Ecological Divergence\nAdmixture (%)\nTime since Devergence Cimatic Vegetation\na ilarity (9%) di larity (%)\nmtDNA distance nDNA distance\n{corrected PixY} (Du)\ncontacts around the\nring:\n\nplat ‏ت‎ vi croc 9 29 an ats a9\n‏أحام‎ a ws plat b 6 1000 86 4 825 64\npot cus plot ‏تك‎ 1 515 55 av 1000 333\n\n9 ‏ت‎ vi oreg 5 8 ‏غك‎ 68 av 13 36.)\n\nareg 65 pict 23 31 1 9١ 476\noreg c vi oneg ‏ع‎ 0 16 000 194\nareg d ws oreg ¢ 8 10 853 320\noveg f vs want @ 6 138 802 53\n‏يجبت‎ g vi wont 5 8 14 8D 290\nnant ows wont 5 9 7$0 56 1000 18\n\nmid-ring contact:\nwont > vs pvor b 323 129 a4 863 40\ncontacts at the terminus of the ring:\nech ws kau 6 18 wi 10.1 as 4? ao\n\nerch ws kau ‏بيع ت‎ 57 105 06 1000 240","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_172","product_type":"parse","source_file_path":"complex_header_172.pdf"},"started_at":"2026-11-12T14:55:21.258743"} {"completed_at":"2026-11-12T14:55:28.415884","latency_in_ms":3262,"output":{"example_id":"complex_table_headers/complex_header_173","grounded_pages":[],"layout_pages":[],"markdown":"Pyrosequencing results\n\nMedian and 108\ncalculated from\n\nmean CpG methylation\n\n16\\.98\n(10.97-38.29)\n\n47\\.14\n{1850-6287}\n\n34\\.03\n{12.42-54.83)\n\nMethylated samples\n\n34/35\n(97.1%)\n\n88/134 (657%)\n\nQMSP results\nMedian and 108\ncakulsted from PMR\nMethylated samples MGMT MGMT\\_1\nassay assay\n9/35 3.30 050\n(25.7%) (0.78-19.66) 10.29-2.57)\n10 o4\n{\n11\n37/99 9.18 5.59\n(37.4%) 1439-1781) = (1.89-12.37)\neat\n1 1 /\n10 668-1609\nox\n3 18-1 1 06\n46/134 8.33 436\n(34.3%) (3.40-18.55) (0.88-11.54)\n\nustic oligedendegior\n\non\n\nnaplastic oligoastrocy\n\nLow-grade gliomas\n\n1) grade Il\n\nNigedendrogioma\n1 grade Il\n\nNigoastro\nWHO grax\n\nLawe-grade rn\n\nInce athermise\n\n10 grade ‏اا‎\n\nshoblustoma\n\nWHO grade [Vv\n\nAll glioma samples","pages":[{"line_numbers":[],"markdown":"Pyrosequencing results\n\nMedian and 108\ncalculated from\n\nmean CpG methylation\n\n16\\.98\n(10.97-38.29)\n\n47\\.14\n{1850-6287}\n\n34\\.03\n{12.42-54.83)\n\nMethylated samples\n\n34/35\n(97.1%)\n\n88/134 (657%)\n\nQMSP results\nMedian and 108\ncakulsted from PMR\nMethylated samples MGMT MGMT\\_1\nassay assay\n9/35 3.30 050\n(25.7%) (0.78-19.66) 10.29-2.57)\n10 o4\n{\n11\n37/99 9.18 5.59\n(37.4%) 1439-1781) = (1.89-12.37)\neat\n1 1 /\n10 668-1609\nox\n3 18-1 1 06\n46/134 8.33 436\n(34.3%) (3.40-18.55) (0.88-11.54)\n\nustic oligedendegior\n\non\n\nnaplastic oligoastrocy\n\nLow-grade gliomas\n\n1) grade Il\n\nNigedendrogioma\n1 grade Il\n\nNigoastro\nWHO grax\n\nLawe-grade rn\n\nInce athermise\n\n10 grade ‏اا‎\n\nshoblustoma\n\nWHO grade [Vv\n\nAll glioma samples","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_173","product_type":"parse","source_file_path":"complex_header_173.pdf"},"started_at":"2026-11-12T14:55:25.153069"} {"completed_at":"2026-11-12T14:55:33.070409","latency_in_ms":2531,"output":{"example_id":"complex_table_headers/complex_header_174","grounded_pages":[],"layout_pages":[],"markdown":"First evakation\n\nBernese Mountain dogs (N = 53) Coraral dogs\n(N = 30)\n& burgdorferi serology\nSerology result at the second evaluation positive negative positive negative\n(N = 22) (N= 3h) (Ne@ 11) (N= 19}\nremained negative 21 (68%) 14 (74%)\nremained poskive 1S (68%) 7 (64%)\nserocomwerted\\* 7 (32%) 4 (36%)\nserorewerted\\*\\* 10 (32%) § (26%)","pages":[{"line_numbers":[],"markdown":"First evakation\n\nBernese Mountain dogs (N = 53) Coraral dogs\n(N = 30)\n& burgdorferi serology\nSerology result at the second evaluation positive negative positive negative\n(N = 22) (N= 3h) (Ne@ 11) (N= 19}\nremained negative 21 (68%) 14 (74%)\nremained poskive 1S (68%) 7 (64%)\nserocomwerted\\* 7 (32%) 4 (36%)\nserorewerted\\*\\* 10 (32%) § (26%)","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_174","product_type":"parse","source_file_path":"complex_header_174.pdf"},"started_at":"2026-11-12T14:55:30.538552"} {"completed_at":"2026-11-12T14:55:39.456434","latency_in_ms":2910,"output":{"example_id":"complex_table_headers/complex_header_175","grounded_pages":[],"layout_pages":[],"markdown":"Ethnicity Country of Totalnumber Mean age, Asthma\nbirth of patients years (sd)\n(%)\nTotal New/first C itations/ 1000 patient years\nconsultations!\n1000 patient\nyears\nUnadi 4 Unadi 4 A di\ndj i Age-ad)\nMean Mean Mean 9S%CI\nWhites UK 393,200 (78.3) 46 (23) 357 27.1 265 26.2 to 26.8\nNon-UK 12.247 (2.4) 43 (21) 29.3 198 49 23.3 to 264\nTotal 405,547 (80.7) 37 (23) 35.5 269 26.4 26.4 to 26.4\nSouth Asians UK 2,187 (0.4) 1211) 54.5 463 7 26.0 wo 43.5\nNon-UK 3,501 (0.7) 38 (16) 27.6 246 237 20.2 wo 27.3\nTotal 5,688 (1.1) 28 (1% 79 ng WA 30.3 w 305\nAfro- UK 1,428 (0.3) 19 (15) 61.2 $23 392 31.5 to 46.8\nCaribbeans\nNon-UK 1,080 (0.2) 40 (16) 28.0 220 04 14.2 to 26.5\nTotal 2,508 (0.5) 28 (1% 47.0 93 35.1 34.9 to 35.3\nOthers UK 932 (0.2) 13(13) 73.0 382 wo 186 to 43.1\nNon-UK 853 (0.2) 32 (16) 27.8 278 w3 23.20 374\nTotal 1,785 (0.4) 22 (18) 51.9 334 2748 27.7 w 28.0\nMissing 86.954 (17.3) Ml) 16.4 tia 13.4 12900 13.8\nTotal 502,482 (100) 36 (23) 35.7 23.7 24.8 24.3 to 25.2","pages":[{"line_numbers":[],"markdown":"Ethnicity Country of Totalnumber Mean age, Asthma\nbirth of patients years (sd)\n(%)\nTotal New/first C itations/ 1000 patient years\nconsultations!\n1000 patient\nyears\nUnadi 4 Unadi 4 A di\ndj i Age-ad)\nMean Mean Mean 9S%CI\nWhites UK 393,200 (78.3) 46 (23) 357 27.1 265 26.2 to 26.8\nNon-UK 12.247 (2.4) 43 (21) 29.3 198 49 23.3 to 264\nTotal 405,547 (80.7) 37 (23) 35.5 269 26.4 26.4 to 26.4\nSouth Asians UK 2,187 (0.4) 1211) 54.5 463 7 26.0 wo 43.5\nNon-UK 3,501 (0.7) 38 (16) 27.6 246 237 20.2 wo 27.3\nTotal 5,688 (1.1) 28 (1% 79 ng WA 30.3 w 305\nAfro- UK 1,428 (0.3) 19 (15) 61.2 $23 392 31.5 to 46.8\nCaribbeans\nNon-UK 1,080 (0.2) 40 (16) 28.0 220 04 14.2 to 26.5\nTotal 2,508 (0.5) 28 (1% 47.0 93 35.1 34.9 to 35.3\nOthers UK 932 (0.2) 13(13) 73.0 382 wo 186 to 43.1\nNon-UK 853 (0.2) 32 (16) 27.8 278 w3 23.20 374\nTotal 1,785 (0.4) 22 (18) 51.9 334 2748 27.7 w 28.0\nMissing 86.954 (17.3) Ml) 16.4 tia 13.4 12900 13.8\nTotal 502,482 (100) 36 (23) 35.7 23.7 24.8 24.3 to 25.2","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_175","product_type":"parse","source_file_path":"complex_header_175.pdf"},"started_at":"2026-11-12T14:55:36.545600"} {"completed_at":"2026-11-12T15:27:13.507349","latency_in_ms":3170,"output":{"example_id":"complex_table_headers/complex_header_176","grounded_pages":[],"layout_pages":[],"markdown":"CMK received\n\nSelf-test performed Self-cest not performed N = 1068\nSelf-vest result RR Corrected\n(95%) RRP\n(95XCI]\n\nPositive Negative\nN49 N= S08\n\nVisited doctor for malaria sympcoms N Yes (%) 40 2 is 1a uy\n(82) (46) [15-20] [!.4-2.0] (ty)\nDoctor's diagnosis malaria N Yes (%) nu ei 110 103 sy\n(67) () (8132) 74128) (6)\nLaboratory confirmed malaria N Yes (%) 28\\* \\\\a\\* is Ls 4°\n(es) 6) Lt) Ly (80)\nHospiralizacion for malaria N Yes (%) \\* as 1.0\n\n\\* ’\n(12) (3) (02-29) (0.23.0) (14)","pages":[{"line_numbers":[],"markdown":"CMK received\n\nSelf-test performed Self-cest not performed N = 1068\nSelf-vest result RR Corrected\n(95%) RRP\n(95XCI]\n\nPositive Negative\nN49 N= S08\n\nVisited doctor for malaria sympcoms N Yes (%) 40 2 is 1a uy\n(82) (46) [15-20] [!.4-2.0] (ty)\nDoctor's diagnosis malaria N Yes (%) nu ei 110 103 sy\n(67) () (8132) 74128) (6)\nLaboratory confirmed malaria N Yes (%) 28\\* \\\\a\\* is Ls 4°\n(es) 6) Lt) Ly (80)\nHospiralizacion for malaria N Yes (%) \\* as 1.0\n\n\\* ’\n(12) (3) (02-29) (0.23.0) (14)","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_176","product_type":"parse","source_file_path":"complex_header_176.pdf"},"started_at":"2026-11-12T15:27:10.336528"} {"completed_at":"2026-11-12T14:56:24.761586","latency_in_ms":29658,"output":{"example_id":"complex_table_headers/complex_header_177","grounded_pages":[],"layout_pages":[],"markdown":"Superior (score of 5] уз. other\n\nN 2005-2006 2006-2007 Odds Ratio 05-06 vs 06-07 2007-2008 Odds Ratio 05-06 vs 07-08\n30 78 aS\n; \\* % # %\n\nMedical Knowledge 68 & 66 5 1D (04-26) 6. 83 1.5 05-44%\nStinulates Critical Thinking 58 73 66 85 21 3-50] 55 sy 28 [1.1-74}\nОку of Didactic sesdors 43 61 67 86 39 (1.7-9 3] a] 8) 25 (1245.4)\n\nClanty of Expectations 51 64 62 > 22 (10-48 55 73 16 07-33\n\nAvailability у 63 62 23 (1.1-5.1) 62 83 23 (14-66)\n\nАрреаасна Ну 62 и -] 73 94 42 -15.3] oS 83 2.1 0855)\n\nTeaching Commemmert 55 83 74 4 3.9 (1.1-17.0) 71 95 38 [11-164\n\nFeedbock/Evahuation (WiitteryWerbal Skills) x» 4% 62 4.7 (22-104) 64 85 7.1 31-1709\n\nFeedback/Evaluation (Data Gathering’ 23 г. 49 63 42 (20-85) 54 72 64 130-135)\nPhysical Exarn)\n\nCommunication with the team ay a 68 8 4.5 (19-112) 61 81 29 (13-65)\n\nTimeliness 55 69 64 |- + 2.1 (09-47) 54 72 1.2 06-25}\n\nApped аз а Role Model 61 № 68 8 2.1 93-55] i Sy 23 S62)\n\nQuality of Bedside teaching 33 41 $? 73 39 (13-89 52 63 3.2 [1.665","pages":[{"line_numbers":[],"markdown":"Superior (score of 5] уз. other\n\nN 2005-2006 2006-2007 Odds Ratio 05-06 vs 06-07 2007-2008 Odds Ratio 05-06 vs 07-08\n30 78 aS\n; \\* % # %\n\nMedical Knowledge 68 & 66 5 1D (04-26) 6. 83 1.5 05-44%\nStinulates Critical Thinking 58 73 66 85 21 3-50] 55 sy 28 [1.1-74}\nОку of Didactic sesdors 43 61 67 86 39 (1.7-9 3] a] 8) 25 (1245.4)\n\nClanty of Expectations 51 64 62 > 22 (10-48 55 73 16 07-33\n\nAvailability у 63 62 23 (1.1-5.1) 62 83 23 (14-66)\n\nАрреаасна Ну 62 и -] 73 94 42 -15.3] oS 83 2.1 0855)\n\nTeaching Commemmert 55 83 74 4 3.9 (1.1-17.0) 71 95 38 [11-164\n\nFeedbock/Evahuation (WiitteryWerbal Skills) x» 4% 62 4.7 (22-104) 64 85 7.1 31-1709\n\nFeedback/Evaluation (Data Gathering’ 23 г. 49 63 42 (20-85) 54 72 64 130-135)\nPhysical Exarn)\n\nCommunication with the team ay a 68 8 4.5 (19-112) 61 81 29 (13-65)\n\nTimeliness 55 69 64 |- + 2.1 (09-47) 54 72 1.2 06-25}\n\nApped аз а Role Model 61 № 68 8 2.1 93-55] i Sy 23 S62)\n\nQuality of Bedside teaching 33 41 $? 73 39 (13-89 52 63 3.2 [1.665","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_177","product_type":"parse","source_file_path":"complex_header_177.pdf"},"started_at":"2026-11-12T14:55:55.103022"} {"completed_at":"2026-11-12T14:56:06.152464","latency_in_ms":2924,"output":{"example_id":"complex_table_headers/complex_header_178","grounded_pages":[],"layout_pages":[],"markdown":"Assessment of level of asthma Outcomes\ncontrol:\ndriving treatment step\nPatient preferences Quality of life Patient utilities Costs\nalrway lung asthma beliefs about adherence adherence patient generk asthma patient asthma \\_— societal health care +\ninflammation function control medicines statisfaction related perspective related other costs\nFeo FEV, aca IPQ MARS 6MQ FACCT S =6AQLO Tro ASUI £Q-5D CostQ\nBaseline x x » x x x g x x x x x x\nUnplanned f x x ¥\nvisit\n3 months f « x ’\n6 months [ x x x x x x x x .\n3 months f x\n\n12 months","pages":[{"line_numbers":[],"markdown":"Assessment of level of asthma Outcomes\ncontrol:\ndriving treatment step\nPatient preferences Quality of life Patient utilities Costs\nalrway lung asthma beliefs about adherence adherence patient generk asthma patient asthma \\_— societal health care +\ninflammation function control medicines statisfaction related perspective related other costs\nFeo FEV, aca IPQ MARS 6MQ FACCT S =6AQLO Tro ASUI £Q-5D CostQ\nBaseline x x » x x x g x x x x x x\nUnplanned f x x ¥\nvisit\n3 months f « x ’\n6 months [ x x x x x x x x .\n3 months f x\n\n12 months","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_178","product_type":"parse","source_file_path":"complex_header_178.pdf"},"started_at":"2026-11-12T14:56:03.228309"} {"completed_at":"2026-11-12T14:56:30.850083","latency_in_ms":22238,"output":{"example_id":"complex_table_headers/complex_header_179","grounded_pages":[],"layout_pages":[],"markdown":"TIME IN-HOURS AFTER VR GPS NON VR GPS\nPERIOD HOURS\n(POPULA\nNot \"UNSOCIABLE” \"UNSOCIABLE\"HOURS NOT\"UNSOCIABLE\" “UNSOCIASLE” HOURS\nHOURS HOURS\nNot CON CON NOT CON CON NOT CON CON Not CON CON\nROOMS ROOMS ROOMS ROOMS ROOMS ROOMS ROOMS ROOMS\n' 2 601 602 97 98 on 698\nOr57/5ep58 4025.3 30.0 118 42 206 07 78 22 19 02\n(16.344730)\nOrt58/5ep39 3975.5 25.2 114 4.1 24 os 64 is 23 o\n(16.517.748)\nOQrt5%/Sep20 38717 23.0 16.7 a9 10 io 63 13 24 24\n\n(16.639.060)","pages":[{"line_numbers":[],"markdown":"TIME IN-HOURS AFTER VR GPS NON VR GPS\nPERIOD HOURS\n(POPULA\nNot \"UNSOCIABLE” \"UNSOCIABLE\"HOURS NOT\"UNSOCIABLE\" “UNSOCIASLE” HOURS\nHOURS HOURS\nNot CON CON NOT CON CON NOT CON CON Not CON CON\nROOMS ROOMS ROOMS ROOMS ROOMS ROOMS ROOMS ROOMS\n' 2 601 602 97 98 on 698\nOr57/5ep58 4025.3 30.0 118 42 206 07 78 22 19 02\n(16.344730)\nOrt58/5ep39 3975.5 25.2 114 4.1 24 os 64 is 23 o\n(16.517.748)\nOQrt5%/Sep20 38717 23.0 16.7 a9 10 io 63 13 24 24\n\n(16.639.060)","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_179","product_type":"parse","source_file_path":"complex_header_179.pdf"},"started_at":"2026-11-12T14:56:08.611285"} {"completed_at":"2026-11-12T14:56:57.533284","latency_in_ms":43001,"output":{"example_id":"complex_table_headers/complex_header_180","grounded_pages":[],"layout_pages":[],"markdown":"Entire Cohort Evaluated Cohort Evaluated Cohort\n‏مزع‎ = 512) (n = 359) (n = 359)\nUnknown pvalue SNAS<4.26 SNAS>426 pvalue CNR<5 CNR>S p value\n‏مز‎ = 153) (mn = 201) ‏ما‎ = 158) (n= 198) (n= 161)\n\n175148 048 8 aa? os! FASO 047 2598\nTeale 600512 at HSE B65) a\n84{79.2 0 J 10016 17 50340 4 (687) 1210752 050\n221 3126.4) 15 61(31.3) 1248\n1\n66 052 955 5517 1151559 aah 07\n1202 673 4534 61/341) (292\n5 7\n3600/6 0.788 45725 59672 5005 112601 1203 0607\n315 05 399) ‏غ2 (الرار4‎\n201 0 3 1002 1103 53210 3071 257 0638\n0 ‏الراك‎ 1 1 1117\n046 068 50414 5442 Oss 89 (45.4) O21292 0243\n55/524 o(S86 8 4 ons ‏انه‎ 2\n‏الال‎ 0926 S243 9 1630 0010 55297 4482 200\n59/628 06/56 004 0 este\n} 0\n901 045١ ‏اقرف 1 (49|761 05005 94063 كافك‎ 0618\n2040204 3 170 47|239( 213.5\n\nAge (Years)\nMedian (Range)\nmedian (25-65)\n\nmedian (65-56)\n\nTumour Size\n0 - 20 mn\nren\nUnknawen\n\nNodal status\nNO\nNI+\n\nUnkrawer\nNHG\n\nالها\n\ni\n\nUnknawer\n\nER status\n\nER i\nUnknown\nPR Status\nPR < 10%\nPR > 10%\nUnknown\n\nKhe?\n\n08\n\nOh\nUnknown\nHer2 IHC\n\nNoma\n\nOveresprressed (2°)\n\nUnknown","pages":[{"line_numbers":[],"markdown":"Entire Cohort Evaluated Cohort Evaluated Cohort\n‏مزع‎ = 512) (n = 359) (n = 359)\nUnknown pvalue SNAS<4.26 SNAS>426 pvalue CNR<5 CNR>S p value\n‏مز‎ = 153) (mn = 201) ‏ما‎ = 158) (n= 198) (n= 161)\n\n175148 048 8 aa? os! FASO 047 2598\nTeale 600512 at HSE B65) a\n84{79.2 0 J 10016 17 50340 4 (687) 1210752 050\n221 3126.4) 15 61(31.3) 1248\n1\n66 052 955 5517 1151559 aah 07\n1202 673 4534 61/341) (292\n5 7\n3600/6 0.788 45725 59672 5005 112601 1203 0607\n315 05 399) ‏غ2 (الرار4‎\n201 0 3 1002 1103 53210 3071 257 0638\n0 ‏الراك‎ 1 1 1117\n046 068 50414 5442 Oss 89 (45.4) O21292 0243\n55/524 o(S86 8 4 ons ‏انه‎ 2\n‏الال‎ 0926 S243 9 1630 0010 55297 4482 200\n59/628 06/56 004 0 este\n} 0\n901 045١ ‏اقرف 1 (49|761 05005 94063 كافك‎ 0618\n2040204 3 170 47|239( 213.5\n\nAge (Years)\nMedian (Range)\nmedian (25-65)\n\nmedian (65-56)\n\nTumour Size\n0 - 20 mn\nren\nUnknawen\n\nNodal status\nNO\nNI+\n\nUnkrawer\nNHG\n\nالها\n\ni\n\nUnknawer\n\nER status\n\nER i\nUnknown\nPR Status\nPR < 10%\nPR > 10%\nUnknown\n\nKhe?\n\n08\n\nOh\nUnknown\nHer2 IHC\n\nNoma\n\nOveresprressed (2°)\n\nUnknown","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_180","product_type":"parse","source_file_path":"complex_header_180.pdf"},"started_at":"2026-11-12T14:56:14.531380"} {"completed_at":"2026-11-12T14:56:26.356442","latency_in_ms":3095,"output":{"example_id":"complex_table_headers/complex_header_181","grounded_pages":[],"layout_pages":[],"markdown":"Group A (<64 yrs) Group 8 (65-84 yrs) Group © (>85 yrs}\n\nN= 46 N= 57 N=177\nin 1 Benk 1 Repl: 1 1 ‏إأصعة‎\n‎fi hroplasty fi arthroplasty fo arthroplasty\nN= 1 Nels N= 96 N= 261 N= 29 N= 148\nNo. No. No. No. No. No.\nPre ‏درك‎ iving at home 10 12 68 169 9 09\nPre ‏سرض‎ walking urakied/ane 8 13 a4 205 20 105\nstick\nLying at home in 4 months 26 12 56 130 a %\nWalking unaided at 4 mornhs/ 200 10 4a 9 9 14\none stick\nRe operations 4 1 6 12 1 11\n\nTatal death 2 1 13 19 4 4?","pages":[{"line_numbers":[],"markdown":"Group A (<64 yrs) Group 8 (65-84 yrs) Group © (>85 yrs}\n\nN= 46 N= 57 N=177\nin 1 Benk 1 Repl: 1 1 ‏إأصعة‎\n‎fi hroplasty fi arthroplasty fo arthroplasty\nN= 1 Nels N= 96 N= 261 N= 29 N= 148\nNo. No. No. No. No. No.\nPre ‏درك‎ iving at home 10 12 68 169 9 09\nPre ‏سرض‎ walking urakied/ane 8 13 a4 205 20 105\nstick\nLying at home in 4 months 26 12 56 130 a %\nWalking unaided at 4 mornhs/ 200 10 4a 9 9 14\none stick\nRe operations 4 1 6 12 1 11\n\nTatal death 2 1 13 19 4 4?","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_181","product_type":"parse","source_file_path":"complex_header_181.pdf"},"started_at":"2026-11-12T14:56:23.260975"} {"completed_at":"2026-11-12T14:56:33.832699","latency_in_ms":5016,"output":{"example_id":"complex_table_headers/complex_header_182","grounded_pages":[],"layout_pages":[],"markdown":"Chamber measurements\n\nFilm measurements, single field irradiations\n\nHomogeneous Phantom Ph Perpendicul b ig Ph Parallel\nMeasured - AAA Measured PBC Measured - AAA Measured- PBC SO Measured - AAA Measured - PBC SD\n(cGy) (cGy) (cGy) (cGy) (cGy) (cGy) ieey) ieGy)\nOLS em 10x 10 cm 1 og og 5,1 ‘ g 64 og\n1Sx2Sem° ~\n\nPrevalence\nWhite\n(4)\n\n47%\n03\n\nPrevalence Ratio\nBlack/White Hispanic/White\n(2) (3)\n0\\.6 05\n0\\.6 03\n\nBlacks\n=\nAOR\n133%\n\nPrevalence\n()\n\n147\n42%\n\n\\-33%\n193%\n\nMental Disorder\n\nMood disorder/depression\nSchizophrenia\n\nMood disorder/depression\nSchizophrenia","pages":[{"line_numbers":[],"markdown":"جه\n\nPrevalence Ratio\nHispanic/White\n\n(6)\n\n03\n07\n\nRelative Misreporting of Prevalence in Multiple Cause-of-Death Data\n\nBlack/White\n\n(5)\n\n04\n7\n\nHispanics\n\n>\n\nPrevalence\nWhite\n(4)\n\n47%\n03\n\nPrevalence Ratio\nBlack/White Hispanic/White\n(2) (3)\n0\\.6 05\n0\\.6 03\n\nBlacks\n=\nAOR\n133%\n\nPrevalence\n()\n\n147\n42%\n\n\\-33%\n193%\n\nMental Disorder\n\nMood disorder/depression\nSchizophrenia\n\nMood disorder/depression\nSchizophrenia","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_191","product_type":"parse","source_file_path":"complex_header_191.pdf"},"started_at":"2026-11-12T14:56:00.178632"} {"completed_at":"2026-11-12T14:55:21.142356","latency_in_ms":2891,"output":{"example_id":"complex_table_headers/complex_header_192","grounded_pages":[],"layout_pages":[],"markdown":"Leisure time physical inactivity\n\nRomanians\nOR (95% Cl}\n\nMungarians\nOR (95% Cl)\n\nHealth-related behaviour\nUnhealthy diet\n\nOR (95% Cl)\n100\n408 (28 ‏فد‎\n\nسما\n\nOR (95% Cl)\n\nSmoking\nHungarians fe us\n06 (95% Ch) OR (95% Ci)\n\n095 ‏د‎ 7 8] 1\not x\nox x\nwi 14 ٠ | 1 4\n24 1 1\n‏0ه‎ 0\n43 (097-209 8\n1 4 1+ 16 08\n\nalc\n\nVariables","pages":[{"line_numbers":[],"markdown":"Leisure time physical inactivity\n\nRomanians\nOR (95% Cl}\n\nMungarians\nOR (95% Cl)\n\nHealth-related behaviour\nUnhealthy diet\n\nOR (95% Cl)\n100\n408 (28 ‏فد‎\n\nسما\n\nOR (95% Cl)\n\nSmoking\nHungarians fe us\n06 (95% Ch) OR (95% Ci)\n\n095 ‏د‎ 7 8] 1\not x\nox x\nwi 14 ٠ | 1 4\n24 1 1\n‏0ه‎ 0\n43 (097-209 8\n1 4 1+ 16 08\n\nalc\n\nVariables","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_192","product_type":"parse","source_file_path":"complex_header_192.pdf"},"started_at":"2026-11-12T14:55:18.250929"} {"completed_at":"2026-11-12T14:55:35.767525","latency_in_ms":15205,"output":{"example_id":"complex_table_headers/complex_header_193","grounded_pages":[],"layout_pages":[],"markdown":"Malezin = 544) Females[n = 1118)\n\nDistance of residence to main road Distance of residence to main road\n<100 m 100-250 m 250-800 m <100 m 100-250 m 250-800 m\nn= 263M n= 279 n= 402 n= 322 m= 332 n= 464\n% % % % % %\nAge (years)\n8-24 194 226 197? 134\\* 169 181\n25-68 86.7 aos 587 655 614 580\n65-97 199 168 216 31.1 217 239\nSmoking habits\nsmokers 273 269 x16 77 175 166\nexmohers 414 358 393 17.7 162 166\nnerrzmoker 293 333 I 646 663 668\nPassive smoking exposure\nyes $9.1 i? 2 43128 491 813\nno 409 23 41.8 S68 $09 487\nEducational level\nhaw 41.1 452 423 ose $78 569\nmedum 204 uo N1 146 214 226\nhigh 285 229 276 199 208 205\nWork postion\nmanager/whre collar 137 179 192 89 \\* 167 137\nblue collar/farmer 195 197 203 101 6.1 87\nmerchant/craftsmman 176 154 120 95 64 87\nunemployed 492 47D 485 715 708 689\nOccupational exposure\nyes 570 595 sr? 264% 259 323\nno 430 405 423 746 74.1 av?\nNumber af hours at home\nz15h 41.1 376 393 742 na 698\n<15h $89 624 a? 258 289 302\nTime of residence\nc S years 142 108 110 116 8.1 112\n=S years 858 892 890 824 919 288\n\nType of selfeported emwronmental cortamination\ntraffic oe\" 62 762 92,6 \\*\\*\\* 7428 788\nother 76 248 248 64 252 215","pages":[{"line_numbers":[],"markdown":"Malezin = 544) Females[n = 1118)\n\nDistance of residence to main road Distance of residence to main road\n<100 m 100-250 m 250-800 m <100 m 100-250 m 250-800 m\nn= 263M n= 279 n= 402 n= 322 m= 332 n= 464\n% % % % % %\nAge (years)\n8-24 194 226 197? 134\\* 169 181\n25-68 86.7 aos 587 655 614 580\n65-97 199 168 216 31.1 217 239\nSmoking habits\nsmokers 273 269 x16 77 175 166\nexmohers 414 358 393 17.7 162 166\nnerrzmoker 293 333 I 646 663 668\nPassive smoking exposure\nyes $9.1 i? 2 43128 491 813\nno 409 23 41.8 S68 $09 487\nEducational level\nhaw 41.1 452 423 ose $78 569\nmedum 204 uo N1 146 214 226\nhigh 285 229 276 199 208 205\nWork postion\nmanager/whre collar 137 179 192 89 \\* 167 137\nblue collar/farmer 195 197 203 101 6.1 87\nmerchant/craftsmman 176 154 120 95 64 87\nunemployed 492 47D 485 715 708 689\nOccupational exposure\nyes 570 595 sr? 264% 259 323\nno 430 405 423 746 74.1 av?\nNumber af hours at home\nz15h 41.1 376 393 742 na 698\n<15h $89 624 a? 258 289 302\nTime of residence\nc S years 142 108 110 116 8.1 112\n=S years 858 892 890 824 919 288\n\nType of selfeported emwronmental cortamination\ntraffic oe\" 62 762 92,6 \\*\\*\\* 7428 788\nother 76 248 248 64 252 215","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_193","product_type":"parse","source_file_path":"complex_header_193.pdf"},"started_at":"2026-11-12T14:55:20.561679"} {"completed_at":"2026-11-12T14:55:26.209906","latency_in_ms":2282,"output":{"example_id":"complex_table_headers/complex_header_194","grounded_pages":[],"layout_pages":[],"markdown":"Rajnandgson Bastar\n\nPlacental parasitaemia’\n\nPlacental parasitaemia\n\nPresent Absent Present\n\nnid’ (9%) nid’ (%) nid’ (%)\n\nAbsent\nnid” (9%)\n\nStillbirth avis 2/487 (25 1/16 (3) 1/448 (2.2\n\nLow birth weight » OO aia nat} W715 (60.0 128/437 (29.3)°\n\nGestational hypertersion\\* a (133 a4 18 1/15 (67) 44/432 (10.1)\n\nBirth weight jqrams) 0 2x =D 2500\n\nMedian (range) 2060-2250 ra] 1700-2000 1075-90\"\nage B (38-47 38 (32-42 % (42-40) 36 (40-44)","pages":[{"line_numbers":[],"markdown":"Rajnandgson Bastar\n\nPlacental parasitaemia’\n\nPlacental parasitaemia\n\nPresent Absent Present\n\nnid’ (9%) nid’ (%) nid’ (%)\n\nAbsent\nnid” (9%)\n\nStillbirth avis 2/487 (25 1/16 (3) 1/448 (2.2\n\nLow birth weight » OO aia nat} W715 (60.0 128/437 (29.3)°\n\nGestational hypertersion\\* a (133 a4 18 1/15 (67) 44/432 (10.1)\n\nBirth weight jqrams) 0 2x =D 2500\n\nMedian (range) 2060-2250 ra] 1700-2000 1075-90\"\nage B (38-47 38 (32-42 % (42-40) 36 (40-44)","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_194","product_type":"parse","source_file_path":"complex_header_194.pdf"},"started_at":"2026-11-12T14:55:23.927050"} {"completed_at":"2026-11-12T14:55:30.537529","latency_in_ms":2120,"output":{"example_id":"complex_table_headers/complex_header_195","grounded_pages":[],"layout_pages":[],"markdown":"Global scores' (recommended) Behaviour counts? (recommended)\n\n{mean (SD}}\n\nEmpathy Spirit Darection RE:QU OQ (%) CR (%6) MIA (5%)\n\n(>3.5) (>3.5) (>3.5) lin favour of RF) (mean (SD) (>50%6) (> 40%) (>90%)\n1 (Os 0 $(0 9 (0.38 Nn (12 4 |\n\n42 (21 By ish\n\n15 (bY 22 (09) af 23 (14) 62(1\n\n39 41","pages":[{"line_numbers":[],"markdown":"Global scores' (recommended) Behaviour counts? (recommended)\n\n{mean (SD}}\n\nEmpathy Spirit Darection RE:QU OQ (%) CR (%6) MIA (5%)\n\n(>3.5) (>3.5) (>3.5) lin favour of RF) (mean (SD) (>50%6) (> 40%) (>90%)\n1 (Os 0 $(0 9 (0.38 Nn (12 4 |\n\n42 (21 By ish\n\n15 (bY 22 (09) af 23 (14) 62(1\n\n39 41","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_195","product_type":"parse","source_file_path":"complex_header_195.pdf"},"started_at":"2026-11-12T14:55:28.417208"} {"completed_at":"2026-11-12T14:56:21.936795","latency_in_ms":47608,"output":{"example_id":"complex_table_headers/complex_header_196","grounded_pages":[],"layout_pages":[],"markdown":"et al.{)\n\nPresent study\n\nHealthy Patients\nStudents Joggers Conservatives Preoperatives\n9827 9922 732142 4S8+14\nAn 48 3 is 1s\nHealthy 63 0.138\n“Me?\nJoggers 20 0.198\n23\nConservatives 4s 0.050\nely\nPreoperatives 4 o.00s\n\n“4228","pages":[{"line_numbers":[],"markdown":"et al.{)\n\nPresent study\n\nHealthy Patients\nStudents Joggers Conservatives Preoperatives\n9827 9922 732142 4S8+14\nAn 48 3 is 1s\nHealthy 63 0.138\n“Me?\nJoggers 20 0.198\n23\nConservatives 4s 0.050\nely\nPreoperatives 4 o.00s\n\n“4228","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_196","product_type":"parse","source_file_path":"complex_header_196.pdf"},"started_at":"2026-11-12T14:55:34.328519"} {"completed_at":"2026-11-12T14:56:23.254152","latency_in_ms":42824,"output":{"example_id":"complex_table_headers/complex_header_197","grounded_pages":[],"layout_pages":[],"markdown":"SHIP Oral zzudy/SHIP Premix study\n\nDimensions Clinician actual treatment decision regarding insulln inmiation! Patients\" imenden regarding\nlenensification\ninsulin injection inhaled insulin\ninidation! Initiarion/\ninvenstication interstication\ninclusion & months 12 months Inchusion Inclusion:\n“Acceptance and 0.80065 0.65/0.64 0.59/0.64 0.86/0.86 0.465/0.72\nmotivation’\n\\*Corsvraints and fears’ 0.721062 0.580.461 0.56.60 0750.78 0.60/0.68\n'Rezurainas and 042/058 0.59060 OSa04! 0720.65 0.57/0.63\n\nbarriers’","pages":[{"line_numbers":[],"markdown":"SHIP Oral zzudy/SHIP Premix study\n\nDimensions Clinician actual treatment decision regarding insulln inmiation! Patients\" imenden regarding\nlenensification\ninsulin injection inhaled insulin\ninidation! Initiarion/\ninvenstication interstication\ninclusion & months 12 months Inchusion Inclusion:\n“Acceptance and 0.80065 0.65/0.64 0.59/0.64 0.86/0.86 0.465/0.72\nmotivation’\n\\*Corsvraints and fears’ 0.721062 0.580.461 0.56.60 0750.78 0.60/0.68\n'Rezurainas and 042/058 0.59060 OSa04! 0720.65 0.57/0.63\n\nbarriers’","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_197","product_type":"parse","source_file_path":"complex_header_197.pdf"},"started_at":"2026-11-12T14:55:40.430026"} {"completed_at":"2026-11-12T14:56:00.177222","latency_in_ms":11058,"output":{"example_id":"complex_table_headers/complex_header_198","grounded_pages":[],"layout_pages":[],"markdown":"Coding inter-rater agreement\nsystem Kappa with 95% confidence interval and the absolute number of films (-/-+/+-/++)\nIPP VA-VN\n[2] [3]\nTatal number wes (245) (245)\nof tested films CRAS (245) (246) (245)\nParenchymal wes NA NA NA\nabnormality CRAS O63 (051-075) 024 [016032] aN (ba80e2] 02501608) O58 H4e0%) 027 [017-037]\n(32/21/7/188) (ovasoy192) (24/29/6/187) (7/32/2/206) (22/17/4198) (6f2/24/222)\nCakificatian” cS 062 (049075) O47 (035-059) 9421 (012-020) «9085 (042068) «= 0.20 21-0139] =. [0.1 7-045]\n(188/73/14/30) (189/14/22/24) (19aya/3av7 (190/1 2/18/25) QoVoysay (218/2/31/7)\nCRAS 028 (018-041) 035 [023-047] «1S (004-026) «= 0.36 (025-047) 9=a6 A 2S-47] =F (009-025)\n(219/10\"11/5) (206/22/6/ 10} (226/4/14/2) 2008/23/57 10) (228/2/11/4} (219/2/30'4)\nPleural cS O58 (045-071) OFF esto) a6 (0S4078] dea (OSiO7\") 054 41-067) O73 (061-085)\neffusion (222/a/S/ 104 (226/5/2/13) (222/8/3/12) 2221/64/12) (209097/11} (230V0/4/15)\nPleural CS 045 (0224147) 022 (014-030) 045 [023-057 0.28 (0.18-0.33) 045 (1324158) 0.3) (022-040)\nthickening (18/357 19/29) (38/1 10/2/46) {161/36/1 4/34) (84/93/4602) (148/28/26/42) (ST/495/6H\nPleural CARAS 030 (020040) «0.16 (009-023) = 4.46 [024-058] «= 045 (032-057) =S4 H4Ar166] «= 0.82 [022-042]\nabnormalities (1390/72/96) eaayayay (19944/7/36) Perea a1 og (124/12/42/67) S1HeV7y\nPlourd effusion’ —CRAS O48 (03600) 034 [022146] OSS [043-067] O49(0%042) O67 KSSO)] 048 (046-060)\nthickening™\\* (16/38/28) (1680/43/17 1/24) (189722/5/26) (196/26/23/41) (1766/22/41) arn","pages":[{"line_numbers":[],"markdown":"Coding inter-rater agreement\nsystem Kappa with 95% confidence interval and the absolute number of films (-/-+/+-/++)\nIPP VA-VN\n[2] [3]\nTatal number wes (245) (245)\nof tested films CRAS (245) (246) (245)\nParenchymal wes NA NA NA\nabnormality CRAS O63 (051-075) 024 [016032] aN (ba80e2] 02501608) O58 H4e0%) 027 [017-037]\n(32/21/7/188) (ovasoy192) (24/29/6/187) (7/32/2/206) (22/17/4198) (6f2/24/222)\nCakificatian” cS 062 (049075) O47 (035-059) 9421 (012-020) «9085 (042068) «= 0.20 21-0139] =. [0.1 7-045]\n(188/73/14/30) (189/14/22/24) (19aya/3av7 (190/1 2/18/25) QoVoysay (218/2/31/7)\nCRAS 028 (018-041) 035 [023-047] «1S (004-026) «= 0.36 (025-047) 9=a6 A 2S-47] =F (009-025)\n(219/10\"11/5) (206/22/6/ 10} (226/4/14/2) 2008/23/57 10) (228/2/11/4} (219/2/30'4)\nPleural cS O58 (045-071) OFF esto) a6 (0S4078] dea (OSiO7\") 054 41-067) O73 (061-085)\neffusion (222/a/S/ 104 (226/5/2/13) (222/8/3/12) 2221/64/12) (209097/11} (230V0/4/15)\nPleural CS 045 (0224147) 022 (014-030) 045 [023-057 0.28 (0.18-0.33) 045 (1324158) 0.3) (022-040)\nthickening (18/357 19/29) (38/1 10/2/46) {161/36/1 4/34) (84/93/4602) (148/28/26/42) (ST/495/6H\nPleural CARAS 030 (020040) «0.16 (009-023) = 4.46 [024-058] «= 045 (032-057) =S4 H4Ar166] «= 0.82 [022-042]\nabnormalities (1390/72/96) eaayayay (19944/7/36) Perea a1 og (124/12/42/67) S1HeV7y\nPlourd effusion’ —CRAS O48 (03600) 034 [022146] OSS [043-067] O49(0%042) O67 KSSO)] 048 (046-060)\nthickening™\\* (16/38/28) (1680/43/17 1/24) (189722/5/26) (196/26/23/41) (1766/22/41) arn","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_198","product_type":"parse","source_file_path":"complex_header_198.pdf"},"started_at":"2026-11-12T14:55:49.118692"} {"completed_at":"2026-11-12T14:56:04.929125","latency_in_ms":4627,"output":{"example_id":"complex_table_headers/complex_header_199","grounded_pages":[],"layout_pages":[],"markdown":"Study Duration of Treatment Groups Pegaptanib sodium 0.3 mg Sham = Reference\n\nTreatment\nSubjects\nWith Without\n\nrm Rist Dish,\n\nN=165 N#=1421 N=26\nNCTO0321997 (EOP1 003 randomized) Upto Syears Pegaptanib 03, 1, 3 mg; sham 22 (13.3%) 208 (14.0%) 7 (20998) [ๆ\nNCTOO021796 061004 randomized) Upto Syears Pegaptanib 03, 1, 3 mg; sham 20 (12.1%) 182 (12.2%) 14 (63.8%) [7]\nNCTO021 5670 (EOP 1 00% randomized) Up to 2 years Pegaptanib 03, 1,3 mg า๒อชะ 41 (4+) 0 เกค 23]\nNCTOOUS 7763 (EOP1 00S, randomized) lyear; with ๓ก๐0 Pegaptanib 03, 1 mg sham 4 (24%) 60 (4.2%) $ (19.2%) °\n\ntreatment\nweeks 12 to 24\nNCTOO088192 (ECPI OIG, opentabel Up to 3 years Peguptarib 03 mg OF (20.0%) 370 26.D%) 0 (DR) |\nพ0100134667\\*\\* 606า1012 randamized) = Up to 2 years คครมเลท๒ 0.3 mg, 1649.790 149 (10.5%) 0 (DR)\npegaptanb 03 mg+POT\nพ06100150202/ NCTO0239928 Up to 4 years Pegaptanib 03, 1 mg Fame) 72 (5.154 0 (DR) [มม\n[5751010/ AS?S1015; ๓๒๕๓๓“๒๒๕0\n\nพ100324116 (45751016 apendabel) 1 year Pegaptanib 03 mg า16ล0 70 (เซผม 0 เห t\n\nNCTOO327490 (AS75101? apentabel) Up to 2 years Pequptarib 13 mg 17 (10.3%) 265 (18.5%) 0 เย] t","pages":[{"line_numbers":[],"markdown":"Study Duration of Treatment Groups Pegaptanib sodium 0.3 mg Sham = Reference\n\nTreatment\nSubjects\nWith Without\n\nrm Rist Dish,\n\nN=165 N#=1421 N=26\nNCTO0321997 (EOP1 003 randomized) Upto Syears Pegaptanib 03, 1, 3 mg; sham 22 (13.3%) 208 (14.0%) 7 (20998) [ๆ\nNCTOO021796 061004 randomized) Upto Syears Pegaptanib 03, 1, 3 mg; sham 20 (12.1%) 182 (12.2%) 14 (63.8%) [7]\nNCTO021 5670 (EOP 1 00% randomized) Up to 2 years Pegaptanib 03, 1,3 mg า๒อชะ 41 (4+) 0 เกค 23]\nNCTOOUS 7763 (EOP1 00S, randomized) lyear; with ๓ก๐0 Pegaptanib 03, 1 mg sham 4 (24%) 60 (4.2%) $ (19.2%) °\n\ntreatment\nweeks 12 to 24\nNCTOO088192 (ECPI OIG, opentabel Up to 3 years Peguptarib 03 mg OF (20.0%) 370 26.D%) 0 (DR) |\nพ0100134667\\*\\* 606า1012 randamized) = Up to 2 years คครมเลท๒ 0.3 mg, 1649.790 149 (10.5%) 0 (DR)\npegaptanb 03 mg+POT\nพ06100150202/ NCTO0239928 Up to 4 years Pegaptanib 03, 1 mg Fame) 72 (5.154 0 (DR) [มม\n[5751010/ AS?S1015; ๓๒๕๓๓“๒๒๕0\n\nพ100324116 (45751016 apendabel) 1 year Pegaptanib 03 mg า16ล0 70 (เซผม 0 เห t\n\nNCTOO327490 (AS75101? apentabel) Up to 2 years Pequptarib 13 mg 17 (10.3%) 265 (18.5%) 0 เย] t","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_199","product_type":"parse","source_file_path":"complex_header_199.pdf"},"started_at":"2026-11-12T14:56:00.302051"} {"completed_at":"2026-11-12T14:56:08.622283","latency_in_ms":2849,"output":{"example_id":"complex_table_headers/complex_header_200","grounded_pages":[],"layout_pages":[],"markdown":"incidence Cardiac Events\n\nVascular Measure Risk Model Discrimination\nOverall Developmental Teste\nModel ROCA Measure N= 6060 N= 14 N= 2219\n\nHR (95% Ch) AUC AUC\n\nt MT 1.49 (1.38-1.61) 0.621 o608\n\n2 MT 1.40 (1.281.853) 0.682 O67s\n\n3 MT 1.19 (1,081.31) 0s oB80s\n\nt @ameter 2.01 (1.76-229) 046% ose7y\n\n2 @ameter 183 (1.5911) 0724 O72\n\n3 @ameter 1.26 (1.08148) 083! osi2\n\nt Wall area 1.65 (1.52178) 0.490 O66!\n\n2 Wall area 1.56 (142-171) 0.702 oe”\n\n3 Wall area 1.23 (1.101 38) 083! oan\n\nModel Two Measures HR (95% Ch Developmental Test\n\nAUC AUC\n\nI IMT + 1.26 (1.15-1.39) 0.705 0674\n@ameter 1.75 (1.51202)\n\n2 IMT + 1.23 (1.10-1.37) 0.724 O70S\nGameter 1.65 (1.42-1.93)\n\n3 IMT + 1.14 (1.03-1.27) oat! o.eos\nGameter 1.18 ¢1.00--1.40)","pages":[{"line_numbers":[],"markdown":"incidence Cardiac Events\n\nVascular Measure Risk Model Discrimination\nOverall Developmental Teste\nModel ROCA Measure N= 6060 N= 14 N= 2219\n\nHR (95% Ch) AUC AUC\n\nt MT 1.49 (1.38-1.61) 0.621 o608\n\n2 MT 1.40 (1.281.853) 0.682 O67s\n\n3 MT 1.19 (1,081.31) 0s oB80s\n\nt @ameter 2.01 (1.76-229) 046% ose7y\n\n2 @ameter 183 (1.5911) 0724 O72\n\n3 @ameter 1.26 (1.08148) 083! osi2\n\nt Wall area 1.65 (1.52178) 0.490 O66!\n\n2 Wall area 1.56 (142-171) 0.702 oe”\n\n3 Wall area 1.23 (1.101 38) 083! oan\n\nModel Two Measures HR (95% Ch Developmental Test\n\nAUC AUC\n\nI IMT + 1.26 (1.15-1.39) 0.705 0674\n@ameter 1.75 (1.51202)\n\n2 IMT + 1.23 (1.10-1.37) 0.724 O70S\nGameter 1.65 (1.42-1.93)\n\n3 IMT + 1.14 (1.03-1.27) oat! o.eos\nGameter 1.18 ¢1.00--1.40)","page_index":0}],"pipeline_name":"parallel_extract","task_type":"parse"},"pipeline_name":"parallel_extract","product_type":"parse","raw_output":{"num_pages":1},"request":{"example_id":"complex_table_headers/complex_header_200","product_type":"parse","source_file_path":"complex_header_200.pdf"},"started_at":"2026-11-12T14:56:05.772658"}